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1 Abstract 
Idebenone is a synthetic compound which shares analogous structures with coenzyme Q10 (CoQ10). It has been 
shown to attenuate the pathology of disorders with a mitochondrial phenotype or increased levels of oxidative 
damage. Not surprisingly, idebenone was primarily associated with antioxidant function and interaction with 
enzymes of the electron transport chain of mitochondrial respiration. In line with the proposed antioxidant 
function, idebenone protects cells from hydrogen peroxide-induced cell death. This work also confirms that 
idebenone inhibits mitochondrial complex I of healthy cells in vitro and for the first time, complex I inhibition is 
described in vivo, manifesting in an increased food intake relative to body weight and a transient drop in blood 
glucose. Furthermore, the reduction of idebenone by the cytosolic enzymes NQO1 and NQO2 are shown for the 
first time. In cells with a dysfunctional complex I, idebenone is able to promote mitochondrial respiration in an 
NQO1- and complex III-dependent manner. Hence, a new activity for idebenone is proposed in which 
idebenone facilitates the electron flow from the cytosol into the mitochondria and thereby restores depleted 
ATP content in complex I-deficient cells. This new mechanism is one of several justifications for the use of 
idebenone in mitochondrial disorders such as mitochondrial encephalomyopathy, lactic acidosis, and stroke-like 
syndrome (MELAS) and Leber’s hereditary optic neuropathy (LHON). Additionally, over 50 novel idebenone 
analogs are characterized in different bioassays. 
 
 
Idebenone ist eine synthetische Verbindung, die analoge Strukturen zu Coenzym Q10 (CoQ10) aufweist. 
Idebenone, so wurde gezeigt, verringert die pathologischen Symptome von mitochondriellen Krankeiten oder 
solchen mit erhöhtem oxidativen Stress. Daher ist es nicht überraschend, dass Idebenone hauptsächlich als 
Antioxidans angesehen wurde und  auch in die Regulation der mitochondrialen Elektronentransportkette 
involviert wurde. In Übereinstimmung mit der vorgeschlagenen antioxidativen Wirkung schützt Idebenone 
Zellen vor oxidativem Stress. Diese Arbeit bestätigt ebenfalls, dass Idebenone den mitochondriellen Komplex I 
gesunder Zellen in vitro hemmt. Diese inhibitorische Aktivität wurde erstmals in vivo beschrieben und 
manifestiert sich in einer erhöhten Futteraufnahme und in einem kurzzeitigen Abfall des Blutzuckers. Zusätzlich 
wird zum erstenmal gezeigt, dass Idebenone durch die zytosolischen Enzyme NQO1 und NQO2 reduziert wird. 
In Zellen mit defektem mitochondriellen Komplex I kann Idebenone die mitochondrielle Atmung abhängig von 
NQO1 und Komplex III begünstigen. Demzufolge wird ein neuer Wirkmechanismus für Idebenone 
vorgeschlagen: Idebenone ermöglicht den Elektronenfluss aus dem Zytosol in die Mitochondrien, um dadurch 
den reduzierten zellulären ATP Gehalt bei defektem Komplex I zu normalisieren. Dieser neue Mechanismus ist 
eine von mehreren Gründen für den Einsatz von Idebenone bei mitochondriellen Krankheiten wie Leber’sche 
hereditäre Optikusneuropathie (LHON) oder mitochondriale Encephalomyopathie, Lactatacidose, und 
Schlaganfall-ähnliche Episoden (MELAS). Darüber hinaus werden über fünfzig neuartige Analoge von Idebenone 
in verschiedenen biologischen Untersuchungen charakterisiert. 
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2 Introduction 
In recent years, more evidence for mitochondrial involvement in a variety of diseases has been reported 
[Wallace 1999, de Moura et al. 2010, and Moreira and Oliveira 2010]. Aside from a growing knowledge on 
primary mitochondrial disorders—such as mitochondrial encephalomyopathy, lactic acidosis, and stroke-like 
syndrome (MELAS), Leber’s hereditary optic neuropathy (LHON), and myoclonic epilepsy and ragged-red fibers 
(MERRF) [Schon 2000]—impaired mitochondrial function has been discussed in diseases generally caused by 
non-mitochondrial factors as diverse as depression and bipolar disorder [Rezin et al. 2008, Jou et al. 2009, and 
Clay et al. 2011], several types of cancer [Chatterjee et al. 2010, de Moura et al. 2010], diabetes [Moreira and 
Oliveira 2011] and autism [Haas 2010]. In addition, growing evidence of mitochondrial dysfunction emerged in 
many neurodegenerative diseases like Alzheimer’s disease (AD) [Ferreira et al. 2010, Tillement et al. 2011], 
Parkinson’s disease (PD) [Xie et al. 2010], and Huntington’s disease (HD) [Mochel and Haller 2011]. In this 
regard, it is important to note that mitochondrial impairment is also discussed as a cornerstone for normal and 
accelerated aging [Romano et al. 2010]. 
Given the fundamental role of mitochondria in the cell, i.e. for the generation of energy, it is not astonishing 
that their impairment leads to a number of disorders. Whereas incidences of primary mitochondrial disorders—
with approximately 12 indidences per 100,000—are rather low [Chinnery and Turnbull 2001], neurodegenerative 
diseases, depression and diabetes affect a large part of human population. Thus, research on mitochondria and, in 
addition, treatment against mitochondrial dysfunction becomes more and more important. In this context, 
mitochondrial disorders constitute useful models for developing compounds that can modify mitochondrial 
function to ameliorate not only their molecular dysfunction, but also the course and pathology of the mentioned 
prevalent diseases. 
2.1 Mitochondria-Related Diseases 
Mitochondria are pivotal organelles in most cells and are mainly responsible for the generation of energy. 
Genetic disorders showing a mitochondrial phenotype can be either caused indirectly as consequence of primary 
failures of cellular integrity or directly by mutations of genes involved in mitochondrial function. Since 
mitochondria hold a genome of their own, genes associated with their function can be either encoded by the 
mitochondrial genome or within the nucleus of the cell. It is important to note that mutations of mitochondrial 
genes do not follow Mendelian rules of inheritance [Sproule and Kaufmann 2008], since mitochondria are solely 
maternally derived. Implementation and inheritance of such mutations are further complicated by two concepts 
of mitochondrial replication: heteroplasmy and segregation. The first one refers to the fact, that one cell can 
contain up to several thousand copies of mitochondrial DNA (mtDNA) and that these copies may differ in 
sequence [Sproule and Kaufmann 2008]. Segregation compromises the distribution of mitochondria among 
daughter cells during mitosis. This partition of the vast number of mitochondria of a cell in two daughter cells 
occurs randomly. Therefore, accumulation of a given mutation in a specific cell or even tissue happens 
incidentally and the same mutation may not manifest itself similarly in two carriers thereof [Sproule and 
Kaufmann 2008]. In a special case of segregation, higher incidence of mutated mtDNA in children than in the 
mother can be explained by a genetic bottle neck effect; namely if mutated mtDNA is not distributed evenly 
during generation of female germ cells. These concepts can therefore explain the diverse clinical phenotypes 
observed in patients with mitochondrial mutations.  
Despite the heterogeneity of the course of disease, mutations of mtDNA lead to symptoms that sometimes 
overlap between the different diseases as patients often show muscle atrophy, blindness, deafness, impaired 
cognitive functions and diabetes [Schon 2000]. This is not surprising, since these symptoms affect organs with 
high energy demand such as muscles, eyes, and the brain. Mitochondrial myopathies (MELAS, MERRF), some 
ophthalmological neuropathies (LHON, macular degeneration, MELAS), and maternally-inherited diabetes and 
deafness (MIDD) fall in this category [Sproule and Kaufmann 2008].  
Mutations in nulcear-encoded genes responsible for mitochondrial function can also lead to disorders with a 
mitochondrial phenotype. Loss of frataxin, which is assumed to participate in iron cluster formation in 
mitochondria [Mühlenhoff et al. 2002], is the underlying cause of Friedreich’s ataxia (FRDA). As a result, 
mitochondrial energy production is impeded in patients possessing a mutation in the according gene [Rötig et al. 
1997]. 
Furthermore, dysfunction of mitochondria can be elicited as a consequence of accumulation of toxic 
compounds unrelated to mitochondria or to exogenous toxins. This is the case in neurodegenerative disorders as 
the example of AD suggests: high levels of oxidative stress assaults mitochondrial health by accumulation of 
amyloid-β and this can result in an accelerated decline of neurons [Ferreira et al. 2010]. In Duchenne muscular 
dystrophy (DMD), it is assumed that mitochondrial function is impaired as a result of membrane disruption and 
disturbed calcium homeostasis (see 2.1.3 for details). Finally, the neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) blocks an enzyme complex of mitochondrial energy production and, upon 
administration of this compound, a Parkinson-like phenotype is apparent [Degli Esposti 1998]. 
Three mitochondria-related diseases will be looked at in more details in the forthcoming sections; namely two 
diseases with mutations in mtDNA (MELAS and LHON) and a disease wherein mitochondrial impairment 
results as a consequence of preciding pathological changes (DMD). 
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2.1.1 Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Syndrome (MELAS) 
The pathology of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like syndrome (MELAS) is 
defined by the occurrence of the following criteria: (i) stroke-like episodes in the first four decades, (ii) at least 
one of the encephalopathic symptoms seizures or dementia, and (iii) at least one of the myopathic symptoms 
lactic acidosis or red-ragged fibers [Hirano and Pavlakis 1994]. Sproul and Kaufmann [2008] reported that, in 
addition, a majority of patients suffers from exercise intolerance, headache, hearing loss, and gastrointestinal 
disturbances. Disease onset is usually stated between the age of 2 and 20 [Pavlakis et al. 1984, Hirano and Pavlakis 
1994].  
Even though MELAS is a polygenetic disorder associated with at least 29 specific point mutations, all 
mutations causing this phenotype are found in mtDNA [Sproul and Kaufmann 2008]. The most prominent 
mutation is an A-to-G transition mutation at position 3243 (3243A>G mutation; meaning the adenine is 
exchanged with a guanine nucleotide) found in approximately 80% of patients [Testai and Gorelick 2010]. 
Whereas many mutations affect genes encoding for mitochondrial transfer ribonucleic acids (tRNA)—nucleotide 
3243 lies within the gene for a lysine tRNA (tRNAlys)—some affect genes encoding for subunits of mitochondrial 
complexes which are also associated with other mitochondrial disorders like LHON, MERRF, or Leigh disease. 
Thus, two interesting, yet unaccounted incidents for mitochondrial disorders become apparent: they could be 
both (i) polygenetic disorders, i.e. a mutual set of symptoms is caused by different mutations, and (ii) 
overlapping, meaning that exactly the same mutation can lead to multiple phenotypes as reported for 
LHON/MELAS, MELAS/Leigh syndrome, and LHON/MELAS/Leigh syndrome in regard to mitochondrially 
encoded complex I subunits [Wong 2002]. 
Since tRNA are required for building new proteins, mutations lead to dysfunctional mitochondrial enzyme 
complexes. Accordingly, deficiency of energy production by mitochondria has to be counteracted by increased 
anaerobic glycolysis. As will be explained in a following subchapter (see 2.2.1), this change in energy source 
results in elevated levels of lactate in the blood. Indeed, lactic acidosis in blood is not only found in all 
mitochondrial disorders, but also specifically in brain areas affected by stroke in MELAS patients [Kaufmann et 
al. 2004, Davidson et al. 2009]. 
Deficiency in mitochondrial energy production in MELAS patients has been described by several groups. James 
et al. [1996] reported that fibroblasts from a MELAS patient carrying the 3243A>G mutation had decreased 
complex I and IV activity, but increased complex II activity and normal complex III activity compared to 
control fibroblasts. They therefore suggested an elevated complex II-III activity in MELAS patients. They also 
found increased acidification of culture medium and concluded enhanced anaerobic glycolysis in these cells. This 
is consistent with the lactic acidosis found in blood of MELAS patients. Furthermore, their studies showed 
decreased mitochondrial membrane potential also adding to the picture of dysfunctional mitochondria. 
Other groups reported failures of additional respiratory complexes. Sarnat and María-García [2005] described a 
patient with an unidentified mutation but showing MELAS symptoms who has decreased activity of 
mitochondrial complexes I, III, IV, and ATP synthase. Davidson et al. [2009] introduced the 3243A>G mutation 
into an immortalized brain capillary endothelial cells and astrocytes and they found not only reduced complex I 
activity, but also decreased activity of complex IV and, to a lesser extent, complex II. In a study by Sarasman et 
al. [2008], 3243A>G mutation prevented the assembly of complexes I, IV and ATP synthase in myoblasts by a 
combination of faulty incorporation of amino acids and shorter half-lives of mitochondrial translation products. 
Further evidence for direct involvement of mitochondrial respiration and MELAS comes from several findings 
of point mutations within subunits of complex I. Kirby et al. [2004] reported three unrelated MELAS patients 
with mutations within subunit ND1 of complex I, namely 3697G>A, 3946G>A, and 3949T>C. In fibroblasts of 
a MELAS patient harboring the 13528A>G mutation, which affects the ND5 subunit of complex I, decreased 
mitochondrial membrane potential and increased lactate production was found [McKenzie et al. 2007]. The 
authors showed in the same study that ATP generated by glycolysis was used to support the remaining 
mitochondrial membrane potential. Malfatti et al. [2007] described a MELAS patient harboring the 3481G>A 
mutation affecting subunit ND1 of complex I who showed markedly reduced complex I activity in muscle 
biopsy homogenates and fibroblasts, which was countered by increased complex II and ATP synthase activity at 
least in the latter. Activities of complexes II-V and complexes III and IV in muscle homogenates and fibroblasts, 
respectively, remained unchanged. A failure in mitochondrial respiration was also affirmed by Sano et al. [1995] 
who found a decreased ratio of oxygen consumption to glucose metabolism in the brain of a 3243A>G point 
mutation carrier.  
Hence, disruption of mitochondrial energy production leads to the described phenotype of MELAS. However, 
MELAS differs from other mitochondrial diseases which also involve mitochondrial-encoded enzymes of the 
respiratory chain [Sproule and Kaufmann 2008]. The heterogeneity of symptoms in mitochondrial diseases is still 
far from understood.  
2.1.2 Leber’s Hereditary Optic Neuropathy (LHON) 
Another devastating disease with underlying mitochondrial dysfunction is Leber’s Hereditary Optic 
Neuropathy (LHON). The clinical symptoms manifest as a sudden loss of vision, mostly experienced in the 
second or third decade of life, caused by the degeneration of retinal ganglion cells (RGCs) and their axons [Sadun 
2010]. Three mutations in the mitochondrial gene for complex I subunits account for 98% of all LHON cases, 
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namely 11778G>A in subunit ND4, 3460G>A in subunit ND1 and 14484T>C in subunit ND6 [Mackey et al. 
1996]. Even though mutations affect the same enzyme complex as in MELAS, the phenotypes—i.e. age of onset, 
affected tissues—significantly differ in these two diseases. 
Cells harboring a mutation in conserved components of the mitochondrial electron transport chain, such as 
cells from LHON patients, are expected to show signs of energy deprivation. Indeed, some groups have 
demonstrated a clear deficit of mitochondrial membrane potential, ATP synthesis and oxygen consumption rates. 
This was shown in primary peripheral blood mononuclear cells (PBMCs) of affected LHON patients as well as 
unaffected carriers [Korsten et al. 2010], but was also observed previously in cybrid cells harboring the three 
common LHON mutations [Baracca et al. 2005, Floreani et al. 2005] and skin fibroblasts [Bonnet et al. 2008].  
Surprisingly, no consistent reduction of cellular ATP levels in LHON cybrids and LHON PBMCs compared to 
control cells could be demonstrated [Beretta et al. 2004, Baracca et al. 2005, and Pommer et al. 2008], which 
suggest that LHON cells in vitro, or in the case of PBMCs ex vivo, have activated compensatory mechanisms to 
ensure energy homeostasis. Whether part of the compensatory mechanism is an up-regulation of complex II 
activity as suggested by an earlier study using LHON PBMCs [Yen 1996] is still disputed [Brown et al. 2000, 
Korsten et al. 2010]. Likewise, the presence of LHON mutations neither seems to affect mitochondrial content 
[Pommer et al. 2008] nor the amount or composition of the complexes of the mitochondrial electron transport 
chain [Korsten et al. 2010]. In three related 3460G>A mutation-carrying LHON patients, markedly reduced ATP 
levels compared to its degradation products were detected in the brain, assuming impairment of cellular energy 
production [Lodi 2002].  
Although data so far generally demonstrates a connection between the severity of the mutation and the 
severity of the respiratory defect, they are unable to account for the pathomechanism of LHON. This is also 
reflected by observations that ATP synthesis defects can be observed in multiple cellular systems of LHON 
patients, whereas the phenotype of LHON is restricted to the optic nerve and RGCs. One possible explanation 
could be that mitochondria or complex I in particular function differently in a neuronal context compared to 
other cell types [Wong et al. 2002]. 
Since mitochondrial dysfunction is often associated with elevated levels of reactive oxygen species (ROS) 
produced by a dysfunctional respiratory chain, ROS as mediators of cellular impairment were regarded as an 
attractive hypothesis. ROS are highly aggressive agents that promiscuously and indiscriminately react with 
whatever molecule in their vicinity and thereby, they cause devastating damage to proteins and membrane lipids 
[see 2.3.1]. However, normal levels of an antioxidant defense molecule, glutathione (GSH) [see 2.3.1 for further 
information], in blood samples from LHON patients [Klivenyi et al. 2001] and in LHON cybrid cells [Ghelli et 
al. 2008] would ostensibly speak against a major involvement of ROS in the pathology of LHON. On the other 
hand, support for the hypothesis of excess ROS production stems from elevated levels of 8-hydroxy-2’-
deoxyguanosine (8-oxo-dG) that were observed in leucocytes from LHON patients [Yen et al. 2004]. 
Nevertheless, production of ROS in LHON cells might be more complex than anticipated. LHON-NT2 cybrid 
cells that can be differentiated into a neuronal phenotype were reported to be indistinguishable with regards to 
ROS levels when comparing the undifferentiated LHON-NT2 cybrid cells with cybrids harboring wild-type 
(WT) mitochondria [Wong et al. 2002]. However, in a differentiated, neuronal-like state, the same LHON cybrid 
cells showed about 2.5-fold increased ROS levels compared to control cells [Wong et al. 2002], which led the 
authors to suggest a different function of complex I in a neuronal retinal background. Indeed, work by Levin 
[2007] demonstrated fundamentally different rates of ROS production in brain neurons compared to RGC-5 
cells—a rodent cell line with some characteristics of retinal ganglion cells. Finally, ribozyme-mediated down-
regulation of mitochondrial superoxide dismutase (SOD2) in mouse eyes was reported to induce a LHON-like 
phenotype including axonal loss, demyelization of the optic nerve and ganglion cells in the retina [Qi et al. 2003]. 
The atrophy of the optic nerve, characteristic to LHON patients, immediately raises the question whether 
apoptosis is involved in this process. Apoptosis is an active, orchestrated self-degradation of a cell which is often 
referred to as suicide; whereas the other form of cell death, necrosis, is a chaotic rupture of the cell membrane 
leading to inflammation and impairment of neighboring cells. Since cell death in patients is generally painless and 
only few signs of inflammation could be detected in the optic nerve [Saadati et al. 1998], it is likely that 
apoptosis represents the predominant mode of cell death in LHON. This is also supported by detection of 
nuclear fragmentation of LHON cybrids in response to the oxidizing agent tBH [Ghelli et al. 2008]. In addition, 
LHON cybrids in glucose-deficient galactose media and thereby forced to rely on the mitochondrial electron 
chain as their primary energy source, experienced apoptotic death and increased cytochrome c release [Ghelli et 
al. 2003]. Thus, despite the general agreement that apoptosis is the most likely mode of cell death in LHON, 
proof that these in vitro model systems recapitulate the mechanism of cell death that occurs in vivo, is still 
lacking. 
2.1.3 Duchenne Muscular Dystrophy 
Duchenne muscular dystrophy (DMD) is a severe degenerative disease of both skeletal and cardiac muscle. 
Despite the characterization of one single gene responsible for the disease, its subsequent cellular and molecular 
pathological mechanisms are still not fully elucidated [McArdle et al. 1995, Zhou et al. 2006, Deconinck and Dan 
2007].  
Patients are diagnosed with DMD at the age of four to five years mainly on the basis of gait abnormalities 
[Boland et al. 1996]. Regarding skeletal muscles, the characteristic feature of DMD is a progressive proximal 
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muscular dystrophy and a pseudohypertrophy of the calves [Reimers et al. 1996]. The progression of fibrosis 
accompanied by muscle degeneration leads to wheelchair dependency at a median age of ten years. Smooth 
muscle impairments are detected in a portion of patients in the gastrointestinal tract [Barohn et al. 1988]. By the 
age of six, most patients display myocardial symptoms, which become progressively severe over the course of the 
disease. Eventually, death occurs due to respiratory or cardiac failure in the early twenties. The mutations within 
the affected gene arise either spontaneous in approximately 30% of the cases or are inherited in an X-linked 
recessive manner in the remaining cases which is why DMD is predominantly found in males with a prevalence 
of one in 3,500 births [Emery 1991].  
The defective protein dystrophin, causing both DMD and the allelic disease Becker muscular dystrophy 
(BDM), is encoded by the largest human gene which is located on chromosome Xp21. The 2.4 mega base pair 
gene contains 79 exons, leading—as a fully transcribed isoform—to a 14 kb mRNA. Several different promoters 
allow cell- and developmental stage-specific expression of seven different isoforms, which can be further 
diversified by alternative splicing of pre-messenger ribonucleic acid (mRNA) [Sadoulet-Puccio and Kunkel 
1996]. Dystrophin binds to both actin and a membrane-spanning complex called dystrophin-associated 
glycoprotein complex which in turn is connected to laminin [Suzuki et al. 1992, Ehmsen et al. 2002]. Thus, full-
length dystrophin in muscle cells links the sacrolemmal cytoskeleton to the extracellular matrix. Knowing this 
central role of dystrophin, it is not surprising that its loss has severe clinical consequences. Although the disorder 
can be linked to a single gene, the emphasis and chronology of the molecular consequences—such as increased 
levels of intracellular calcium (Ca2+) and oxidative stress—is controversially debated [McArdle et al. 1994, 
Whitehead et al. 2006]. Furthermore, it was reported that cellular deficiency in dystrophin leads to altered 
expression of about 1,000 genes [Chen et al. 2000]. These alterations were not only detectable in the expression 
of genes closely interacting with dystrophin, but also of genes involved in a variety of processes such as 
proteolysis, muscular regeneration, and immune response. 
To delineate which of those changes are crucially responsible for the pathology observed in patients, research 
is conducted in an animal model bearing a spontaneous mutation of dystrophin. However, the so-called mdx 
mouse, deficient of functional dystrophin [Bulfield et al. 1984], shows a significantly milder phenotype than 
human patients [Peri et al. 1994]. Nevertheless, mdx mice show disruption of sacrolemmal integrity and muscle 
cell necrosis. These findings were affirmed by the detection of high plasma levels of creatine kinase and pyruvate 
kinase as a consequence of muscle cell death [Bulfield et al. 1984] which is associated with intracellular 
accumulation of serum markers like albumin. This was also used to experimentally detect muscle damage, using 
cellular uptake of low molecular weight diazo dyes such as Evans blue as a diagnostic tool [Straub et al. 1997, 
McArdle et al. 1994]. The specific vulnerability of membrane integrity in dystrophin-deficient muscle cells was 
assumed to be correlated with the magnitude of mechanical stress applied to the membrane during muscle 
contraction in the absence of functioning dystrophin protein [Petrof et al. 1993, Straub et al. 1997]. However, a 
lack of uptake of another diazo dye, procion orange, in young and pre-necrotic mdx animals [McArdle et al. 
1994] would suggest that membrane fragility is rather a consequence of the advanced pathology and not one of its 
eliciting features. Nevertheless, loss of membrane integrity could be a catalyst in the progression of the disease, 
for example by impairing the homeostasis of intracellular calcium (Ca2+) levels. Elevated levels of intracellular 
Ca2+ have been reported in DMD patients and mdx mice [Fong et al. 1991, Turner et al. 1991]. The aberrant Ca2+ 
homeostasis in dystrophic muscle—i.e. the inability to maintain a low intracellular Ca2+ level at rest and a 
prolonged elevation of Ca2+ concentration during stimulation—results in activation of proteases, such as calpain, 
and thus, enhanced protein degradation [Turner et al. 1988] and increased production of reactive oxygen species 
(ROS), which can cause protein and membrane damage [see 2.3.1]. A connection between DMD and oxidative 
stress was first hypothesized due to the similarities of DMD and muscle pathology provoked by deficiency of the 
antioxidant vitamin E [Binder et al. 1965]. Despite decades of research, the question whether oxidative stress is a 
necessary precondition for dystrophic cell death or just a parenthetic consequence of the pathology still remains 
unclear [Tidball and Wehlings-Hendrick 2007]. However, substantial evidence stronlgy suggests a pivotal role of 
oxidative damage in DMD: (i) Kar et al. [1979] detected byproducts of free radical damage to unsaturated fatty 
acids, (ii) Hunter and Mohamed [1986] reported elevated products of lipid peroxidation in DMD muscle cells, 
and (iii) two independent groups found enhanced levels of enzymes engaged in the cellular response to oxidative 
stress in both pre-necrotic and affected muscle in mdx mice [Ragusa et al. 1997, Disatnik et al. 1998]. For 
example, levels of the antioxidant enzymes catalase, superoxide dismutase (SOD), and glutathione peroxidase 
(GPX) [see 2.3.1] are increased in both human DMD patients and mdx mice. Furthermore, (iv) Touboul et al. 
[2005] concluded that the sarcolemma might be under oxidative stress based on the observation that the 
concentrations of the antioxidants vitamin E and coenzyme Q10 (CoQ10) are elevated within the membranes of 
DMD patients. In addition, Rando et al. [1998] discovered a specific susceptibility of dystrophin-deficient cells to 
exogenously induced oxidative stress in vitro; whereas non-oxidant metabolic stressors were equally harmful to 
both mdx and control muscle cells. Whilst the question about the chronological position of oxidative stress in the 
pathology of DMD still remains unanswered, these experiments all taken together suggest that muscle 
degeneration and oxidative stress are closely connected. 
Among the compartments most vulnerable to ROS-induced damage are mitochondria. Interestingly, 
mitochondria are also a major source of ROS. Especially under conditions where mitochondrial function is 
impaired, they generate high levels of ROS which are hazardous by damaging macromolecules and can ultimately 
lead to necrosis. Additionally, owing to its role as important Ca2+ storage organelle, mitochondria are linked to 
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DMD pathology via Ca2+ overload. Dystrophic muscle cells seem to counteract increased intracellular Ca2+ 
concentrations by mitochondrial uptake of Ca2+ [Chen et al. 2000]. There is evidence that Ca2+ imbalance 
impairs the mitochondrial function, especially its metabolic processes [Brini 2003, Kinnally et al. 2011]. 
Consistent with this hypothesis, Chen et al. [2000] reported that approximately one third of all down-regulated 
genes in muscle biopsies of DMD patients coded for enzymes involved in energy production and mitochondrial 
activity. One of the first describing impaired oxidative phosphorylation as a feature of DMD was the report by 
Scholte et al. [1985]. Later, using 31P magnetic resonance spectroscopy, increased adenosine diphosphate (ADP) 
and inorganic phosphate (Pi) levels relative to adenosine triphosphate (ATP) and reduced phosphocreatine levels 
were found in muscle of DMD patients [Kemp et al. 1993]. Sperl et al. [1997] also reported decreased oxidation 
rates in muscle biopsies from DMD patients and some indication of loose coupling of oxidative phosphorylation 
in mitochondria from those patients. These findings were also supported by Kuznetsov et al. [1998] who 
detected reduced rates of respiration and lower activities of enzymes of the mitochondrial respiratory chain in 
biopsy samples of a DMD patient. Furthermore, several studies demonstrated decreased mitochondrial activity in 
dystrophic humans and mdx animals [Barbiroli et al. 1992, Gannoun-Zaki et al. 1995, and Kuznetsov et al. 1998]. 
Analysis of skeletal mdx muscle showed a 50% decrease in the activity of all respiratory chain-linked enzymes 
compared to control animals [Kuznetsov et al. 1998]. The authors also reported that isolated mitochondria from 
mdx muscles had only 60% of maximal respiration rates compared to control and attributed this impairment to a 
Ca2+ overload of dystrophin-deficient muscle fibers. Interestingly, this study identified no deficiencies in the 
cardiac muscle. Contrary to that, Braun et al. [2001] reported that irrespective of muscle type, the absence of 
dystrophin had no effect on the maximal capacity of oxidative phosphorylation, or on coupling between 
oxidation and phosphorylation. However, in the myocardium and m. soleus, the coupling of mitochondrial 
creatine kinase to adenine nucleotide translocase was attenuated as evidenced by the decreased effect of creatine 
on the Km for ADP in the reactions of oxidative phosphorylation.  
In conclusion, despite the documented loss of function of one single gene, coherent knowledge of the origin of 
biochemical and cellular consequences is still not consolidated. Nevertheless, there is certainty that absent or 
defective dystrophin protein leads to reduced mechanical stability and increased leakiness of the sarcolemma and 
elevated intracellular Ca2+ levels. The pathology also includes increased oxidative damage and impaired 
mitochondrial function. Therefore, DMD is a good example for a mitochondrial phenotype in a disorder which is 
not primarily a mitochondrial disease. 
2.2 Mitochondria and Energy-Generating Systems 
As stated in the previous subchapter [2.1], mitochondrial dysfunction was reported in three diseases with 
differing underlying causes, showing mitochondrial involvement in a broad range of disorders. In contrast to 
DMD, wherein impairment of mitochondria occurs indirectly, the affected genes in MELAS and LHON code for 
proteins directly involved in mitochondrial function. Furthermore, mitochondrial dysfunction has not only been 
reported in diseases directly associated with mitochondria, but also in a variety of disorders cauzed by nuclearly 
encoded genes [Smeitink et al. 2000] and in degenerative diseases such as Parkinson’s or Alzheimer’s disease and 
even in cancers and ageing [Wallace 1999, Schon 2000, and Moreira and Oliveira 2010].  
In the light of the fact that malfunctions of this organelle are a feature in such a broad range of disorders, a 
closer look on its cellular role seems appropriate. Mitochondria can be found in eukaryotic cells and are the main 
site of cellular energy production. Current discussion favors an endo-symbiont theory of mitochondrial origin: 
this theory states that mitochondria evolved from bacterial ancestors which were integrated into eukaryotic cells 
[Gross 2011]. A mitochondrion is composed of two phospholipid bilayer membranes of which the outer 
membrane separates the organelle from the cytoplasm. An inner membrane encloses the matrix which contains 
ribosomes and mitochondrial DNA (mtDNA) [Diaz and Moraez 2007]. Additionally, the matrix and the inner 
membrane shelter enzymes and enzyme complexes of the mitochondrial energy machinery [Campbell and Reece 
2005]. Even though the main function of mitochondria is their role in cellular energy production, two additional 
prominent functions are necessary to keep in mind. First, mitochondria play a central role in the orchestrated cell 
death called apoptosis [Brunelle and Letai 2009]. And second, mitochondria are large intracellular repository for 
calcium ions which are crucial in muscle contraction or function as second messenger [Brini 2003].  
In contrast to observations in dead cells or illustrations in textbook pictures, mitochondria of living cells are 
not static rod-shaped cylinders, but dynamic, steadily transforming compartments. In the last decades, constant 
remodeling processes in mitochondria have been discovered and suggested to be involved in mitochondrial and 
cellular health [Diaz and Moraes 2007, Suen et al. 2008, and Twig et al. 2008]. Mitochondria can either undergo 
fusion, i.e. the merging of two individual organelles, or fission which describes the separation of one organelle in 
two successors. Fusion facilitates the exchange of metabolites, whereas malfunctional parts of the mitochondria 
can be isolated during fission and degraded by a process called mitophagy [Twig et al. 2008]. In case of the 
orchestrated cell death called apoptosis, alleviation of mitophagy by increased fission was observed and reviewed 
by Suen et al. [2008].  
The number or—more precisely—the total mass of mitochondria in a cell is dependent of its metabolic 
activity. For example, muscle fibers can be divided according to their latency towards fatigue: type I and IIa 
fibers tire slowly and are used for prolonged activity dependent on endurance. They contain a high quantity of 
mitochondria and rely on oxidative phosphorylation. In contrast, type IIb and IIc fibers have an intermediate or 
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low number of mitochondria, respectively, and use glycolysis as their main source of energy. Therefore, they are 
quicker to perform, but—as a consequence—quicker to fatigue.  
However, the following subchapters will outline energy production by non-mitochondrial and mitochondrial 
means and their implications.  
2.2.1 Glycolysis Produces ATP Independent of Mitochondria 
From a physical point of view, energy is never destroyed nor created, but converted from one sort into 
another. From the subjective point of view of a creature, however, energy is constantly used up by its activities. 
Therefore, mammals need to gain energy from food for (i) fueling the processes needed to maintain pivotal 
functions and (ii) producing heat. The energy of food molecules, such as glucose or fatty acids, is stored in their 
chemical bonds and can be released upon breakdown. Cells dispose diverse methods to store the thus gained 
energy, one being the generation of molecules containing energy-rich bonds. The most prominent thereof is ATP 
which stores the energy in the covalent bond between its second and third phosphate group. Hydrolysis of this 
bond yields ADP, Pi and disposable energy which is used by a myriad of enzymes to run energy-consuming 
reactions.  
To sustain cellular functions, the production of this main energy currency, ATP, is fundamental. ATP is 
primarily produced during breakdown of food molecules such as sugars, amino acids and fats and by oxidative 
phosphorylation (OXPHOS) which takes place in the mitochondria and is basically one of its main functions [see 
2.2.2]. OXPHOS—being an additional step to primary decomposition of food particles—increases the amount of 
energy gained from nutrition particles. The primary degradation of different types of food molecules is separated 
into distinct and elaborate pathways. Fatty acids, for example, are disassembled within peroxisomes and 
mitochondria in a process called β-oxidation [see 2.2.3]. Since glucose and other sugars are the most prominent 
source of energy in human diet, the breakdown of sugars, called glycolysis, takes an important place in cellular 
metabolism. 
Glycolysis describes the enzyme-driven breakdown of glucose into pyruvate. During this elaborate process 
involving ten enzymes, two molecules of ATP per glucose molecule are produced [Alberts et al. 2000]. In 
addition, each two molecules of nicotinamide adenine dinucleotide (NADH) and pyruvate result from this 
cytosolic pathway. Both NADH and pyruvate can be further processed to gain more ATP during OXPHOS [see 
2.2.3]. Despite the rather low yield of ATP, glycolysis produces sufficient energy for some human cells to survive. 
For example, cancer cells—even in the presence of sufficient amount of oxygen—predominantly rely on 
glycolysis as source of energy, neglecting OXPHOS, a process called Warburg effect or aerobic glycolysis 
[Mathupala et al. 2010]. Thus, glycolytic activity can be seen (i) under hypoxic conditions where mitochondria 
do not contribute to energy production (anerobic glycolysis), (ii) under normoxic conditions where only 5% of 
glycolytically produced pyruvate is conveyed to mitochondria (aerobic glycolysis), or (iii) under normoxic 
conditions where all pyruvate is degraded in mitochondria (OXPHOS) [Vander Heiden et al. 2009 and Figure 1]. 
 
 
Figure 1: Schematic Representation of ATP Production by Anaerobic and Aerobic Glycolysis and Oxidative 
Phosphorylation.  
The energy stored in glucose can be retrieved to produce ATP. After the production of pyruvate by the break-down of glucose by glycolysis, 
pyruvate can either enter the electron transport chain (ETC) of the mitochondria or be converted into lactate. This conversion results in the 
production of NAD+ which is used to maintain glycolysis. In anaerobic glycolysis, mitochondria are not used and pyruvate is converted into 
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lactate. Under these conditions, two molecules of ATP are produced per molecule of glucose. In aerobic glycolysis (which is also known as 
the Warburg effect), mitochondrial energy production is barely active despite normoxic conditions. Instead, the majority of pyruvate is 
converted to lactate and only a small fraction (~5%) of pyruvate enters the ETC. The marginal usage of mitochondria increases the amount 
of ATP produced from glucose compared to anaerobic glycolysis (~4 mol ATP/mol glucose). If oxygen is available and pyruvate is entirely 
transported into the ETC, ATP production relies mainly on oxidative phosphorylation (OXPHOS) with a substantially higher efficacy (36 
mol ATP/mol glucose) [ATP yields are denoted according to Vander Heiden et al. 2009]. 
 
During glycolysis, NAD+ is reduced to NADH. Under normal conditions, NADH is used to fuel OXPHOS 
which thereby regenerates the NAD+ pool [see 2.2.2]. Thus, this cycling does not only link glycolysis and 
OXPHOS, but also allows constant turnover of glucose by maintaining a sufficient amount of NAD+. Under 
conditions of suppressed OXPHOS—for example in anaerobic cells or cells with defective mitochondria—the 
recycling of NAD+ has to be guaranteed differently. Generation of NAD+ by other means in order to maintain 
glycolysis and ATP production is all the more important in these cases, since such cells primarily rely on 
glycolysis as a source of energy. Mainly, this reaction is carried out by a process called lactic acid fermentation in 
which pyruvate is converted into lactate [Campbell and Reece 2005]. 
Hence, lactate is a waste product of anaerobic glycolysis. In some physiological processes, for example in 
glycolytic muscle cells, lactate production is used to support the generation of the required high ATP levels. 
Glycolytic muscle fibers—i.e. type IIb and IIc fibers—contain few mitochondria and are characterized by fast 
contractions. These contractions are conducted by a short, massive consumption of energy which is generated by 
glycolysis. After contraction, the cells require a long recovery time. In this type of muscle cells, lactic 
fermentation is used to restore NAD+ levels [Robergs et al. 2004]. The thereby generated lactate is released from 
the muscle and can be recycled to glucose in the liver under the expense of six molecules of ATP. This 
sumptuous process, called Cori cycle, provides glycolytic muscle cells with new glucose [Waterhouse and 
Keilson 1969]. Nonetheless, this remedy is only favorable for a limited time when glycolytic muscle cells demand 
a large quantity of available sugar. Since the net yield of energy is negative for the whole body, it is not propitious 
for the Cori cycle to be maintained over an extended period of time.  
A cell solely relying on glycolysis for ATP production faces further problems. Since the protons generated by 
hydrolysis of ATP (i.e. the breakdown of ATP to release the energy stored within its phosphoester bond) cannot 
be buffered by glycolytic cells [Hochachka and Mommsen 1983], the pH within the cell and also the blood 
decreases. Because this acidosis is accompanied by the release of lactate into the blood—two independent 
incidents caused by the same process—the clinical symptoms have been subsumed in the term lactic acidosis. It 
is important to emphasize that lactate, and not lactic acid is produced by fermentation and while the rise of 
lactate in the blood coincides with, it does not cause acidosis [Robergs et al. 2004, Lindinger et al. 2005]. 
However, the simultaneous appearance of lactate and protons in the blood makes lactate a good marker for 
acidosis provoked by anaerobic glycolysis. 
Lactic acidosis is most prominently known to occur during exercise. There, glycolytic muscle cells work under 
anaerobic, hypoxic conditions and use glycolysis as sole mechanism of ATP production. As a result, blood lactate 
levels increase, whereas blood pH decreases simultaneously and the examinator experiences muscle soreness. 
However unpleasant this feeling might be perceived, the effect is reversible. In contrast, in some pathological 
settings, hypoxic conditions are constantly mimicked by impairment of mitochondrial function and therefore, 
glycolysis remains the sole source of energy. In MELAS for example, lactic acidosis is such a prominent feature 
that it even appears in the name of the disease. Although elevated lactate levels in blood and cerebrospinal fluid 
are a hallmark of most mitochondrial diseases [Sproule and Kaufmann 2008], they have been most extensively 
described for MELAS patients by many different groups [among others van Hellenberg Hubar et al. 1991, 
Malfatti et al. 2007, Fornuskova et al. 2008, and Tam et al. 2008]. The accumulation of lactate in the ventricles 
was explained by Davidson et al. [2009] as a result of severe energy failure caused by deficient mitochondria and 
stroke-like episodes-induced hypoxia. Kaufmann et al. [2004] reported a correlation between lactate levels in the 
cerebrospinal fluid with the severity of clinical symptoms. Similar findings have been reported in vitro where 
excess lactate in the supernatant coincided with impaired mitochondrial membrane potential [McKenzie et al. 
2007].  
Hence, mitochondrial dysfunction leads to a switch in energy production, i.e. focusing on glycolysis, which 
causes cellular and systemic impairments. To better understand the importance of mitochondria in cellular 
metabolism, it is necessary to look at OXPHOS more closely.  
2.2.2 Electron Transport Chain and Oxidative Phosphorylation 
In mitochondria, the products of anaerobic glycolysis and other metabolic pathways can be further processed 
to increase the energetic yield from the organic starting material. In a first step, electrons obtained in the 
breakdown of organic molecules are donated to a final acceptor, oxygen, in a chemical reaction type called redox 
reaction. Redox reactions describe the transfer of a single electron from one molecule to another. The reducing 
agent donates an electron to and thereby reduces the oxidant whilst being oxidized itself [Riedel 2002]. The 
electron transfer from orgnic molecule to oxygen, however, is not performed in one single step but separated in 
many minor redox reactions. The energy released therein is used to transport protons across the inner 
mitochondrial membrane into the intermembrane space and during this process, an electrochemical gradient is 
generated.  By re-entering the matrix through the F1Fo ATP synthase, the protons change the conformation of 
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this rotor-shaped protein complex, thereby catalyzing the generation of ATP [Campbell and Reece 2005 and 
Figure 2].  
 
 
Figure 2: Schematic Representation of Mitochondrial Respiration.  
Glucose is degraded in the cytoplasm into pyruvate via glycolysis. Pyruvate is transported into the mitochondria where it is converted into 
acyl-CoA which then enters the tricarboxylic cycle (TCA) to produce NADH and succinate as intermediates. The latter is oxidized by 
complex II (C II), a component of the TCA. NADH produced by glycolysis and shuttled into the mitochondria or by TCA is oxidized by 
complex I (C I), thereby transferring electrons onto the lipophilic carrier CoQ10 (Q). Subsequently, Q donates the electrons to cytochrome c 
(cyt c) via complex III (C III). Electrons from reduced cyt c are then transfered to molecular oxygen via complex IV (C IV) to form water. 
During redox reactions of complexes I, III, and IV, protons (H+) are transported from the matrix to the intermembrane space. The force of 
this proton gradient is then used by the ATP to produce adenosine triphosphate (ATP). 
 
The reactions for ATP production mainly take place in the inner membrane and the matrix. The 
intermembrane space is used as a repository of protons which are pumped in there from the matrix during 
OXPHOS. The inner membrane is extensively folded to increase the total surface area, since the complex 
apparatus of the respiratory chain is mainly located in and adjacent to the inner membrane. The matrix finally 
holds enzymes, substrates and intermediates of the tricarboxylic acid cycle which provides the machinery and 
fuel for OXPHOS as will be explained in detail below. 
OXPHOS consists of two coupled entities: first, the electron transport chain (ETC), where the passage of 
high-energy electrons to oxygen generates a proton gradient, and the secondary synthesis of ATP, driven by this 
gradient. To elucidate the system more closely, the fate of the products of glycolysis, pyruvate and NADH, is 
described in more detail. 
Since the inner mitochondrial membrane is impermeable for NADH, cytoplasmic NADH from glycolysis is 
transported into the mitochondria using special shuttle systems. One of them, the malate-aspartate shuttle 
employs malate dehydrogenase and aspartate aminotransferase on both sides of the inner membrane, as well as 
two amino acid antiporters located within the inner membrane. Malate dehydrogenase catalyzes the delivery of 
the electrons of NADH from the inter membrane space onto oxaloacetate. The thereby generated malonate is 
then transported into the matrix by an antiporter, where it is oxidized back to oxaloacetate by malate 
dehydrogenase, giving rise to NADH. The shuttle is completed by an orchestrated interplay of transformations 
and transports of different amino acids including aspartate, glutamate and α-ketoglutarate [Washizu 2010 and 
Figure 3A].  
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Figure 3: Two Different Shuttle Systems Transport Electron Equivalents from NADH into the Mitochondria.  
Since mitochondrial membranes are impermeable for NADH, the energy-rich electron equivalents are transported into the mitochondria via 
different pathways. (A) The malate-aspartate shuttle employs the NADH-dependent reduction of oxaloacetate by malate dehydrogenase in 
the intermembrane space. Malate is then transported into the matrix where it is re-oxidized to oxaloacetate, thereby oxidizing matrix-based 
NAD+. An elegant system of an aminotransferase and antiporters keep energy costs for the transport of malate across the inner membrane 
low. The route of electrons transported from cytosolic to mitochondrial NADH is depicted in bold black arrows. (B) A more direct pathway 
for transporting electron equivalents into the mitochondria is accomplished by the glycerol-3-phosphate (G3P) shuttle. Cytosolic G3P 
dehydrogenase (cyto G3PDH) couples the reduction of dihydroxyacetone (DHAP) to the oxidation of NADH. The thereby generated G3P is 
oxidized back to DHAP by a mitochondrial G3PDH (mito G3PDH) located in the inner membrane. The electrons from G3P are then 
transferred onto CoQ10 via a prothetic flavin adenine dinucleotide (FAD).  
 
Complex I 
When in the matrix, NADH transfers its electrons into the ETC. The entry site for these electrons is located 
on an impressive enzymatic complex consisting of 46 subunits; called complex I (EC 1.6.5.3). The subunits for 
complex I are encoded both in the mitochondrial and nuclear genome [for complex I-related mutations of the 
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mitochondrial DNA see also 2.1.1 and 2.1.2]. Complex I has an L-shape with one arm—containing one flavin 
mononucleotide (FMN) and eight iron-sulfur (FeS) clusters as pivotal prosthetic groups —inclining into the 
matrix [Brandt et al. 2003]. NADH delivers its electrons to the FMN site from where they are passed via the FeS 
clusters to the mobile electron carrier CoQ10. During the electron transport throughout complex I, four protons 
are added to the proton gradient. Ohnishi and Salerno [2005] proposed a mechanism, in which two protons are 
pumped across the membrane and two more are removed from the matrix by binding to CoQ10. They agree with 
Brandt et al. [2003] which linked the proton pumping to conformational energy transfer and not to a separate, 
direct proton pump. The two electrons bound to H2-CoQ10 are passed onto complex III further downstream of 
the ETC. 
Complex III 
Complex III (EC 1.10.2.2) is a multi-subunit, membrane-spanning protein complex that catalyzes the transfer 
of electrons from H2-CoQ10 to cytochrome c and further adds to the proton gradient. Re-oxidation of CoQ10 
enables the redox cycle conducted by this mobile electron carrier between complexes I and III. The electrons are 
passed onto cytochrome c which constitutes the second mobile electron carrier of the ETC. During this process, 
four protons are released into the intermembrane space and two electrons are dislodged from the matrix 
[Campbell and Reece 2005].  
Complex IV 
The final step of the ETC occurs in complex IV (EC 1.9.3.1) is a multi-subunit, transmembrane enzyme 
complex which catalyzes the reduction of molecular oxygen to water. For this reaction, four molecules of 
reduced cytochrome c and four protons from the matrix are used to reduce one molecule of O2. Thus, complex 
IV fulfills the redox cycle for cytochrome c by re-oxidation and, in addition, pumps four protons from the 
matrix into the intermembrane space, further enhancing the proton gradient [Campbell and Reece 2005].  
F1Fo ATP synthase 
In the course of the ETC, electrons are passed from molecules with low electronegativity to such with high 
electronegativity. This transfer is energetically favorable and is coupled to the production of a proton gradient. In 
a subsequent step of ETC, this gradient is used to drive the synthesis of ATP. Therein, by allowing protons to re-
enter the matrix, F1Fo ATP synthase (EC 3.6.3.14) undergoes conformational changes that bring ADP and 
inorganic phosphate closely together, facilitating the production of ATP [Campbell and Reece 2005]. The ATP 
synthase is sometimes also referred to as complex IV. 
Finally, one molecule of NADH oxidized at complex I results in the generation of 2.5 molecules of ATP at the 
F1Fo ATP synthase [Campbell and Reece 2005]. Hence, alone from this source, OXPHOS enhances ATP yield 
from one molecule of glucose—which is degraded into two molecules of NADH during glycolysis—to seven 
molecules of ATP instead of only two in anaerobic glycolysis. However, the second product of anaerobic 
glycolysis, pyruvate, is not included in this calculation. 
Complex II 
Pyruvate enters the mitochondrial matrix via the pyruvate dehydrogenase complex which transforms pyruvate 
into acetyl-coenzyme A (CoA) and leaves NADH and carbon dioxide (CO2) as side products. Acetyl-CoA then 
enters the tricarboxylic acid cycle (TCA) which is also called citric acid cycle or Krebs cycle. This cycle, 
consisting of eight enzymes or enzyme complexes and nine intermediates (one being succcinate), breaks acetyl-
CoA down to two molecules of CO2 and thereby generating three molecules of NADH and one molecule of 
guanosine triphosphate (GTP). Thus, out of one molecule of pyruvate, 7.5 molecules of ATP may be generated 
via the ETC. Furthermore, one enzyme of the TCA is the succinate:CoQ10 dehydrogenase (EC 1.3.5.1), also called 
complex II, which catalyzes the reduction of CoQ10. As its name suggests, complex II is a part of the ETC and—
next to complex I—a source for the entry of electrons. Again, the mobile electron carrier H2-CoQ10 can then 
transfer its electrons to complex III and, upon execution of the ETC and the F1Fo ATP synthase, 1.5 molecules of 
ATP are generated per molecule of pyruvate [Alberts 2002].  
Hence, under aerobic conditions, the breakdown of one molecule of glucose yields in theoretically 25 
molecules ATP and two molecules GTP. Other estimates suggest a production of 30 to 36 molecules of ATP 
[Vander Heiden et al. 2009]. Either way, this amount outshines the two molecules of ATP produced by 
anaerobic glycolysis many fold and thus, the energy production of mitochondria cannot be underestimated. 
Considering the excess of ATP produced by mitochondria, it is not surprising that their deficiency leads to major 
alterations in cellular metabolism as seen in patients with mitochondrial disorders and their overdrawn reliance 
on glycolysis [see Figure 1]. 
2.2.3 Other Relevant Electron Transport Systems 
The classic ETC described in the previous subchapter 2.2.2 consists of complexes I and II as the only entry site 
for electrons derived from the breakdown of organic molecules. There are, however, other electron transport 
systems involved in ATP production. NADH derived from glycolysis can enter the ETC directly via another 
dehydrogenase than complex I. Furthermore, other organic food molecules, for example fatty acids, are degraded 
to different products than glucose. 
In contrast to the malate-aspartate shuttle [see description in 2.2.2], the glycerol-3-phosphate (G3P) shuttle 
does not reconstitute NADH within the mitochondrial matrix, but delivers electrons directly into a branch of 
the electron transport chain [Figure 3B]. Specifically, cytosolic NADH is oxidized to NAD+ by the cytosolic 
enzyme G3P dehydrogenase (cG3PDH; EC 1.1.1.8), generating G3P by reduction of dihydroxyacetone phosphate 
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(DHAP) along the way. G3P can easily enter the intermembrane space and bind to the mitochondrial G3PDH 
(EC 1.1.5.3), where its electrons are transferred to CoQ10, thereby generating DHAP and reduced CoQ10 (H2-
CoQ10). DHAP is then shuttled back into the cytosol, thus closing the loop. When bound to H2-CoQ10, the 
electrons finally enter the classical ETC at the site of complex III and, in consequence, are able to generate 1.5 
molecules of ATP per molecule of NADH [Campbell and Reece 2005]. 
Fatty acids are an important and abundant source of dietary energy input – at least in modern western 
countries. Their breakdown within cells is separated in three steps [Figure 4]: first, fatty acids are activated—i.e. 
they are substituted with CoA—in the cytosol, whereupon they are secondly transported into the mitochondria 
where they are degraded in a third stage (branched or very long (≥ 20 carbons) fatty acid chains are first broken 
down into smaller ones in peroxisomes before activation). Cytosolic activation gives rise to acyl-CoA to the 
expense of one molecule ATP being twice hydrolyzed to adenosine monophosphate (AMP). Acyl-CoA then 
enters the mitochondrial matrix via the carnitine shuttle: carnitine is added to acyl-CoA to form acyl-carnitine by 
carnitine palmitoyl transferase I (CPT1; EC 2.3.1.21) located on the outer membrane. Acyl-carnitine is then 
transported into the matrix by the antiporter carnitine-acylcarnitine translocase spanning the inner membrane. 
CPT2 (EC 2.3.1.21) reverses the reaction of CPT1, thus giving rise to acyl-CoA in the matrix [Longo et al. 2006]. 
Acyl-CoA is then broken down into acetyl-CoA—the substrate for the TCA [see 2.2.2]—by a process called β-
oxidation [Figure 4]. Since fatty acids vary in their chain lengths and degree of saturation, the basic principle of 
the β-oxidation will be explained by means of a fully saturated fatty acid with an even-numbered chain (special 
enzymes and additional reactions deal with unsaturated or odd-numbered chain containing fatty acids). In 
general, four enzymes are responsible for the step-wise decomposition of the acyl chain from the thioester site. 
In this process, the carbon on the β-position of the chain is oxidized—hence the name—to form a keton which 
can be attacked by a nucleophile, such as CoA. This β-ketothiolase-mediated reaction (EC 2.3.1.16) results in one 
acetyl-CoA and one acyl-CoA. The latter is shorter by two carbons than it was before this cycle. This process is 
repeated until the chain of acyl-CoA consists of only two carbons (which essentially is acetyl-CoA). In addition 
to one molecule of the TCA substrate, acetyl-CoA, each cycle produces each one molecule of NADH and 
reduced flavin adenine dinucleotide (FADH2). Similarly to NADH, FADH2 can convert the energy gained by its 
oxidation—re-constituting its more stable, aromatic form—into the generation of a proton gradient via the ETC 
with a value of 1.5 molecules ATP [Campbell and Reece 2005]. 
Knowing the entry sites for NADH and acetyl-CoA into the ETC, the question arises where FADH2 may 
donate its high-energy electrons. Although FADH2 is used by complex II as a prosthetic group, free FADH2 
cannot bind to it. In contrast, FADH2 transfers its electrons to an electron-transferring-flavoprotein (ETF) which 
is thereupon oxidized by an ETF dehydrogenase (ETFDH; EC 1.5.5.1) [Figure 4]. ETFDH is a FeS cluster-
containing flavoprotein located in the inner mitochondrial membrane and acts as junction between fatty acid 
catabolism and OXPHOS [Frerman 1987]. It catalyzes the reduction of CoQ10 which then can donate the 
electrons to cytochrome c via complex III.  
Hence, ETFDH, as well as G3PDH, belongs to the ETC, even though they are not listed in its classic 
itemization. 
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Figure 4: Fatty Acid Metabolism and β-Oxidation.  
Fatty acids are activated, i.e. substituted with coenzyme A (CoA) to form acyl-CoA in the cytosol to the expence of ATP being doubly 
hydrolysed to AMP. Acyl-CoA is then transported into the mitochondrial matrix via carnitine palmitoyl transferase I and II (CPT1 and 
CPT2) where it is degraded by β-oxidation. During this process, the initial molecule of acyl-CoA is shortened by two carbons and enters β-
oxidation again. Furthermore, NADH, FADH2, and acetyl-CoA are generated which are used to produce ATP via mitochondrial respiration. 
The Acetyl-CoA enters the tricarboxylic acid cycle (TCA), whereas NADH and FADH2 donate electrons to the electron transport chain 
(ETC) via complex I or electron-transferring-flavoprotein dehydrogenase (ETFDH), respectively. The insertion shows structures of the 
intermediates in the β-oxidation. 
 
2.2.4 Janus-faced Mitochondria: The Rise of Reactive Oxygen Species during Respiration  
Persuading with an impressive yield of ATP, mitochondria advertise their function in cellular energy 
metabolism. As always, however, there are two sides to a coin: the very mechanism employed to produce the 
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highly needed, energy-bearing molecule ATP gives rise to hazardous toxins. Given a chance, electrons leak from 
their designated route of the ETC to spontaneously react with molecular oxygen and in turn, form reactive 
oxygen species (ROS).  
ROS unite different molecules possessing highly redox-active oxygen such as superoxide (O2
•—), hydroxyl 
radical (HO•—), and hydroperoxides (ROOH). Functionally, they are related to reactive nitrogen species (RNS) 
and other aggressive free radicals. They all possess at least one unpaired electron and therefore, imperatively 
request another electron. They can do so by purloining an electron from any unspecific, close-by molecule and 
thereby generating a new free radical in turn. This leads to a chain reaction in which macromolecules—
prevalently membrane lipids and proteins—are damaged. To counteract such a process of destruction—generally 
called oxidative stress—cells utilize a refined apparatus of detoxifying agents and enzymes [see 2.3.1].  
The generation of ROS occurs even during healthy, normal respiration [Murphy 2009]. However, due to the 
negligible amount and effective innate protection mechanisms, their free electrons are quickly captured. 
Nonetheless, mitochondria are the major source of ROS in cells with oxidoreductases such as complexes I and III 
responsible for their formation [Murphy 2009]. In contrary, to the save two-electron reductions carried out 
enzymatically by the complexes of the ETC, molecular oxygen (O2), a strong electron acceptor, spontaneously 
accommodates one electron at the time and thereby, it is reduced to superoxide. 
Murphy [2009] proposed three modes of mitochondrial ROS production [Figure 5]: Under normal conditions, 
he admitted the abundance of low levels of mitochondrial ROS but lacked an explanation for their formation 
[Figure 5A]. As second mode he suggested a combination of an ample ratio of NADH/NAD+ and low ATP 
demand that would lead to superoxide production at the FMN prosthetic group of complex I [Figure 5B]. 
Finally, a high proton-motive force—i.e. the increased mitochondrial membrane potential (∆Ψm) caused by the 
proton gradient—and a reduced CoQ10 pool would drive reverse electron transport (RET) and consequently 
ROS production [Figure 5C]. The previously described forward electron transport [see 2.2.2] transfers electrons 
from NADH to CoQ10; a process coupled to pumping protons across the inner membrane. A high ∆Ψm can 
invert this process if a suitable amount of electron donor in form of reduced CoQ10 is available. In that case, 
RET—driven by the reverse action of the proton pump—shuttles electrons from H2-CoQ10 back to NAD
+ until 
complete reduction of the latter. Whilst this process is not associated with ROS formation, Treberg and Brand 
[2011] proposed a model for radical production during RET after full reduction of the NADH pool: if the 
pressure from an elevated ∆Ψm still persists and a sufficient amount of H2-CoQ10 remains, electrons are 
transferred from a partially reduced CoQ10 within the binding pocket to O2. Superoxide generated by this means 
is believed to be the major source of mitochondrial ROS [Murphy 2009, Treberg and Brand 2011]. 
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Figure 5: Schematic Represenation of Different Modes for Mitochondrial ROS Production.  
Murphy [2009] proposed three modes of reactive oxygen species (ROS) production in mitochondria. (A) Under normal conditions, low 
levels of ROS are produced by mitochondrial complexes I and III (C I and C III) by yet undisclosed mechanisms. (B) An increased 
NADH/NAD+ ratio combined with a low demand for ATP production promote the direct transfer of electrons from NADH to molecular 
oxygen at the flavin mononucleotide, i.e. the NADH-binding site, of complex I. (C) In case of high proton (H+) gradient (∆Ψm) across the 
inner mitochondrial membrane and a reduced CoQ10 pool (QH2), electrons can be transferred from QH2 to molecular oxygen by reverse 
electron transport (RET) and thereby producing ROS. 
 
Another mode of complex I-dependent ROS formation is induced by some inhibitors of complex I at the site 
of the quinone-binding pocket [Degli Esposti et al. 1996b, Fato et al. 2009]. A well-known inhibitor falling in 
this category, rotenone, promotes the delivery of electrons to O2 in forward electron transfer [Treberg and Brand 
2011]. 
Complex III has also been frequently quoted to be a major source of mitochondrial ROS formation [Cadenas et 
al. 1977, Turrens et al. 1985]. Other mitochondrial oxidoreductases implicated in superoxide production are α-
ketoglutarate dehydrogenase (EC 1.2.4.2) [Starkov et al. 2004], G3PDH [Tretter et al. 2007], and ETFDH [St-
Pierre et al. 2002]; however, their portion in radical generation—including that of complex III—is negligible 
compared to RET-driven superoxide emission by complex I [Murphy 2009].  
Hence, complex I is—next to being the most important entry site for electrons into the ETC—potentially 
hazardous, since ROS induced by it may lead to devastating effects if protection mechanisms fail to suppress 
their propagation. 
2.3 The Importance of the Redox Environment 
Radicals were long considered to be detrimental to cells and organisms [Oliveira et al. 2010], but this picture 
altered within recent years granting them a more versatile role in cellular function than just the part of playing a 
detrimental agent [Schafer and Buettner 2001, Miura and Endo 2010]. Redox reactions, as well as compounds and 
pathways involved therein, are a prime example for the delicate, intricate and dynamic processes taking place in 
biological systems. Free radicals—harmful to cells when abundant above a certain threshold—are employed as 
messengers in signaling cascades. Changes in the redox environment can lead to altered conformations and thus 
functions of certain enzymes. These interactions are highly complex and important, but still far from understood. 
In biological systems, radicals arise in processes involving redox reactions. Unfortunately, compounds with 
unpaired electrons—the so-called free radicals—might be unintentionally generated during such reactions as 
described for ROS production by complex I [see  2.2.4]. Their high reactivity diminishes the selectivity against 
reactants and thus, the sophisticated balance of cellular interactions between macromolecules of all sorts can be 
disrupted. Hence, tight control over redox reactions, redox-active agents and free radicals—which are merged in 
the term redox state [Schafer and Buettner 2001]—are absolutely necessary for a cell’s function. 
2.3.1 Oxidative Stress 
An excess of free radicals—mostly ROS in biological systems—leads to hazardous alterations of 
macromolecules such as lipids and proteins by a process termed oxidative stress. Generally, chemical reactions—
even if they form energetically more stable products and are thus favorable—require energy to be started. 
Enzymes are employed to reduce this initial energy barrier and thus, the chemical reactions of a cell to produce 
the needed components are catalyzed by enzymes. In contrast, free radicals are very aggressive agents which do 
not depend on enzymatic activity to react with other molecules: their high reactivity leads to spontaneous 
reactions with any molecule in its vicinity.  
In the case of complex I-dependent ROS production during RET, superoxide is formed within the quinone-
binding pocket which has access to the inner membrane of the mitochondria. This membrane consists of 
phospholipids which are a susceptible to undergo redox reactions with superoxide in a process called lipid 
peroxidation [Figure 6]. The free radical catches an electron from a fatty acid chain of a phospholipid thereby 
generating a lipid radical. Addition of molecular oxygen forms a lipid peroxyl radical which steals an electron and 
a proton of a proximate fatty acid chain resulting in the production of a lipidperoxide and a new lipid radical 
which in turn continues this cycle [Gutteridge and Halliwell 1990]. Thus, the formation of lipidperoxides 
propagates throughout the membrane. 
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Figure 6: Schematic Representation of Lipid Peroxidation.  
Lipid peroxidation is initated by the reaction of unsaturated lipids with superoxide (O2
•—). Thereby, the unstable lipid peroxyl radical is 
formed which reacts with an adjacent unsaturated lipid. This results in the formation of two products: (i) the relatively stable lipid peroxide 
with a bulky peroxide group and (ii) a lipid radical. The latter can react with molecular oxygen to produce a new lipid peroxyl radical, which 
again reacts with another unsaturated lipid. Thus, the formation of lipid peroxides is propagated via a chain reaction. When lipid 
peroxidation occurs in phosholipid membranes, the bulky peroxide groups diminish membrane integrity. 
 
The composition of fatty acids determines the stability and fluidity of a membrane. Accordingly, addition of 
polar, bulky components like the peroxyl group alters the arrangement of fatty acids and undermines the proper 
function of the membrane. Due to the induced sterical hindrance, the permeability across the membrane is 
elevated and this can entail detrimental effects such as apoptosis. 
Hence, a cell is well advised to counteract radical propagation at an early stage. Therefore, several mechanisms 
for capturing radicals have evolved. Control of the cellular redox state combines a myriad of transcriptional, 
enzymatic and small molecule-mediated actions as will be explained. For the latter, certain redox couples are 
especially important, such as nicotinamide adenine dinucleotide (phosphate) (NAD(P)+/NAD(P)H) and 
glutathione (GSSG/2 GSH). Linked redox couples are compounds that can be interconverted by reduction or 
oxidation, respectively and they are responsible for the redox environment as by definition of Schafer and 
Buettner [2001] is the “summation of the products of the reduction potential and reducing capacity of the linked 
redox couples” which are found in a given biological compartment, be it an organelle, a cell or tissue. The 
reduction potential is determined by the likelihood of a given chemical species to be reduced and the reducing 
capacity characterizes the number of electrons available.  
A cell employs both enzymatic and small molecule-driven detoxifying of radicals. With cellular concentrations 
up to 10 mM, glutathione (L-γ-glutamyl-L-cysteinyl-glycine, GSH) represents the major agent for detoxifying 
oxidative species such as ROS and reactive nitrogen species (RNS) [Smith et al. 1996]. It consists of a tripeptide 
with a γ-bond between glutamate and cystein which is suggested to be resistant against degradations by enzymes 
responsible for protein breakdown [Sies 1999]. The redox-active moiety of GSH is its sulfhydryl group which is 
employed as a reducing agent. In most instances, oxidation of GSH gives rise to glutathione disulfide (GSSG) 
which is the homodimer of GSH. However, GSH can also interact with cystein residues of proteins via disulfide 
bonds (PSSG; whereas PSH denotes the protein (P) with the sulfhydryl group (SH) of the accordant cystein) 
[Schafer and Buettner 2001]. Glutathione S-transferases (GTS; EC 2.5.1.18) catalyze the addition of GSH to pro-
oxidant exogenous agents [Hayes et al. 2000], whereas glutathione peroxidase (EC 1.11.1.9) promotes the 
reaction of hydrogen peroxide to water [Park et al. 2011]. Depletion of GSH was shown to be fatal to cells under 
increased oxidative insults revealing its importance in oxidative protection [Sortino et al. 1999]. GSSG is recycled 
to GSH by the enzyme GSH reductase (EC 1.8.1.7) utilizing NADPH gained from the pentose phosphate 
pathway (PPP) which will be described below [2.3.2]. 
Other redox-reactive, antioxidant compounds are CoQ10 and vitamin E; the latter being a collective name 
summarizing structurally similar agents, i.e. tocopherols and tocotrienols. Both molecules are highly hydrophobic 
and are thus well suitable for preventing the radical propagation across membranes. Vitamin E and/or CoQ10 
supplementation has shown to be beneficial both in vivo and in vitro [Serbinova et al. 1991, Shargorodsky et al. 
2010, and Kalayci et al. 2011]. However, some argue that antioxidants, being redox-reactive, bear the risk of 
turning into pro-oxidants [Linnane et al. 2007, Lam et al. 2010]. In fact, knowledge on the properties of this class 
of compounds needs to be deepened.  
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Next to these small molecule-dependent defense mechanisms, cells also enact several enzymatic strategies to 
detoxify free radicals. The elimination of superoxide, a very aggressive radical agent, is carried out by a class of 
enzymes called superoxide dismutases (SOD; EC 1.15.1.1) which convert superoxide into molecular oxygen and 
hydrogen peroxide. Even though the latter remains a potential threat to cells, it is far less reactive than 
superoxide. Two sorts of SOD are found in cells: the zinc (Zn)-containing enzyme (ZnSOD) within the cytosol 
and the manganese-containing SDO (MnSOD) specifically found in mitochondria [Weisiger and Fridovich 1972]. 
That mitochondria employ their own form of SOD confirmed the importance of antioxidant protection of this 
compartment [Murphy 2009]. In mice lacking mitochondrial SOD, several detrimental pathological symptoms, 
which result in early neonatal death, have been described [Melov et al. 1998]. The hydrogen peroxide produced 
by SOD can be further detoxified to water by the enzyme catalase [Chelikani et al. 2004].  
High levels of oxidative stress also trigger transcriptional changes which are also induced by exogenous 
toxicants. Transcription factors bind to so-called promoter regions on DNA strands and initiate or repress the 
transcription of genes encoded within the successive DNA sequence. A major role in the response to ROS is 
played by the nuclear factor (erythroid-derived 2)-like 2 (Nrf2). Under physiological conditions, Nrf2 is located in 
the cytosol and readily degraded; a process which is interrupted by high levels of ROS [see 2.3.2]. Then, however, 
Nrf2 enters the nucleus where it binds to DNA regions which contain an antioxidant response element (ARE) 
[Jaiswal 2000]. These can be found in promoters of genes that are involved in the detoxification of ROS. Hence, 
Nrf2 promotes the transcription of antioxidant enzymes and redox regulators such as GSH-related enzymes (for 
example GSH reductase and GSTs) and NAD(P)H:quinone oxidoreductase (NQO1; EC 1.6.5.2) [Klaassen and 
Reisman 2010, Sykiotis and Bohmann 2011]. NQO1 is a cytosolic enzyme which is engaged in detoxifying 
exogenous compounds. Some detoxifying enzymes such as NADPH:cytochrome p450 reductase (EC 1.6.2.4)  
hold the disadvantage of employing a one-electron reduction of hazardous agents which might paradoxically 
result in the production of radicals. In contrast, NQO1 catalyzes a complete, two-electron reduction [O’Brien 
1991, Monks et al. 1992]. Experiments in nrf2-mutant mice provided data for the importance of Nrf2 for inducing 
detoxifying enzymes, since disruption of the gene prevented the expression of GTS and NQO1 after treatment 
with a pro-oxidant [Itoh et al. 1997]. 
All the described strategies help to protect cells from oxidative damage. However, when these defensive 
mechanisms fail to reduce the toxic threat, cells might die due to disintegration of membranes and dysfunction 
of enzymes. Next to the aforementioned deficiencies of glutathione or SOD, it has been shown that increased 
levels of pro-oxidants can overcharge cellular response mechanisms [Cardoso et al. 1998, Mordente et al. 1998]. 
2.3.2 Redox Environment and ROS Signaling 
Nonetheless, the reputation of ROS has changed from being exclusively detrimental for they are now regarded 
as more versatile agents [Miura and Endo 2010]. In fact, ROS and redox reactions are fundamental for cells and 
cover a broad range of cellular processes. Indeed, the redox environment defines the fate of a cell to a great 
extend and seem to reflect or force states such as proliferation, differentiation and even death [Schafer and 
Buettner 2001]. 
The important role of redox reactions and environments can be appreciated by their prominent appearance. 
For example, different cellular compartments possess specific redox environments: whereas the cytosol holds 
reduced conditions, the functioning of some organelles such as lysosomes require on rather oxidative 
composition [Alberts et al. 2000]. Furthermore, breakdown of food molecules and energy production heavily 
rely on redox reactions and redox reactive agents such as NADH, CoQ10 and prosthetic groups like FeS clusters 
[see 2.2]. 
Two related and pivotal redox couples are NADH and NADPH. Both—in addition to directly affect a cell’s 
redox environment—are important co-factors in many enzymatic processes. Despite their chemical similarity—
NADH and NADPH vary only in that NADPH bears a phosphate group, whereas NADH does not—their 
cellular functions cover fields that are quite diverse. NADH, as discussed before, is used as a carrier of high-
energy electrons from glycolytic metabolism to OXPHOS. NADPH, in contrast, is employed as reducing agent in 
anabolic reactions such as fatty acid synthesis and in the restoration of GSH.  
NADPH is mainly produced by reduction of NADP+ during the oxidative phase of the pentose phosphate 
pathway (PPP), an alternative pathway to glycolysis for the breakdown of glucose [Kruger and Schaewen 2003]. 
Nonetheless, PPP is rather an anabolic pathway, since not only NADPH, but also the other products, ribose-5-
phosphate and erythrose-4-phosphate, are used in the synthesis of nucleotides and aromatic amino acids, 
respectively. The ratio of NADH/NADPH therefore represents the metabolic state of a cell [Ying 2008]. 
Furthermore—in accordance to its role of catabolism—the ratio of the redox couple NAD+/NADH is regarded 
as a sensor of the cell’s energy status [Lin et al. 2004] and as such also employed in the measures against limited 
food supply. When there is abundant food and thus, glucose, NADH is produced on the expense of NAD+ and 
the ratio drops. However, lack of glucose shifts this equilibrium towards NAD+ and increases the ratio. Hence, it 
is not surprising that NAD+ is a substrate for sirtuins [Lin et al. 2004]. Sirtuins promote transcription of certain 
genes by deacetylating DNA strands. Acetylated DNA tends to be inaccessible for transcription factors and 
enzymes. Basically, sirtuins respond to decreased glycolytic activity by activating alternative pathways of energy 
production that may differ from tissue to tissue. In the liver, sirtuins stimulate gluconeogenesis. In white adipose 
tissue, sirtuins trigger the release of fatty acids into the blood stream. And filnally, in muscle cells, sirtuins 
promote the expression of the transcriptional co-activator peroxisome proliferator-activated receptor gamma 
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(PPARγ) coactivator 1-alpha (PGC-1α) which in turn promotes mitochondrial genesis and fatty acid oxidation 
[Haigis and Sinclair 2010]. 
As impressive as the aforementioned consequence of the NAD+/NADH ratio might seem, influences of redox 
couples or the redox state may not always have systemic effects. They might, however, be able to direct the fate 
of a cell by signaling cascades or alterations of proteins. ROS signaling can be explained using the enzyme Keap1 
as an example. The binding of Keap1 to Nrf2 promotes the degradation of the latter. Keap1 contains several 
cystein groups in the reduced form, since the protein is located within the reduced environment of cytosol. 
These cystein groups act as redox sensors for a decrease in reduced environment manifests in the oxidation of 
these groups causing the release of Nrf2 binding [Sykiotis and Bohmann 2004]. As a consequence, the degradation 
of Nrf2 is abandoned and it can translocate into the nucleus to promote transcription of antioxidant enzymes [see 
2.3.1]. Thus, defence mechanisms against oxidative stress are triggered by high levels of ROS via induction of 
oxidative damage to the control enzymes themselves. The resulting conformational changes are then responsible 
for alterations in enzyme activity. Accordingly, the redox reactive cystein groups of Keap1 are sensors for high 
levels of oxidative stress. 
2.4 Idebenone 
2.4.1 Quinones 
A compound which was mentioned before in two different roles, namely as electron carrier in the ETC [2.2.2] 
and as antioxidant compound [2.3.1], is CoQ10 [Figure 7A]. Chemically, CoQ10 belongs to a class called quinones 
[reviewed in O’Brien 1991 and Monks et al. 1992]. This class includes an immense number of important and 
naturally occurring substances. All quinones share the same basic structure which consists of a quinoid ring 
system; chemically termed a fully conjugated cyclic dione structure according to IUPAC’s Compendium of 
Chemical Terminology [2nd Edition, 1997]. Quinones are ubiquitously found in fungi, plants, animals, and bacteria 
in nature as essential mediators of normal cellular functions or as toxic defendants against natural enemies 
[Monks et al. 1992], but are also contained in pollutants such as cigarette smoke [Schmeltz et al. 1977].  
 
Figure 7: Chemical Structures of Selectec Quinones and Related Molecules.  
The selection shows CoQn (for example, CoQ10 represents the electron carrier in human electron transport chain,) in the oxidized (A) and 
reduced (B) form. Upon in vivo administration, idebenone (C) can be metabolized into QS-10 (F), QS-6 (G), and QS-4 (H). Decylubiquinone 
(decylQ; I) lacks the terminal hydroxygroup compared to idebenone. The isomeric juglone (D) and lawsone (E) feature different 
toxicological properties. The most common representive of vitamin E, α-tocopherol (J), is converted into a quinone after oxidation and water 
addition (K). 
 
Covering such a broad range of physiological properties suggest that, despite the underlying mutual group, this 
class unites molecules with distinct pharmacological activities. In contrast to CoQ10, for example, juglone [Figure 
7D], a component found in hulls and leaves of black walnut, is highly toxic [Monks et al. 1992]. This 
characteristic of juglone is used by the black walnut to defense its territory against competitive plant species. 
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Hence, juglone is used mainly as an herbicide, even though its toxicity is harmful for insects or human cells as 
well [Paulsen and Ljungman 2005].  
Surprisingly, the contradictory effects of these two molecules which belong to the same chemical class are 
partially defined by the chemical reactivity of this class. Quinones have three properties: first, they are oxidants, 
second, quinones are elecrophiles and third, quinones are colored [Monks et al. 1992]. The color represents 
absorption of ultraviolet and visible light energy. Though photo-excited quinones might be fairly reactive, this 
reaction type might be negligible when examining effects in cells lacking direct contact to light in vivo. 
Nonetheless, this photochemical property has been taken advantage of since ancient history: an isomeric 
molecule of juglone called lawsone [Figure 7E] is the active ingredient of the Henna dye used since antiquity. 
Juglone itself exhibits a dark orange-brown color and is also used to dye hair or wool clothes or fabrics and 
CoQ10 features a yellowish orange color [Monks et al. 1992].  
In one potential reaction mechanism for quinones, nucleophiles can attack the partially positively charged 
carbon bound to oxygen. The second oxygen of the quinone, however, decreases the polarization of the quinoid 
ring and thereby reducing the electrophilic reactivity of the carbon atom. Hence, even though quinones are 
potential electrophiles, nucleophilic addition to quinones is seldom seen [Cummunings et al. 1990, Monks et al. 
1992]. Instead of that, quinones are rather involved in redox reactions. 
Reduction of quinones occurs at one of the partially positively charged carbon atom attached to the oxygen. 
The excess electron is delocated over the π-orbitals of the quinoid ring system, whereas the electronegative 
oxygen allures both electrons used for the former double bond to the carbon atom. Thus, one-electron reduction 
of a quinone leads to a semiquinone anion radical whose negative charge might be neutralized by binding to a 
proton (called semiquinone radical or more often just semiquinone). Donation of a second electron—attacking at 
the second oxygen-binding carbon atom—gives rise to the hydroquinone which is—as implied by its name—
unlikely to be unprotonized. Beside the correct name hydroquinone one also might find the chemically erroneous 
term quinol in some publications.  
Thus, quinones, semiquinones and hydroquinones are the same molecule in different oxidative states and 
feature different physicochemical properties. Indeed, the redox capacity of quinones is potentially their most 
relevant property in a biological context. For example, some quinones can oxidize cellular macromolecules such 
as lipids or proteins promoting their malfunctioning; whereas some hydroquinones—such as the reduced form of 
CoQ10, H2-CoQ10—are described to be potent antioxidants [Crane 2001] that is they are able to stop the 
hazardous actions of oxidizing agents. Vitamin E, another antioxidant, becomes a quinone upon oxidation 
[Figure 7J&K]. In its reduced state, however, one oxygen atom is covalently bound to a carbon atom of the alkyl 
tail. 
Since some quinones are toxic to cells, mechanism for their detoxification evolved. NADPH:cytochrome p450, 
a key enzyme in degradation of exogenous compounds, and NADH:cytochrome b5 reductase (EC 1.6.2.2) interact 
with quinones in an incomplete, one-electron reduction, producing potentially hazardous semiquinones [O’Brien 
1991]. Additionally, the gene family of NAD(P)H:quinone oxidoreductases (NQOs) are cytosolic flavoproteins 
that catalyze the reduction of highly reactive quinones and their derivates and consists of the two members 
NQO1 and NQO2 (EC 1.10.99.2). Despite substantial differences in expression patterns and inhibitor sensitivity 
[Winger et al. 2009], both enzymes feature the ability to perform complete, two-electron reduction of quinones 
[Monks et al. 1992]. This reaction results in the formation of hydroquinones and hence, eliminates the production 
of semiquinones. Accordingly, NQOs are key detoxifying enzymes which are induced by stressors such as 
xenobiotics or pro-oxidants. In the promoter regions of both genes, cis-elements like the antioxidant response 
element (ARE) have been identified [Jaiswal 2000 and subchapter 2.3.1]. While NQO1 uses both NADH and 
NADPH as electron donor, NQO2 shows a high preference for dihydronicotinamide riboside (NRH) [Long and 
Jaiswal 2000]. 
Although—beside a very low reduction rate for CoQ10 [Siegel et al. 1997, Dinkova-Kostova and Talalay 
2010]—the physiological electron acceptors have not been identified yet, NQOs have been shown to interact 
with numerous pharmacologically active compounds. Among the substrates are chemicals belonging to the 
groups of quinone epoxides, aromatic nitro and nitroso compounds, azo dyes and Cr(VI) compounds [Colucci et 
al., 2007]. However, NQO1 has the highest affinity towards quinones. Interestingly, the two well-described 
quinone substrates mitomycin C and β-lapachone exhibit their biological activity only upon NQO1-dependent 
reduction. In presence of functional NQO1, mitomycin C is converted into its active form which is regarded as a 
valuable anti-cancer candidate [Adikesavan et al. 2007]. Similarly, β-lapachone, a naphthoquinone, needs bio-
activation by NQO1 to accomplish its anti-tumor effect [Pink et al. 2000]. Additionally, reduced β-lapachone is 
unstable and auto-oxidizes back into its parent form. Thus, this futile cycling continuously stimulates NADH 
oxidation. The resulting elevated NAD+ levels stimulates energy metabolism [Hwang et al. 2009 and 2.3.2]. This 
finding suggests that the function of NQO1 is not limited to protection against oxidative stress but is also 
involved in more general processes concerning physiological states of a cell. In accordance with this hypothesis, 
NQO1 was suggested to participate in the redox shuttling of CoQ10 [Beyer et al. 1996].  
2.4.2 Idebenone: An Overview 
As became evident in the precedent chapters, CoQ10 serves two beneficial functions, namely its role in energy 
production within mitochondria and its antioxidant effect. In disorders with either high levels of oxidative stress 
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or diminished OXPHOS, treatment with CoQ10 might seem considerable. CoQ10, however, exhibits a major 
limitation for clinical administration: the long, lipophilic alkyl chain decreases its absorption. For this reason, 
analogs have been synthesized to increase their solubility while at the same time retaining their beneficial effects.  
Idebenone (2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-cyclohexa-2,5-diene-1,4-dione) is such a less 
lipophilic, synthetic molecule with structural similarities to CoQ10, differing from its archetype solely in the alkyl 
tail: instead of ten repeats of isoprenoid elements, idebenone possesses a ten-carbon alkyl tail holding a hydroxyl 
group at its end [Okamoto et al. 1988 and Figure 7C]. Idebenone was first synthesized by Takeda Pharmaceutical 
Company and developed for treatment of Alzheimer’s disease and improvement of memory and cognitive 
functions. 
Idebenone crosses the blood brain barrier as it has been detected within the brain [Nagai et al. 1985]. The 
distribution of idebenone in rat brains was reported to correspond to 0.5% of dosage at peak time [Nagai et al. 
1989]. Studies in rats and dogs have revealed that radioactively labeled idebenone peaked in blood 15 min after 
administration [Torii et al. 1985]. It was found most abundantly in the stomach—which means that it remained 
unabsorbed—as well as in liver and kidneys. In plasma, metabolites called QS-4, QS-6 and QS-10 [Figure 7F-H] 
outnumbered idebenone. However, when idebenone reached the brain, a 30% was found in mitochondria (the 
same amount was found in the cytosol and the remaining 40% could not be allocated to). Furthermore, Torii et 
al. [1985] found no accumulation after repeated administration. In human adults, administration of 30-50 mg 
idebenone evoked peak plasma levels of 300-400 µg/l after one to two hours [Gillis et al. 1994]. 
Despite some reports rising concerns bout potential toxicity [Lustyik and O’Leary 1990, Wempe et al. 2009, 
Tai et al. 2011], idebenone was considered as a safe drug in many toxicological studies [unpublished data 
Takeda/Santhera] and clinical trails [Bodmer et al. 2009, Kutz et al. 2009]. The objections of Lustyik and 
O’Leary [1990] and Wempe et al. [2009] hold limitations: whereas the first report used concentrations which are 
not achieved in vivo—Lustyik and O’Leary reported toxicity for concentrations higher than 75 µM—the latter 
employed an assay for cell viability, the so-called 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay, which interferes directly with idebenone [personal communication with M. Erb]. 
2.4.3 Idebenone: Preclinical Data of the Brain 
Since idebenone enters the brain, several studies investigating neurological effects of the drug have been carried 
out. Gillis et al. [1994] found moderate improvements in humans suffering from a mild form of dementia. In aged 
rats, administration of 10 or 20 mg/kg idebenone increased levels of nerve growth factor (NGF) in hippocampus 
and both frontal and pariental cortices [Nitta et al. 1993]. On a functional basis, idebenone ameliorated memory 
as assessed in behavioral test such as the water maze, passive avoidance and habituation test [Yamada et al. 1997]. 
Production of NGF has also been confirmed in vivo with concentrations of 10-18 µM idebenone in astrocytes 
[Takeuchi et al. 1990]. Furthermore, Takuma et al. [2000] demonstrated protection of astrocytes after 
reperfusion injury by a broad range of idebenone (10 nM – 10 µM). According to the authors, this protection was 
not achieved by an antioxidant effect, but by production of NGF. 
In addition, idebenone might also be involved in neurotransmitter action. In a rat model of cerebral ischemia, 
10-100 mg/kg idebenone inhibited the decrease in acetylcholine [Kakihana et al. 1998]. Miyamoto and Coyle 
[1990] found that a single per os (p.o.) application of 3 or 10 mg/kg idebenone 0.5 hours prior to injection of 
either a kainate receptor (KAR) agonist or an 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid 
(AMPA) receptor (AMPAR) agonist into the striatum protects cholinergic or γ-aminobutyric acid (GABA)-ergic 
neurons. However, this protection was not seen after injection of an N-methyl-D-aspartate (NMDA) receptor 
(NMDAR) agonist. Similarly, Kaneko et al. [1991] did not detect an influence of idebenone on NMDARs, but 
they reported augmented currents of KARs and AMPARs in presence of their agonist induced by 10 µM or 
higher concentrations of idebenone.  
2.4.4 Idebenone: Interaction with the Electron Transport Chain 
Based on the structural analogy of idebenone and CoQ10, idebenone was proposed to interact with enzymes of 
the ETC. In fact, influence of idebenone on complexes I, II, and III were described. Sugiyama and coworkers 
reported that idebenone interfered with complex I, even though their data from in vitro and ex vivo experiments 
delivered conflicting results: in isolated rat mitochondria, in vitro treamtent with 0.25-100 µM idebenone reduced 
NADH-linked respiration [Sugiyama et al. 1985]; whereas idebenone increased complex I-mediated respiration 
when administred in vivo (100-300 mg/kg for three days) [Sugiyama and Fujita 1985]. These data suggested that 
the interaction of idebenone with ETC components is far more complicated than anticipated. Imada et al. [1989] 
reported that idebenone restored both complex I- and complex II-dependent respiration in CoQ10-depleted 
mitochondria. In healthy mitochondria, however, idebenone did not alter respiration of complex II, but it 
inhibited complex I-mediated respiration [Imada et al. 1989]. In 1996, Degli Esposti et al. dedicated their 
attention to the role of idebenone in the ETC. They described that idebenone inhibited complex I, whereas it 
was an effective substrate for complexes II and III. In agreement with these data, Brière et al. [2004] found that 
in presence of pyruvate and succinate, idebenone almost completely inhibited complex I activity whilst leaving 
the gross metabolic rate unaltered. Lenaz et al. [2002] confirmed that idebenone is an inhibitor of complex I 
using submitochondrial particles. Furthermore, they also reported that idebenone-mediated complex I-inhibition 
led to superoxide production.  
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Interestingly, despite the well documented complex I inhibition by idebenone, 69% of idebenone was reduced 
by mitochondria in presence of NADH [Sugyiama et al. 1985]. This suggests that the inhibition of complex I by 
idebenone might succeed its reduction by complex I; in other words: by reducing idebenone, complex I would 
give rise to an inhibitor of itself. Indeed, this hypothesis was further substantiated by King et al. [2009], who 
classified idebenone as a competitive substrate to CoQ10 and suggested that it unfolds its inhibitory action by 
reacting very slowly at the active quinone binding site. The slow reactivity was explained with limited product 
dissociation and an augmented affinity towards the binding site. King et al. [2009] also suggested that idebenone, 
in addition to the quinone binding site, is reduced at the NADH oxidation site of complex I, since they reported 
not only reduction of idebenone in presence of the inhibitors of the quinone-binding site, but they also found 
reduced idebenone when only the NADH binding site-containing subcomplex Iλ was present. Since their 
experiments were carried out on isolated complex I, reduction of idebenone by other oxidoreductases such as 
NQO1 was omitted. This finding is backed up by the report by Degli Esposti et al. [1996a] who showed that the 
reduction of idebenone is only 63% sensitive to rotenone-inhibition, suggesting an alternative reduction site for 
idebenone. In contrast, James et al. [2005] demonstrated that idebenone—apart from being a good substrate for 
complex II and III—elicited similar complex I activity as CoQ2, a described complex I inhibitor [Degli Esposti 
1998]. However, these data were generated using yeast which do not employ CoQ10, but a shorter, six isoprenoid 
repeats-long CoQ as physiological electron carrier [Tran and Clarcke 2007]. Therefore, it is difficult to predict if 
CoQ2 maintains its inhibitory effect of complex I in this organism. Indeed, ROS production associated with the 
inhibition of complex I was reported for idebenone [Geromel et al. 2008, Fato et al. 2008]. 
In 2008, Rauchovà et al. confirmed complex I inhibition by idebenone, but demonstrated that it also 
stimulates electron transfer from G3PDH to complex III, suggesting an alternative route for idebenone-mediated 
respiration. Indeed, idebenone improved energy production in yeast under low oxygen conditions by an increase 
in mitochondrial membrane potential, allowing yeast to grow similarly compared to yeast under normoxic 
conditions [Chapela et al. 2008]. 
2.4.5 Idebenone: Preclinical Evidence for an Antioxidant Effect 
Antioxidant effects of idebenone have been described in a myriad of publications. In an artificial system for 
estimating antioxidant activity using superoxide quenching, 30 mM idebenone proved to be as effective as 213 
mM vitamin E, a well described antioxidant [Zhai et al. 2008]. Abdel Baky et al. [2010] reported a decrease in 
lipid peroxidation and an increase in GSH, SOD and catalase levels by a single 100 mg/kg intraperitoneal (i.p.) 
administration in a rat hemic hypoxia model. In a rat stroke model, 30 mg/kg p.o. administration of idebenone 
inhibited lipid peroxidation in erythrocytes and thus, protected membrane integrity [Suno et al. 1989]. 
Since most cells can prevent ROS on their own under normal conditions in vitro, oxidative stress sometimes 
has to be induced either by adding pro-oxidant agents or by inhibiting cellular defense mechanisms. In GSH-
depleted cells, viability was ameliorated by as little as 1 µM idebenone [Sortino et al. 1999]. In 1999, Rustin et al. 
reported antioxidant activity of a high dose of idebenone (60 µM) in homogenates of heart biopsies from FRDA 
patients. FRDA is a devastating disorder characterized by progressive muscle wasting which is elicited by a 
mutation in frataxin, a protein thought to be involved in the assembly of FeS clusters in mitochondria. Jauslin et 
al. [2002, 2003, and 2007] utilized the susceptibility of FRDA lymphoblasts to the GHS-depleting agent L-
buthionine (S,R)-sulfoximine (BSO) which induces ROS. Idebenone rescued cells from BSO-mediated cell death 
with half maximal effective concentration (EC50) of 0.4-0.5 µM. Ferric iron (Fe
3+) is another ROS-inducing 
compound often used to provoke oxidative stress and mitochondrial swelling in vitro. Idebenone was reported to 
reduce or even inhibit both symptoms at concentrations varying from two to 84 µM idebenone [Suno and 
Nagaoka 1984a-c, Cardoso et al. 1998, and Mordente et al. 1998]. Interestingly, the beneficial effect of idebenone 
in this model was enhanced in presence of complex II substrate succinate [Suno and Nagaoka 1989a], suggesting 
that the antioxidant effect of idebenone is increased when continuing reduction of the molecule is assured. 
Indeed, the reduced form of idebenone per se was attributed with higher antioxidant capacity [Mordente et al. 
1998]. 
Bile acid induces high levels of oxidative stress, mitochondrial swelling, and apoptosis. Idebenone was reported 
to reduce both ROS and RNS production, mitochondrial swelling, and apoptosis at concentrations of 30 or 100 
µM [Yerushalmi et al. 2001, Gumpricht et al. 2002, and Sokol et al. 2005].  
2.4.6 Idebenone: Additional Findings 
However, beside the two major fields of research on idebenone, i.e. its effect as antioxidant and its role in 
ETC, it has been reported that the drug also modulates other cellular mechanisms. For example, idebenone has 
been described to inhibit neuronal (N-type Cav2.2) and Purkinje cell-encoded (P-type Cav2.1) Ca
2+ channels at 
concentrations ranging from 1-100 µM [Houchi et al. 1991, Kaneko et al. 1990, Chang et al. 2011, and Newmann 
et al. 2011]. In their study from 2003, Gil et al. reported that 1 µM idebenone reduced intracellular Ca2+ levels in 
an in vivo model of apoptosis. Furthermore, idebenone inhibited platelet aggregation, prostaglandin synthesis and 
thromboxane B2 production [Suno and Nagaoka et al. 1989c]. This was confirmed by Civenni et al. in 1999 
when they showed that 10-20 µM idebenone was able to inhibit cyclooxygenase (EC 1.14.99.1) and lipoxygenase 
(EC 1.13.11.31), two enzymes involved in prostaglandin synthesis and arachidonic acid metabolism, in astroglias 
and platelets. Further literature adds to a potential involvement of idebenone in this metabolism, since it was 
found to inhibit an enzyme involved in the regulation of arachidonic acid-mediated inflammation, phospholipase 
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A2 (EC 3.1.1.4), with a IC50 of 32 µM [Amano et al. 1995]. Interestingly, similar protection against staurosporin-
induced apoptosis to that elicited by idebenone was found for a phospholipase A2 inhibitor [Gil et al. 2003]. 
Tsuruo and coworkers [1994] reported that 1-3 µM idebenone is a substrate for an NO-synthesizing NADPH 
diaphorase (nNOS; EC 1.14.13.39) in the brain. Although NQO1—formerly known as DT diaphorase—has a 
similar name, these two enzymes are distinct and should not be mixed up. 
2.4.7 Idebenone: Clinical Data 
According to its proclaimed antioxidant activity, idebenone was considered a possible treatment in a series of 
disorders with high levels of oxidative stress. It has been most prominently investigated in FRDA, a disorder 
characterized by deficiency of FeS complexes and high susceptibility to radicals [Rötig et al. 1997]. Several 
studies have provided data that idebenone is beneficial in FRDA patients by slowing the progression of the 
disease, especially in young patients [among others Hausse et al. 2002, Buyse et al. 2003, Di Prospero et al. 2007, 
Tonon and Lodi 2008, Pineda et al. 2008, Schulz et al. 2009, and Brandsema et al. 2010]; however, phase III 
clinical trials missed significant endpoints [Lynch et al. 2010], so the proof of efficacy needs to be substantiated. 
Currently, idebenone is marketed in Canada under the trade name Catena® for the treatment of FRDA and is 
also available in Europe under a Named-Patient Program. 
Since a preclinical study using mdx mice showed that idebenone reduced inflammation and fibrosis in the 
heart and prevented death due to cardiac pump failure [Buyse et al. 2009], idebenone was also investigated as a 
treatment for DMD. In a phase IIa double-blind randomized placebo-controlled clinical trial, idebenone showed 
a trend towards ameliorating the cardiac phenotype and significantly increasing respiratory function [Buyse et al. 
2011].  
Furthermore, idebenone is also studied for the treatment of MELAS. In one patient, 5-month treatment of 
idebenone improved blood flow and mitochondrial respiration in the cerebrum [Ikejiri et al. 1996] and in 
another patient, 24-month treatment ameliorated neurological symptoms [Napolitano et al. 2000]. In addition, 
treatment with idebenone and L-arginine for over two years prevented stroke-like episodes in one MELAS 
patient with the exception of two incidences when the treatment was halted [Lekoubou et al. 2011]. At present, 
a phase IIa, double-blind, placebo-controlled clinical trail, entitled ‘‘Study of Idebenone in the Treatment of 
Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes (MELAS)’’ (www.clinicaltrials.gov, 
NCT00887562), by Santhera Pharmaceuticals Ltd. and Columbia University, NY, is conducted.  
Idebenone is also often administered to LHON patients; however, its effects are discussed controversially. 
Whereas Barnils et al. [2007] did not find an improvement by idebenone when administered in combination with 
vitamin C, other groups reported faster visual recovery after treatment with idebenone alone [Mashima et al. 
1992, Carelli et al. 1998, and Mashima et al. 2000,]. Recently, a significant improvement in visual performance 
and an arrest in visual deterioration were found in a phase II, double-blind, randomized, placebo-controlled 
clinical trial [Klopstock et al. 2011]. When patients with mitochondrial mutations 3460G>A, 11778G>A, and 
14484T>C were treated with idebenone over a period of 24 weeks, changes in visual acuity of either the best eye 
at start and the best eye at the end of the treatment, the best eye at start of the treatment, or both eyes were 
ameliorated in patients with discordant visual acuities.  
Finally, in line with the effects cescribed above, idebenone showed improvement of brainstem functions, 
particularly respiration, in a patient with Leigh syndrome, a necrotizing encephalomyopathy with underlying 
mitochondrial respiratory chain deficiency [Haginoya et al. 2009].  
2.5 Perspectives 
The aim of this thesis was to shed light on the molecular effects of idebenone. Even though it has been used 
for the treatment of several diseases, the underlying mechanism(s) for the observed, beneficial effects remain still 
unclear. Data so far also do not draw a conclusive picture of its mode of action. Beside rather obvious predictions 
such as antioxidant activity or employment in ETC, idebenone was described to modify arachidonic acid 
metabolism, to block Ca2+ channels, and to stimulate NGF production among other fibres. Considering the range 
and diversity of effects attributed to idebenone, the emphasis of this work lies in the following questions: (i) of 
what nature is the interaction between idebenone and the mitochondria, especially in regards to the ETC, (ii) is 
there a difference in this mitochondrial interaction between healthy and impaired mitochondria, and (iii) which 
possible implications can be drawn from potential molecular mechanisms in regards to mitochondrial disorders 
or in vivo.  
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3 Results 
3.1 Confirmation of Duchenne Muscular Dystrophy Model Systems 
Duchenne muscular dystrophy (DMD) is a devastating disease which manifests in a disruption of membrane 
integrity and defective calcium (Ca2+) homeostasis on the cellular level. In addition, involvement of reactive 
oxygen species (ROS) in the course of the pathology was reported [Kar et al. 1979, Hunter and Mohamed 1986, 
Ragusa et al. 1997, Disatnik et al. 1998, and Rando et al. 1998]. In addition, impairment of mitochondrial 
function and energy production was also described in DMD patients and the mdx mouse model [Barbiroli et al. 
1992, Kemp et al. 1993, Gannoun-Zaki et al. 1995, Sperl et al. 1997, Kuznetsov et al. 1998, Brini 2003, Burelle et 
al. 2010, and Kinnally et al. 2011]. Hence, primary muscle cells from DMD patients appear to be a model system 
for mitochondrial involvement in pathology and appear to be suited for investigating mitochondrial effects of a 
particular compound. 
Before setting out to use DMD cells as model system, it was imperative to characterize the cell lines used. 
Cultured cells might diverge from the phenotype they exhibited under the physiological conditions in vivo. Cells 
which are less affected and thus fitter than others might be more successful in proliferation. As a consequence, 
the impaired phenotype observed in vivo could be eliminated by selection in vitro. An additional difference of 
great importance between conditions in vivo and in vitro is the mode of energy production. In vivo, cells might 
rely on different ATP-generating processes depending to their function, their supply with certain types of food 
molecules and metabolic setup. In muscles dominated by type I fibers, mitochondrial density is high and ATP is 
mainly generated via oxidative phosphorylation (OXPHOS). The primary myoblasts used in the following 
experiments were isolated mostly from type I muscle fibers (3DMD, 5DMD, 2TE, 4TE, and 8TE) with the 
exception of 5TE myoblasts which were established from muscle tissue with equal distribution of fiber types I 
and II. Unfortunately, the accurate origin of 6DMD cannot be traced back. However, since the myoblasts in 
culture are derived from satellite cells and not differentiated muscle, it is possible that the changes leading to an 
OXPHOS-preferring metabolism in vivo might not be evident in cultured cells. 
 It has to be pointed out that, under normal cell culture conditions in vitro, glucose is abundant in 
concentrations exceeding those found in vivo. While glucose concentrations in blood are approximately 5 mM, 
standard culture media exhibit concentrations of 25 mM. Such a five-fold surplus of glucose promotes the use of 
glycolysis over OXPHOS and therefore diminishes mitochondrial activity [Boquist 1977]. In order to measure 
mitochondrial activity, glucose in medium had to be adjusted. 
Therefore, the following experiments [Figure 8, Figure 9, and Table 1] were conducted in four media differing 
in their glucose and serum content. Aneural media, the growth medium for primary myoblasts, is moderate in 
glucose (approximately 5 mM). In contrast to the three other media used, aneural is supplemented with growth 
factors and non-heat-inactivated serum. The other media were based on DMEM and on heat-inactivated serum 
which itself contributed to estimated 0.5 mM glucose. In addition, Hi Glu medium contained 25 mM glucose, 
whereas in Lo Glu medium serum content contributed to 0.5 mM glucose. In order to force cells to use 
mitochondria but still supply adequate amounts of organic energy, in the fourth medium, glucose was substituted 
by galactose. Being a six-carbon sugar like glucose, galactose breakdown via glycolysis yields an equivalent 
amount of ATP as glucose (two molecules per molecule of sugar). However, galactose needs to be converted 
into glucose-6-phosphate in order to enter glycolysis by a process costing two ATP molecules [Marroquin et al. 
2007]. Hence, glycolytic breakdown of galactose does not generate ATP directly, but provides pyruvate and 
NADH for OXPHOS. This so-called Gal medium utilized in the following experiments exhibited a 
concentration of 10 mM galactose. 
Four endpoints were selected to characterize human primary myoblasts: cellular energy status as measured by 
ATP levels in homogenates, cytoplasmic and mitochondrial ROS production, and mitochondrial mass. To 
determine the levels of ROS two widely used fluorophores employed which cover distinct manifestations of 
oxidative stress. The mitochondrial-targeting dye MitoTracker® Red CM-H2Xros—which will henceforward be 
abbreviate as MitoROS—indicates the abundance of mitochondrially derived superoxide (O2
•—). Superoxide is a 
free radical of the most aggressive type and origins mainly as toxic byproduct of respiration primarily produced 
by complexes I and III. A second dye called CM-H2DCFCA is a plasma membrane-permeable compound and a 
rather unspecific marker that indicates general ROS levels within a cell. 
Given the impaired mitochondrial function described above in patients suffering from DMD, one would 
expect a clear distinction between cells derived from DMD patients and those from healthy donors with regards 
to the selected parameters. Surprisingly, this was not the case. The amount of ATP, ROS, and mitochondrial 
mass could not be easily attributed to either affected or healthy cells. For example, ATP content under aneural 
conditions varied as much in control cells as it did in DMD cells [Figure 8]. As a result, in vitro impairment of 
energy status was not specific to DMD cells, but rather to particular cells regardless of their genotype. This was 
also true when observing changes in mitochondrial ROS or mass. For these parameters, differences within 
affected or within control cells seemed to outplay differences between affected and control cells. In contrast, 
cellular ROS levels were similar in most cells with the exception of one or two outliers [Figure 8], making it 
impossible to distinctly separate healthy for affected cells in general on the basis of mitochondrial parameters.  
As a consequence, primary myoblasts from DMD patients had to be considered unsuitable as model systems to 
investigate mitochondrial impairment sui generis. The mitochondrial phenotype described by others in muscle 
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fibers in vivo [Barbiroli et al. 1992, Kemp et al. 1993, Gannoun-Zaki et al. 1995, Sperl et al. 1997, Kuznetsov et al. 
1998, Brini 2003, Burelle et al. 2010, and Kinnally et al. 2011] failed to substantiate in vitro. Dysfunction of 
mitochondrial activity or elevated ROS levels was therefore exogenously induced in subsequent experiments.  
 
 
Figure 8: Primary Muscle Cells of Healthy Donors and DMD Patients Cannot Be Discriminated by Mitochondrial 
Mass, Energy Status or ROS Levels.  
Basal levels of energy status (ATP concentration and mitochondrial mass) and oxidative stress (general and mitochondrially generated ROS 
levels) were analyzed in primary muscle cells from healthy donors (2TE, 4TE, 5TE, and 8TE; filled bars) or patients suffering from DMD 
(3DMD, 5DMD, 6DMD; empty bars). Cells were seeded in Aneural medium (10% non heat-inactivated serum, 100 ng/ml FGF, 100 ng/ml 
EGF and 10 µg/ml insulin; total 5 mM glucose) at a density of 4,000 cells/well in 96-well plates. After 24 h, medium was changed to either 
fresh aneural medium, DMEM LoGlu (10% serum; total 0.5 mM glucose), DMEM HiGlu (10% serum, 25 mM glucose), or DMEM Gal (10% 
serum, 10 mM galactose; total 0.5 mM glucose). After 96-h incubation, ATP was measured using a luciferase-based luminescence assay, 
protein concentrations were quantified using BCA-mediated change in absorption and ROS, MitoMass and MitoROS were analyzed using 
specific fluorescent dyes. ATP and protein concentrations were calculated by means of standards; auto-fluorescence of cells and medium was 
deducted from raw values in fluorescence assays. Bars depict mean + stdev of 12 samples of one or two experiments. ATP levels are displayed 
as nmol per mg protein, ROS, mitochondrial mass and ROS are depicted as fluorescence units per mg/ml protein.  
 
One could argue that ATP levels and the amount of mitochondria abundant in a cell are interconnected and 
not truly independent parameters. As a consequence, measuring ATP levels could substitute for measuring 
mitochondrial mass and vice versa. In order to confirm this hypothesis, the parameters should correlate with each 
other. Analyses of correlations revealed that most parameters measured are independent of one another in the 
cells used [Figure 9 and Table 1]. Statistically significant (p < 0.05), positive correlations were found between 
mitochondrial mass and mitochondrial ROS production independent of the type of media. This is not surprising, 
since mitochondrial targeting of the employed dyes is achieved through the same mechanism: both MitoTracker 
and MitoROS are positively charged molecules which accumulate in the negatively charged mitochondria. This 
correlation should be kept in mind for further data analyses.  
Furthermore, a statistically significant (p < 0.05), positive correlation between cellular and mitochondrial ROS 
production was observed in all media, except for Gal medium where significance for this correlation was clearly 
missed (p = 0.2818) [Figure 9 and Table 1]. In LoGlu medium, and in this medium alone, cellular ROS 
production was statistically significantly (p = 0.0422) correlated with mitochondrial mass.  
Taken together, the four parameters analyzed in these experiments could be considered as generally 
independent from one another, with the exception of mitochondrial ROS production and mitochondrial mass 
and, in some cases, cellular and mitochondrial ROS production.  
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Figure 9: Correlation between ATP Levels, Cytosolic and Mitochondrial ROS Level, and Mitochondrial Mass in 
Primary Muscle Cells of Healthy Donors and DMD Patients.  
Basal levels of energy status (ATP concentration and mitochondrial mass) and oxidative stress (general and mitochondrially generated ROS 
levels) were analyzed in primary muscle cells from healthy donors (2TE, 4TE, 5TE, and 8TE; filled circles) or patients suffering from DMD 
(3DMD, 5DMD, 6DMD; open circles). Cells were cultivated in (A) Aneural medium (5 mM), or DMEM medium containing (B) 0.5 mM 
glucose, (C) 10 mM galactose, or (D) 25 mM glucose. After 96-h incubation, ATP was measured using a luciferase-based luminescence assay, 
protein concentrations were quantified using BCA-mediated change in absorption and ROS, MitoMass and MitoROS were analyzed using 
specific fluorescent dyes. ATP and protein concentrations were calculated by means of standards; auto-fluorescence of cells and medium was 
deducted from raw values in fluorescence assays. Correlation and significance were calculated (p* < 0.05; two-tailed Pearson correlation). 
ROS, mitochondrial mass and ROS are depicted as fluorescence units per mg/ml protein. 
 
Table 1: Correlation Parameters for Energy Status and Oxidative Stress Levels in Primary Muscle Cells of Healthy 
Donors and DMD Patients.  
Correlation and significance were calculated (p* < 0.05; two-tailed Pearson correlation). Significant correlations are listed in bold. 
 
Medium    R
2
 p 
Aneural 
(5 mM Glucose) 
ATP vs. ROS 0.388 0.390 
ATP vs. MitoMass 0.094 0.859 
ATP vs. MitoROS 0.291 0.576 
ROS vs. MitoMass 0.499 0.314 
ROS vs. MitoROS 0.832 0.040* 
MitoMass vs. MitoROS 0.859 0.029* 
Lo Glu 
(0.5 mM Glucose) 
ATP vs. ROS 0.614 0.142 
ATP vs. MitoMass 0.204 0.698 
ATP vs. MitoROS 0.274 0.599 
ROS vs. MitoMass 0.827 0.042* 
ROS vs. MitoROS 0.886 0.019* 
MitoMass vs. MitoROS 0.864 0.027* 
Gal 
(10 mM Galactose) 
ATP vs. ROS 0.532 0.219 
ATP vs. MitoMass 0.023 0.966 
ATP vs. MitoROS -0.208 0.693 
ROS vs. MitoMass 0.719 0.107 
ROS vs. MitoROS 0.528 0.282 
MitoMass vs. MitoROS 0.856 0.030* 
Hi Glu 
(25 mM Glucose) 
ATP vs. ROS 0.463 0.295 
ATP vs. MitoMass -0.006 0.990 
ATP vs. MitoROS 0.048 0.929 
ROS vs. MitoMass 0.786 0.064 
ROS vs. MitoROS 0.900 0.015* 
MitoMass vs. MitoROS 0.863 0.027* 
 
As a last parameter mitochondrial structure was investigated in DMD cells, since functional deficits could be 
attributed to changes in structure [Twig et al. 2008]. Therefore, human primary myoblasts were loaded with the 
fluorescent dye 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide (JC-1). Green 
fluorescent JC-1 accumulates within the mitochondria in a membrane potential-dependent manner and 
aggregates with a strong red fluorescence when at high concentrations. Hence, green fluorescence indicates 
mitochondria per se, whereas red fluorescence indicates a high membrane potential. However, in primary muscle 
cells, the dye did not demonstrate a staining pattern described for other cell types [Reers et al. 1991]. Red 
fluorescence did not accumulate in mitochondria-like as described and was thus insufficient for quantification 
[data not shown]. Nonetheless, only focusing on green fluorescence channel, the mitochondria showed distinct 
morphology in human primary myoblasts of either healthy donors (2TE, 4TE, 8TE) or cells obtained from DMD 
patients (5DMD, 6DMD, 12DMD) [Figure 10]. Whereas control cells formed tubular networks of continuous 
mitochondria which resembled a ring-shaped net, mitochondria in myoblasts from DMD patients were more 
fragmented and disjointed, indicating a higher rate of fission which would correlate with a higher proportion of 
depolarized mitochondria [Twig et al. 2008]. Nonetheless, this difference in mitochondrial morphology was not 
sufficient to impair mitochondrial function in a magnitude observable in functional assays [Figure 8]. 
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Figure 10: Mitochondrial Morphology in Primary Myoblasts of Healthy Donors and DMD Patients.  
Mitochondria of primary myoblasts of healthy donors (2TE, 4TE and 8TE) and from Duchenne patients (5DMD, 6DMD, and 12DMD) were 
stained using the fluorescent dye JC-1. Only pictures from green fluorescent channel are shown. Scale bar: 50 µm.  
 
Contradictory to the work by others using DMD cells [Hunter and Mohammed 1986, Barbiroli et al. 1992], 
DMD cells available in our lab could not be used as an experimental model of mitochondrial dysfunction in vitro 
[Figure 8]. However, a mouse model for DMD, the mdx mouse [Bulfield et al. 1984], was also described to have 
an impaired mitochondrial metabolism [Gannoun-Zaki et al. 1995, Ragusa et al. 1997, and Distanik et al. 1998]. 
The mdx mouse possesses a mutated dystrophin gene in the genetic background of the C57Bl/10 strain [Bulfield 
et al. 1984] and shows muscle degeneration and regeneration at the age of four to six weeks [Dupont-
Versteegden et al. 1994] which is associated with decreased membrane integrity and elevated levels of cytosolic 
enzymes in the blood [Bulfield et al. 1984]. It was thus of interest to see if reduced levels of ATP could be found 
in mdx mice. 
First, wild type (WT) and mdx animals were genotyped to surely discriminate from one another on a genetic 
basis [data not shown]. Subsequently, differences in creatine kinase (CK) blood levels were analyzed in WT and 
mdx animals in order to verify differences in their phenotype [Figure 11A]. The blood level of CK, a cytosolic 
enzyme, is a commonly used marker for plasma membrane disruption and increased blood CK levels were 
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described as a hallmark phenotype in the mdx mouse [Bulfield et al.  1984]. Indeed, 6-week old mdx mice 
showed a five-fold, but nevertheless insignificant increase in blood CK levels (573.7±314.8%1) compared to WT 
animals (100±109.8%). Older, WT animals showed increased blood CK levels (298.7±434.4%) at 12 week 
compared to 6-week old WT mice. Blood CK levels of 12-week old mdx mice significantly exceeded those of 
WT animals of the same age by a factor (1139.9±448.8%). Hence, the mdx mice in our lab showed the 
phenotype of elevated blood CK levels described by others [Bulfield et al. 1994]. 
After confirmation that WT and mdx mice are genetically and phenotypically distinct, ATP levels in different 
tissues were analyzed in WT and mdx mice at the age of six and 12 weeks. To minimize the temporal 
degradation of ATP, extracted tissues were immediately snap frozen in liquid nitrogen and stored at -80 °C until 
ATP levels of all samples were assayed simultaneously. At the age of six weeks, no differences of ATP levels 
were observed either in any of the tested muscles—be it m. soleus (1.12±0.19 µmol/ml protein in WT and 
1.22±0.17 µg/ml protein in mdx), diaphragm (1.09±0.33 µmol/ml protein vs. 0.90±0.27 µmol/ml protein), 
gastrocnemicus lateralis (2.75±0.75 µmol/ml protein vs. 2.94±1.17 µmol/ml protein), or the heart (0.75±0.29 
µmol/ml protein vs. 1.00±0.35 µmol/ml protein)—or in the cerebellum (0.34±0.11 µmol/ml protein vs. 
0.53±0.42 µmol/ml protein) [Figure 11B].  
Similarly, no difference in ATP levels was found in most of the analyzed tissues2 [Figure 11C] such as m. soleus 
(0.89±0.19 µmol/ml protein in WT and 0.72±0.23 µg/ml protein in mdx), diaphragm (0.41±0.13 µmol/ml 
protein vs. 0.33±0.24 µmol/ml protein), the heart (0.14±0.10 µmol/ml protein vs. 0.10±0.02 µmol/ml protein), 
and the cerebellum (0.22±0.19 µmol/mg protein vs. 0.14±0.08 µmol/mg protein). In gastrocnemicus lateralis, 
however, a significant decrease of ATP levels was observable, from 1.30±1.02 µmol/mg protein to 0.39±0.24 
µmol/mg protein. Nonetheless, the remarkably high standard deviation of the average WT ATP level should 
advice caution. After a closer look at the individual values obtained from each animal [inlay figure of Figure 11C], 
it becomes apparent, that this difference is due to approximately half of the WT animals which showed high 
ATP levels in that muscle, whereas the rest showed comparable values as seen in mdx mice. Hence, in the 
selected tissues, no convincing difference in cellular ATP levels was able to discriminate WT from mdx mice. 
The lack of mitochondrial characteristics discriminating unaffected from dystrophic animals or cells also 
questioned the suitability of these animals or cells as models for mitochondrial impairment. Since DMD cells and 
mdx mice showed no indications of mitochondrial malfunction per se, subsequent experiments were performed 
in cell lines with exogenously induced mitochondrial dysfunction.  
 
                                                        
1 Results are always noted as mean ± stdev (standard deviation) if not stated otherwise. 
2 ATP measurements of six- and 12-week old animals were not performed at the same time point. Therefore, a 
direct comparison between the two cohorts should be conducted with caution. 
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Figure 11: Blood CK and Muscle ATP Levels in Six- and 12-Weeks Old Mice.  
(A) Creatine kinase (CK) levels in blood were measured in six- and 12-week old WT (empty bars) and mdx (filled bars) mice. ATP levels in 
homogenized muscle tissue of m. soleus, the diaphragm, gastrocnemicus lateralis, the heart and the cerebellum were analyzed in (B) six-week 
and (C) 12-week old WT (empty bars) and mdx (filled bars) mice. ATP/protein is denoted as µM ATP per mg protein. Bars represent mean 
+ stdev of averaged triplicates of six to eight individual mice. Insert dot-plot depicts averaged triplicates of individual mice for gastrocnemicus 
lateralis. p*** < 0.001; two-way ANOVA Bonferroni’s Multiple Comparison test. 
 
3.2 Influence of Idebenone on Mitochondrial Activity 
Since DMD cells showed no coherent intrinsic impairment of mitochondrial parameters such as mitochondrial 
mass [Figure 8], the effect of idebenone and related benzoquinones on exogenously impaired mitochondrial 
activity was observed in other cells. Before doing so, however, the influence of the quinones on healthy 
mitochondria was investigated under conditions of low mitochondrial dependency for ATP production. In cell 
culture, high levels of glucose cause cells to rely mainly on glycolysis for ATP generation which reduces the 
extent of mitochondrial activity [Vander Heiden et al. 2009]. If a compound which is involved in mitochondrial 
activities other than energy production was added to cells under high glucose conditions, it should be possible to 
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observe changes in parameters such as mitochondrial membrane potential (∆Ψm) or mitochondrial mass without 
impairing cellular energy production. 
Therefore, idebenone and structurally related compounds were assessed in primary skin fibroblasts under high 
glucose conditions (25 mM glucose). Alterations in the alkyl tail of short-chain quinones had mild influence on 
mitochondrial parameters on ∆Ψm and the mitochondrial mass [Figure 12]. The changes, however, were quite 
small and could still lie within the limits of variation for this assay. Idebenone, for example, elevated ∆Ψm by 
16% in fibroblasts, but at the same time decreased mitochondrial mass by 11%. In contrast, CoQ0, which lacks an 
alkyl tail all together, increased both ∆Ψm and mitochondrial mass by 22% and 24%, respectively. CoQ1 did alter 
neither ∆Ψm nor mitochondrial mass (102% and 100%, respectively), whereas CoQ2 and the idebenone 
metabolite QS-10 [Okamoto et al. 1998] caused opposing effects on both parameters: whilst the first decreased 
∆Ψm by 15% and increased mitochondrial mass by 6%, the latter increased ∆Ψm by 8% and decreased 
mitochondrial mass by 15%. CoQ10 elevated ∆Ψm to 109% of DMSO-treated controls and reduced 
mitochondrial mass by 5%. Finally, DQ slightly increased both ∆Ψm and mitochondrial mass by 3% and 5%, 
respectively.  
 
 
Figure 12: Quinones Only Moderately Influence Mitochondrial Parameters.  
Human fibroblasts were treated with different quinones (10 µM) in 25 mM glucose-containing medium for three days before mitochondrial 
membrane potential (A; ∆Ψm) or mitochondrial mass (B) was measured using the fluorescent dyes JC-1 and MitoTracker Green, respectively. 
Percentage relative to values from DMSO-treated was calculated. Bars represent mean of two independent experiments. 
 
Thus, idebenone seemed to have a slight influence on mitochondrial parameters per se. Since the most 
prominent mitochondrial function is the production of ATP, further emphasis was laid on the effect of 
idebenone on cellular energy status. When glucose is abundant, cells rely mainly on glycolysis as source of energy, 
abandoning the use of mitochondria. In absence of glucose, however, the highly effective ATP production of 
OXPHOS is employed in order to gain as much energy as possible from all available food molecules. Thus, 
compounds negatively interfering with OXPHOS are thought to reduce ATP levels when glucose concentrations 
are low [Figure 13]. Lymphoblastoid cells (LCL BC1) were cultured in DMEM medium containing 10% fetal 
bovine serum (FBS) and either none or 4.5 g/l glucose in addition (combined with the glucose from the serum, 
this amounts to 0.5 and 25 mM glucose in total). Idebenone slightly increased ATP production under conditions 
of high glycolysis (111±31% of residual ATP levels; mean±SEM). However, when glycolysis could not contribute 
sufficiently to energy production, ATP levels dropped to 63±66% compared to DMSO-treated cells under the 
same conditions. CoQ1 reduced ATP levels under conditions of both high and low glucose concentrations to 
12±15% and 9±20%, respectively. Both CoQ10 and QS-10 increased glycolysis-mediated ATP synthesis (177±82% 
and 142±75%). However, whereas CoQ10 also moderately increased OXPHOS-dependent ATP production 
(124±62%), QS-10 showed no alteration thereof (103±67%). Rotenone, a known complex I inhibitor, was used as 
a positive control for the suppression of OXPHOS-dependent ATP production, and indeed, under low glucose 
conditions, rotenone decreased ATP levels to 20±20%. When high levels of glucose were available, however, 
rotenone increased ATP synthesis (142±32%) [Figure 13]. 
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Figure 13: Influence of Quinones on Cellular ATP Status Depending on Glycolysis- or OXPHOS-Mediated 
Energy Production.  
Human lymphoblastoid cells (LCL BC1) were treated with 10 µM idebenone, CoQ1, CoQ10, QS-10, and 10 nM rotenone for 72 h in DMEM 
medium containing 10% serum and either 25 mM glucose (high glucose; filled bars) or 0.5 mM glucose (low glucose; empty bars). The 
percentage difference from ATP levels of DMSO-treated control conditions were calculated for both high and low glucose conditions. Bars 
represent mean + SEM of triplicates from 4-15 independent experiments. p* < 0.05%, p** < 0.01%, and p*** < 0.001% relative to DMSO-
treated cells in the according medium; Student t-test. 
 
3.3 Idebenone Rescues ATP Levels under Conditions of Dysfunctional Complex I 
Despite the fact that the short-tail benzoquinones idebenone and CoQ1 reduced ATP levels after long-term 
incubation in glucose-deprived medium [Figure 13], some reports suggested that these compounds are able to 
donate electrons to the ETC when reduced [Beyer et al. 1996, Chan et al. 2001, and Audi et al. 2003]. To test 
such a possible involvement in ETC, conditions of mitochondrial dependence for energy production are required 
as well as a potential entry site for the electrons carried by the quinone. Most likely, this entry site is complex III, 
which was described to oxidize idebenone and CoQ1 [Degli Esposti et al. 1996]. However, in order to see an 
effectual input of electrons into the ETC by hydroquinones, the actual entry sites for electrons into the ETC (i.e. 
complex I and II) needed to be blocked.  
Guided by these demands, the following experimental conditions were established: HepG2 cells were cultured 
for 24 h under conditions of low glucose (DMEM medium containing 0.3 g/l glucose, 2% FBS amounts to 1.77 
mM glucose) to promote mitochondrial energy production. Then, glucose was removed to force cells to use 
mitochondrial activity in order to produce energy. Consistently, removal of glucose alone did not alter ATP 
levels over a period of 90 min (without glucose, ATP levels were defined as 100±7%, in presence of 1.77 mM 
glucose, ATP levels reached 111±3%), indicating that the cells still had sufficient glucose and/or pyruvate 
available to fuel OXPHOS. Now that cells relied on mitochondria to generate ATP, controlled and specific 
inhibition of discrete parts of OXPHOS provided models for the interaction of quinones with mitochondrial 
respiration. In order to impair OXPHOS, cells were treated with known inhibitors disrupting the electron 
transport chain (ETC) for 60 min starting 30 min after medium change.  
Treatment with the complex I inhibitor rotenone reduced ATP levels almost completely already with 
relatively low concentrations (5±0% of residual levels at 100 nM, 2±0% at 1 µM and 1±0% at 10 µM) [Figure 
14A]. An inhibitor of complex II, 3-nitropropionate (3-NPA), did not alter ATP levels (98±2% at 100 µM, 
101±4% at 1 mM and 103±2% at 10 µM) and was therefore omitted in further experiments. Blocking complex 
III function by antimycin A pushed ATP levels down to 5±0% of residual levels at 100 nM, 2±0% at 1 µM and 
2±0% at 10 µM. Oligomycin decreased ATP levels to 14±0% at 100 nM, 17±0% at 1 µM and 18±0% at 10 µM 
by blocking the proton pump (i.e. the FO subunit) of the ATP synthase. Similarly, FCCP, an uncoupler 
decreasing the proton gradient needed for ATP production by ATP synthase, also depleted ATP levels (64±5% 
at 100 nM, 13±1% at 1 µM and 11±0% at 10 µM). 
As a result, in vitro models for specific OXPHOS dysfunctions were established. These models could be used 
to investigate potential ameliorations in mitochondrial ATP production of a particular compound when 
OXPHOS was inhibited at either complex I, complex III, or ATP synthase, or through abolishing the proton 
gradient. 
To determine if idebenone could rescue ATP levels in cells that are dependent of mitochondrial energy 
production which in turn exhibits impaired mitochondrial function, cells were pretreated with either DMSO or 
10 µM idebenone in glucose-deprived medium for 30 min before inhibitors of ETC were added for additional 60 
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min [Figure 14B&C]. Idebenone rescued ATP levels when complex I (from 10±5% to 88±1% during co-
incubation with 100 nM rotenone), but not when complex III was blocked (from 8±2% to 6±3% during co-
incubation with 100 nM antimycin A). Likewise, idebenone failed to restore cellular ATP levels when the 
function of ATP synthase was inhibited by either directly by 100 nM oligomycin (from 29±1% to 15±1% during 
co-incubation) or indirectly by 1 µM FCCP (from 7±3% to 6±1% during co-incubation). 
A similar picture was obtained when idebenone was substituted by CoQ1 [Figure 14D] which only rescues 
ATP levels when cells are stressed by rotenone (106±2% of residual levels), but not when they are treated with 
antimycin A (4±1%), oligomycin (13±2%) or FCCP (18±0%). 
 
 
Figure 14: Influence of ETC Inhibitors, Idebenone, or CoQ1 on ATP Levels.  
HepG2 cells were kept on 1.77 mM glucose overnight before glucose was removed for 60 min. (A) Simultaneously, different inhibitors of the 
electron transport chain (complex I inhibitor rotenone (Rot), complex II inhibitor 3-nitroproprionate (3-NPA), complex III inhibitor 
antimycin A (Ant), uncoupler FCCP, and ATP synthetase inhibitor oligomycin (Oli)) was added at different concentrations. ATP was 
measured after the 1-h incubation of inhibitors. In presence of 100 nM rotenone, 100 nM antimycin A, 1 µM FCCP, and 100 nM oligomycin, 
cells were pretreated with DMSO (B), 10 µM idebenone (C), or 10 µM CoQ1 (D) 30 min prior to glucose removal and addition of inhibitors. 
Bars represent mean + stdev of triplicates of a typical experiment. 
 
Thus, idebenone and CoQ1 were able to rescue ATP levels in presence of rotenone [Figure 14B-D]. Due to the 
similarity of their chemical structure, one could assume that this effect is intrinsic to idebenone-like 
benzoquinones. In order to test this hypothesis, additional to idebenone and CoQ1, CoQ10 and QS-10 were 
subjected to rotenone-stressed HepG2 cells [Figure 15A]. Incubation with 60 µM rotenone for one hour reduced 
ATP levels to 2±0% of residual levels, whilst treatment with 5 µM quinone alone for the same duration caused 
no substantial changes in cellular ATP content (idebenone: 91±12%, CoQ1: 120±15%, CoQ10: 99±10%, and QS-
10: 104±9% of control). When quinones and the complex I inhibitor were administered simultaneously, 
idebenone and CoQ1 were able to restore ATP levels (71±6% and 64±6%, respectively); whereas CoQ10 and QS-
10 entirely failed to ameliorate cellular energy status (2±1% for both quinones). 
In order to evaluate the importance of temporal administration of idebenone to ameliorate energy status under 
conditions of dysfunctional complex I, 10 µM idebenone was administered at different time points before, during 
or after addition of 6 µM rotenone [Figure 15B]. ATP levels were then quantified after 1-h incubation with 
rotenone. As observed previously, rotenone had a detrimental effect on ATP levels (3±0% of residual levels) and 
simultaneous administration of idebenone restored ATP levels to 73±7% (co-treatment). If cells were pre-treated 
with idebenone up to 40 minutes before rotenone challenge (total 100-min incubation with idebenone), ATP 
levels were elevated to 81±1%. Strikingly, the protection of ATP levels by idebenone was also detectable when 
idebenone was administered after the addition of rotenone. Incubation with idebenone for only five min which 
took place 55 min after rotenone was added (labeled as post-treatment), an ATP rescue to 54±4% of residual 
levels was detected [Figure 15B].  
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Similar results were observed in freshly isolated mouse hepatocytes. After isolation, hepatocytes were 
immediately treated with 60 µM rotenone in presence or absence of 5 µM idebenone. Again, idebenone 
protected cells from rotenone-induced ATP depletion [Figure 15C]. Although, acute incubation of primary 
hepatocytes with rotenone did not lead to the same striking reduction of ATP levels compared to HepG2 cells 
(72±18% of control), idebenone fully restored ATP levels (106±21%) in this system. At the same time, in the 
absence of rotenone, idebenone did not alter ATP levels in these cells (111±16%). This ex vivo activity of 
idebenone on ATP levels after rotenone-mediated impairment of complex I raised the question, whether this 
protective action could also be observed in vivo. Therefore, idebenone (400 mg/kg/day; p.o.) was administered 
to mice over a period of four weeks before hepatocytes were isolated and immediately treated with 20 µM or 60 
µM rotenone for one hour as in previous experiments. In this experiment, however, idebenone was not freshly 
added to hepatocytes during this stress phase. Freshly isolated hepatocytes of idebenone-treated and sham- 
treated mice had similar basal ATP levels (113±16% and 100±21% respectively) [Figure 15D]. Consistent with 
our in vitro and ex vivo data, rotenone led to a drop in ATP levels in hepatocytes of sham-treated animals (45±2% 
residual ATP levels at 20 µM rotenone, 46±8% at 60 µM rotenone). However, hepatocytes of idebenone-fed 
mice were significantly more resistant to rotenone challenge (81±7% residual ATP at 20 µM rotenone and 
77±4% at 60 µM rotenone).  
Recently, some evidence emerged that longer incubation periods of up to one week are required to detect 
some protective effects by CoQ10 [López et al. 2010]. Therefore, we investigated whether rescue of ATP levels, 
as demonstrated for acute exposure to idebenone and CoQ1, would be detectable after a 1-week treatment with 
CoQ10 [Figure 15E]. Rescue of ATP levels could not be detected for any quinone when administered only once at 
the beginning of a 1-week treatment. However, further addition of quinone simultaneously to the rotenone 
challenge after the 1-week treatment restored ATP levels in the case of idebenone and CoQ1, whereas under 
these conditions, CoQ10 again failed to protect ATP levels [Figure 15E]. 
 
 
Figure 15: Idebenone and CoQ1 Rescue ATP Levels in Rotenone-Treated HepG2 Cells.  
(A) HepG2 cells were incubated with different quinones (5 µM idebenone, CoQ1, CoQ10 or QS-10) in absence (empty bars) or presence 
(filled bars) of rotenone (Rot; 60 µM) for one h. ATP levels were normalized to protein and expressed as percentage of DMSO-treated cells 
in absence of rotenone. (B) HepG2 cells were incubated with 6 µM rotenone for 60 min, while 10 µM idebenone was pre-, co- or post-
incubated regarding the time point of rotenone addition. ATP levels are expressed as percentage of untreated cells. Bars represent mean + 
stdev of triplicates of one typical out of two independent experiments. (C) Rescue of ATP levels of rotenone-treated (20 and 60 µM) 
primary mouse hepatocytes by either acute in vitro idebenone treatment (5 µM) for one hour or four-week in vivo administration of 
idebenone. Therefore, idebenone (400 mg/kg/day; p.o.) was administered to mice over four weeks and protection of ATP levels was 
maintained in rotenone-treated (20 and 60 µM for one hour) primary hepatocytes ex vivo without acute addition of idebenone. Bars represent 
either mean + stdev of six independent experiments (in vitro) or mean +stdev of duplicates from each one idebenone- and sham-treated 
mouse (in vivo). ATP levels were normalized to cell number and expressed as percentage of sham-treated hepatocytes in absence of 
rotenone. (D) HepG2 cells were treated for one week with 10 µM quinones. In freshly added, glucose-free medium, ATP rescue experiment 
was performed using 6 µM rotenone and in absence (1 week) or presence (1 week + acute) of freshly added 10 µM quinones. Bars represent 
mean + stdev of one typical experiment. p**,0.01, p***,0.001; two-way ANOVA. 
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ATP rescue experiments were mostly performed using rotenone as inhibitor for complex I. In this series of 
experiments, other inhibitors of complex I were used to determine if the rescue of ATP levels mediated 
idebenone is dependent on a specific site of inhibiting complex I [Figure 16]. Therefore, several different 
inhibitors binding at specific sites were used [Table 2]. Inhibitors of quinone-binding site were classified 
according to the nomenclatur of Degli Esposti [1998] as class A, B, or C inhibitors (binding at the site of CoQ10, 
semiquinone, or hydroquinone interaction site of complex I). Rhein, in contrast, blocks complex I at the NADH 
binding site [Kean 1970]. Previously, the lowest concentration which is effective to reduce ATP levels by 30% 
after one hour in glucose-deficient medium was determined for each inhibitor [data not shown]. 
 
Table 2: Selection of Complex I Inhibitors.  
A List of inhibitors according to their inhibitor class, mode of inhibition and concentrations for half maximal inhibition of complex I (IC50) 
according to Degli Esposti [1998], if not otherwise stated. Concentrations employed in experiments are listed as well. 
 
 class 
mode of 
inhibition IC50 
Concentrations 
used notes 
berberine - not known  100 µM stimulates mitochondrial 
permeability transition as well 
capsaicin C QH2 antagonist 20-30 mM 1 mM   
coenzyme Q2 B semiQ & QH2 
antagonist upon 
reduction 
2 uM not used  
diphenylene 
iodonium 
none NADH 
antagonist 
230 nM not used [Majander et al. 1994] 
idebenone A Q antagonist 0.4 uM not used   
metformin - indirect 
inhibition 
 50 mM [El Mir et al. 2000] 
pyridaben A Q antagonist 2.4 uM 10 nM [Schuler 2001] 
piericidin A/B Q & semiQ 
antagonist 
0.06 
nmol/mg 
not used  
rhein none NADH 
antagonist 
30 uM 10 µM [Kean 1970] 
rolliniastatin A Q antagonist 0.06 
nmol/mg 
not used  
rotenone B semiQ 
antagonist 
0.4 
nmol/mg 
6 µM   
stigmatellin C QH2 antagonist 100 
nmol/mg 
10 nM inhibits complex III as well 
 
Consistent with previous experiments, 6 µM of the class B inhibitor rotenone reduced ATP levels from 
100.0±4.1% in DMSO-treated cells to 6.0±2.0%. In the presence of 10 µM idebenone, ATP levels were increased 
to 61.0±9.0%. In addition, idebenone rescued ATP levels to 88.2±8.5% when 50 mM metformin were used to 
inhibit complex I. This inhibition alone amounted to a reduction of ATP levels to 38.2±6.1%. However, the 
complex I inhibition by metformin was assumed to embody indirect pathways [El Mir et al. 2000]. Accordingly, 
the mode of inhibition by berberine is not described yet. However, 100 µM berberine was able to reduce ATP 
levels to 72.0±9.1%, and idebenone was not able to significantly rescue this drop of ATP (78.8±5.0%). Pyridaben, 
a class A inhibitor, acts at the quinone-binding site of the quinone-reduction pocket of complex I and potently 
reduces ATP levels after 1-h incubation (8.9±3.7%). In presence of idebenone, ATP levels were slightly increased 
to 16.7±0.0%. Two class C inhibitors, capsaicin and stigmatellin, were employed to investigate the effect of 
inhibitors acting on the hydroquinone-binding site in the quinone reduction pocket of complex I. Capsaicine (1 
mM) reduced ATP levels to 2.0±1.2% and 1.4±0.3% in absence and in presence of idebenone, respectively. This 
was also seen for the second class C inhibitor, since idebenone was not able to restore ATP levels decreased by 
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10 nM stigmatellin (60.3% instead of 62.9±14.2%). However, it has to be noted that stigmatellin was also 
described as an inhibitor of complex III, which should be taken into account when interpreting these results 
[Degli Esposti 1998]. 
 
 
Figure 16: ATP Rescue in Presence of Different Complex I Inhibitors.  
In glucose-deficient medium, HepG2 cells were treated with different complex I inhibitors for one hour and in absence (empty bars) or 
presence (filled bars) of 10 µM idebenone. Inhibitors comprise metformin (met; 50 mM) and berberine (berb; 100 µM), whose sites of 
inhibition are still unknown, the class A inhibitor pyridaben (pyr; 10 nM), class B inhibitor rotenone (rot; 6 µM), class C inhibitors capsaicin 
(cap; 1 mM) and stigmatellin (stig; 10 nM), and NADH-binding site inhibitor rhein (rhe; 10 µM). Bars represent average + stdev of at least 
three samples per condition. 
3.4 Investigating the Mode of Quinone-Dependent ATP Rescue 
The experiments described above showed that some quinones are able to restore ATP levels under conditions 
of impaired complex I [Figure 14 and Figure 15]. Confronted with these data, the question arose how idebenone 
and a small selection of related compounds were able to restore ATP levels under conditions of impaired 
complex I and if this rescue could be attributed to a certain molecular mode of action. First and foremost, 
idebenone is described as an antioxidant [amongst others Mordente et al. 1998, Jauslin et al. 2002, and Abdel 
Baky et al. 2010]. Furthermore, an increasing number of reports also implied that idebenone can block Ca2+ 
channels [Houchin et al. 1991, Chang et al. 2011, Kaneko et al. 2011, and Newman et al. 2011]. Both ROS 
production and abnormal Ca2+ levels are hallmarks of processes that lead to cell death. Thus, since reduced ATP 
levels might be a representation of rotenone-induced cell death, idebenone could rescue cells by blocking 
apoptotic or necrotic processes. This would imply that the idebenone-mediated restoration of ATP levels 
represent just an epiphenomenon of reduced cell death.   
Pathways of oxidative stress, Ca2+ imbalance and cell death unite at a particular crossroad: the mitochondrial 
permeability transition pore (mPTP). The mPTP is a protein complex in the inner mitochondrial membrane 
which is formed upon several stimuli including stress and apoptotis- or necrosis-inducing factors [Kinnally et al. 
2010]. The formation of the pore enables molecules up to 1.5 kDa to pass the inner membrane and thus, 
prolonged opening of the mPTP triggers multiple pathways leading to cell death. For example, osmotic gradients 
force ions and molecules to enter the mitochondria and this entails the influx of H2O causing the mitochondria 
to swell. As a consequence, swelling of the mitochondria leads to a decreased integrity of the inner and outer 
membrane and thus, the proton gradient needed to fuel ATP synthesis becomes corrupted. Furthermore, in order 
to maintain the proton gradient, ATP synthase starts to catalyze the hydrolysis of ATP and thereby the levels 
decrease further. 
Since idebenone protects cells against different stressors [Yerushalmi et al. 2001, Gumpricht et al. 2002, and 
Jauslin et al. 2002, 2003, and 2007], one could hypothesize that this protective action is due to an inhibition of 
apoptotic or necrotic pathways such as the formation of mPTP. Consistent with this mechanism, idebenone was 
described to prevent mitochondrial swelling [Suno and Nagaoka 1989b, Sokol et al. 2005] which was attributed 
to its antioxidant effect. However, if idebenone interacted directly with the mPTP, swelling of mitochondria 
would be detained by averting the opening of the pore. Notably, rotenone deregulates intracellular Ca2+ 
homeostasis which can be reversed by cyclosporin A (CsA), an inhibitor of mPTP opening [Gieseler et al. 2009]. 
Thus, the rescue of ATP levels by idebenone in presence of rotenone could potentially originate from the 
inhibition of mPTP opening. 
To test this hypothesis, HepG2 cells cultured for 24 h in low glucose medium were treated with different 
compounds known to influence the mPTP and quantified their impact on ATP levels in the absence of glucose. 
Compounds thought to inhibit mPTP opening were pretreated for 30 min prior to the 1-h incubation with 
compounds thought to open the pore. 
Since Ca2+ promotes opening of mPTP, compounds influencing intracellular Ca2+ concentrations were used. 
The ionophore A23187 shuttles Ca2+ ions through the plasma membrane into the cytosol; whereas thapsigargin 
promotes Ca2+ release from the ER. In contrast, BAPTA-AM is a membrane-permeable Ca2+ chelator.  
In preliminary experiments, the potential of Ca2+ concentrations-elevating agents to decrease ATP levels was 
assayed [Figure 17A]. In contrast, a drop in ATP levels induced by an antagonist of Ca2+ concentrations increase 
were regarded as objectionable, since their potential to reverse the negative effects of Ca2+-elevating agents on 
ATP levels was of interest in subsequent experiments. A23187 decreased ATP levels in a dose-dependent manner 
(70±5% for 100 nM, 39±1% for 1 µM and 10±0% of residual ATP levels for 10 µM A23187). The second 
compound increasing cytosolic Ca2+ levels, thapsigargin, did not alter ATP levels at any concentration used 
(98±6% for 100 nM, 102±2% for 1 µM and 90±4% for 10 µM) and was therefore not employed in later 
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experiments. BAPTA-AM reduces ATP levels only at a high concentration (9±1% for 100 µM); whereas lower 
concentrations did not alter ATP levels (98±1% for 1 µM and 95±1% for 10 µM) and CsA itself did itself not 
affect ATP levels (92±8% for 100 nM, 94±9% for 1 µM and 93±3% for 10 µM) [Figure 17A].  
Subsequently, 10 µM A23187 was used to inhibit mitochondrial ATP production instead of rotenone. Two 
antagonistic agents, as well as idebenone, were tested for their potential to reverse the detrimental effect [Figure 
17B]. Similarly to the preliminary experiments [Figure 17A], 10 µM A23187 reduced ATP levels to 7±1%, 
whereas 10 µl idebenone, 10 µl BAPTA-AM, or 10 µl CsA did not alter ATP levels after 1-h incubation 
(99±10%, 97±0%, or 107±15%, respectively) [Figure 17B]. Co-incubation of each of these three compounds with 
A23187, however, did not rescue the drop of ATP induced by A23187 alone (5±0%, 5±0%, or 5±1%, 
respectively). 
 
 
Figure 17: Influence of Calcium on Mitochondrial ATP Production.  
(A) ATP levels of HepG2 cells were measured after 1-h incubation of Ca2+-inducing agents A23187 and thapsigargin (Thap), cell-permeable 
Ca2+ chelator BAPTA-AM (BAPTA), and cyclosporin A (CsA), an inhibitor of mPTP opening, in glucose-free medium. (B) Under the same 
conditions, ATP levels were determined after treatment with 10 µM idebenone (Ide), 10 µM BAPTA, or10 µM CsA in absence (empty bars) 
or presence (filled bars) of 10 µM A23187. Bars represent mean + stdev of triplicates of a typical experiment. 
 
These results indicated that increased Ca2+ levels led to a massive reduction of ATP content and that 
idebenone was not able to restore ATP levels under conditions of elevated Ca2+ concentrations [Figure 17]. Since 
the only rescue of ATP levels by idebenone were observed when complex I was inhibited [Figure 14 and Figure 
16], the mode of action of this rescue was further investigated in the presence of rotenone. As stated earlier, 
idebenone was suggested to act as an antioxidant, by blocking Ca2+ channel, or by triggering anti-apoptotic or –
necrotic pathways. Therefore, well known and widely used agonists of these pathways were used in order to see 
if the observed rescue can be attributed to one of these functions. The antioxidants tempol and N-acetyl-L-
cysteine (NAC), the antiapoptotic omigapil and an anti-necrotic inhibitor of poly(ADP-ribose) polymerase 1 
(PARP1), PJ34 [Fiorillo et al. 2006] were tested for their ability to rescue ATP levels after rotenone-mediated 
inhibition of complex I. For the case that rotenone could mediate the ATP drop through alteration of Ca2+ 
homeostasis, the membrane-permeable Ca2+ chelator BAPTA-AM and the inhibitor of mPTP opening, CsA, 
were included in these experiments again. 
When HepG2 cells were cultivated overnight in medium containing 0.3 g/l glucose before 1-h incubation with 
these compounds in glucose-free medium, ATP levels basically remained unaltered (108±1%, 112±2%, and 
111±3% for 10 µM, 100 µM, and 1 mM tempol, respectively; 86±3%, 85±3%, and 94±3% for 500 µM, 5 mM, and 
50 mM NAC; 93±5%, 95±4%, and 95±4% for 10 nM, 100 nM, and 1 µM omigapil, respectively; and 101±2%, 
108±1% and 110±2% for 100 nM, 1 µM, and 10 µM PJ34, respectively [Figure 18A]. Influence of BAPTA-AM 
and CsA on ATP levels have been described previously [Figure 17A]). 
When cells were simultaneously treated with 100 nM rotenone—beside 10 µM idebenone (87±1% of residual 
ATP levels) and 10 µM CoQ1 (107±3%)—only 50 mM NAC (31±4%) was able to partially rescue ATP levels 
[Figure 18B]. The other compounds employed could not attenuate the detrimental effect of rotenone on ATP 
levels (10 mM tempol: -7±0%; 10 µM BAPTA-AM: -5±0%; 10 µM CsA: -1±2%; 10 µM omigapil: -3±2%; and 10 
µM PJ34: -4±1%). Thus, the fact that NAC showed a mild ATP rescue compared to idebenone raised the 
question, if the mode of action for this rescue could be similar to the one of idebenone. Therefore, 50 mM NAC 
were co-incubated with ATP-depleting agents (100 nM antimycin A, 10 µM A23187, 1 µM FCCP, and 100 nM 
oligomycin) whose effects could not be reversed by idebenone. Interestingly, NAC showed some rescue of ATP 
levels regardless of the mode of respiration inhibition (10±7% ATP rescue for antimycin A, 23±20% for A23187, 
139±10% for FCCP, and 64±13% for oligomycin) [Figure 18C]. Idebenone was not able to rescue ATP levels in 
presence of these inhibitors [Figure 18C] which is in line with results shown before [Figure 14C].  
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An interesting finding was that both the quinones idebenone and CoQ1, but not CoQ0 (-7±1% rescue) were 
able to rescue the rotenone-mediated drop in ATP [Figure 18B]. Hence, it was of interest to test several 
structurally related quinones for their ability to reduce the rotenone-induced ATP drop. As in previous 
experiments [Figure 15A], CoQ10 and QS-10 showed no rescue (2±1% and 2±1% ATP rescue, respectively), 
whereas idebenone and CoQ1 were once more confirmed as potent rescuers (59±10% and 65±6%) [Figure 18D]. 
In this series of experiments, a rescue mediated by CoQ0 was observed (11±2%) which, however, is negligible in 
contrast to the rescue ability of idebenone or CoQ1. Interestingly, DQ and CoQ2, two benzoquinones with an 
eight- and ten-carbon alkyl tail, respectively, also showed rescue values of 60±6% and 60±10%, respectively, 
which were comparable to that of idebenone and CoQ1. A quinone with a longer, 20-carbon chain, CoQ4, failed 
to rescue ATP levels at all (1±1%).  
 
 
Figure 18: ATP Rescue Is Specific to Certain Short-Chain Benzoquinones.  
(A) Different concentrations of tempol (Temp), N-acetyl-L-cysteine (NAC), omigapil (Omi), or PJ34 were added for one hour to glucose-
deprived HepG2 cells before ATP levels were measured. Values are expressed as percentage relative to DMSO-treated controls. (B) HepG2 
cells were incubated with 100 nM rotenone simultaneously with 10 µl idebenone, 10 µM CoQ1, 10 mM tempol, 50 mM NAC, 10 µM 
BAPTA-AM (BAPTA), 10 µM cyclosporin A (CsA), 10 µM omigapil, or 10 µM PJ34 for one hour in glucose-free medium before ATP levels 
were measured. (C) Idebenone (10 µM; black bars) or NAC (50 mM; grey bars) were co-incubated with 100 nM rotenone, 100 nM 
antimycin A (Ant), 10 µM A23187, 1 µM FCCP, or 100 nM oligomycin (Oli) for one hour in glucose-free medium. (D) Different quinones 
altering only in their alkyl chains (sorted in order of ascending chain length) such as idebenone and decylQ (DQ) were co-incubated with 6 
µM rotenone for one hour in glucose-deprived HepG2 cells before ATP was measured. Percentage ATP rescue is defined as the compound-
dependent increase of ATP in presence of rotenone relative to rotenone-induced ATP drop. Bars represent mean + stdev of triplicates from 
one experiment (A-C) or mean + stdev of three independent experiments.  
3.5 Can Idebenone Ameliorate ATP Levels Via AMPK? 
Idebenone was shown influence ATP production through OXPHOS [Figure 13], to rescue of ATP levels under 
conditions of deficient complex I [Figure 15], but at the same time, it was also reported as an inhibitor of 
complex I [Sugiyama et al. 1985, Degli Esposti et al. 1996, Brière et al. 2004, Fato et al. 2008, and Rauchová et al. 
2008, Santhera unpublished data]. Inhibition of complex I leads to a reduction of ATP synthesis and, as a 
consequence, to the activation of AMP-activated protein kinase (AMPK) [Hutchinson et al. 2007]. AMPK is a 
sensor for energy shortage and phosphorylation of AMPK at threonine 172 (Thr172) leads to energy-conserving 
processes such as glucose uptake, fatty acid oxidation, and mitochondrial biogenesis [Han et al. 2010].  
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To assess if complex I inhibition by idebenone could activate AMPK and thereby promote cellular responses 
to low ATP levels, phosphorylation status of AMPK in rat L6 myoblasts was assessed by western blots. To detect 
rapid, transcriptionally or translationally unrelated changes in AMPK activation, cells were treated with 
idebenone for only a very short time. Since AMPK can be activated by growth factors, cells were serum starved 
24 h before treatment with idebenone [Bikman et al. 2010]. Phosphorylation-specific antibody against 
phosphorylation of AMPK at Thr172 was employed and total amount of AMPK in the sample was used as a 
normalizing reference [Figure 19]. Although some activated AMPK protein was observed in lysates of untreated 
cells, different concentrations of idebenone ranging from 100 mM to 10 µM did not alter the total amount or the 
activity of AMPK evidenced by phosphorylation at Thr172. Similarly, increasing the incubation period with 
idebenone had no influence on phosphorylation strength, since signals from AMPK and phospho-AMPK were 
perfectly congruent. Furthermore, 15-min treatment with berberine, a complex I inhibitor described to activate 
AMPK [Han et al. 2010], was also not able to increase phosphorylation signal compared to untreated cells [Figure 
19]. 
Thus, the notion that increased ATP production induced by idebenone was driven via AMPK-involving 
pathways is unlikely. 
 
Figure 19: Idebenone Treatment Does Not Alter Phosphorylation of AMPK. 
L6 cells were cultivated in medium containing 1 g/l glucose and 2% serum for 24 h before medium was replaced with serum-free 1 g/l 
glucose-containing medium. After 24 h, cells were treated with different concentrations of idebenone (IDE) or berberine (10 µM) for 15 min 
or with 10 µM idebenone for a duration ranging from one minute to one hour. Total AMPK protein (red) and Thr172-phosphorylated AMPK 
(pAMPK; green) content in cell lysates were analyzed using Western blotting. 
3.6 Quinone-Dependent ATP Rescue Is Dependent on NQO1 and Complex III 
Since the restoration of ATP levels under conditions of impaired complex I could not be attributed to 
antioxidant, Ca2+ homoestasis-interferring, anti-apoptotic or -necrotic, mPTP-blocking or AMPK-activating 
activity, a possible explanation therefore would be direct intervention of idebenone into the ETC. For doing so, 
idebenone would be required to induce mitochondrial electron transport in the presence of dysfunctional 
complex I. This would require idebenone to be reduced by (an) unknown oxidoreductase(s) and then to donate 
its electrons into the ETC, probably at the site of complex III since it has been described that idebenone is an 
excellent substrate for complex III [Degli Esposti et al. 1996]. Strikingly, such a mechanism was described 
previously for CoQ1: Chan et al. [2002] reported that this quinone could be reduced within the cytosol by NQO1 
and then donates its electrons to cytochrome c via complex III. If acting as cytosolic-mitochondrial electron 
carrier accounted for the ATP rescue in presence of rotenone, the rescue should be sensitive to inhibition of 
complex III and of the cytosolic oxidoreductase proposed by Chan and co-workers: NQO1.  
Consequently, ATP rescue was performed as in previous experimental settings: after culture in 0.3 g/l glucose-
containing medium supplemented with 2% FBS, HepG2 cells were deprived of glucose and treated with 60 µl 
rotenone for one h. This led to the reduction of ATP levels to 2% of residual levels [Figure 20]. Idebenone and 
CoQ1 restored ATP levels to 71±6% and 64±6%, respectively; whilst CoQ10 and QS-10 were not able to elevate 
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ATP levels in presence of rotenone (2±1% for both quinones) [see also Figure 15]. Strikingly, when the inhibitors 
of NQO1 or complex III—dicoumarol or antimycin A, respectively—were added to cells simultaneously with 
rotenone, the impressive ATP rescue by idebenone and CoQ1 was lost [Figure 20]. 
 
 
Figure 20: ATP Rescue of Idebenone and CoQ1 Is Dependent on NQO1 and Complex III.  
(A) HepG2 cells were incubated with rotenone (Rot; 60 µM), dicoumarol (Dic; 20 µM), and antimycin A (Ant; 6 µM) in absence (empty 
bars) or presence (filled bars) of different quinones (5 µM idebenone, CoQ1, CoQ10 or QS-10)for one h. ATP levels were normalized to 
protein and expressed as percentage of DMSO-treated cells in absence of rotenone. p*** < 0.001; two-way ANOVA. 
 
This data supported the assumption, that idebenone might shuttle electrons into the ETC upon reduction in 
the cytosol by NQO1. However, in order to endorse this hypothesis, it was necessary to demonstrate the 
reduction of idebenone by NQO1. In vitro assays using recombinant enzyme provided a suitable model system to 
confirm or refute this argument.  
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Idebenone, CoQ1, CoQ10, and QS-10 were investigated for their ability to oxidize NAD(P)H in presence of 
NQO1. The loss of absorption at 340 nm after oxidation of NAD(P)H to NAD(P)+ was employed to determine 
kinetic parameters of NQO1-quinone interaction. Experiments with recombinant enzymes clearly demonstrated 
that these four quinones are differentially reduced by NQO1 [Table 3 and Figure 21A&B]. Generally, NQO1 
demonstrated a slight preference of NADPH over NADH as electron donor with either idebenone, CoQ1 or QS-
10 as acceptor substrate [Table 3]. Whereas maximal reduction velocity (vmax) for NQO1 presented in the 
following order: CoQ1 > idebenone > QS-10, we could not find any evidence for a NQO1-mediated reduction of 
CoQ10 [Table 3]. Due to poor solubility of CoQ10 in aqueous solutions, we repeated the assay with different 
formulations of CoQ10 in accordance to its lipophilic requirements. Nevertheless, when complexed with fetal 
bovine serum (FBS) or incorporated into phosphatidylcholine-based leptosomes [Mayer et al. 1985, Paolino et al. 
2004], we were unable to detect any NQO1-dependent reduction of CoQ10 [Figure 21C]. In contrast, idebenone 
was clearly reduced by NQO1 under all conditions tested. 
NQO2, although much less studied, is reported to possess similar oxidoreductase activity with some 
differences in substrate specificities [Wu et al. 1997]. Despite similar cDNA and amino acid sequences of NQO1 
and NQO2, NQO2 has different co-factor requirements [Long and Jaiswal 2000]. Indeed, using either NADH or 
NADPH as electron donor, NQO2 failed to reduce quinones [data not shown]. Thus, 1-(3-sulfonatopropyl)-3-
carbamoyl-1,4-dihydropyrimidine, a synthetic analog of the NQO2 substrate dihydronicotinamide ribosid (NRH) 
[Knox et al. 2000], was employed as electron donor instead. However, before calculating turnover rates of 1-(3-
sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine, the absorption coefficient had to be determined. 
Therefore, several concentrations of the compound (1, 5, 10, 50, and 100 µM) were added into a 1-cm cuvette 
containing reaction buffer. The difference between the absorption at A355 and the absorption of blanks was 
divided by the molar concentration, resulting in an absorption coefficient of εNRH-derivate = 4430 M
-1 cm-1. For all 
four quinones, we found similar results with regards to the Km and vmax for NQO2-dependent reduction 
compared to the data generated with NQO1 [Table 3 and Figure 21D]. 
The use of dicoumarol as inhibitor of NQO1 was in line with publications showing that this compound 
selectively blocks NQO1 activity at an IC50 of 10 nM [Ernster 1962, Wu et al. 1997, and Long and Jaiswal 2000]. 
Nevertheless, the specificity for dicoumarol to inhibit NQO1 was confirmed in this experimental setting of 
NADH or 1-(3-sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine oxidation by recombinant NQO1 in 
presence of CoQ0 as electron acceptor, respectively: dicoumarol (20 µM) potently inhibited recombinant NQO1 
activity (4% residual activity), while at the same time NQO2 activity was only inhibited by 14% (86% residual 
activity) [Figure 21E]. 
To analyse whether the reduction of idebenone by NQO1 is mechanistically comparable to other NQO1 
substrates, idebenone was co-incubated with a widely used electron acceptor, 2,6-dichlorophenolindophenol 
(DCPIP), whose interaction with NQO1 was described [Cabello et al. 2009, Cabello et al. 2011]. Reduced DCPIP 
does not absorb at 600 nm in contrast to its oxidated form. A rise in idebenone concentration reduced the 
conversion of DCPIP and thus, Km values of DCPIP increased. However, vmax remained constant. This means, 
idebenone and DCPIP are competitive substrates for NQO1 as depicted by the conjunction on the ordinate of 
the linear regressions of different samples in a Lineweaver-Burk plot [Figure 21F]. 
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Figure 21: Idebenone and Related Quinones Are Substrates for NQO1 and NQO2. 
Hanes-Woolf plots depict oxidation of NADH (A) or NADPH (B) by NQO1 in presence of different quinones as electron acceptors. Each 
data point represents the average of three independent measurements. (C) Effect of different quinone formulation in DMSO, liposomes (Lip) 
and fetal bovine serum (FBS) on metabolism by NQO1. Graph depicts electron donor oxidation rate expressed as percentage of control; 
mean + stdev of three independent measurements. (D) Hanes-Woolf plot of NRH-derivate dihydronicotinamide riboside oxidation by 
NQO2 in presence of different quinone analogs. Each data point represents the average of three independent measurements. (E) Dicoumarol 
(20 µM) selectively inhibited NADH oxidation by recombinant NQO1 with CoQ0 as electron acceptor (96% inhibition, filled bars) in vitro, 
whereas it reduced NQO2-mediated NRH derivative oxidation by only 14% (empty bars). Graph depicts electron donor oxidation rate (% 
Vsubstrate oxidation) expressed as percentage of control; mean + stdev of three independent measurements; p***,0.001, p**,0.01, two-tailed t-test. 
(F) Idebenone is a competitive inhibitor of DCPIP as electron acceptor for NQO1-mediated NADPH oxidation as the intersection of the 
ordinate in a Lineweaver-Burk plot (magnified in inlay) indicates. Each data point represents the average of three independent measurements. 
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Table 3: Steady-state kinetic constants of NQO1 and NQO2 with different quinones.  
a) For NQO2 enzymatic assays 1-(3-sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine (NRH-derivative) was used as electron donor as 
described [Knox et al. 2000]; b) No enzymatic activity above background could be detected for CoQ10, thus, steady-state kinetics could not 
be calculated.  
 
Enzyme NQO1 NQO2 
Substrate NADH NADPH NRH-derivatea 
 Km [µM] 
vmax [µmol/ 
mg/min] 
Km [µM] 
vmax [µmol/ 
mg/min] 
Km [µM] 
vmax [µmol/ 
mg/min] 
Idebenone 27 41.9 30 53.4 38 97.4 
CoQ1 31 115.5 36 172.2 47 128.0 
CoQ10 -
 b - b - b - b - b - b 
QS-10 8 20.5 13 23.3 5 29.6 
 
Idebenone and CoQ1 were able to restore ATP levels in rotenone-treated cells [Figure 15] and this rescue was 
sensitive to the NQO1 inhibitor dicoumarol [Figure 20]. In addition, interaction of idebenone and NQO1 was 
verified using recombinant enzyme, demonstrating that idebenone is a good substrate for NQO1 [Figure 21]. 
Subsequently, it was of interest to demonstrate the reduction of idebenone by NQO1 in living cells. Tan and 
Berridge [2010] reported the use of the tetrazolium dye WST-1 to detect quinone-mediated NQO1 activity. In 
their model, quinones entering the cell are reduced by NQO1 and are then able donated the electrons to WST-1, 
possibly via plasma membrane electron transport enzymes, since WST-1 is membrane-impermeable. Upon 
reduction, WST-1 is converted into its formazan structure which resulted in an increased absorption at 450 nm.  
Hence, the WST-1 assay appeared to be a suitable instrument to measure quinone reduction in vitro. The assay 
was performed in different cells in order to detect cell-specific reduction rates of idebenone and CoQ0 [Figure 
22A]. Both quinones were reduced in almost all cells tested3, but CoQ0 was converted at an approximately two-
fold rate compared to idebenone. With regards to the expression levels of NQO1 [Haefeli et al. 2011 and 
personal communication by D. Robay], WST-1 signal and NQO1 abundance seemed to lack a correlation. Human 
fibroblasts C2 and C3, and human myoblast 2TE showed distinctly lower NQO1 expression levels, whereas 
WST-1 turnover were comparable. However, in cell lines featuring very low NQO1 expression—RGC-5, SH 
SY5Y, and HEK293—addition of idebenone did not result in an increase of absorption at 450 nm [Figure 22A]. 
In cell lines where idebenone and CoQ0 were well converted, human HepG2 hepatic cells and rat L6 
myoblastoids, three related quinones—decylQ, CoQ1, and QS-10—were tested [Figure 22B]. None of these 
quinones were nearly as strongly reduced as CoQ0, or even idebenone. The fact that each substrate for NQO1 
exhibited individual turnover rates was in line with different affinities of substrates towards the recombinant 
enzyme [Table 3]. Intriguingly, CoQ1, a stronger substrate for recombinant enzyme than idebenone, seemed to 
show a weaker response in the WST-1 assay compared to idebenone within living cells. 
 
 
Figure 22: Idebenone and Related Quinones Are Reduced in a Selection of Cells and Cell Lines.  
Quinone reduction was measured using WST-1 assay. (A) The reduction of idebenone (open bars) and CoQo (filled bars) in different cells 
and cell lines was measured using the WST-1 assay. (B) Reduction of the selected quinones, idebenone (Ide), DecylQ, CoQ1, CoQ0 and QS-
10, varied markedly as is shown here for HepG2 (open bars) and L6 (filled bars) cells. Bars represent mean + stdev of at least three 
independent experiments. 
 
                                                        
3 BC1 LCL lymphoblastoid cells were also subjected to the WST-1 assay but no usable data was obtained in this 
cell line, since (i) their NQO1 levels were negligible [data not shown] and (ii) the unequal distribution of 
suspension cells interfered with absorption measurement. Therefore, data obtained with BC1 LCL were omitted. 
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3.7 The Influence of Cell Medium on ATP Rescue Experiments 
The fact that rotenone and other OXPHOS inhibitors were able to completely deplete cellular ATP content in 
the previous experiments excluded glycolytic involvement in these experimental settings [Figure 14]. 
Nonetheless, it was of interest to determine how elevating glycolytic activity would interfere with the observed 
effects. In the previous experiments investigating the ATP rescue by idebenone, glucose content was kept to a 
minimum in order to promote mitochondrial energy production. HepG2 cells cultivated in medium containing 
low glucose content (1.77 mM glucose; the so-called Lo Glu medium) were highly susceptible to rotenone after 
withdrawal of glucose and idebenone and related quinones were able to reverse rotenone-mediated ATP 
depletion in an NQO1-dependent manner [Figure 14 - Figure 20]. In contrast, cultivating cells in Hi Glu medium 
(25 mM glucose) promotes the use of glycolysis over mitochondrial energy production [Vander Heiden et al. 
2009]. Thus, it is likely that after withdrawal of glucose, cells relying on glycolysis are not able to quickly shift 
their ATP production to OXPHOS. As a result, ATP levels would not be that strongly sensitive towards 
mitochondrial impairment.  
In order to discriminate the influence of glycolysis and OXPHOS on the ATP levels observed in the previous 
experiments, glucose was substituted by galactose (25 mM galactose; the so-called Gal medium). Galactose, in 
turn, can be broken down by glycolysis; however, since activation of galactose to enter glycolysis requires two 
molecules of ATP and glycolysis results in two molecules ATP, the net value of glycolytic decomposition of 
galactose is zero. Therefore, substitution of glucose by galactose is used to force cells to rely on mitochondrial 
respiration. 
Basal ATP levels after incubation in glucose-free medium for one hour did not differ in cells cultivated in Hi 
Glu, Lo Glu, or Gal medium [data not shown]. When cells were then subjected to 6 µM of rotenone, the 
reduction of ATP levels was differently affected when comparing cells cultivated in media which promote 
glycolysis-dependent energy production with those relying on mitochondrial ATP synthesis. In HepG2 cells 
cultivated in (A) Hi Glu, 1-h incubation with rotenone did not affect ATP levels as much as in cells cultivated in 
either (B) Lo Glu or (C) Gal medium (63±2% of residual levels for cells cultivated in Hi Glu, 25±2% in Lo Glu, 
and 7±1% in Gal  medium, respectively) [Figure 23A-C]. According to the mitochondrial dependency of 
galactose-mediated energy production, rotenone had a substantially negative effect on ATP levels in cells 
cultivated in Gal medium and treated in Gal medium (8±0% of residual levels) [Figure 23D]. Treatment with 20 
µM dicoumarol failed to reduce ATP levels as significant compared to rotenone (83±6% for Hi Glu  No Glu, 
81±8% for Lo Glu  No Glu, 81±10% for Gal  No Glu, and 94±1% for Gal  Gal). Co-incubation of 
rotenone and dicoumarol, however, had a more dramatic influence on ATP levels than rotenone alone (46±2% 
for Hi Glu  No Glu, 9±2% for Lo Glu  No Glu, 3±3% for Gal  No Glu, and 5±0% for Gal  Gal). As 
anticipated, cells which ignored mitochondrial energy production during cultivation were less susceptible to 
OXPHOS inhibition. 
Addition of idebenone emerged in an interesting picture. When cells were cultivated in Lo Glu medium and 
treated with either 10 µM idebenone alone or in presence of 6 µM rotenone, 20 µM dicoumarol, or both, the 
pattern seen in previous experiments could be observed again (94±3% when treated with idebenone alone, 
81±3% in presence of rotenone, 13±3% in presence of dicoumarol, and 7±1% in presence of both) [Figure 23B]. 
The strong negative effect on ATP levels induced by the co-treatment with idebenone, rotenone, and dicoumarol 
was also detected in the three other conditions tested (26±4% for Hi Glu  No Glu, 7±1% for Gal  No Glu, 
and 26±7% for Gal  Gal) [Figure 23A,C&D].  
Similar as in Lo Glu  No Glu cells, cells cultivated in galactose were not affected by addition of idebenone, 
regardless of the medium in which the treatment occurred (105±8% for No Glu, 95±2% for Gal). In contrast, 
cells cultivated in Hi Glu showed susceptibility to idebenone when transferred to glucose-free medium as seen 
by decreased ATP levels (70±3%) [Figure 23A]. Addition of rotenone (62±4%) resulted in an only slightly more 
pronounced reduction of ATP levels. This was in line with the results obtained in glycolysis-preferring 
lymphoblastoids where idebenone reduced ATP levels under conditions of low glucose content [Figure 13]. 
An intriguing finding was observed in galactose-cultivated cells. As anticipated, idebenone rescued ATP levels 
of rotenone-treated cells; however, the rescue was severely reduced when cells were still incubated in Gal 
medium (53±6%) compared to cells transferred in No Glu medium (86±10%) [Figure 23C&D].  
Interestingly, the drop in ATP levels observed in cells co-incubated with idebenone and dicoumarol in cells 
cultivated in Lo Glu (7±1%) was observed in cells cultivated in either Hi Glu or Gal medium to a much less 
prominent extend (56±1% or 49±16%, respectively). Strikingly, when Gal medium-cultivated cells were treated 
in the same medium with both idebenone and dicoumarol, no decrease of ATP levels could be observed 
(89±8%) compared to dicoumarol treatment only. These data suggest that a product of glycolysis can prevent 
idebenone from depleting ATP levels in presence of dysfunctional NQO1. This assumption was further 
supported by the fact that decrease in ATP mediated by co-incubation of dicoumarol and idebenone was 
attenuated in cells cultivated in Lo Glu and Hi Glu medium, suggesting that glycolysis and the drop in ATP 
induced by oxidized idebenone was negatively correlated. 
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Figure 23: Influence of Media Sugar Content on ATP Rescue by Idebenone.  
HepG2 cells were cultivated in medium containing either (A) 4.5 g/l glucose (Hi Glu), (B) 0.3 g/l glucose (Lo Glu), or (C&D) 4.5 g/l 
galactose (Gal) before medium was replaced by either (A-C) glucose-free medium (NoGlu) or (D) Gal medium. Simultaneously, cells were 
treated with 6 µM rotenone (Rot), 20 µM dicoumarol or both in the absence (empty bars) or presence (filled bars) of 10 µM idebenone for 
one h. Bars represent averaged percentage + stdev of two independent experiments. 
3.8 Idebenone Reduced ATP Levels in Cells Deficient of NQO1  
The NQO1 inhibitor dicoumarol was shown to inhibit the idebenone-dependent ATP restoration after 
rotenone incubation [Figure 20] and idebenone was demonstrated to interact with NQO1 [Figure 21 and Figure 
22]. In addition to the importance of NQO1 for idebenone-mediated ATP rescue, inhibition of NQO1 in cells 
relying on OXPHOS caused idebenone to reduce ATP by itself [Figure 23]. It thus seemed that NQO1 activity is 
a pre-requisite for the beneficial effect of idebenone. 
This interaction was further elaborated in a publication by our lab [Haefeli et al. 2011]. In this study, we 
demonstrated that the expression of NQO1 positively correlated with the protection of cells from rotenone-
mediated energy decrease by idebenone. For example, HEK293 cells were described to be deficient of NQO1 and 
that this deficiency was in line with the inability of idebenone to rescue ATP levels in presence of rotenone.  
The main function attributed to NQO1 for far is its role in detoxification of exogenous or pro-oxidant 
compounds [O’Brien 1991, Monks et al. 1992]. Hence, HEK293 cells are a good model to test the toxicity of 
exogenous compounds since the pivotal protection by NQO1 is deficient without the use of dicoumarol. 
HEK293 cells were cultivated in normal growth medium and incubated with 10 µl of idebenone, CoQ1, CoQ10, 
or QS-10 for one, 48, or 72 h [Figure 24A]. After 1-h incubation, none of the quinones altered cellular energy 
status. After 48-h incubation, both idebenone and CoQ1 decreased ATP levels, however, not significantly 
(86±10% and 84±19% for idebenone and CoQ1, respectively, compared to 93±5% for DMSO-treated cells 
relative to 100±8% of cells treated with DMSO for one h). This tendency toward a decline in ATP levels was 
not observed for CoQ10 and QS-10 (96±7% and 91±7%, respectively) after 48 h. Again, after 72-h treatment, 
CoQ10 and QS-10 did not lead to alterations in ATP content (108±9% and 101±10%, respectively, compared to 
100±17% for DMSO-treated cells at this time point). In contrast, both idebenone and CoQ1 reduced ATP levels 
to 59±5% and 45±2% after three days [Figure 24A].  
It was then of interest if this reduction could also be observed in NQO1-deficient HepG2 cells. Since HepG2 
cells were demonstrated to have high expression of this enzyme [Haefeli et al. 2011], NQO1 was inhibited using 
20 µM dicoumarol and ATP levels were analyzed in absence or presence of increasing concentrations of 
idebenone [Figure 24A]. Otherwise, the setup of the ATP rescue experiments, i.e. the cultivation of cells in 
medium containing 0.3 g/l glucose and 2% FBS and the treatment of cells in glucose-free medium for one hour 
before ATP measurement, was maintained. Dicoumarol alone had a slightly reduced ATP levels by 15±6%. In 
presence of 1 µM idebenone, this reduction was similar (15±7%) [Figure 24A]. However, increasing 
concentrations of idebenone reduced ATP levels compared to residual levels in a dose-dependent manner 
(77±14% for 2.5 µM, 74±13% for 5 µM, 70±2% for 7.5 µM idebenone). Using 10 µM idebenone in presence of 20 
µM dicoumarol, ATP levels were reduced to 40±6% of residual levels after one hour in glucose-free medium 
[Figure 24A]. 
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Figure 24: Idebenone and CoQ1 Reduce ATP Levels in NQO1-Deficient Cell Lines.  
(A) HEK293 cells were cultivated for one (white bars), 48 (grey bars) and 72 (black bars) h in 25 mM glucose-containing medium in the 
presence of 10 µM quinones (idebenone (Ide), CoQ1, CoQ10, and QS-10). ATP levels were normalized to amount of protein before the 
percentage ATP/protein levels were calculated relative to levels of DMSO-treated cells after 1-h incubation. Bars represent mean + stdev of 
four individual samples of a typical experiment. (B) HepG2 cells were cultivated in 0.3 g/l glucose-containing medium (Lo Glu) before 
medium was replaced by glucose-free medium (No Glu) and cells were incubated for one hour with different concentrations of idebenone in 
the presence of 20 µM dicoumarol (Dic). Bars represent averaged mean + stdev of triplicates of one typical experiment. 
 
To rule out objections that the idebenone-mediated decrease in ATP levels in presence of dicoumarol was not 
due to inhibition of NQO1 but caused by potentially unknown effects of dicoumarol, NQO1 activity should also 
be blocked without the use of an inhibitor. Therefore, NQO1 expression was silenced using short-hairpin RNA 
(shRNA)-expressing lentiviral particles.  
HEK293 and HepG2 cells were transduced with 20 viral particles per cell coding for shRNA against NQO1 
expression. Knock-down of NQO1 expression was then confirmed using qPCR. HEK293 cells showed only 
2.5±0.4% expression of NQO1 compared to HepG2 cells [data not shown]. Nevertheless, shRNA reduced NQO1 
mRNA levels in HEK293 cells to 38±3% of basal levels [Figure 25A]. In contrast, HepG2 cells were more 
reluctant to NQO1 silencing by shRNA [Figure 25B]. After transduction using 20 viral particles per cell, NQO1 
mRNA levels were still 34±8% of basal levels. 
To further investigate the role of NQO1 levels on the molecular mechanisms of idebenone, stable clones were 
selected using puromycin for subjecting them to functional assays. In line with the ratio of gene knock-down, 
dicoumarol-sensitive reduction of idebenone measured using WST-1 assay was also diminished by approximately 
a third. Whereas dicoumarol inhibited idebenone reduction in untransduced cells by 66±4%, dicoumarol was 
only able to inhibit 38±8% of idebenone reduction in stable clones expressing shRNA [Figure 25C] indicating 
that the amount of gene knock-down was comparable to the inhibition of enzymatic activity. Intriguingly, the 
ability of idebenone to rescue ATP levels in presence of rotenone was not significantly reduced in shRNA-
expressing cells [Figure 25D]. Idebenone was capable to restore 70±11% of ATP depleted by rotenone in 
untransfected cells which was only slightly higher than the rescue observed in stable clones (59±6%). 
Even though NQO1 silencing did not substantially reduce the ability of idebenone to rescue ATP levels, it was 
well in line with resultzs from cells expressing different levels of NQO1 [Haefeli et al. 2011]. Indeed, the 
correlation between ATP rescue by idebenone in presence of rotenone and NQO1 mRNA levels could be 
perfectly integrated in results of experiments with other cells. 
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Figure 25: Knock-down of NQO1 Expression using shRNA.  
HepG2 and HEK cells were transduced using 20 viral particles coding for NQO1 shRNA per cell. Gene expression of NQO1 in transduced 
(A) HEK and (B) HepG2 cells was quantified using qPCR with GAPDH as house-keeping gene. (C) Stable clones of transduced HepG2 cells 
were treated with 6 µM rotenone in presence or absence of 10 µM in glucose-deprived medium. Percentage ATP rescue was defined as the 
difference between ATP levels of rotenone-treated cells in presence and absence of idebenone relative to the difference between ATP levels 
of cells in presence and absence of rotenone. (D) WST-1 absorption in presence of 10 µM idebenone was quantified in presence or absence of 
20 µM dicoumarol (Dic) in stable clones of untransfected HepG2 cells and HepG2 cells transfected with 20 viral particles per cell. Relative 
difference between signals in presence and absence of dicoumarol were defined percentage of dicoumarol-dependent WST-1 reduction. Bars 
represent mean + stdev of (A&B) two individual measurements or (C&D) four six individual measurements from a typical experiment. Data 
for amount of NQO1 mRNA in HepG2 cells transduced with 50,000x viral particles/well were excluded due to experimental mishandling.  
3.9 Interactions of Idebenone with Additional Oxidoreductases 
The previous experiments raised the question whether idebenone might be a substrate for additional 
oxidoreductases [Figure 25B-D]. Furthermore, absence of NQO1 did not lead to an idebenone-mediated 
depletion of ATP when galactose was abundant [Figure 23]. Since the glycolytic breakdown of galactose itself 
does not yield ATP, the missing ATP depletion by idebenone in presence of galactose could not be compensated 
for directly. However, it is likely, that NADH produced by glycolysis could be used to reduce idebenone via an 
NQO1-independent mechanism.  
Oxidoreductases with a potential to reduce idebenone comprise for example NQO2, complex I, electron 
transfer flavoprotein dehydrogenase (ETFDH), NADH:cytochrome b5 reductase, and NADPH:cytochrome p450 
reductase and these enzymes are inhibited by imatinib, rotenone, pentachlorophenol (PCP), 4-
(hydroxymercuri)benzoic acid (HMB), and diphenylene iodonium (DPI), respectively.  
Specific inhibitors of the dehydrogenases are an elegant tool for the investigation of the role of these enzymes 
in idebenone turnover in cells. Unfortunately, since dehydrogenases have similar substrates, the specificity of 
their inhibitors might be undermined. Thus, to test the specificity of these six aforementioned inhibitors towards 
NQO1 and NQO2, the sensitivity of NADH or dihydronicotinamide riboside (NRF) turnover, respectively, in 
presence of CoQ1 was detected [Figure 26A&B]. As expected, NQO1 was specifically inhibited by dicoumarol 
(99±3%) [Figure 26A]. Intriguingly, the five other compounds tested partially reduced NQO1-dependent NADH 
oxidation by approximately a third or a forth. Imatinib and DPI inhibited NQO1 by 23±5% and 23±9%, 
respectively, HMB and PCP blocked this dehydrogenase by 28±7% and 31±2%, respectively. The most potent 
inhibitor of NQO1 after dicoumarol was rotenone which suppressed its activity by 34±5% [Figure 26A]. In 
contrast, NQO2 was inhibited more selectively, since only two of the six inhibitors tested—imatinib and DPI—
blocked NRH turnover [Figure 26B]. The NQO2-specific inhibitor imatinib almost totally prevented the 
oxidation of NRH by NQO2 (95±1%), whereas DPI inhibited NQO1 by 51±1%.  
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Thus, these results confirmed that NQO1 and NQO2 are specifically inhibited by dicoumarol and imatinib, 
respectively. Nonetheless, imatinib also detained NADH oxidation by NQO1. DPI, described as an 
NADPH:cytochrome p450 reductase inhibitor [McGuire et al. 1994], blocked the activity of NQO1 and NQO2 
as well. The remaining three inhibitors—rotenone, PCP, and HBM—inhibited NQO1, but to a lesser extent 
compared to dicoumarol. In contrast, they, as well as dicoumarol, left NQO2 activity totally unaltered.  
 
 
Figure 26: Specificity of Oxidoreductase Inhibitors towards NQO1 and NQO2.  
Several dehydrogenase inhibitors (dicoumarol (Dic), imatinib (Ima), rotenone (Rot), pentachlorophenol (PCP), 4-(hydroxymercuri)benzoic 
acid (HMB), and diphenylene iodonium (DPI)) were tested for their ability to inhibit recombinant (A) NQO1 or (B) NQO2. Bars represent 
mean + stdev of averaged inhibition of NADH or dihydronicotinamide riboside (NRH) reduction by NQO1 or NQO2, respectively, in the 
presence of 50 µM CoQ1 of three individual samples. p** < 0.01, p*** < 0.001; one-way ANOVA with Bonferroni’s Multiple Comparison 
test. HepG2 cells were treated with (C) 10 µM idebenone or (D) 10 µM CoQ1 in presence of 20 µM dicoumarol, 5 µM imatinib, 6 µM 
rotenone, 5 µM PCP, 5 µM HMB, or 5 µM DPI. Bars represent mean + stdev of three independent experiments.  
 
Thus, NQO1 was completely inhibited by dicoumarol and slightly inhibited by the rest of the inhibitors 
employed. Thus, it is important to know to what extent these inhibitors could prevent the reduction of 
idebenone in cells.  
The reduction of idebenone or CoQ1 in the presence or absence of different oxidoreductase inhibitors was 
measured using WST-1 assay in HepG2 [Figure 27A&B]. As expected, dicoumarol repressed the reduction of 
idebenone and CoQ1 by 66±4% and 56±12%, respectively. Similarly, quinone reduction was inhibited by DPI 
(67±7% inhibition for idebenone and 83±10% inhibition for CoQ1). Despite their ability to inhibit NADH 
oxidation by recombinant NQO1, imatinib, rotenone, and HMB failed to prevent the reduction of quinones in 
HepG2 cells. Intriguingly, treatment with PCP emerged in different pictures when idebenone or CoQ1 was added 
to cells: whereas PCP did not block the reduction of CoQ1 (-2±5% inhibition), it inhibited reduction of 
idebenone by 35±6% [Figure 27A&B]. Thus, it seemed that PCP might selectively interfere with redox reactions 
concerning idebenone. 
Since PCP partially inhibited the reduction of idebenone as measured using the WST-1 assay [Figure 27A], it 
was of importance to verify if co-incubation with idebenone had a similar effect on ATP levels as the one 
observed with dicoumarol [Figure 24B]. Indeed, 5 µM PCP reduced ATP levels to 91±7% of residual levels 
[Figure 27B] and this negative effect was increased by addition of ascending concentrations of idebenone (88±4% 
for 1 µM, 85±1% for 2.5 µM, 68±4% for 5 µM, 49±8% for 7.5 µM idebenone). Co-incubation of 10 µM idebenone 
and 5 µM PCP even led to the reduction of ATP levels to 18±4% of residual levels after one hour in glucose-free 
medium [Figure 27C].  
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Figure 27: Pentachlorophenol Selectively Inhibits Reduction of Idebenone.  
HepG2 cells were treated with (A) 10 µM idebenone or (B) 10 µM CoQ1 in presence of 20 µM dicoumarol (Dic), 5 µM imatinib (Ima), 6 µM 
rotenone (Rot), 5 µM pentachlorophenol (PCP), 5 µM 4-(hydroxymercuri)benzoic acid (HMB), or 5 µM diphenylene iodonium (DPI). 
Inhibition of reduction of the quinone was measured using WST-1. Bars represent mean + stdev of three independent experiments. (C) 
HepG2 cells were cultivated in 0.3 g/l glucose-containing medium (Lo Glu) before medium was replaced by glucose-free medium (No Glu) 
and cells were incubated for one hour with different concentrations of idebenone in the presence of 5 µM pentachlorophenol (PCP). Bars 
represent averaged mean + stdev of triplicates of one typical experiment. 
 
PCP inhibited the reduction of idebenone but not of CoQ1 or other related quinones in HepG2 cells. To rule 
out the possibility that this effect was specific to HepG2 cells or to CoQ1, the same experiment reported in 
Figure 27A&B was expanded by including different cells and further quinones [Figure 28]. A similar pattern was 
detected in human fibroblasts (C2 and C3), human primary myoblasts (2Te), and rat myoblastoids (L6): PCP only 
inhibited the reduction of idebenone whilst it had no influence on the redox reaction of the remaining quinones. 
These data raised the question if idebenone was a substrate of a PCP-sensitive oxidoreductase which did not 
interact with related quinones at all. 
Furthermore, the experiments showed that reduction of all employed quinones—i.e. idebenone, CoQ0, CoQ1, 
QS-10 and decylQ—was preferably inhibited by dicoumarol and DPI. This was in line with reports of Tan and 
Berridge [2010] who reported that WST-1 assay is sensitive to both inhibitors. The explained the efficacy of DPI 
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to decrease WST-1 signal by its function as inhibitor of the plasma membrane electron transport chain which is 
exploited to transfer electrons from hydroquinones within cells to WST-1 in the supernatant. 
Rotenone and HBM did not interfere with quinone reduction at all, whereas imatinib caused minor limitation 
of quinone turnover. Differences between decylQ and remaining quinones could be explained in regard to In 
comparison with the other quinones, reduction rates of decylQ were marginal in all cells used [data not shown], 
especially in HepG2 [Figure 22B]. Addition of oxidoreductase inhibitors could not restrict decylQ conversion; 
since reduction of decylQ was nearly absent in these cells per se [Figure 28]. 
 
 
Figure 28: Reduction of Quinone Is Diversely Inhibited by Different Inhibitors, in Different Cells and in Presence 
of Different Quinones.  
Quinone reduction was measured using WST-1 assay. The percentage of WST-1 signal inhibition induced by dehydrogenase inhibitors 
dicoumarol (Dic; 20 µM), imatinib (Ima; 5 µM), rotenone (Rot; 6 µM), pentachlorophenol (PCP; 5 µM), 4-(hydroxymercuri)benzoic acid 
(HBM; 5 µM), or diphenylene iodonium chloride (DPI; 5 µM) was assessed in presence of idebenone (ide), CoQ0, CoQ1, QS-10, and decylQ 
at a concentration of 10 µM. The assay was performed in a human hepatic cell line (HepG2), human fibroblasts (C2 and C3), human primary 
myoblasts (2Te), and rat myoblasts (L6). Bars represent mean + stdev of at least three independent experiments.  
 
PCP selectively inhibited the reduction of idebenone in vitro [Figure 28]. In a study of Šimkovič and Frerman 
[2004], PCP was described to inhibit ETFDH and idebenone was reported to be a good substrate for this enzyme. 
Similarly, they demonstrated that CoQ1 and decylQ, two quinones whose reduction was not inhibited by PCP 
[Figure 28], were also converted by this oxidoreductase. Even though they assessed the enzyme-substrate 
interaction not in cellular systems but using recombinant enzyme, the fact that idebenone was one electron 
acceptor of ETFDH among others compromised the chance of finding an idebenone-specific mode of action. 
Nevertheless, ETFDH, which links fatty acid metabolism to the ETC, was an interesting target to take a closer 
look at. 
If the inhibition of idebenone reduction by PCP was essentially due to blocking of ETFDH, knock-down of 
this enzyme should produce similar results as PCP addition. Therefore, small interference RNA (siRNA) was 
used to knock-down ETFDH. The employed siRNAs against ETFDH were not validated to knock-down 
transcription in vitro, but were selected for their potential efficacy in silico [information by manufacturer]. For this 
reason, two different siRNAs against ETFDH were applied; either in combination or by themselves. For NQO1, 
whose knock-down by siRNA was included in this set of experiments, validated siRNA was available. 
The best conditions for gene knock-down in HepG2 cells were established preliminary using siRNA for 
glycerol-3-phosphate dehydrogenase (GAPDH) silencing. Knock-down was quantified using an assay measuring 
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the conversion of NAD+ to NADH by GAPDH. In these experiments, a concentration of 30 nM siRNA showed 
the best results in the trade-off of silencing GAPDH and minimizing cytotoxicity [data not shown].  
Efficacy of gene knock-down was assessed using WST-1 assay with idebenone as electron acceptor [Figure 29]. 
Whereas negative siRNA had no influence on WST-1 signals (104±14% of basal absorption), siRNA to knock 
down NQO1 decreased idebenone reduction to 88±2%, indicating that gene silencing via siRNA was not as 
strong as anticipated. In contrast, addition of 20 µM dicoumarol diminished idebenone reduction by 37±4%. This 
inhibition is slightly weaker than the one observed in previous experiments (67±4%) [Figure 28]. Nonetheless, 
the inhibition by PCP (15±3%) amounted to half of that by dicoumarol in both experiments.  
In contrast, transfection of HepG2 cells with siRNA against ETFDH did not inhibit idebenone reduction at all 
[Figure 28]: neither did transfection with single siRNA decrease WST-1 signal (103±5% for siRNA ID# 14819 
and 109±9% for #113116), nor did the combination of both siRNAs (105±9%).  
 
 
Figure 29: Knock-Down of ETFDH Expression Using siRNA.  
HepG2 cells were transfected with 30 nM siRNA in order to silence ETFDH by reverse transcription; NQO1 and non-sense negative siRNA 
was used as control. Gene silencing was measured using WST-1 assay in presence of 10 µM idebenone. Cells were transfected with two 
variants of ETFDH siRNA (#14819 and #113116) or the combination thereof (black bars), negative siRNA (light grey bar) or NQO1 siRNA 
(#9134; grey bar). Untransfected cells (empty bars) were treated with 20 µM dicoumarol or 5 µM pentachlorophenol (PCP) as negative 
control. Bars represent mean + stdev of five to six individual measurements from a typical experiment. 
 
Since PCP was described to be an inhibitor of ETFDH [Šimkovič and Frerman 2004] and PCP selectively 
inhibited idebenone reduction [Figure 27 and Figure 28], the question arose if idebenone contrary to CoQ1 
accepts electrons from ETFDH. Even though this question was already affirmed by Šimkovič and Frerman in 
experiments using recombinant enzyme [2004], confirmation of this interaction in cells was preferable. In these 
experiments [Figure 29], however, siRNA failed to knock down ETFDH as detected by functional analysis and 
thus, a functional interaction between idebenone and ETFDH in living cells could not be verified yet. Therefore, 
to investigate the role of ETFDH in the redox metabolism of idebenone in cells, experiments following an 
indirect path were conducted. 
ETFDH shuttles electrons derived during β-oxidation of fatty acids into the ETC. Thus, if the inhibition of 
idebenone reduction by PCP occurred at the site of ETFDH, inhibition of β-oxidation—which is upstream of 
ETFDH—would also lead to a decreased reduction rate of idebenone. Therefore, two inhibitors of β-oxidation—
3-mercaptopropionic acid (MPA) [Wang et al. 2010] and valproic acid (VPA) [Coudé et al. 1983]—were 
employed in WST-1 assay experiments where PCP showed efficacy to block the actions of idebenone [Figure 27 
and Figure 28]. Both 2 µM MPA and 1 mM VPA did not decrease WST-1 signal (-3±10% and -5±1%, 
respectively) [Figure 30C]. As a control, 5 µM PCP inhibited idebenone reduction by 30±0% which is in line 
with previous experiments.  
Thus, it seemed that ETFDH was not responsible for the drop in WST-1 signal when PCP and idebenone were 
co-incubated. Nonetheless, to refute a potential influence of ETFDH on the reduction of idebenone in living 
cells, another functional assay dependent on the reduced form of idebenone was employed. Since dicoumarol 
inhibits idebenone reduction and idebenone-mediated ATP restoration in presence of rotenone, PCP was 
suggested to prevent ATP rescue as well. If ETFDH was responsible for donating electrons to idebenone in this 
experimental setup, then blocking β-oxidation and thereby the source of electrons for ETFDH would also 
disable the capacity of idebenone to protect ATP content from rotenone-mediated energy depletion.  
As anticipated, ATP rescue by idebenone in presence of rotenone was inhibited by 5 µM PCP (7±1% instead 
of 60±2%) [Figure 30B]. In line with their inability to reduce idebenone in WST-1 assay, the inhibitors of β-
oxidation did not markedly decrease idebenone’s capacity to rescue ATP levels from rotenone-mediated energy 
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failure (67±31% for MPA, 47±6% for VPA, and 54±16% for SA). Thus, ETFDH was refuted as a target for 
idebenone in these experimental setups.  
PCP did not only inhibit the reduction of idebenone [Figure 27 and Figure 30A], but also prevented the 
idebenone-mediated restoration of ATP levels after their depletion by rotenone [Figure 30B]. Since the inhibition 
of quinone reduction by PCP was limited to idebenone and ATP rescue seemed dependent on the reduced forms 
of quinones [Figure 20], it was likely that PCP inhibited ATP rescue mediated by idebenone but not by other 
quinones. Indeed, whereas PCP almost completely blocked the capacity of idebenone to counteract rotenone-
induced ATP drop (7±1%), a substantial ATP rescue was observed when CoQ1 was co-incubated with rotenone 
and PCP (34±24%) [Figure 30B]. As positive controls, ATP rescues by idebenone and CoQ1 in the presence of 
rotenone only (60±2% and 66±14%) were in line with previous experiments. Similarly, when idebenone was 
replaced with 10 µM CoQ0, QS-10, or decylQ, the drop in ATP levels was not observed as well [data not shown]. 
 
 
Figure 30: Inhibition of Idebenone-Mediated ATP Rescue by Pentachlorophenol Is Not Linked to β-Oxidation.  
Pentachlorophenol (PCP; 5 µM) and two inhibitors of β-oxidation 3-mercaptopropionic acid (MPA; 2 µM) and valproic acid (VPA; 1 mM) 
were tested for their ability to inhibit (A) NQO1-dependent reduction of idebenone as measured using WST-1 assay or (B) idebenone-
mediated ATP rescue in presence of 6 µM rotenone. Bars represent mean + stdev of duplicates from a typical experiment. (C) HepG2 cells 
were cultivated in medium containing low glucose concentrations before deprivation of glucose in presence of 6 µM rotenone (Rot) and 5 
µM pentachlorophenol (PCP) for one hour. Simultaneously, 5 µM idebenone (black bars) or CoQ1 (grey bars) were added to cells. Percentage 
ATP rescue is defined as the compound-dependent increase of ATP in presence of rotenone relative to rotenone-induced ATP drop. Bars 
represent mean + stdev of duplicates from one experiment. 
3.10 Potential Benefits from ATP Rescue in Disorders with Deficient Complex I 
These data suggested that idebenone might be beneficial to cellular energy status under conditions where (i) 
complex I is dysfunctional and (ii) idebenone can be reduced. Therefore, one could assume that idebenone 
rescues ATP levels in cells bearing a mutation in a subunit of complex I which is the case in cells from LHON, 
Leigh syndrome or Kearns-Sayre syndrome.  
Thus, the ability of idebenone to rescue ATP content in presence of rotenone was investigated in 
lymphoblastoid cell lines of LHON patients [see 2.1.2] and patients suffering from Leigh syndrome and Kearns-
Sayre syndrome. Even though these cell lines featured a mutation in a subunit of complex I, they did not exhibit 
reduced basal levels of ATP when deprived of glucose [data not shown]. Hence, the suitability of these cell lines 
as a model for complex I deficiency was questionable. In glucose-deprived medium, 1-h incubation with 1 µM 
rotenone decreased ATP levels to zero in all cell lines. Addition of 10 µM idebenone to rotenone-treated cells 
failed to rescue ATP levels and this finding was also observed in three lymphoblastoid cell lines from healthy 
donors [data not shown]. Nevertheless, this failure of idebenone to ameliorate energy status of complex I-
deficient lymphoblastoid cells could be explained by the generally low NQO1 expression in lymphoblastoid cell 
lines [personal communication by D. Robay]. This confirmed the importance of the reduction of idebenone in 
order to improve cellular ATP production. 
Another disorder characterized by dysfunctional mitochondrial respiration is called mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) [see 2.1.1]. Mitochondria of lymphoblastoid 
cells from MELAS patients were transferred into a mitochondria-depleted cell with cancerous nuclear 
background, thus generating so-called cybrids which hold the advantages of immortality and MELAS-specific 
mitochondria. MELAS and wild-type (WT) cybrids were a kind gift from M. Hirano and M. Davidson and 
cultivated in galactose-containing challenge medium which forced them to use mitochondria to produce energy.  
In MELAS cells, low levels of ATP synthesis and excess lactase production were described [Pallotti et al. 2004]. 
The observed excess lactate is largely a result of increased glycolysis to maintain sufficient energy levels under 
conditions of defective OXPHOS. The reason for producing lactate is to regenerate NAD+ levels which were 
utilized in the initial steps of glycolysis. Without sufficient NAD+, glycolysis cannot proceed. Since quinone-
dependent rescue of ATP levels under conditions of impaired complex I [Figure 18D] and NQO1-dependent 
metabolism is described to increase NAD+/NADH ratio [Dragan et al. 2006], the role of quinones on cellular 
metabolism in cybrids harboring either WT mitochondria or mitochondria from MELAS patients were of 
interest.  
Intriguingly, ATP levels in MELAS cybrids did not increase after 1-h incubation with idebenone [data not 
shown], despite reports of impaired complex I [James et al. 1996, Sarnat and María-García 2005, Sarasman et al. 
2008, and Davidson et al. 2009].  Unlike the situation where acute short-term incubation with quinones 
increased ATP levels after rotenone challenge in HepG2 cells [Figure 18D], MELAS cells did not show increased 
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ATP levels after 48-hour treatment with idebenone or CoQ1 [Figure 31A]. In contrast, there was a trend of 
slightly decreased ATP levels in presence of idebenone (87±17%) or CoQ1 (84±12%) compared to DMSO-
treated MELAS cybrids (100±21%), even though these changes did not reach statistic significance. In presence of 
10 µM dicoumarol, this trend towards decreased ATP levels was abolished (106±24% and 94±8% for idebenone 
and CoQ1, respectively). In WT cybrids, idebenone did not alter ATP content in presence or absence of 
dicoumarol (106±6% and 100±17%, respectively). Strikingly, a statistically significant drop in ATP levels was 
observed after 48-h incubation with CoQ1 (51±11%) which was reversed by addition of dicoumarol (94±11%) 
[Figure 31A].  
Even though idebenone and CoQ1 did not restore ATP levels in rotenone-treated MELAS cybrids, an 
amelioration of energy production was observed in these cells. Mitochondrial impairment in MELAS led to a 
decrease in mitochondrial membrane potential: after two-day incubation in galactose-containing challenge 
medium, ∆Ψm was slightly lower in MELAS cybrids (85±17%) compared to WT cybrids (100±11%) [Figure 
31B]. Strikingly, both idebenone and CoQ1 substantially increased ∆Ψm in this experimental setup (146±26% and 
120±20%, respectively) [Figure 31B]. CoQ10 and QS-10—two quinones which failed to restore ATP levels in 
rotenone-treated HepG2 cells [Figure 20]—did not influence ∆Ψm (80.3±15.2% and 78.8±23.9%). Thus, these 
results were in line with previous experiments in healthy cell lines with rotenone-mediated complex I 
deficiency. In WT cybrids which contained functional mitochondria, none of the quinones led to alteration of 
[Figure 31B]; a result which observed in human fibroblasts before [Figure 12A]. 
Idebenone and CoQ1 strengthened ∆Ψm of MELAS cybrids, but this beneficial effect could not be utilized by 
the cells to increase ATP content. The question then arose how this profitable effect of idebenone and CoQ1 
could manifested in an amelioration of cellular metabolism. Impairment of mitochondrial energy production 
forces MELAS cells to produce ATP via glycolysis. This process is maintained by the production of lactate which 
accounts for pathological symptoms described in MELAS [Kaufmann et al. 2004, Davidson et al. 2009]. It was 
therefore of interest, if quinones might influence lactate production. 
As also reported by Davidson et al. [2009] who generated the MELAS cybrids used in our lab, these cells had 
markedly increased lactate levels (46.3±1.5 mM/mg protein) compared to WT cybrids (11.5±0.6 mM/mg) 
[Figure 31C]. In WT cybrids, lactate levels remained unchanged after 48-h treatment with idebenone (13.5±1.0 
mM/mg), QS-10 (12.3±0.5%), or CoQ10 (12.0±0.8%). In line with the massive drop in ATP levels upon 48-h 
treatment [Figure 31A], CoQ1 doubled the amount of lactate production under these conditions (22.7±2.9 
mM/mg) [Figure 31C].  
Interestingly, both idebenone and CoQ1 effectuated a statistically significant decrease in lactate production in 
MELAS cybrids (35.3±5.0 mM/mg and 19.8±2.1 mM/mg, respectively) [Figure 31C]. In contrast, neither CoQ10 
nor QS-10 altered extracellular lactate concentrations of MELAS cybrids (53.8±6.7 mM/mg and 49.0±5.7 
mM/mg, respectively). In a subsequent experiment, the lowering of lactate levels by idebenone and CoQ1 was 
confirmed (reduction to 54.2±5.1mM/mg and 46.0±6.9 mM/mg from 74.6±16.5 mM/mg in sham-treated 
MELAS cybrids, respectively) [Figure 31D]. Strikingly, this reduction was significantly abrogated by inhibition of 
NQO1: in presence of dicoumarol, lactate production in MELAS cells was not substantially altered by idebenone 
(67.4±5.2 mM/mg) or CoQ1 (59.8±7.3 mM/mg) [Figure 31D].  
Thus, increased mitochondrial activity of MELAS cells induced by idebenone and CoQ1–as manifested in the 
elevation of ∆Ψm—could actually be utilized to reduce lactate production in MELAS cybrids. As a consequence, 
overall ATP content did not chance, but the production of lactate, the toxic byproduct to maintain glycolysis 
under conditions of impaired OXPHOS, could be substantially reduced by both idebenone and CoQ1. 
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Figure 31: Effect of Quinones on Mitochondrial Membrane Potential and Lactate Production in MELAS Cybrids.  
(A) Effect of quinones (10 µM) on ATP levels in wild-type (WT) and MELAS cybrid cells was assessed after two-day incubation in 
galactose-containing challenge media for in the presence or absence of dicoumarol (10 µM). Data depict one typical experiment out of three 
and each data point represents the mean + stdev of four individual dishes. (B) Cells were cultivated in galactose-containing challenge media 
for two days in the presence or absence of quinones (10 µM). Mitochondrial membrane potential (∆Ψm) in cybrids was measured after two-
day treatment with 10 µM quinones using TMRM. Bars represent mean + stdev of four separate wells of a typical experiment as relative 
percentage compared to TMRM/protein in DMSO-treated WT cybrids. (C) Quinones (10 µM) were added to WT and MELAS cybrids for 
two days before lactate was measured in the supernatant and standardized to protein content. Data depict one typical experiment out of 
three and each data point represents mean + stdev of three individual wells. (D) Co-incubation with dicoumarol (10 µM) partially reverses 
the drop of lactate levels induced by 10 µM idebenone or CoQ1. Extracellular lactate levels were standardized to protein content. Bars 
represent mean + stdev of four separate dishes within a typical experiment. p* < 0.05; Student t-test p* < 0.05; Student t-test. 
3.11 Toxicological Analyses of Idebenone and Related Quinones 
Despite the beneficial shift in energy production in MELAS cybrids induced by idebenone and CoQ1, the latter 
also reduced ATP levels in WT cybrids which relied on mitochondrial ATP generation [Figure 31A]. Idebenone 
and CoQ1 also decreased ATP levels in OXPHOS-dependent cells with dysfunctional NQO1 [Figure 13 and 
Figure 24]. These detrimental effects of the two quinones were in line with previous studies reporting that 
idebenone and CoQ1 inhibit mitochondrial complex I function [Sugiyama et al. 1985, Degli Esposti et al. 1996, 
Briere et al. 2004, Fato et al. 2008, and Rauchová et al. 2008]. 
Even though the observed reductions of ATP content by idebenone were only visible under conditions forcing 
cells to use mitochondrial activity for energy production, it was of interest to see if idebenone or other quinones 
have detrimental effects on energy-consuming cellular functions such as proliferation. Therefore, BC1 
lymphoblastoid cells which display a high proliferation rate were treated with quinones over an extended period 
and the rates of population doublings were calculated. This cell line also bore the advantage of very low NQO1 
expression [personal communication by D. Robay], making them potentially more susceptible to toxicity induced 
by quinones.  
Proliferation rates were calculated as cumulative cell doubling (CCD) which is defined as sum of exponential 
growth. In a scatter plot depicting CCD vs. time, immortalized cell lines with a steady cell growth follow a 
perfect line as seen for DMSO-treated lymphoblastoid cells (9.7±1.5 CCD after 18 days) [Figure 32 In agreement 
with effects on ATP levels, 10 µM idebenone reduced CCD (5.1±1.2 CCD after 18 days), reaching statistic 
significance after seven days (p* < 0.05; and p*** < 0.001 after ten days). Upon treatment with 10 µM CoQ1, 
lymphoblastoid cells died after four days [Figure 32A]. Likewise, reflecting previous experiments demonstrating 
that 10 µM CoQ10 or QS-10 had no negative effect on cellular energy production [Figure 13 and Figure 24A], 
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both compounds did not affect cumulative cell doubling either (10.2±0.7 CCD and 9.6±1.7 CCD after 18 days, 
respectively) [Figure 32A].  
At a concentration of 10 µM, idebenone impaired proliferation of lymphoblastoid cells. This harmful effect of 
idebenone, however, was dependent on the dose applied: lower concentrations of idebenone did not substantially 
alter proliferation rates (7.6±1.6 CCD at 2 µM idebenone and 8.0±0.8 CCD at 5 µM idebenone after 18 days, 
respectively) [Figure 32B].  
Similar results were also observed in primary human myoblasts (4TE) cultured in aneural medium where 10 
µM idebenone led to a drastic decrease in growth already after ten days [C]. Whereas DMSO-treated myoblasts 
showed linear proliferation with a 7.5±0.6 CCD after 21 days, increasing concentrations of idebenone reduced 
proliferation (4.1±0.7 CCD at 2 µM idebenone, 4.7±0.5 CCD at 5 µM idebenone, and 1.7±0.8 CCD at 10 µM 
idebenone). Since these cells had intermediate levels of NQO1 expression, the observed effect could not solely 
be attributed to the oxidized form of idebenone. 
 
 
Figure 32: Alteration of Cumulative Cell Doubling by Different Quinones.  
Lymphoblastoid (A&B) or human 4Te myoblast (C) cells were treated with 10 µM DMSO, idebenone, CoQ1, CoQ10 or QS-10 (A) or 
different concentrations of idebenone (B&C; 0, 2, 5, and 10 µM). Every second to fourth day, cells were counted to calculate cumulative cell 
doubling rates (CCD) and to re-seeded at a density of 500,000 cells/ml (lymphoblastoids) or 20,000 cells/ml (myoblasts). Values represent 
mean ± stdev of triplicates of cumulative cell doubling rates (CCD).  
3.12 Idebenone Influences Akt-1 Status  
Despite the abundance of NQO1 in primary 4TE myoblasts which is supposed to elevate the reduced form of 
idebenone [Merker et al. 2007], it could still not be ruled out that the decrease in proliferation induced by high 
concentrations of idebenone in these cells [Figure 32] was associated with a potential pro-oxidative effect of 
idebenone. One possible target, which integrates metabolism, proliferation and anti-apoptotic pathways, is Akt-
1/protein kinase B (PKB). Akt-1 does not only directly inhibit apoptosis by phosphorylation of apoptosis-
inducing factor B-cell lymphoma (Bcl) 2/BclX antagonist (BAD), but it also activates transcription factors such 
as members of the Forkhead (FoxO) family or the nuclear factor κβ (NF-κβ) which in turn promote the 
expression of survival genes [Hanada et al. 2004]. Strikingly, beside anti-apoptotic agents such as growth factors, 
oxidative stress also activates Akt-1 by inducing a phosphorylation event at serine (Ser) 473 [Higaki et al. 2008, 
Nishimoto et al. 2010].  
Western blot analysis of Akt-1 protein in human 4TE primary myoblasts revealed that neither 10 µM 
idebenone treatment for three days, 100 µM H2O2 stress for 30 min immediately before lysis, or a combination 
thereof had any influence on total Akt-1 protein levels4 [Figure 33]. Intriguingly, when SDS, a strong detergent 
was added to the lysis buffer an additional band at 73 kDa instead of 64 kDa was observed despite the use of a 
rather selective antibody against Akt-1[Figure 33] [personal communication by M. Erb and D. Robay]. The fact 
that the shift of approximately 9 kDa resulted in a distinct band rather than a smear suggested that this higher 
molecular weight form of Akt-1 was post-translationally modified, for example by covalent attachment to small 
ubiquitin-like modifier (SUMO). Phosphorylation would increase the molecular weight of the protein in a lesser 
extent, whereas ubiquination or glycosylation would lead to a smear in western blot analysis. Interestingly, in 
DMSO-treated cells, the 73 kDa band showed an over 15-fold higher signal than the 63 kDa band. Furthermore, 
three-day incubation with 10 µM idebenone substantially reduced the 73 kDa species by approximately 20-fold. 
This finding combined with the reduced proliferation observed in idebenone-treated 4TE myoblasts [Figure 32] 
proposes that idebenone reduces a modification necessary for Akt-1-mediated proliferation. 
However, H2O2 completely inhibited the signal of the 73 kDa band, which suggests that the potential 
proliferating action of Akt-1 is reduced under oxidative stress. Indeed, H2O2-mediated phosphorylation of Akt-1 
at Ser473 was rather linked to anti-apoptotic pathways than cell proliferation, since pre-treatment with H2O2 was 
described to make cells less susceptible latter stress [Nishimoto et al. 2010]. Therefore, a potential pro-oxidative 
effect of idebenone on Akt-1 was anticipated to manifest in phosphorylation at Ser473 site. Therefore, the 
phosphorylation status of the site was analyzed using a phospho-specific antibody [Figure 33]. Since the same 
                                                        
4 Akt-1 was reported to have a molecular weight of 56-60 kDa according to the manufacturer of the antibody 
but manifested as 64 kDa protein. However, since GAPDH ran at a higher position than expected as well (39 
kDa instead of 36 kDa), it rather seemed that the protein marker was running too quickly under the buffer 
conditions used.  
  Results 
 
 
Molecular Effects of Idebenone  63 
membrane was used a second time for this antibody, the background signal was higher (as observable in the 
differences between the first two (overlay and phospho-Akt) and latter two (Akt-1 and GAPDH) detail sections 
in Figure 33), and unspecific bands slightly below the expected position emerged. As anticipated, 
phosphorylation of Akt-1 at Ser473 was increased after 30-min H2O2 treatment. This effect was independent of 
pre-treatment with either idebenone or DMSO. Idebenone itself did not increase Ser473 phosphorylation of Akt-
1.  
Taken together, these findings indicated that long-term idebenone treatment had a weaker effect on Akt-1 
than acute H2O2 treatment. Whereas short-term addition of H2O2 resulted in phosphorylated Akt-1 and 
completely prevented the modification resulting in a 9 kDa heavier protein, three-day incubation with 
idebenone was not able to phosphorylate Akt-1 and reduced, but did not fully block, the 73 kDa band. Despite 
the lack of phosphorylation at Ser473, it can not be ruled out that idebenone could still act as a mild pro-oxidant 
given the strong reduction of modified Akt-1. 
 
 
Figure 33: Idebenone Decreases Modification of Akt-1.  
Primary 4TE myoblasts were treated with 10 µM idebenone for three days in aneural medium before half of the cells were subjected to 100 
µM H2O2 for 30 min. Total Akt-1 protein levels were determined in a Western blot using GAPDH protein levels for normalization. In a 
subsequent step, a serine 473 phosphorylation-specific Akt-1 (pAkt) antibody was used on the same membrane. 
 
Thus, the dependence of pro-oxidant properties on quinone toxicity was elaborated further using cells with 
high (HepG2), intermediate (4Te) and low (HEK293, SH SY5Y) levels of NQO1 [Haefeli et al. 2011 and personal 
communication by D. Robay], wherein extent of DNA damage promoted by 24-hour incubation with 10 µM 
quinones in normal growth medium was investigated. Therefore, the percentage of cells positive for 
immunochemical staining against a phosphorylated histone, γH2AX, which indicates DNA double strand breaks, 
was counted. HepG2 cells showed a high basal level of γH2AX-positive cells (25%) compared to HEK293, SH 
SY5Y, and 4Te cells (4%, 2%, and 0.5%, respectively) [Figure 34A-D]. In HepG2 cells, impact of quinones on 
DNA damage levels was rather marginal: both idebenone and QS-10 showed no substantial alteration in γH2AX-
positive cells (22% and 26%, respectively), whereas CoQ1 slightly increased DNA damage (33%) and CoQ10 even 
led to a decrease in of γH2AX signal (16%) [Figure 34A]. In contrast, CoQ1 elicited high genotoxicity in the two 
cell lines with low NQO1 levels, HEK293 and SH SY5Y, as seen in the massive elevation of γH2AX-positive cells 
(34% and 10%, respectively) [Figure 34B&C]. In these two cell lines,  idebenone and CoQ10 did not alter γH2AX-
positive cell number. In contrast, QS-10 elevated the number of γH2AX-postive cells to 14% in HEK293, but not 
SH SY5Y cells. [Figure 34B&C]. In a primary human 4Te myoblasts, idebenone slightly increased DNA damage-
positive nuclei to 1.2% [Figure 34D]. The highest, approximately four-fold increase of DNA double strand breaks 
was seen in CoQ1-treated cells (2.0%). As seen before, CoQ10 and QS-10 did not alter the frequency of γH2AX-
positive cells (0.5 and 0.7%, respectively) [Figure 34D]. A similar picture was detected in primary human 
fibroblasts. After 72-hour incubation with 10 µM quinones, only fibroblasts treated with CoQ1 were positive for 
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the nuclear DNA damage marker γH2AX, while for all other quinones, including idebenone, no increase above 
basal levels could be detected [Figure 34B]. 
Contradictory to previously stated assumptions that CoQ1 would exhibit pro-oxidant effects in cells whose 
NQO1 levels are to low to detoxify the compound, CoQ1 induced genotoxicity regardless of NQO1 expression 
levels in cells. Thus, promotion of DNA double strand breaks by CoQ1 must be regarded as independent of its 
role in energy metabolism. 
 
Figure 34: CoQ1 Elicits DNA Damage Regardless of NQO1 Content.  
DNA double strand breaks were stained using γH2AX in (A) HepG2, (B) HEK293, (C) SH-SY5Y, and (D) 4Te cells cultured in normal 
growth medium. After 24-h incubation with 10 µM quinones, cells were fixed and stained against the DNA damage marker γH2AX. More 
than thousand cells per condition were counted manually for each condition and γH2AX-positive cells were expressed as percentage of the 
total number of cells counted (stained using DAPI). (E) Human primary fibroblasts were incubated for 72 h with quinones (10 µM) under 
ambient conditions before cells were fixed and stained against the DNA damage marker γH2AX (red). DAPI dye was used as nuclear counter 
stain (blue). Scale bar: 10 µM. 
 
In addition to these data, a pro-oxidative function for some short-chain quinones such as idebenone was 
discussed [Degli Esposti et al. 1996, Lenaz et al. 2002, Genova et al. 2003, Lenaz et al. 2007, and Fato et al. 2008]. 
These authors suggested that idebenone and other short-chain quinones inhibited the electron transport from 
NADH to CoQ10 via complex I, but not from NADH to molecular oxygen. Thus, the pro-oxidant effect of 
idebenone was mainly attributed to its complex I-inhibiting characteristics. Therefore, potential adverse effects 
had to be assessed. 
Pro-oxidative agents harm cells by demolishing their macromolecules such as proteins, DNA, or lipids. Even 
though idebenone was described to reduce lipid peroxidation after toxic insults in vitro and in vivo [Suno and 
Nagaoka 1989a&b, Suno et al. 1989, Cardoso et al. 1998, Mordente et al. 1998, and Abdel Baki et al. 2010], it was 
of interest if exposure to quinones could lead to increased lipid peroxidation. Therefore, human fibroblasts were 
incubated for three days with 10 µM quinone before the magnitude of lipid peroxidation was assayed using the 
fluorescent dye BODIPY. Not surprisingly, 72-h incubation with 10 µM idebenone alone did not increase lipid 
peroxidation in human fibroblasts (98±2%) [Figure 35A]. Long-term effects on lipid peroxidation induced by 
other benzoquinones were investigated as well. Similar to idebenone, CoQ10 did not alter the degree of oxidative 
damage of the membrane at all (97±2%). In contrast to idebenone, CoQ1 elevated lipid peroxide levels after 
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three days to 176% of DMSO-treated cells. Similarly, CoQ0 caused a massive, 2.5-fold increase in lipid 
peroxidation (254%) [Figure 35A].  
Since quinones are redox active compounds, it was of interest to observe how they behave under conditions of 
elevated ROS levels. These conditions were induced by short-term addition of H2O2 to the cells. The reduced 
form of quinones, in particular idebenone, is thought to be oxidized by ROS and thereby attenuating oxidative 
damage [Germonel et al. 2002]. However, one-electron reduction of quinones gives rise to semiquinones which 
could in turn act to generate ROS [Monks et al. 1992]. Therefore, human myoblasts were pretreated with 10 µM 
quinone and the fluorescent dye CM-H2DCFDA for 15 min before 10 µM H2O2 was added for another 15 min 
[Figure 35B]. Idebenone and its metabolite QS-10 both slightly aggravated this rapid oxidative damage by 
increasing the H2O2-induced fluorescence signal by 115±10% and 120±8% (mean±SEM), respectively. 
Interestingly, CoQ10 did not substantially prevent ROS levels (95±6%). In contrast, CoQ0, an agent otherwise 
described to induce ROS itself, reduced H2O2-induced ROS by 30±2% [Figure 35B]. Even though 10 µM 
idebenone slightly exacerbated ROS levels after addition of H2O2, lower concentrations of idebenone showed 
antioxidant effects [Figure 35C]. Indeed, idebenone reduced H2O2-induced ROS levels in a dose-dependent 
manner: as little as 100 pM idebenone reduced ROS levels by 12±3% (mean±SEM) and this antioxidant 
amelioration augmented with increasing concentrations reaching 34±3% at 1 µM idebenone [Figure 35C]. 
In conclusion, idebenone might have a mild pro-oxidant effect; however, this property of idebenone was not 
able to induce genotoxic damage or lipid peroxidation. 
 
 
Figure 35: Quinones Affect ROS Levels Differently. 
(A) Human fibroblasts were treated with 10 µM quinones for 72 h, before amount of lipid peroxidation was measured using the fluorescent 
dye BODIPY. Changes in fluorescence signal were calculated as percentage of values from DMSO-treated cells. In human 4TE myoblast cells, 
CM-H2DCFDA fluorescent dye was co-incubated with (B) 10 µM different quinones or (C) different concentrations of idebenone for 15 min 
before 10 µM H2O2 was added for another 15 min. Bars represent (A) mean of two independent experiments or (B&C) mean + SEM of two 
to 15 independent experiments. 
3.13 Idebenone Protects Cells from Oxidative Stress-Induced Cell Death 
Idebenone had thus elicited negative effects on ATP levels [Figure 24B] and proliferation [Figure 32] in NQO1-
deficient cells. However, in cells expressing significant levels of NQO1, idebenone improved resistance against 
energy failure induced by complex I inhibitor rotenone [Figure 15] and idebenone also reduced toxic lactate 
production in MELAS cybrids [Figure 31]. This is in line with a number of reports describing the rescue from cell 
death of exogenously stressed cells by idebenone [Yerushalmi et al. 2001, Gumpricht et al. 2002, Jauslin et al. 
2002, 2003, and 2007, Gil et al. 2003, and Chapela et al. 2008]. The authors of these reports mostly accounted a 
potential antioxidant effect of idebenone for averting the destruction. Therefore, idebenone-mediated survival 
after strong oxidative damage induced by an exogenous pro-oxidant was assessed.  
When human lymphoblastoid cells were subjected to radiation-induced DNA damage after two-day 
cultivation, idebenone reduced cell death observed two days after radiation [personal communication by M.F. 
Lavin, Queensland Institute of Medical Research, Australia]. The same regime was selected for studying the effect 
on survival by idebenone with the exception that H2O2 was employed as stressor. Experiments were conducted 
in rat L6 myoblasts, since they expressed high levels of NQO1 [personal communication by D. Robay]. After two-
day cultivation in normal growth medium, the medium was with 200 µM H2O2 in PBS replaced for 30 min, 
before old medium was restituted again. Idebenone (10 µM) was added at different time points relative to the 
stress. Two days after the toxic insult, survival was assayed using two fluorescent dyes which exploited the loss 
in membrane integrity found in dead cells. The cell-permeable calcein exhibits green fluorescence upon cleavage 
by cytosolic esterases. The red ethidium homodimer binds to DNA but is not able to cross membranes. Thus, 
red nuclei represented dead cells, whereas green cell bodies stained living cells. 
As anticipated, PBS-treated control cells showed no signs of cell death or even impaired proliferation; the cells 
developed their characteristic spindle-shaped form regardless of the presence of idebenone in the medium 
[Figure 36]. In contrast, a majority of cells subjected to H2O2 treatment were dead 48 h after pro-oxidant 
exposure. The same result was observed when 10 µM idebenone was added to the cells at 30 min or 24 h after 
stress. In contrast, when cells were pre-treated with 10 µM idebenone either 1 or 24 h prior to H2O2 stress the 
number of surviving cells substantially increased [Figure 36], indicating a protective effect of idebenone on 
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survival. However, the morphology of cells still alive differed dramatically from cells not subjected to H2O2 
treatment: instead of the normal elongated spindle shape they appeared rounded up, suggesting that the cells 
were in a vulnerable condition. Nevertheless, the survival of total cells by pre-treatment with idebenone was 
impressive. When idebenone was administered simultaneously with H2O2, however, the rescue was even more 
pronounced for cells were not only almost completely protected from cell death but they also showed normal 
morphology [Figure 36]. 
 
 
Figure 36: Pre-Treatment with Idebenone Increases Survival of Myoblastoids after Hydrogen Peroxide Stress.  
L6 myoblasts were treated with DMSO or 10 µM idebenone either one (-1 h) or 24 h (-24h) prior, simultaneously to (co), or 30 min (+0.5 h) 
or 24 h (+24h) after a 30-min stress with PBS or H2O2. Cells were allowed to recover in the previous medium for 48 h after the stress, before 
cells were stained for survival. Calcein (green) labeled living cells, whereas ethidium homodimer (red) was used to tag dead cells. Scale bar: 
500 µM. 
 
The observation of idebenone-mediated protection against cell death induced by H2O2 was then also quantified 
by calculating the percentage of living cells relative to the total amount of cells. In absence of idebenone, the 
percentage survival amounted to nearly 50% after cells were stressed for 20 min by H2O2 [Figure 37A]. When 10 
µM idebenone was added after H2O2 treatment, similar proportions of viable cells were observed (50±15% and 
50±12% when idebenone was added six or 24 hours after stress, respectively). As observed under the microscope 
[Figure 36], pre- and co-treatment of idebenone with H2O2 led to an increase in cell survival [Figure 37A]. 
Pretreatment with idebenone elevated survival with statistic significance (78±8% (**p < 0.01) and 75±6% (*p < 
0.05) when idebenone was added 24 or one hour prior to H2O2 shock, respectively). Intriguingly, simultaneous 
administration of idebenone and H2O2 led to only 72±13% viable cells, despite the clearly visible protection 
observed under the microscope [Figure 36]. This surprisingly low proportion could be partially explained by the 
relatively higher area which was covered by morphologically healthy cells.  
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In fibroblast subjected to 15-min H2O2 treatment, idebenone concentrations lower than 10 µM showed a much 
better antioxidant effect [Figure 35C]. Thus, a dose dependency of idebenone on cell survival was of interest as 
well. In contrast to the short-term antioxidant effect in fibroblasts, dilution of idebenone did not increase its 
capacity for protection [Figure 37B]. On the contrary, the proportion of surviving cells gradually decreased with 
descending concentrations. When cells were pre-treated with idebenone 24 h before treatment with H2O2, a 
concentration of 3.33 µM, 1.11 µM, or 0.37 µM idebenone solely amounted for 72±4%, 70±3%, or 63±6% 
survival, respectively, in contrast to 51±9% survival in absence of idebenone [Figure 37B]. 
 
 
Figure 37: Survival of Rat Myoblasts after Hydrogen Peroxide Stress.  
Cultured rat L6 myoblasts were seeded in 96-well plates in normal growth medium. After 48 h, cells were treated with 200 µM H2O2 in PBS 
for 30 min before cells were allowed to recover in the medium they were cultivated seeded in before H2O2 shock for additional 48 h. Percent 
Survival was calculated as percentage of live cells relative to the sum of live and dead cells as detected using the fluorescent dyes calcein and 
ethidium homodimer. (A) Cells were treated with 10 µM idebenone at different time points (one or 24 h before or six or 24 h after H2O2 
shock, or simultaneously with H2O2 shock). p* < 0.05, p** < 0.01, two-way ANOVA with Bonferroni’s Multiple Comparison tests. (B) Cells 
were pretreated with different concentrations of idebenone (0.37 – 10 µM) 24 h prior to H2O2 shock. p** < 0.01, one-way ANOVA with 
Bonferroni’s Multiple Comparison test. 
 
The surprising finding that contrary to all other combinations tested, co-treatment of idebenone and H2O2 over 
the short period of 30 min protected cells almost completely from toxicity could be attributed to a potential 
direct interaction of these two compounds. In this scenario idebenone would directly interact and detoxify H2O2 
outside the cell, so that in essence the cells are not exposed to H2O2 at all. To investigate this possibility, a redox-
sensitive dye, CM-H2DCFDA, was employed for investigating this issue. First, the proper detection of H2O2 by 
CM-H2DCFDA was analyzed. In a cell-free assay, 2.45 M H2O2 yields a 10-fold higher fluorescence than PBS 
control [Figure 38A]. This high concentration was used, since lower concentrations—as the one employed for the 
survival assays (200 µM)—did not detectably alter dye fluorescence [data not shown]. Second, a potential 
perturbing interference of idebenone with the dye was excluded, since idebenone did not change CM-
H2DCFDA fluorescence at the henceforward used concentrations [Figure 38A].  
Surprisingly, but consistent with the observation from cell based assays, increasing concentrations of idebenone 
markedly reduced the H2O2-mediated oxidation of CM-H2DCFDA [Figure 38B]. At an approximately 25 million-
fold molar excess of H2O2 in comparison to idebenone (10 µM), the quinone suppressed the fluorescence signal 
to nearly half of control, which implies a catalytic mode of action.  
Since its quinone ring is already fully oxidized, classical chemistry would suggest that idebenone could solely 
be oxidized at the hydroxyl group of the alkyl tail. Hence, if the reduced fluorescence was the result of direct 
oxidation of idebenone at its primary alcohol group by H2O2, both decylQ and QS-10 would not be converted by 
H2O2, since decylQ lacks the primary alcohol moiety and the corresponding carbon of QS-10 is already fully 
oxidized. However, both decylQ and QS-10 behaved similarly as idebenone in this assay [Figure 38B]. To exclude 
involvement of the two methoxy substituents at the quinone ring, the plastoquinone analogs of idebenone 
(SNT210486) and decylQ (SNT210201), in which the methoxy groups are interchanged by methyl groups were 
also tested and again showed no deviant characteristics. 
Another H2O2-sensitive dye, MitoSOX™ Red mitochondrial superoxide indicator or MitoSOX in short, was 
used to eliminate artifacts derived by a putative interaction between idebenone and CM-H2DCFDA. Again, the 
same results were obtained with this chemically different dye [Figure 38C]. 
An interesting finding is the velocity of the reaction between quinone, H2O2 and dye. If one assumed that 
oxidation of the dye under the experiment’s conditions was irreversible, an accumulation of fluorescence signal 
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over time would occur in sham-treated samples. Not only was that the case for the controls, but also for quinone 
containing samples [data not shown]. In addition, the reduced fluorescence signal of quinone-treated samples in 
contrast to controls abated after prolonged incubation as well [Figure 38D], suggesting that the interaction 
between quinone and H2O2 could decelerate, but not prevent the total oxidation of dye.  
Chemically, these findings were challenging to discuss, since there is no reasonable mechanism by which an 
oxidized quinone and H2O2 could interact. Nonetheless, these results suggest that idebenone is able to detoxify 
H2O2 in solution and that therefore, a protection during co-treatment of idebenone and H2O2—even at an 
approximately 10,000-fold lower concentration than used in this assay—cannot be attributed to cellular 
mechanisms but possibly cell-independent interactions of these compounds in the medium. Thus, the increased 
survival of rat myoblastoids observed when idebenone and H2O2 were added to cells simultaneously [Figure 36] 
has been dismissed for further experiments investigating the cellular causes for prevention of cell death.  
 
 
Figure 38: Idebenone Reduces Hydrogen Peroxide in Solution.  
H2O2 causes oxidation of redox-active fluorescent dyes such as CM-H2DCFDA (1.7 µM) and MitoSOX (1 µM). (A) Treatment with 2.45 M 
H2O2 (black bar) massively increases fluorescence signal from CM-H2DCFDA; whereas idebenone (white bars) does not interact with the 
dye. Bars represent mean ± SD of four simultaneous measurements. (B) Different quinones such as idebenone (ide), decylQ (DQ), QS-10 as 
well as two plastoquinone derivates produced in-house, SNT210201 (S201) and SNT210486 (S486); reduce the ability of H2O2 to oxidize 
CM-H2DCFDA in a dose dependent manner. (C) Consistently, the same result was observed with MitoSOX as fluorescent dye after 1 min. 
(D) After 10 min, the reaction was completed. Fluorescence signal was normalized to the control (white bars) and the concentrations used 
were 0.37 µM (bright grey), 1.11 µM (grey), 3.33 µM (dark grey) and 10 µM quinone (black bars). Bars represent mean ± SD of three to six (0 
and 10 µM quinone) simultaneous measurements.  
 
It was then of interest if the cell survival mediated by pre-treatment with idebenone in NQO1-expressing L6 
myoblasts was mediated by an antioxidant effect or by ameliorating a potential decrease in ATP induced by 
H2O2. Treatment with 10 µM idebenone for 30 h did not affect ATP levels in 25 mM glucose-containing medium 
(101.6±3.0% compared to 100.0±7.5% in DMSO-treated cells) [Figure 39A]. Interestingly, neither did the 
incubation with 200 mM H2O2 for up to 30 min, when ATP levels were measured immediately after this stress. 
However, when cells were allowed to recover for 30 min in the medium they were incubated with before the 
stress after 30-min incubation with 200 mM H2O2, ATP levels dropped to 11.3±0.3% and did not improve if time 
for recovery was prolonged to six h (12.4±9.6%). In cells pretreated with idebenone, ATP levels also decreased to 
7.7±1.3% after 30-min recovery. However, after 6-h recovery following 30 min of H2O2 stress, ATP levels were 
rescued to 73.9±13.0% only when cells were pretreated with idebenone [Figure 39A]. 
Since H2O2 is a potent pro-oxidant, it is conceivable that idebenone reduces oxidative damage induced by 
H2O2 via an antioxidant mechanism [Figure 39B]. Indeed, ROS levels were increased already after 1-min 
incubation with H2O2 by 55.4±13.2%, and after 5 min, ROS levels were doubled (201.8±26.5% compared to 
100.0±7.9% in untreated cells). After 10 min, a plateau of a four-fold increase in ROS was achieved 
(403.7±93.8%), which was also detectable after 30 min (415.1±18.3%). Pre-treatment with 10 µM idebenone 
dramatically protected from this short-term increase in ROS: up to 20-min incubation with H2O2, idebenone 
prevented an increase in ROS (104.5±8.7%). After 30 min, however, ROS levels were doubled (203.0±51.9%); an 
effect observed after as little as five minutes in cells not pre-treated with idebenone. Interestingly, cells which 
were allowed to recover after the 30-min stress with H2O2 showed less oxidative damage than cells not distressed 
by H2O2 [Figure 39B].  
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Figure 39: ATP and ROS Levels after Hydrogen Peroxide Stress:  
L6 myoblasts were pretreated with DMSO (empty bars) or 10 µM idebenone (filled bars) for 24 h before they were stressed with 200 mM 
H2O2 for up to 30 min. After that, cells were allowed to recover for different time intervals before (A) ATP and (B) ROS (CM-H2DCFDA) 
levels were measured and standardized to protein levels. Bars represent average + stdev of triplicates from a typical experiment. 
 
These results raised the question whether the H2O2-induced acute oxidative damage is followed by energy-
demanding repair mechanisms after removal of the pro-oxidant which possibly could involve a 
transcriptional/translational response. To see if such mechanisms depend on protein synthesis or gene expression, 
the translation inhibitor cyclohexin and the transcription inhibitor actinomycin D were administered together 
with 10 µM idebenone 24 h prior to H2O2 treatment [Figure 40A&C]. It was further of interest, if inhibition of 
NQO1 by dicoumarol could reduce the capacity of idebenone to protect cells from death by increased oxidative 
stress. In this series of experiments, 24-h pre-treatment with 10 µM idebenone again showed a statistically 
significant protection against H2O2-induced cell death (79±2% compared to 60±8% living cells in DMSO-treated 
cells; **p < 0.01) [Figure 40A]. Intriguingly, pre-treatment with cyclohexin and actinomycin D increased the 
probability of survival by 25±3% or 12±7%, respectively. Addition of idebenone to these cells did not 
significantly ameliorated survival further (89±3% and 86±2%, respectively). Inhibition of NQO1 by dicoumarol 
did not affect the protective effect of idebenone (81±4% living cells). Thus, pre-treatment with idebenone did 
not seem to induce expression of protective genes which in turn could attenuate the harm done by a latter 
oxidative stress as induced with H2O2. 
However, idebenone could also promote the expression of genes involved in repair mechanisms after H2O2 
treatment. To test this, cyclohexin and antimycin D were added immediately after the 30 min stress paradigm 
[Figure 40B&D]. Idebenone protected cells from dying to an extent comparable to previous experiments 
(79±9% living cells) [Figure 38A and Figure 40A], but since an unusually high percentage of DMSO-treated 
control cells subjected to the same stress survived as well (65±7%), the protection against cell death mediated by 
idebenone was not statistically significant. Similarly to the results obtained when pre-treating cells with 
cyclohexin and actinomycin D, the two inhibitors protected L6 myoblastoids from H2O2-induced cell death 
when administered after the stress as well (80±5% and 75±15% living cells, respectively). Again, cyclohexin and 
actinomycin D did not reduce the ability of idebenone to protect cells from death (78±9% and 90±4% living 
cells, respectively, with idebenone added to cells 24 h before H2O2 stress).  
To check whether idebenone might elicit its cytoprotective action via interaction with NQO1 explicitly after 
addition of H2O2, the enzyme was inhibited by dicoumarol only posterior to the 30-min H2O2 incubation. 
Similarly as when administered before H2O2 stress, post-treatment with dicoumarol did not alter the 
cytoprotective effect of idebenone (76±7% living cells). Dicoumarol itself did also not influence the number of 
living cells per se (63±7%) [Figure 40B].  
As expected, pre-treatment of cells with cyclohexin and actinomycin D reduced the total cell number from 
approximately 1,000 cells per image to roughly 500 or 550 cells per image, respectively [Figure 40C]. In contrast, 
when cyclohexin and actinomycin D were added after two-day cultivation and 30-min H2O2-stress, the cell 
number did not vary compared to control cells [Figure 40D]. This suggested that after two-day cultivation, that 
proliferation had ceased and cells were in G0 phase of the cell cycle. Idebenone or dicoumarol had no influence 
on total cell number regardless of the time point of administration [Figure 40C&D]. 
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Figure 40: Idebenone-Mediated Survival Is Independent of Transcription, Translation and NQO1 Enzymatic 
Activity.  
Cultured rat L6 myoblasts were seeded in 96-well plates in normal growth medium. After 24 h, cells were treated with 10 µM idebenone and 
subsequently, 24-h after that, cells were treated with 200 µM H2O2 in PBS for 30 min before cells were allowed to recover in the medium 
they were cultivated seeded in before H2O2 shock for additional 48 h. An inhibitor of transcription, actinomycin D (AD; 1 µg/ml), an 
inhibitor of translation, cyclohexin (CHX; 1 µg/ml), and an NQO1 inhibitor, dicoumarol (Dic; 20 µM) were added either simultaneous with 
idebenone (A&B) or together with resuspending in the old medium after H2O2 shock (C&D). (A&C) Percent survival was calculated as 
percentage of live cells relative to the sum of live and dead cells as detected using the fluorescent dyes calcein and ethidium homodimer. Sum 
of live and dead cells are depicted as total cell number in (B&D). p** < 0.01, two-way ANOVA with Bonferroni’s Multiple Comparison tests.  
3.14 Alteration in Gene Expression as a Mode of Action of Idebenone? 
Even though idebenone-mediated survival of rat myoblastoids two days after H2O2 treatment in vitro was 
independent of translation and transcription [Figure 40], it was of interest whether long-term administration of 
idebenone might still initiate expression of specific genes in vivo. To find out which genes or pathways—if any—
were differently expressed after treatment with idebenone, 200 mg/kg p.o. idebenone was administered to 
healthy mice for three weeks and differences in gene expression between treated and untreated control groups 
was analyzed using gene chip-based micro arrays. The strain C57Bl/6 was selected since it is one of the most 
widely used inbred strains. Thus, three advantages were taken by this choice: (i) individuals of inbred strains do 
not vary largely in their genome, (ii) since C57Bl/6 mice is a common background for transgenic mice, further 
studies with transgenic animals based on this strain could be compared to this one, and (iii) potential results 
obtained in this experiment then could be more easily evaluated in regard to findings of others due to the high 
usage of this strain. Animals were started to be given idebenone at the age of nine weeks when development was 
thought to be completed and thus, genetic programs involved in development did not interfere with the results. 
To avoid potential differences in individual gene regulation dependent on the female reproduction cycle only 
male animals were used. In humans, idebenone was described to reduce cardiac hypertrophy in left ventricles of 
FRDA patients [Hausse et al. 2002] and ameliorate cardiac parameters in the mdx mouse [Buyse et al. 2009], 
indicating that idebenone not only reached the heart but also accumulated in sufficient concentrations to induce 
observable alterations Furthermore, due to the high energy demand of the heart muscle, and therefore a high 
density of mitochondria, suggested that it was likely to observe a potential effect of idebenone in this tissue.  
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After treatment of male C57Bl/6 mice with 200 mg/kg idebenone for three weeks, gene expression patterns 
induced by idebenone compared to sham treatment (n = 5) in the left ventricle of the heart were analyzed using 
one Affymetrix mouse gene chip per animal to ensure statistical power. First, the potency of idebenone 
treatment was investigated using principal component analysis (PCA), a statistical method reducing the 
dimensionality of thousands of possibly correlated variables to three uncorrelated components which can be 
visualized in a three-dimensional Cartesian coordinate system. The more distinct the spatial separation between 
the ellipsoids enclosing the representatives of two groups the more pronounced are the differences between 
these groups.  Idebenone, in this tissue and using this treatment regime, appears to have a moderate effect on 
gene expression, since its ellipsoid overlaps widely with the one of the mock-treated group [Figure 41A]. The 
homogenous distribution of the single points representing individual animals also excludes the possibility of 
responder vs. non-responder groups.  
Thus, PCA indicated that the effects of idebenone on gene expression were to be found in a small number of 
genes if at all. Indeed, when expression patterns between idebenone and control groups were analyzed using 
analysis of variances (ANOVA) models on the basis of single genes, no differently expressed genes were 
detected. Lowering the barrier by employing a less solid statistical method, the Student’s t-test, a small number 
of genes was found to be expressed differently in animals treated with idebenone. Using Partek® software, 677 
genes exhibited significantly altered scores (p* < 0.05); with a maximum fold change of 1.85 compared to control 
animals. Another program, Agilent Genespring GX 10, was employed for confirmation of these results and 
presented comparable results: 616 differentially expressed genes and a maximum fold change of 1.79 (p* < 0.05). 
Results of single gene analysis were visualized in a volcano plot which localized samples according to the binary 
logarithm of the fold change in the abscissa and the decimal logarithm of the statistical p-value in the ordinate 
[Figure 41B]. Thereby, samples which exceed (i) a certain arbitrarily set threshold in fold change of expression 
levels between groups and (ii) a required statistical significance could be visually separated from samples which 
did not meet the demands. A selection of the 54 genes which were expressed differently with statistical 
significance (p* < 0.05, Student’s t-test) and exceeding a cut-off of ±1.3-fold change as computed using Partek® 
software are listed in Table 4. However, some genes identified such as the testis-specific H1fnt or the sperm-
specific Odf3l1, for example, were not expected to be expressed in heart tissue at all. Furthermore, many 
olfactory receptors were found to be differently expressed [omitted in Table 4]. 
The genes which were selected due to their statistical significant (p < 0.05; Student’s t-test) difference in 
expression exceeding ±30% between idebenone- and vehicle-treated groups were then further analyzed on the 
basis of individual expression levels in each animal. In a so-called heat-map, binary logarithm-transformed signal 
intensities—i.e. the expression level as assayed by the binding strength on the chip—of a particular gene from a 
particular animal were arrayed in a matrix spanned by single animals in vertical and single gene in horizontal 
direction [Figure 41C]. Hence, the heat-map can be viewed as a sequence of color-coded dot-plots in a two-
dimensional space [Figure 41D]. 
The amount of distinction between red and blue quadrants in heat maps is a measure for the discrimination 
between groups according to differences in their gene expression. Since statistical significance was only reached 
with a rather inapt model (Student’s t-test) and the fold change between averaged expression levels of particular 
genes was rather low (maximum fold change was 1.79 or 1.85 using either Partek® or Aligent Genespring GX10 
software, respectively), the separation into two times two uniformly colored rectangles fell below desired 
proportion [Figure 41C].  
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Figure 41: Quality Control of Micro Array Data.  
(A) Principal component analysis is a statistical method used to reduce the dimensionality of thousands variables to three uncorrelated 
components. Single dots represent components for individual animals either treated with idebenone (blue) or vehicle (red). Ellipsoids 
incorporate points of individual animals of a group. (B) Volcano plot was used to visually separate single genes that are differently expressed. 
Green lines indicate cut-offs for p-value of 0.05 and for fold change of 1.3. Red dots indicate probes that are significantly differently expressed 
more than ±1.3-fold compared to control and (C) were further analyzed for the expression in individual animals using a heat map. Individual 
animals and hierarchically clustered genes are mounted in rows and columns, respectively, with log2-transformed signal intensities indicated 
by color code. (D) The differential expression for a single gene can also be depicted in a dot plot with arbitrary units for expression levels, as 
shown for the gene hmgsc2. Dots represent individual animals treated with idebenone (blue) or vehicle (red) whereas boxes extend from the 
first to the first to the third quartile with a mark for the median and the whiskers represent the 10th and 90th centile of each treatment. 
Calculations and visualizations were computed using (A; dot plot in D) Partek® Genomic Suite and (B-D) Agilent Genespring GX 10 
software. 
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Table 4: List of Genes Differently Expressed by Idebenone Treatment Selected for Fold Change Exceeding 
Factor 1.3.  
Genes found to be differently expressed after three-week idebenone treatment in mouse hearts exceeding 1.3-fold change from control 
animals and reaching significance (p < 0.05) as assessed using Partek® Genomic Suite™ software. Fold change is relative to control levels.  
 
Gene 
Symbol 
Gene Name Fold 
change 
p-value 
Mapksp1 MAPK scaffold protein 1 1.85 0.0281 
Nfyc nuclear transcription factor-Y gamma 1.81 0.0470 
Ifnk interferon kappa 1.61 0.0125 
Dub2a deubiquitinating enzyme 2a 1.53 0.0445 
Xpo7 exportin 7 1.47 0.0097 
Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 1.46 0.0370 
Med29 mediator complex subunit 29 1.43 0.0257 
Tdg thymine DNA glycosylase 1.36 0.0462 
Ccdc12 coiled-coil domain containing 12 1.35 0.0454 
Fgf18 fibroblast growth factor 18 -1.30 0.0085 
Zfp68 zinc finger protein 68 -1.31 0.0014 
Pcdhb15 protocadherin beta 15 -1.31 0.0004 
Mpzl2 myelin protein zero-like 2 -1.32 0.0499 
Odf3l1 outer dense fibre of sperm tails 3-like 1 -1.33 0.0333 
H2-DMb2 histocompatibility 2, class II, locus Mb2 -1.33 0.0354 
Ctla2a cytotoxic T lymphocyte-associated protein 2 alpha -1.33 0.0080 
Il17rd interleukin 17 receptor D -1.33 0.0375 
V1rd20 vomeronasal 1 receptor, D20 -1.35 0.0270 
Resp18 regulated endocrine-specific protein 18 -1.36 0.0085 
Gng8 guanine nucleotide binding protein (G protein), gamma 8 -1.36 0.0137 
Etd embryonic testis differentiation -1.36 0.0059 
Sfrs12ip1 SFRS12-interacting protein 1 -1.36 0.0412 
H1fnt H1 histone family, member N, testis-specific -1.37 0.0003 
Sap18 Sin3-associated polypeptide 18 -1.38 0.0228 
Ppbp pro-platelet basic protein -1.38 0.0455 
Hist1h4h histone cluster 1, H4h -1.41 0.0316 
Tcstv1 2-cell-stage, variable group, member 1 -1.42 0.0085 
Cd24a CD24a antigen -1.43 0.0322 
Fbxw14 F-box and WD-40 domain protein 14 -1.46 0.0000 
Dnajc17 DnaJ (Hsp40) homolog, subfamily C, member 17 -1.47 0.0200 
Eml5 echinoderm microtubule associated protein like 5 -1.49 0.0103 
V1rc22 vomeronasal 1 receptor, C22 -1.50 0.0291 
Hist1h1b histone cluster 1, H1b -1.58 0.0071 
Krtap5-4 keratin associated protein 5-4 -1.76 0.0089 
 
The failure to find differently expressed genes after idebenone treatment using ANVOA-based statistical 
models and the finding of differently regulated genes alien to heart tissue using Student’s t-test questioned 
whether the list of genes in Table 4 was trustworthy. In order to test if the significantly differently regulated 
genes found using gene chip micro arrays were reliable; a selection thereof was again checked using quantitative 
real time polychain reaction (qPCR). Therefore, complementary DNA (cDNA) from left heart ventricle 
samples, on which the micro array was performed, was used as a template to quantify changes in gene expression 
using qPCR. Intriguingly, from the selection of 17 genes found differently expressed in micro array experiments, 
only three genes (i) showed comparable expression levels in gene chip and qPCR experiments and (ii) reached 
statistically significance (p < 0.05) [Table 5]. These three genes encode the 3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 2 (HmgCoA; +46% or +41% up-regulated by idebenone in gene chips or qPCR 
experiments, respectively), a key enzyme in ketogenesis; thymine DNA glycosylase (Tdg; +36% or +53% up-
regulated by idebenone in gene chips or qPCR experiments, respectively), an enzyme central for the defence 
against DNA damage; and pro-platelet basic protein (Ppbp; -38% or -33% up-regulated by idebenone in gene 
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chips or qPCR experiments, respectively), a growth factor also involved in immunological responses [Table 5]. 
The other genes tested in qPCR experiments did neither reach significance nor exhibited comparable values of 
fold change in gene expression levels. Thus, up- or down-regulation of the remaining 14 genes tested with qPCR 
seemed to be false positives. 
These results combined with PCA findings and the demand to use Student’s t-test in order see differently 
regulated single genes, led one to conclude that idebenone treatment did not lead to an alteration in gene 
expression on the basis of single genes. 
 
Table 5: Confirmation of Micro Array Data using qPCR.  
The fold change in gene expression induced by three-week treatment with 200 mg/kg idebenone as quantified using gene chip micro array 
was controlled using quantitative real time polychain reaction (qPCR) in homogenates of left heart ventricle from 12-week old male C57Bl/6 
mice.   
 
 Micro Array qPCR 
 
fold 
change p 
fold 
change p 
Mapksp1 1.85 0.028 0.96 0.349 
Nfyc 1.81 0.047 0.93 0.085 
Olf550 1.74 0.030 1.19 0.307 
Xpo7 1.47 0.010 1.05 0.525 
HmgCoA 1.46 0.037 1.41 0.044 
Med29 1.43 0.026 1.01 0.757 
His1h1b 0.42 0.007 0.92 0.463 
Tdg 1.36 0.046 1.53 0.037 
Ccdc12 1.35 0.045 0.95 0.325 
Fgf18 0.70 0.008 0.96 0.676 
Zfp68 0.69 0.001 0.95 0.225 
Pcdhb15 0.69 0.000 0.96 0.618 
Ppbp 0.62 0.045 0.67 0.030 
Hist1h4h 0.59 0.032 0.94 0.328 
cd24a 0.57 0.032 0.84 0.223 
Dnajc17 0.53 0.020 1.04 0.481 
Eml5 0.51 0.010 0.99 0.846 
 
Since idebenone did not seem to reliably influence gene expression on the basis of single genes, it was of 
interest if there were at least changes in gene expression by idebenone on the basis of parts or even the whole 
genome. In other words: did idebenone—despite failure in changing expression levels of single genes—
transcriptionally affect entire pathways? That is: were there changes in expression levels of a set of particular 
genes whose products are annotated to a biological pathway which were slight and insignificant on the basis of 
single gene expression but not on the basis of the entire pathway? In order to address these questions, two gene 
ontology analysis models were employed which were based on a larger set of genes. The first computed which 
biological functions were transcriptionally affected by idebenone treatment based on changes in gene expression 
of the whole genome [see Table 8 on page 161 in the appendix]. This analysis disclosed that idebenone affected 
the expression of genes which are involved in biological functions involved in calcium homeostasis and lipid 
metabolism, amongst others. Using a second calculation model for finding gene ontology of biological functions 
which was based solely on the genes which reached significance in the Student’s t-test, similar results were 
obtained [Table 7 on page 162 in the appendix].  
Thus, the finding that lipid metabolism seemed to be involved in the transcriptional reaction to idebenone 
treatment combined with the finding that HmgCoA—an enzyme which is employed to produce ketone bodies 
from fatty acids as energy source when glucose levels are low—was significantly up-regulated after three weeks 
of idebenone administration, led to the question if idebenone might somehow shift energy consumption from 
using glucose to using fatty acids and ketone bodies as fuel.  
3.15 Metabolic Effects of Idebenone in Vivo 
The gene chip experiments provided some hints that idebenone might slightly alter energy consumption in 
vivo. Since idebenone was involved in mitochondrial energy production in vitro as well [see 3.3], it was of interest 
if idebenone might also lead to alterations of ATP levels in vivo. In order to see if idebenone might change 
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OXPHOS in vivo, a tissue with levels of mitochondria such as m. soleus was selected for analysis. The 
experimental setup and treatment regime was identical to the gene chip experiment. 
Three-week incubation of male C57Bl/6 mice with 200 mg/kg idebenone had no influence on ATP content of 
m. soleus in two independent experiments called 0319 and 0350 [Figure 42A&B]. In experiment 0319, vehicle- 
and idebenone-treated showed practically identical ATP levels (100±17% and 97±23% ATP/protein; 
mean±SEM). In experiment 0350, ATP levels in m. soleus were slightly decreased in idebenone-treated mice 
(77±23% ATP/protein) compared to sham-treated control animals (100±59% ATP/protein) but this difference 
did not reach statistical significance (p = 0.43). Thus, total ATP levels in muscle tissue of m. soleus—a prototype 
of muscles rich in mitochondria—was not significantly altered by idebenone. 
Nevertheless, the quantity of ATP found in a tissue does not reveal the manner of energy production in that 
given tissue. Since idebenone seemed to slightly increase expression of HmgCoA [Table 4 and Table 5], a protein 
involved in ketogenesis, there was a possibility that the animal’s metabolism could be shifted towards the use of 
ketone bodies as alternative energy source instead of glucose. Ketone bodies are mainly produced in the liver and 
then transported to consuming tissues via the blood stream. 
Thus, the blood level of ketone bodies was assessed by measuring the concentration of β-hydroxybutyrate (β-
HB) in plasma [Figure 42C]. Daily administration of 200 mg/kg idebenone for two weeks had no effect on blood 
β-HB levels (0.59±0.30 mM β-HB compared to 0.49±0.15 mM β-HB in vehicle-treated animals; mean±SEM). 
After another seven days of treatment, however, control animals had still comparable blood levels of β-HB 
(0.59±0.22-M β-HB) in contrast to idebenone-treated mice in which a trend towards higher levels of ketone 
bodies in the blood emerged (1.06±0.37 mM β-HB). Nevertheless, the difference between idebenone- and sham-
treated animals did not reach statistical significance [Figure 42C]. 
 
 
Figure 42: Idebenone Does Not Affect ATP Levels in Muscle Tissue with High Mitochondrial Density or Serum 
β-Hydroxybutyrate Levels in Vivo.  
ATP levels (µM/mg protein) were measured in m. soleus of male C57Bl/6 mice treated with 200 mg/kg idebenone for three weeks (filled 
bar) in experiment (A) 0319 or (B) 0350. Blood levels of β-hydroxybutyrate (β-HB) were measured after 14 or 21 days of experiment 0350, 
respectively. Bars represent mean + SEM for five animals (for β-HB, outlying values (values which were more than four times higher than 
average of remaining values) were not considered; n was at least equal three). No significance was seen using unpaired t-test (A, B) or two-
way ANOVA with Bonferroni’s Multiple Comparison test (C). 
 
Since idebenone was suspected to interfere with energy consumption and metabolism, two elementary 
parameters of overall metabolic behavior were quantified: body weight of animals and their energy intake. Since 
idebenone was administered via food, total food intake was composed of (i) the amount of the food in which 
idebenone or vehicle was dissolved and (ii) the intake of supplementary food to which animals had access ad 
libitum. Intriguingly, in the same experiment in which three-week administration of 200 mg/kg/day idebenone 
had no significant influence on ATP levels in m. soleus or blood β-HB levels of male C57Bl/6 mice, the sum of 
supplementary food intake was substantially increased by idebenone with statistically significance after ten days 
[Figure 43A].At the end of the three-week experiment, idebenone-treated mice had a significantly higher amount 
of supplementary ingested food (43.2±4.0 g compared to 30.7±5.4 g of sham-treated animals). A similar 
difference was observed in animals which were allowed access to a running wheel at all the time: although the 
total amount of supplementary food intake was increased by the physical activity (40.6±4.7 g), idebenone still 
elevated the food consumption (50.8±5.2 g) [Figure 43A]. 
Hence, idebenone led to a substantial increase in food intake which should have been mirrored in body weight. 
Strikingly, this was not the case. Treatment with idebenone did not result in a higher body weight (2.1±0.3 g 
increase in body weight in idebenone-treated mice after three weeks compared to 2.2±0.5 g increase in body 
weight in control animals) [Figure 43B]. After three-week administration of idebenone in the group with access 
to running wheels, the increase in body weight (1.4±0.2 g) was not significantly higher than in control animals 
(0.7±0.4 g).  
These findings were then integrated by normalization of the supplementary food intake to the body weight 
[Figure 43C]. As anticipated from the previous findings, idebenone increased relative food intake in a statistically 
significant manner. 
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Figure 43: Idebenone Promotes Increased Food Intake but Does Not Affect Body Weight in Vivo.  
Male C57Bl/6 mice (age 9 weeks at start of experiment; n = 5) were treated with 200 mg/kg idebenone (IDE; filled) or vehicle (VEH; 
empty) p.o. in food for three weeks. Animals had access to food ad libitum (ad lib) which was weighted to calculate (A) their cumulative 
supplementary food intake (cFI). Body weight was also measured to calculate (B) differences in body weight (dBW) and (C) the relative 
cumulative food intake (rFI) which was defined as difference in food intake divided by body weight. Two out of four groups had also access 
to a wheel all the time for voluntary locomotion.  
 
Similar experiments as the gene chip experiment (called experiment 0319) or the one described above (0350 
[Figure 43]) were conducted to see if idebenone-induced changes in food intake by simultaneously leaving body 
weight unchanged was also observed when parameters such as age, duration, strain, or dose were altered. 
Experimental setups and results of individual experiments were listed in Table 6 and data of each experiment 
were depicted in separated figures in the appendix [Figure 54 throughout Figure 59 on pages 163 to 168]. Out of 
eight experiments, comparable results were obtained in six cases, whereas in two experiments (0423 and 0436), 
idebenone had no influence on either food intake or body weight [Table 6]. The unresponsivenes of animals in 
these two experiments could be explained by the use of a different chow with a deviant composition of 
vitamins5 (KLIBAG NAFAG 3436 instead of Teklad 2018S; experiment 0423) or the higher age of animals 
(experiment 0436 was conducted in 14 to 18-week old mice).  
In most additional experiments, however, idebenone increased food consumption without changing body 
weight. The only exception was found in experiment 0319 which was also used for gene chip analyses, where 
idebenone did in fact not increase food intake but abolished the weight gain usually observed in mice at that age. 
Thus, the better part of these experiments suggested that idebenone decreased the coupling of food intake to 
                                                        
5 Chow used in experiment 0423 possessed 40 mg/kg vitamin C compared to no vitamin C in chow used in 
other experiments. However, this chow possessed only half of the amounts of vitamins A, D3, B6, one fourth of 
viatmin B1, pantothenic and folic acid, and biotin, and one fiftieth of vitamin K3 [Table 10 in the appendix]. 
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body weight. This finding was not specific to the strain, since it was observed in C57Bl/10 mdx, C57Bl/6, and 
RjHan:NMRI mice. Nevertheless, RjHan:NMRI mice showed a statistically significant increase in food intake 
only after almost four weeks of treatment with idebenone. 
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Table 6: Overview on Different in Vivo Metabolism Experiments.  
a) Ad lib indicates that animals had access to ad libitum food during entire experiment. b) A running wheel for voluntary physical activity was 
available during entire experiment. c) The daily dosage of idebenone mixed in food is indicated as mg/kg. d) Duration of the experiment in 
weeks. e) The age in weeks of mice at the start of the experiment. Mouse strains refer to f) C57Bl/10 mdx, g) C57Bl/6 JRj, and h) RjHan:NMRI. 
i) Day of experiment from which on values continuously differed with statistical significance of p < 0.05 (two-way ANOVA with 
Bonferroni’s Multiple Comparison test). j) Absolute and relative food intake differed from day 10 or days 15 or 19 for groups without or with 
wheel, respectively. 
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ID
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0305 0319 0350 0423 0436 0444 0459a 0459b 
    - - - 0 - - - - 
   + - - - 200 - - - - 
 +   - 0 0 0 - - - - 
 +  + - 200 200 200 - - - - 
  +  0c - - - 0 - - - 
  + + 400 - - - 400 - - - 
 + +  0 - 0 - 0 0 0 0 
 + + + 400 - 200 - 400 400 400 400 
Durationd 4 3 3 4 4 4 4 4 
Agee 7 9 9 8 8 6 6 6 
Strain mdxf Bl/6g Bl/6 Bl/6 Bl/6 Bl/6 Bl/6 NMRI 
n = 8 5 5 10 10 10 6 6 
Food intake (cFI) + o + o o + + + 
p < 0.05 from dayi 7 ns 10/15j ns ns 10 17 26 
Body weight (dBW) o - o o o o o o 
p < 0.05 from day ns 21 ns ns ns ns ns ns 
Relative FI (rFI) + o + o o + + + 
p < 0.05 from day 7 ns 10/19j ns ns 7 12 28 
 
Uncoupling of food consumption and weight gain could be achieved by higher energy expenditure which 
would manifest itself in either higher body temperature or increased agitation. The latter was quantified by 
measuring locomotion. Analyses of the use of running wheels in some experiments indicated that administration 
of idebenone did not increase locomotion [data not shown]. Similarly, body temperature was not increased in 
animals treated with idebenone compared to vehicle treated mice [personal communication by C. Anklin]. 
Increase in body temperature is achieved by uncoupling of mitochondrial respiration, i.e. that the proton gradient 
is not used to produce ATP but heat. Another explanation for the reduction in intake-mediated weight gain 
could be a change in body composition. Therefore, lean and fat mass was studied in a series of experiments using 
magnetic resonance imaging (MRI). However, both idebenone- and vehicle-treated animals showed similar fat 
content which amounted to approximately 8% of body weight. Thus, the effect of idebenone on systemic 
metabolism could not be explained by any of these three potential causes. 
Nevertheless, another pathway involved in metabolic changes might be influenced by idebenone. Insulin is 
released from pancreatic β-cells in response to elevated blood glucose levels. This response is mediated by an 
elegant but elaborate mechanism: glucose enters the cells and is degraded by glycolysis; thereby producing a huge 
amount of ATP which in turn leads to the closing of ATP-dependent potassium channels. The resulting 
depolarization forces voltage-gated Ca2+ channel to open and intracellular Ca2+ concentrations rise (this effect is 
even amplified by IP3-dependent Ca
2+ release from the endoplasmic reticulum). Similar to neurons, the high Ca2+ 
levels cause vesicles filled with insulin to fuse with the plasma membrane, thus releasing insulin into the blood 
stream [Campbell and Reece 2005]. Since idebenone was reported to inhibit voltage-gated Ca2+ channels by 
various authors [Kaneko et al. 1990, Houchi et al. 1991, Chang et al. 2011, and Newman et al. 2011], an influence 
on systemic metabolism by interfering with insulin pathways was assumed as a possible mode of action. 
Hypothetically, administration of idebenone would inhibit the release of insulin and this would then prevent 
glucose release from the liver and a shift in using fat over glucose as a fuel for muscle cells.  
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Glucose tolerance test is used to observe insulin-mediated metabolic changes. When fasted individuals ingest 
glucose, blood concentrations of glucose increase rapidly. Insulin than promotes uptake of glucose by muscle 
cells, thus lowering amount of glucose in blood over time. Inhibition of insulin release would impede the 
reduction of blood glucose. In order to investigate if idebenone interferes with the insulin pathway, overnight 
fasted mice were subjected to the glucose tolerance test after administration of 200 mg/kg idebenone 
simultaneously with 2 g/kg glucose [Figure 44A]. In this experiment, olive oil was employed as a vehicle due to 
the good solubility of idebenone therein. As anticipated, glucose administration increased blood glucose levels 
after 30 an 60 min (72±49% and 46±45% of basal levels). When idebenone was administered simultaneously 
with glucose, a statistically indiscriminate increase in blood glucose concentrations compared to glucose 
treatment alone was observed (101±65% and 76±38% of basal levels after 30 and 60 min, respectively). 
Accordingly, idebenone was not able to prolong the increased blood glucose levels, since two hours after glucose 
administration, blood levels were comparable in presence and absence of idebenone (10±29% and -4±19% of 
basal levels, respectively) [Figure 44A]. Thus, these findings suggested that idebenone did not inhibit the release 
of insulin. 
Furthermore, a variation of this experiment was able to demonstrate a potential effect of idebenone as an 
inhibitor of complex I in vivo. Metformin was described as an inhibitor of complex I activity and treatment with 
metformin prevented hepatic glucose production and glucose release from liver [Periello et al. 1994, Inzucchi et 
al. 1998, and Brunmair et al. 2004]. In addition, metformin was reported to increase the use of glucose turnover 
in peripheral tissues and both, lower glucose production and higher rates of glucose consumption, resulted in 
lower blood glucose levels [Baily and Turner 1996]. Thus, the capacity of idebenone to inhibit complex I would 
be mirrored in a reduction of glucose levels in the blood. Male RjHan:NMRI mice were treated with 400 mg/kg 
idebenone p. o. after overnight fasting. Vehicle-treated animals (0.5% carboxymethyl cellulose) showed no 
variations of blood glucose levels after 20, 40, and 60 min [Figure 44B]. Indeed, the small increase in plasma 
glucose concentration after 20 min (13±16%; mean±SEM) reproduced the findings obtained in C57Bl/6 mice 
[Figure 44A]. In contrast, 200 mg/kg idebenone transiently decreased blood glucose levels of fasted animals after 
20 min with statistical significance (-11±6%; *p < 0.05) [Figure 44B]. However, one hour after administration of 
idebenone, blood glucose levels of idebenone- and sham-treated mice did not differ from values evaluated before 
treatment (-6±18% and -1±9%, respectively). Metformin (300 mg/kg) was added as a positive control as a blood 
glucose-reducing agent [Foretz et al. 2010]. Indeed, metformin significantly (p < 0.05) reduced blood glucose 
levels in fasted mice after one hour by 27±13%. Thus, idebenone transiently reduced blood glucose levels which 
might explain the higher demand for food intake observed in idebenone-treated mice. 
The in vivo experiments described in the previous subchapters revealed that idebenone is involved in 
metabolic functions. Not only did idebenone induce a transient decrease in blood glucose levels shortly after its 
administration, but also led chronic administration of idebenone to increased food intake. Interestingly, the 
higher demand for calories was not reflected in weight gain. This alteration of metabolism could be caused by 
inhibition of complex I. To understand more of its pharmacological properties, it was necessary to dissect some 
of the activities of idebenone with regards to its chemical moieties. 
 
 
Figure 44: Idebenone Transiently Decreases Blood Glucose Levels Via an Insulin-Independent Mechanism.  
(A) Male C57Bl/6 mice or (B) Male RjHan:NMRI mice were fasted overnight for 16 h and randomized after basal blood glucose levels as 
determined using a glucometer (Contour, Bayer). Mice were then given an oral gavage dose of (A) 200 mg/kg idebenone  and 2 g/kg glucose 
(upside-down triangles), 2g/kg glucose alone (upright triangles), or vehicle (olive oil; circle) or (B) 300 mg/kg metformin (diamond), 400 
mg/kg idebenone (square) or vehicle (circle; 0.5% CMC). Blood glucose levels were measured every 20 or 30 minutes for one to two hours. 
Single points depict mean + SEM for n = 7-20 (A) or n = 6-7 (B); p* < 0.05, p*** < 0.001, two-way ANOVA with Bonferroni’s Multiple 
Comparison test. 
3.16 Characterization of Idebenone Analogs 
Experiments concerning the capacity of benzoquinones to rescue ATP levels under conditions of rotenone-
inhibited complex I showed that small chemical modifications of the compounds altered their behavior in vitro 
[Figure 18]. It was therefore of interest to see if chemically similar compounds to idebenone also exhibited 
different behaviors in other functional assays as well. 
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Since idebenone is a synthetic compound sharing the quinone head with CoQ10, this compound and analogs 
thereof with shorter alkyl chains (CoQ1, CoQ2, CoQ4, and the chain-less CoQ0) were also included in the assays, 
as well as two analogs of idebenone differing in the oxidation state of the terminal carbon atom, decylQ and QS-
10. Vitamin E and derivates thereof, i.e. α-tocopherol (SNT209202), α-tocopherol quinone (SNT210202), α-
tocotrienol (SNT210522), and α-tocotrienol quinone (SNT210521) were also included. The difference between 
tocopherols and tocotrienols is the degree of saturation of their alkyl tail: whereas the tocopherols possess only 
saturated bonds, alkyl tails of tocotrienols consists of three isoprenoid entities. α-Tocopherol quinone can be 
converted into α-tocopherol upon reduction and condensation which is also true for α-tocotrienol quinone and α-
tocotrienol, respectively. Since idebenone might act as an inhibitor of complex I, rotenone was employed as a 
positive control. The remaining 51 compounds tested in various assays were synthesized in-house by the 
Chemistry Department of Santhera Pharmaceuticals. For reasons of patent protection, the chemical structures 
are not disclosed in this work; however, some structure activity relationships (SARs) will be discussed. Most of 
the assays used for screening of idebenone analogs were described before. Toxicological assays were performed 
by F. Schärer and B. Cardell (Santhera Pharmaceuticals) and are listed for completeness.  
Influence of idebenone analogs on ATP levels in glycolysis or OXPHOS was assessed in human lymphoblastoid 
cells under conditions of high or low glucose content in media, respectively. In the experiment identical with the 
one reported in Figure 13, cells were incubated with 10 µM compound for 72 h [Table 7]. Interestingly, 
depending on the quinone administered to cells, ATP levels markedly varied. Whereas idebenone reduced ATP 
levels when cells relied on OXPHOS (63±17%, mean±SEM) but left ATP levels unchanged under conditions of 
glycolytic energy production (104±10%), CoQ0 and CoQ1 were highly toxic to ATP production in both scenarios 
(7±5% and 6±3% in high glucose medium, respectively, and 1±0% and 2±1% in low glucose medium, 
respectively). Intriguingly, analogs with comparable chain lengths to idebenone, decylQ and CoQ2, showed a 
similar effect in low glucose medium as idebenone (54±16% and 67±30%, respectively), however, they 
drastically increased glycolytic ATP production (294±115% and 215±84%, respectively).  
Another interesting finding was the influence of redox status on the in vitro behavior of vitamin E derivates. 
Whereas α-tocopherol and α-tocotrienol moderately elevated ATP levels under mitochondrial energy production 
(135±30% and 168±37%, respectively), the α-tocopherol quinone and α-tocotrienol quinone dramatically 
depleted ATP content under these conditions (2±1% and 2±0%, respectively) [Table 7].  
When complex I of glucose-starved HepG2 cells was inhibited by rotenone, idebenone and some analogs with 
similar chain lengths reversed the depletion of ATP levels [Figure 15A]. In the series of experiments whose 
results were listed in Table 7, the capacity for rescuing ATP levels under these conditions was slightly lower than 
in previous experiments (61±9% ATP rescue in contrast to approximately 80% in other experiments) [Table 7]. 
From all the analogs tested, about half showed an ATP rescue. Nonetheless, idebenone was one of the strongest 
agents in regard of restoring ATP levels in presence of rotenone with only two analogs exceeding its capacity for 
ATP rescue (SNT210407: 72±0% ATP rescue and SNT210486: 80±9% ATP rescue). Interestingly, there were 
two types of compounds which were not able to reverse ATP depletion by rotenone: whereas one class of 
compounds exhausted ATP content per se, the second class—including the four derivates of vitamin E—left 
ATP levels unchanged in absence of rotenone. The mechanism for the observed ATP rescue in presence of 
rotenone seemed to be a reaction on complex I inhibition, since not a single quinone which was able to reverse 
rotenone-induced ATP depletion was able to elevate ATP levels after one hour incubation in absence of 
rotenone. 
The influence of idebenone analogs on mitochondrial parameters such as membrane potential, ∆Ψm, and 
mitochondrial mass when cells did not rely on mitochondria for energy production was assessed in human 
fibroblasts. Therefore, cells were incubated with 10 µM compound in 25 mM glucose-containing medium for 
three days. As described before for idebenone, decylQ, CoQ0, CoQ1, CoQ2, CoQ10, and QS-10 [Figure 12], effects 
on these two parameters were only moderate. Even after inclusion of a much broader variety and number of 
quinones into experiments, the two parameters remained basically unaltered [Table 7]. Nonetheless, two 
exceptions are noteworthy: SNT210546—which resembled idebenone covalently linked to a peptide for 
mitochondrial targeting via an ester bond at the hydroxyl group of idebenone—massively increased ∆Ψm to 
180% relative to DMSO-treated cells. On the other side, SNT210371, a compound which will be discussed below 
due its high pro-oxidant activity, increased mitochondrial mass after incubation for three days to 170% compared 
to control cells. 
Short-term antioxidant capacity of idebenone analogs was assayed in human 4TE myoblasts. Cells were 
subjected to a 15-min stress with 10 µM H2O2 15 min after 10 µM quinone was added. Then, the levels of cellular 
ROS was measured and compared to sham-treated myoblasts.  As described before [Figure 35B], idebenone and 
QS-10 slightly aggravated exogenously induced ROS levels (115±10% and 120±8% CH2-CMDCFDA signal 
(mean±SEM), respectively), whereas CoQ1 reduced ROS levels (70±2% CH2-CMDCFDA signal) [Table 7]. 
CoQ10 had no influence on ROS after short-term H2O2 treatment (95±6% CH2-CMDCFDA signal). Additional 
analogs had effects in a similar range from 75±7% (SNT210523) to 132±16% (SNT210380) CH2-CMDCFDA 
signal. Surprisingly, the magnitude of aggravation or diminution of exogenously induced ROS levels seemed to be 
independent of the pro-oxidant capacity of a particular quinone. This capacity was quantified as the induction of 
lipid peroxidation after three-day incubation with 10 µM compound in human fibroblasts as described before 
[Figure 35A]. Intriguingly, most idebenone analogs showed no or—if any—only minor pro-oxidant activities 
[Table 7]. Exceptions were CoQ0 and CoQ1, whose pro-oxidant abilities were reported before [Figure 35A], as 
  Results 
 
 
Molecular Effects of Idebenone  81 
well as the two compounds SNT210378 (282% lipid peroxidation) and SNT210436 (257% lipid peroxidation) 
[Table 7]. These two compounds did not only share a similar structure (the hydroxyl group at the terminal 
carbon of the alkyl tail of idebenone was replaced by a methylpiperazinyl or a pyrrolidinyl group, respectively), 
they also were detrimental to ATP levels in lymphoblastoid cells after three-day incubation in high (3±2% and 
3±1% lipid peroxidation, respectively) and low (3±1% and 2±1% lipid peroxidation, respectively) glucose-
containing medium and in HepG2 cells after one hour in glucose-starved medium (5±1% and 28±31% lipid 
peroxidation, respectively) [Table 7]. The combination of being a strong inhibitor of cellular energy production 
and high pro-oxidant abilities were also observed for CoQ0 and CoQ1. Interestingly, a structurally similar 
compound, SNT201379, whose terminal hydroxyl group was replaced with a morpholinyl group, excessively 
reduced ATP production in lymphoblastoids after 72 h (6±4% and 0±0% lipid peroxidation in high or low 
glucose medium, respectively), but did not show toxicity towards ATP content in glucose-deficient HepG2 cells 
after one hour (80±5%) or pro-oxidant capacity after three days in fibroblasts (116% lipid peroxidation). The 
two compounds showing the largest responses to short-term exogenously induced ROS, SNT210523 and 
SNT210380, had only marginal effects on lipid peroxidation after three days (92% and 95% lipid peroxidation). 
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Table 7: Summary of Idebenone and Analogs in Different Assays.  
Idebenone and a variety of analogs thereof were subjected to different functional assays. Analogs were mostly produced in-house; exceptions 
are commercially available analogs such as decylQ, CoQ0, CoQ1, CoQ2, CoQ4, CoQ10, and vitamin E derivates (SNT209202, SNT210202, 
SNT210521, and SNT210522). a) Cellular ATP levels of lymphoblastoid cells (LCL BC1) were measured after 72-h incubation with 10 µM 
compound in medium containing high doses of glucose (25.5 mM; +GLU) or low doses of glucose (0.5 mM; -GLU). b) Cellular ATP levels of 
HepG2 cells were determined after 1-h incubation with 10 µM compound in medium lacking glucose in the absence (ctrl) or presence (rot) 
of 10 nM rotenone. c) Mitochondrial membrane potential (ΔΨm) was measured using the fluorescent dye JC-1. Human fibroblasts cells were 
incubated with 10 µM compound in 25 mM glucose-containing medium for three days. n = 2. d) Mitochondrial mass was determined using the 
fluorescent dye MitoTracker Green. Human fibroblasts cells were incubated with 10 µM compound in 25 mM glucose-containing medium 
for three days.  n = 2. e) ROS production after co-treatment of compounds and hydrogen peroxide (H2O2) was assayed in 4TE primary muscle 
cells. After a 15-min incubation with 10 µM compounds and CM-H2DCFDA dye, 10 µM H2O2 were added on top for additional 15 min. 
f) In 
human fibroblasts, lipid peroxidation was measured using fluorescent dye BODIPY after three-day incubation with 10 µM compound in 25-
mM glucose-containing medium. g) Solubility was calculated using logC.  h) Toxicological studies were performed in HepG2 cells in medium 
with high glucose concentrations. After 24-h incubation with 10 µM compound, viability was measured by Schärer and Cardel using an 
MTT-based Roche viability kit.  
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Rotenone (10nM) 142 12 32 15 5 63 118 97 3 9
Idebenone 104 10 63 17 15 89 8 61 9 116 89 115 10 15 98 2 120 100
DecylQ 294 115 54 16 4 102 12 63 9 103 105 5.6 100
CoQ0 7 5 1 0 8 122 124 70 2 2 254 2 10.1 38.87
CoQ1 6 3 2 1 4 102 100 176 2 22.2 20.64
CoQ2 215 84 67 30 10 64 12 62 6 85 106 11.3 75.7
CoQ4 145 73 38 14 5 92 6 7 1 93 93 6.6 100
CoQ10 153 25 122 22 13 109 95 95 6 8 97 2 nd 100
QS-10 132 22 99 20 11 108 85 120 8 14 98 2 200 100
SNT209202 152 33 135 30 10 104 11 7 2 102 79 101 1 2 91 2 100
SNT210199 161 52 53 19 7 87 3 61 3 113 89 94 6 16 38.5 97
SNT210201 24 11 2 1 7 76 9 35 6 89 101 90 53.6 48.05
SNT210202 138 30 2 1 5 98 8 8 2 69 93 99 4 18 95 2 11.1 100
SNT210206 92 35 95 21 12 68 9 3 0 95 88 81 5 16 110 173 100
SNT210214 271 104 37 13 4 85 15 57 1 105 83 113 1 152 5.6 100
SNT210371 138 49 67 21 5 59 4 29 13 76 103 127 15 14 98 86.4 70.58
SNT210378 3 2 3 1 5 5 1 3 0 105 170 282 200 14.63
SNT210379 6 4 0 0 3 80 5 48 6 98 91 116 1 40.9 20.9
SNT210380 186 31 63 18 4 63 18 37 10 104 94 132 16 3 92 114.5 71.94
SNT210381 480 245 250 89 5 19 18 7 5 98 86 107 12 11 93 11.1 100
SNT210391 261 47 188 64 5 93 3 5 1 99 87 100 6 15 96
SNT210392 301 190 118 30 9 75 26 4 1 130 105 90 5 17 88
SNT210401 5 3 2 0 4 80 5 48 11 73 98 126 80.5 19.1
SNT210402 125 34 77 6 5 105 16 49 2 105 105 109 6 16 89 1 4 100
SNT210404 232 67 96 13 7 96 5 35 24 117 89 91 7 16 88 35.3 100
SNT210407 241 74 146 88 6 92 9 72 0 101 87 89 5.6 100
SNT210433 118 37 12 7 4 80 8 52 5 100 113 90 7 16 87 94.6 46.91
SNT210434 86 34 11 9 4 113 89 116 8 11 104 200 100
SNT210435 146 28 13 10 4 77 11 62 14 68 93 106 1 83.4 42.54
SNT210436 3 1 2 1 5 28 31 4 0 117 79 94 1 257 1 200 40.43
SNT210459 82 20 10 8 2 25 22 24 8 90 86 98 1 5.6 89.01
SNT210460 113 22 9 5 4 70 14 54 17 89 82 90 11.1 100
SNT210479 127 30 68 20 5 99 6 51 6 137 122 95 4 16 101 11.1 100
SNT210480 184 48 141 26 16 109 3 8 1 82 95 95 2 16 118 2 10.2 100
SNT210486 238 111 179 20 8 89 8 80 9 93 92 79 6 16 110 2 27 100
SNT210487 146 34 53 15 5 35 5 23 1 87 86 120 6 16 100 2 21.2 76.9
SNT210488 269 132 125 43 7 84 4 54 2 103 86 128 8 15 100 2 50.1 75.68
SNT210496 127 30 80 12 4 101 3 23 8 109 95 89 9 15 97 2 8.1 100
SNT210497 147 35 172 41 5 103 4 9 3 87 101 88 4 16 101 2 10.5 100
SNT210498 171 42 18 6 17 92 2 57 15 91 95 88 4 17 81 3.9 100
SNT210504 108 16 17 7 13 82 11 50 6 84 90 96 4 16 90 2 5.6 100
SNT210505 142 29 12 8 12 79 5 46 10 103 84 84 5 16 95 2 5.6 63.21
SNT210521 256 85 2 0 6 95 5 12 10 77 102 118 2 5.6 40.71
SNT210522 335 104 168 37 6 115 5 5 2 120 101 92 1 122 2
SNT210523 246 70 189 58 6 103 4 5 2 110 117 75 7 13 95 2 200 100
SNT210524 175 36 144 45 15 106 3 5 1 95 109 87 5 17 90 200 100
SNT210539 198 53 155 56 14 108 2 5 2 89 105 116 5 16 95 200 100
SNT210545 48 12 13 9 5 99 7 72 7 69 117 125 10 13 98 200 86.91
SNT210546 406 175 194 47 9 85 12 11 0 181 114 90 12 15 107
SNT211677 94 10 12 11 4 43 16 47 20 77 102 92 6 16 4.7 79.7
SNT211678 102 8 58 27 4 102 7 55 11 90 120 96 8 16 103 5.6 100
SNT211686 132 41 62 39 4 6 1 7 4 91 97 97 8 16 4.4 74.77
SNT211687 100 30 43 43 2 59 0 45 4 89 71 104 9 16 101 5.6 98.35
SNT211697 122 21 50 26 3 94 2 4 2 118 107 131
SNT211708 82 14 1 1 3 13 0 11 4 90 1 3.9 41.79
SNT211709 60 8 2 1 3 6 3 5 3 104 2 11.1 33.46
SNT211710 119 16 48 10 12 31 12 20 9 101 4 16 75 5.6 100
SNT211711 110 14 54 9 11 95 10 18 11 110 4 16 104 2 6.5 100
SNT211712 76 9 2 0 11 102 3.7 43.33
SNT211713 81 9 60 11 11 95 1 35 1 94 5 16 100 5.6 100
SNT211715 95 14 2 0 11 69 15 47 6 108 6 16 112 5.6 83.39
SNT211716 74 11 1 0 11 85 12 50 9 97 3 16 91 5.6 100
SNT211717 69 12 11 5 11 84 6 58 9 103 6 16 92 24.4 68.56
SNT211725 85 13 27 17 11 88 7 52 2 98 7 14 93 3 5.6 100
SNT211727 81 14 2 1 4 53 32 46 17 91 5 16 85 2 4.2 52.53
SNT211728 94 20 13 8 11 58 30 54 20 104 5 16 92 2 4 73.45
SNT211729 78 13 43 21 13 66 10 48 9 98 8 16 95 2 13.5 51.39
SNT211770 18 9 14 11 9 5 2 4 1 110 19.4
SNT211771 126 17 85 14 10 98 13 12 5 97 2 22.9
SNT211772 89 11 75 14 10 98 3 42 6 101 5 16 97 66.5
SNT211773 97 20 75 8 10 104 12 11 1 108 6 16 87 2 100
SNT211780 95 11 73 9 9 110 8 7 1 100
SNT211798 84 25 5 3 6 97 18 6 1  
 
Thus, smallest changes in chemical structure led to huge variations in functional assays. It was then of interest 
to see if the behavior of a particular quinone in one functional assay could predict the outcome of this quinone in 
another functional assay. Therefore, correlations and linear regression analysis between functional assays were 
performed [Figure 45]. Linear regressions between assays seldom reached statistical significance. The only 
exceptions were the correlation between ATP levels in lymphoblastoids after three-day incubation in high and 
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low glucose (p*** < 0.001) [Figure 45A], ATP levels in lymphoblastoids after three-day incubation in high 
glucose and mitochondrial membrane potential after three days in human fibroblasts and lipid peroxidation after 
three-day incubation in fibroblasts (both p* < 0.05) [Figure 45B&E], between mitochondrial membrane potential 
after three days in human fibroblasts and ATP levels in lymphoblastoids after three-day incubation in low 
glucose (p* < 0.05) [Figure 45G], ATP rescue after one hour in HepG2 cells and ATP levels in lymphoblastoids 
after three-day incubation in low glucose (p* < 0.05) [Figure 45K], and lipid peroxidation after three-day 
incubation in fibroblasts and mitochondrial mass after three days in human fibroblasts (p** < 0.01) [Figure 45Q]. 
Despite the calculated statistical significance, critical observation of plots revealed that in none of these plots—
with the exception of Figure 45A—reliable correlations were evident. This finding was also mirrored in the 
coefficient of determination (R2) which is a measure for variability. R2 ranges from zero and one and the higher 
R2, the better is the fitting of a linear regression between two data sets. As anticipated by critically looking at the 
data, R2 for most of the statistically significant regressions—with the exception of the one depicted in Figure 45A 
(R2 = 0.555)—the coefficient of determination was very low (R2 ranged from 0.078 (Figure 45K) to 0.1842 
(Figure 45Q)). Nevertheless, even an R2 of 0.555 questions the reliability of a linear regression.  
The finding that structural modifications of quinones led to incoherent outcomes in different assays indicated 
not only that most of these assays measure independent parameters, but also that the analogs of idebenone might 
not only have one common mode of action. Thus, these quinones are likely to have multiple targets and unique 
modifications might strengthen the affinity to one target whilst lowering another. As seen before with the 
example of the closely related compounds STN210378 and SNT210379, simple SAR could not be identified. 
Both quinones were equally detrimental to ATP levels in lymphoblastoids after three-day incubation regardless 
of glucose content of media, whereas pro-oxidant activity was only exhibited by one of two. 
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Figure 45: Correlations of Parameters Quantified for Idebenone Analogs.  
Idebenone and a variety of analogs (10 µM) were subjected to different functional assays as described in Table 7. Assays include (A-F) ATP 
levels in lymphoblastoid cells after three day incubation in medium containing high (¨+¨; 25 mM) or (A, G-K) low (¨-¨; 0.5 mM) glucose 
(Glu); (B, G, and L-N) mitochondrial membrane potential (∆Ψm); (C,H, L, P, and Q) mitochondrial mass (MitoMass); (D, I, M, P, S, and T) 
ROS production after co-treatment with hydrogen peroxide (H2O2); (E, J, N, Q, S, and U) lipid peroxidation levels after three day 
incubation; and (F, K,O, R, T, U); and ATP rescue in presence of rotenone. Correlations were calculated using Pearson’s correlation test with 
p* < 0.05, p** < 0.01, and p*** < 0.001. 
 
In summary, several assays have shown that idebenone is able to interact with mitochondrial energy 
production as an inhibitor of OXPHOS, or by restoring ATP production under conditions of dysfunctional 
complex I via NQO1-dependent reduction. This modulation of mitochondrial function was also suggested as 
mode of action for the observations in vivo, where idebenone increased calorie intake, but left body weight 
unchanged. Furthermore, idebenone rescued cells from H2O2-induced death. Characterization of a vast number 
of idebenone analogs showed complicated structure activity relations of this class of compounds in biological 
systems and the overall good properties of idebenone in these assays. This set of data opens the possibility to 
develop analogs for customized solutions in specific disorders, and for the search for new indications of 
idebenone. 
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4 Discussion 
Currently, no effective treatment strategies are available in the short term to patients suffering from 
mitochondrial disorders. While aproaches that aim to correct the underlying inherited defect, such as gene 
therapy, are certainly promising in their scope, these therapies are still many years away from the clinic. Thus, 
there is an urgent need to supply patients with safe drugs that can at least ameliorate some of the symptoms 
associated with their particular phenotype. Idebenone is a synthetic compound sharing structural analogies to 
CoQ10, and has originally been developped by Takeda for the treamtment of Alzheimer’s disease. 
Importantly, idebenone showed promising results in clinical trials in several disorders with a mitochondrial 
phenotype such as MELAS, LHON, and DMD [Mashima et al. 1992, Ikejiri et al. 1996, Carelli et al. 1998, 
Mashima et al. 2000, Napolitano et al. 2000, Buyse et al. 2011, Klopstock et al. 2011, and Lekoubou et al. 2011]. 
However, most studies investigating the molecular mode of action of idebenone, with regards to mitochondrial 
function, generated contradictory results dependend on the model system or whether idebenone was tested in 
vitro or in vivo. Furthermore, unlike CoQ10, a rather controversial interaction of idebenone with the 
mitochondrial respirators complexes was described. In fact, it seems that on the one hand, idebenone inhibits 
complex I and on the other hand, it is a good substrate for other complexes [Shinamoto et al. 1982, Yu et al. 
1982, Sugiyama et al. 1985, Sugiyama and Fujita 1985, Imada et al. 1989, Nagaoka et al. 1989, Degli Esposti et al. 
1996a, Degli Esposti 1998, Kakihana et al. 1998, Lenaz et al. 2002 and 2007, Brière et al. 2004, Rauchovà et al. 
2008, and King et al. 2009, and Watze et al. 2010]. 
The goal of this thesis was to elucidate the role of idebenone in mitochondria, to rationalize its clinical use in 
different mitochondrial disorders and to explain the sometimes conflicting data in the literature. 
4.1 Choice of Suitable Model Systems 
In order to generate data relevant to clinically observed conditions, it is very important to work with suitable 
model systems that replicate the molecular pathology of a specific disease. Primary cells from patients with 
genetic disorders are often used as suitable model systems to understand the underlying molecular mechanisms 
and to find a potential treatment strategy. Duchenne muscular dystrophy (DMD) is devastating disorder 
characterized by progressive muscle wasting. A loss of function mutation of the structural protein dystrophin 
leads to an increased sensitivity of the muscle sarcolemma towards mechanical damage. A transient injury of the 
sarcolemma membrane in response to muscular contraction stress is believed to elevate levels of intracellular 
calcium (Ca2+) and to increase production of reactive oxygen species (ROS) which finally leads to mitochondrial 
impairment.. In the case of DMD, previous work associated primary myoblasts from these patients with 
impaired mitochondrial function [Barbiroli et al. 1992, Kemp et al. 1993, Camiña et al. 1995, Gannoun-Zaki et al. 
1995, Sperl et al. 1997, Kuznetsov et al. 1998, Brini 2003, Burelle et al. 2010, and Kinnally et al. 2011].  
Surprisingly, my data showed that the only difference between primary myoblast from DMD patients and 
healthy donors was observed in the morphology of mitochondria. Mitochondria in dystrophic myoblasts showed 
a higher degree of fragmentation in vitro compared to those in muscle cells from healthy donors. Mitochondrial 
fragmentation is conducted by a process called fission and occurs mainly as a response to isolate dysfunctional 
parts of mitochondria [Twig et al. 2008]. Furthermore, mitochondrial fission was described to play a fundamental 
role in muscle wasting [Romanello et al. 2010]. In contrast, tubular networks of ring-shaped mitochondria formed 
by fusion were associated with maximization of OXPHOS-dependent energy production and their formation 
was shown to protect mitochondria from degradation [Rambold et al. 2011]. Since fusion and fission were 
reported to regulate intracellular Ca2+ signaling, fragmentation of mitochondria could be a potential adaptation to 
impaired Ca2+ homeostasis in DMD [Diaz and Moraes 2007].  
Intriguingly, despite the observed difference in mitochondrial morphology between dystrophic and healthy 
primary myoblasts, the data presented here indicate that the mitochondrial function in these cells was 
indistinguishable. Mitochondrial parameters such as ATP levels, mitochondrial reactive oxygen species (ROS) 
production, or mitochondrial mass were investigated. Furthermore, ROS levels in the cytosol of primary 
myoblasts from DMD patients were indistinguishable from healthy myoblasts. The lack characteristic changes in 
dystrophic myoblasts appears to be in contrast to previous reports [Kar et al. 1979, Hunter and Mohamed 1986, 
Barbiroli et al. 1992, Kemp et al. 1993, Camiña et al. 1995, Gannoun-Zaki et al. 1995, Sperl et al. 1997, Ragusa et 
al. 1997, Disatnik et al. 1998, Kuznetsov et al. 1998, Rando et al. 1998, Brini 2003, Burelle et al. 2010, and 
Kinnally et al. 2011]. However, none of these studies were conducted in cultured myoblasts from biopsies of 
DMD patients. For example, when Camiña et al. [1995] reported decreased ATP levels, muscle homogenates 
from DMD patients were used rather then cultivated cells.  
The lack of quantifiable parameters associated with the DMD cells in vitro, i.e. elevated ROS levels, reduced 
cellular ATP content, or mitochondrial mass, could simply be due to unsuited assays to detect these parameters. 
Although, these assays showed reliable results in other cell lines as discussed below, the JC-1 dye showed a poor 
performance in primary myoblasts. Thus, cell type-specific dysfunctions of this particular assay cannot be 
excluded. Nevertheless, since conditions in vitro deviate substantially from the physiology in vivo, it is likely that 
these parameters do not manifest fully in vitro in intact cells. In vivo, affected muscle cells are (i) post-mitotic 
cells, whereas cultured primary myoblasts divide. The more severe the pathology is in a particular cell, the less 
likely is the probability for it to proliferate. Thus, this hurdle decreases the degree of pathology observed in vitro 
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over time. In addition, dammage is associated with (ii) stress from stretching of sarcolemma, which is not 
replicated under standard culture conditions. Furthermore, (iii) many experiments on mitochondrial changes in 
DMD were conducted in subcellular systems. For example, a recent conference submission [poster from Sobreira 
et al. EuroMit 2011, Zaragoza, Spain] reported that specific mitochondrial complexes of the respiratory chain are 
dysfunctional in muscle homogenates. Thus, it seems likely that intact cultured cells can compensate for their 
mitochondrial impairment in contrast to cells in vivo or isolated mitochondria. Thus, the relevance of cultured 
myoblasts of DMD patients for studying mitochondrial dysfunction is questionable. Finally, the absence of a 
detectable pathologic phenotype in vitro is reclected by the lack of literature on these parameters in cultured 
myoblasts of DMD patients. 
Thus, since intact primary myoblasts of DMD patients did not manifest characteristics of impaired 
mitochondrial function in culture, the use of these cells as model system for understanding the molecular effects 
of idebenone in a disorder including mitochondrial impairment had to be dismissed. As a result, many 
experiments were conducted in model systems using both healthy, undisturbed cells or animals and cells in 
which specific pathways or enzymes/enzyme complexes were exogenously disabled by inhibitors or by RNAi-
based knock-down approaches. These experiments revealed that the action of idebenone in healthy cells or 
animals differ fundamentally from its action in conditions of impaired mitochondrial function. Whereas 
idebenone induced signs of energy shortage in systems with healthy mitochondria, it had beneficial effects on 
metabolism in cells with dysfunctional complex I, as will be discussed below.  
It has to be noted however, that in comparison with primary cell lines, model systems using artificial 
manipulation of mitochondria hold certain disadvantages: (i) exogenously induced modifications can never fully 
represent the phenotype of the disorder but only single aspects of it. This is particularly true for DMD whose 
complex cellular entanglements are still not fully disclosed [McArdle et al. 1995, Zhou et al. 2006, and 
Deconinck and Dan 2007]. Thus, inhibition of a single enzyme may only imitate one underlying cause of the 
disorder and never replicate the whole picture. In addition, (ii) compounds which mimic symptoms associated 
with a certain disorder may have different underlying causes that lead to a similar phenotype. Additionally, 
inhibitors are thought to (iii) interact with the target enzyme at a specific binding site for which a given 
compound could be competitive. Thus, a compound’s ability to counteract the effects of an enzyme inhibitor is 
no proof that it is also able to ameliorate the pathology of a disorder in which the corresponding enzyme is 
dysfunctional. A further limitation is that (iv) any inhibitor might not only bind to the desired enzyme, but also 
interacts with unspecific off-targets. To avoid these implicated difficulties, certain precautionary measures were 
taken in the experiments of this thesis. For example, specificity of inhibitors against NQO1 was assessed, or ATP 
rescue experiments were performed in presence of complex I inhibitors other than rotenone. 
On the other hand, artificial model systems hold many advantages: they (i) provide a defined setting which 
focuses on only one aspect of a disease. In DMD, for example, failures in Ca2+ homeostasis, membrane integrity, 
elevated oxidative stress and mitochondrial dysfunction overlap and influence each other. This makes it very 
difficult to attribute a potential beneficial effect of a compound to the underlying mode of action. The 
employment of an inhibitor facilitates the distinction of molecular mechanisms. In addition, artificial systems can 
be set up in cell lines that are not associated with problems of primary cells such as (ii) senecence, (iii) unsteady 
or diminishing growth rates, or (iv) limited transfection capacity. Furthermore, the use of cell lines (v) facilitates 
the reproducibility of results in different labs. 
As a consequence, most experiments of this thesis concerning the mode of action of idebenone were 
conducted in healthy cell lines or mice which could be selectively manipulated. The main exceptions were the 
employment of the dystrophin-deficient mdx mouse model and MELAS cybrid cells. MELAS cybrids combined 
the mitochondrial genotype of MELAS cells and the nuclear genetic background of an osteosarcoma cell line. 
Findings in MELAS cybrids will be discussed below [see 4.11]. 
Like human DMD patients, mdx mice have a mutation in the dystrophin gene [Bulfield et al. 1984]. 
Nevertheless, the phenotype in these mice is much milder compared to the human disorder [Vainzof et al. 2008] 
most likely due to differences in telomere length between mice and humans. At the age of six to 12 weeks, the 
pathological symptoms of mdx mice were described to peak [Villalta et al. 2009]. Indeed, my data confirmed 
that blood levels of creatine kinase, a cytosolic enzyme which can be found in the blood when plasma 
membranes are disrupted, were increased in six- and 12-week old mice compared to animals without the 
mutation in the dystrophin gene, but with the otherwise same genetic background (wild-type (WT) mice), even 
though the difference in the younger animals did not reach statistical significance. The certification of the 
described phenotype by these experiments permitted further experiments to find disease-specific differences.  
Since a 50% reduction of the activity of mitochondrial respiration complexes in mdx mice was described 
[Kuznetsov et al. 1998], a decrease of ATP in tissues of mdx compared to WT animals was expected. 
Intriguingly, ATP levels in dystrophic and healthy animals did not alter in different muscle types varying in the 
amount of mitochondria or in the cerebellum. However, a fundamental difference to the experiments described 
herein was that Kuznetsov’s lab measured oxygen consumption directly in isolated mitochondria. Whereas these 
findings suggested that respiration is impaired in mitochondria of mdx mice, my data revealed that these animals 
were able to compensate the anticipated drop of ATP in tissues. Furthermore, Braun et al. [2001] challenged the 
data by Kuznetsov et al. [1998] by reporting that the maximal capacity of oxidative phosphorylation was 
undistinguishable between muscle tissues of mdx and WT mice.  
Since no drop in ATP levels was found in mdx mice, DMD was abandoned as a model system for investigation 
of the role of idebenone in mitochondrial impairment. The dismissal of DMD as a model system does not imply 
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that idebenone might not be beneficial in this disorder. On the contrary, idebenone showed promising results in 
the mdx mouse model [Buyse et al. 2009] and in clinical trials [Buyse et al. 2011] and is still under investigation in 
this indication and potential mechanisms how idebenone could counteract the pathology of DMD are discussed 
below [see 4.11]. However, since the emphasis of this work was the modulating activity of idebenone on 
mitochondrial function, DMD appeared unsuited to answer these questions. 
Despite the surprising finding that primary DMD myoblasts are unsuited to test mitochondrial impairment, an 
interesting result from these experiments could be obtained: the assays employed to measure mitochondrial 
parameters such as ATP production when oxidative phosphorylation (OXPHPOS) was required, mitochondrial 
mass, and ROS production seemed to be independent of one another. Similar results were obtained when the 
effects of idebenone analogs were assessed. The certainty that the employed assays measure independent 
parameters was important to discriminate effects induced by idebenone and other compounds. 
4.2 Influence of Idebenone on Mitochondrial Parameters in Healthy Mitochondria 
Since idebenone and CoQ10 share structural analogy, idebenone was suggested to interact with enzymes of the 
mitochondrial electron chain. In fact, interaction with complexes I, II, and III was described for idebenone. But 
whereas idebenone acts as a good substrate for the latter two, it inhibited both the proton pumping and redox 
activity of mitochondrial complex I [Sugiyama et al. 1985, Sugiyama and Fujita 1985, Degli Esposti et al. 1996a, 
Brière et al. 2004, Rauchovà et al. 2008, and King et al. 2009]. Contradictory data were published by James et al. 
[2005], who described idebenone as a good substrate for not only complex II and III, but also for complex I. 
However, these results should be regarded with caution, since they normalized the measured activities to those 
elicited by CoQ2 which is also described to be an inhibitor of complex I [Degli Esposti 1998]. 
Due to this differential interaction with the electron transport chain (ETC), it was important to know whether 
idebenone changes mitochondrial function per se in healthy cells when the cells do not depend on ETC for 
energy production. When demand for ATP is high, cells employ mitochondrial respiration in order to efficiently 
retrieve as much energy stored in glucose molecules as possible. In contrast, high abundance of glucose alleviates 
the need for mitochondrial energy production and cells undergo aerobic glycolysis in which only a small fraction 
of ATP is mitochondrially generated [Vander Heiden et al. 2009 and Mathupala et al. 2010; and Figure 49]. 
Under these conditions, enforced by addition of excess glucose to the medium, influence of compounds on 
mitochondria can be investigated without provoking interference with ETC-mediated energy production. 
Indeed, three-day incubation of lymphoblastoid cells with rotenone, an inhibitor of complex I, in medium 
containing a five-fold excess concentration of glucose compared to physiological conditions did not affect ATP 
content under these conditions, indicating that mitochondrial respiration was not required in order to produce 
energy. Hence, potential alterations of mitochondrial parameters found were independent of mitochondrial 
respiration. Similarly to rotenone, long-term treatment of human lymphoblastoid cells with idebenone did not 
affect ATP levels under these conditions. Accordingly, long-term treatment with idebenone in an aerobic 
glycolysis-based cell model did not result in alterations of either mitochondrial membrane potential (∆Ψm) or 
mitochondrial mass in human fibroblasts, suggesting that idebenone does not change mitochondrial function per 
se. 
 In contrast, depriving cells of glucose enforces their use of mitochondrial energy production. Thus, in an 
experiment with identical conditions as the one described above (three-day idebenone treatment of 
lymphoblastoid cells) except for a decrease in medium glucose content to physiological conditions would reveal 
the influence of idebenone on mitochondrial respiration. As anticipated by the described inhibitory effect of 
idebenone on complex I [Sugiyama et al. 1985, Sugiyama and Fujita 1985, Degli Esposti et al. 1996a, Brière et al. 
2004, Geromel et al. 2008, Fato et al. 2008, Rauchovà et al. 2008, and King et al. 2009]. ATP levels of glucose-
deprived cells dropped by almost a third in presence of idebenone in long-term experiments. Rotenone, one of 
the most potent inhibitors of complex I known [Degli Esposti 1998], had a more severe effect on mitochondrial 
ATP production, suggesting that the blocking of ETC by idebenone was only partial. Indeed, the potency of 
idebenone to inhibit complex I is reported to be hundred-fold lower than that of rotenone [Degli Esposti 1998].  
4.3 Idebenone Is an Inhibitor of Complex I 
In line with works by others, these data confirmed that idebenone moderately inhibits mitochondrial 
respiration, probably via complex I6 [Sugiyama et al. 1985, Sugiyama and Fujita 1985, Degli Esposti et al. 1996a, 
Brière et al. 2004, Geromel et al. 2008, Fato et al. 2008, Rauchovà et al. 2008, and King et al. 2009]. In order to 
elucidate interaction of idebenone with complex I, a short overview of the biochemistry of complex I would be 
of help. The mammalian complex I is composed of 46 subunits whereof seven are encoded in mtDNA and form 
the lipophilic part of the protein [Brandt et al. 2003]. This multi-subunit complex accomplishes three different 
enzymatic functions: (i) a dehydrogenase activity to oxidize NADH in the mitochondrial matrix, (ii) a 
                                                        
6 Of course, the setup of these experiments does not allow speculating on a mode of action how blocking 
mitochondrial ATP synthesis is achieved. Nevertheless, a plethora of work described idebenone as a complex I 
inhibitor and a good substrate for complexes II and III. In addition, the fact that the ATP rescue in complex I-
deficient cells was sensitive to antimycin A, a complex III inhibitor, indicated that idebenone is efficiently 
oxidized by this mitochondrial complex. 
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hydrogenase activity embedded in the lipid bilayer to reduce CoQ10, and (iii) a membrane-spanning translocation 
of protons out of the matrix. The two former activities are mainly carried out by several iron-sulfur clusters 
which transfer the electrons obtained from NADH to CoQ10. Under normal conditions, two electrons per each 
NADH molecule are passed to CoQ10 and four protons are removed from the mitochondrial matrix during this 
process. The reduction of CoQ10 occurs within an active pocket of the enzyme complex; however, the 
propagation of the two electrons to the final acceptor is thought to take place at two different catalytic sites 
[Brandt et al. 2003]. 
The active pocket for CoQ10 reduction is seated within—and opened towards—the lipid bilayer of the inner 
mitochondrial membrane and is due to its complex configuration not well deciphered [Figure 46]. From electron 
paramagnetic resonance (EPR) experiments, three different binding sites for CoQ10 have been suggested [Ohnishi 
and Salerno 20005]. It is assumed that electrons are passed along different iron-sulfur clusters from NADH to the 
last of these clusters, called N2, and from there to he physiological quinone acceptor, CoQ10. After receiving one 
electron, the resulting semiquinone covalently binds a proton. Subsequently, it receives another electron from 
N2. As a consequence, it incorporates a second proton from the matrix side and hence, a hydroquinone is formed 
which in turn provokes a conformational change which allows for the release of the reduced CoQ10 from the 
active pocket [Fato et al. 2008 and Figure 46]. The different binding sites of quinone, semiquinone, and 
hydroquinone were also used to characterize inhibitors of the complex I corresponding to their assumed binding 
sites [for a review see Degli Esposti 1998, Figure 46 and Table 2]: class A inhibitors include pyridaben, piericidin 
A, and rolliniastatin-1/2 and bind to the site where CoQ10 attaches upon entrance into the active pocket. Class B 
inhibitors include rotenone and two derivates thereof (deguelin, tephrosin), piericidin B, and—as was suggested 
by Degli Esposito [1998]—idebenone, and they are assumed to bind at the semiquinone binding site and block 
the transfer of the first electron from the N2-cluster to the protein-bound quinone. Class C inhibitors, capsaicin 
or stigmatellin, block the hydroquinone binding site where the second electron is delivered to the semiquinone 
and finally, reduced CoQ10 is released from the active pocket. Most class C compounds are simultaneously classic 
complex III inhibitors. Given the narrow space occupied by the quinone, semiquinones, and hydroquinone 
binding sites, the three classes of complex I inhibitors possess partially overlapping binding domains [Okun et al. 
1999]. In addition, complex I can also be inhibited at the prosthetic flavin site where electrons are donated from 
NADH. This mechanism is employed by diphenylene iodonium [Majander et al. 1994] and rhein [Kean 1970]. 
Other compounds, such as berberine and metformin, are also described as complex I inhibitors [El Mir et al. 
2000], although their mode of action is unknown [Figure 46 and Table 2]. 
 
 
Figure 46: Schematic Representation of Electron Transfer in Complex I and Proposed Inhibition Sites.  
Electrons from NADH reduction at a prosthetic flavin side (FMN) are transferred along several iron-sulfur clusters (not depicted) of 
complex I (dark grey) to the final acceptor iron-sulfur cluster, N2. CoQ10 (Q) enters the active pocket (grey) from the inner mitochondrial 
membrane (light grey). There, receiving a first electron from the N2 cluster converts Q into a semiquinone (Q
—•). The transfer of a second 
electron results in the formation of the hydroquinone form (QH2) which can be—after the release of the active pocket of complex I—re-
oxidized by complex III. Different classes of inhibitors might block the binding site for the quinone, semiquinone, or hydroquinone. 
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Considering the structures of some type A and B inhibitors, one can hypothesize how idebenone might 
interact with complex I. First, the difference of piericidin A and piericidin B lies in one single substitution in 
their alkyl tails: whereas piericidin B has a methoxy group at carbon C10 of the tail, piericidin A possesses a 
much more reactive hydroxyl group at this position [Figure 47]. Likewise, rolliniastatin-1 and -2 exhibit a 
hydroxyl group at a similar position, i.e. at carbon C13 of their tails, suggesting this to be a prerequisite for type A 
inhibition [Degli Esposti 1998]. Second, comparison between structures of piericidins and rotenone and its 
derivates deguelin and tephrosin, which also inhibit complex I, reveals that they share a similar structure: all 
compounds feature a planar ring with six delocalized ∏ electrons7 which possess two methoxy groups in ortho 
position [Figure 47]. Thus, from a structural point of view, idebenone, which possesses both the head group 
similar to rotenone and piericidin, would be considered a class A or B inhibitor. The hydroxyl group at C10 of its 
alkyl tail, however, makes it more likely to act as class A inhibitor. Nevertheless, idebenone was suggested to act 
as a class B inhibitor [Degli Esposti 1998], and other publications added up to a more complex mode of action.  
 
 
Figure 47: Chemical Structures of Complex I Inhibitors.  
Complex I inhibitors are classified on the basis of their binding sites within the CoQ10-bindinging pocket of complex I according to Degli 
Esposti [1998]. Class A inhibitors (rolliniastatin-1/2 and piericidin A) block the quinone-binding site, class B inhibitors (rotenone, deguelin, 
tephrosin, and piericidin B) block the semiquinone-binding site, and class C inhibitors (stigmatellin and capsaicin) block the hydroquinone-
binding site. 
                                                        
7 ∏ (pi) bonds are covalent chemical bonds between p-orbitals. Thus, ∏ electrons are located in the aromatic 
ring of benzoquinones and in double bonds between carbon atoms and between carbon and oxygen atoms of its 
hydroquinone form. 
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Rauchovà et al. [2008] using cytochrome c and 2,6-dichlorophenol indophenol (DCIP) as final electron 
acceptors in sub-mitochondrial fractions contributed an important experiment to find out more about the site of 
complex I inhibition of idebenone. In contrast to cytochrome c which is reduced downstream of complex I 
altogether, DCIP is reduced within the active pocket of the CoQ10 dehydrogenase, namely at the site of type B 
inhibitors [Fato et al. 2008a]. Whereas idebenone inhibited cytochrome c reduction by 67%, DCIP reduction was 
inhibited only by 25% [Rauchovà et al. 2008]. This indicates that idebenone might act as a type A or B inhibitor. 
This results were in line with previous work by Sugiyama et al. [1985] who registered a decreased 
NADH:cytochrome c reductase activity, and is in line with the observation that the activity of idebenone as 
electron acceptor at complex I was 63%-sensitive to rotenone-inhibition [Degli Esposti et al. 1996a]. 
Consistent with this finding, 69% of idebenone was reduced by mitochondria in presence of NADH 
[Sugiyama et al. 1985] as mentioned in the Introduction [see 2.4.4]. King et al. [2009] added to the picture that 
the limited dissociation of reduced idebenone blocks the active pocket for the entrance of CoQ10. This view is 
supported by own experiments which suggests that the quinone (oxidized) and hydroquinone (reduced) form of 
idebenone exhibit different capacities towards complex I inhibition. In NQO1-expressing cells relying on 
mitochondrial respiration for energy production, idebenone had no influence on cellular ATP levels8. However, 
in the presence of dicoumarol, a dramatic drop in ATP content induced by idebenone was detected9, indicating 
that only oxidized idebenone is able to block complex I activity. 
In addition, King et al. [2009] suggested that idebenone can also be reduced at the NADH binding site exposed 
to the mitochondrial matrix. This incomplete, one-electron reduction of idebenone, generating semiquinones 
radicals, could explain the ROS production associated with the inhibition of complex I [Fato et al. 2008, 
Geromel et al. 2008]. Contradictory to these results however, inhibition of complex I by idebenone was 
paralleled by a decrease of in vitro lipid peroxidation [Sugiyama et al. 1985a]. 
In conclusion, idebenone inhibits electron transfer from NADH to CoQ10 carried out by complex I via many 
different modes. Internal data from Santhera Pharmaceuticals in collaboration with Scientific Devices 
(Heidelberg, Germany) revealed that for isolated mitochondrial membranes the half maximal concentration 
(IC50) for inhibition of complex I was 5.9 µM which is in line with the concentrations resulting in a decrease in 
ATP levels used in the experiments of this thesis. 
4.4 Idebenone Restores ATP Levels under Conditions of Impaired Complex I 
In contrast to the experiments in cells with normal mitochondrial functional, which revealed that idebenone 
has either no effect on mitochondrial activity in aerobic glycolysis or inhibits complex I during OXPHOS, it was 
of interest to investigate the role of idebenone in mitochondria with a specific, exogenously inflicted dysfunction. 
Clinical data in MELAS [Ikejiri et al. 1996, Napolitano et al. 2000] and LHON [Mashima et al. 1992, Carelli et al. 
1998, and Mashima et al. 2000] patients suggested that idebenone might be beneficial in disorders with a 
mitochondrial phenotype. Therefore, it was essential to establish an in vitro model in which mitochondrial 
respiration could be selectively inhibited.  
In order to force cells to use mitochondria for energy production, a hepatic cancer cell line, HepG2, was 
cultured under low glucose conditions (1.77 mM) for 24 h before they were deprived of glucose for one hour. 
Cells were still able to maintain their cellular ATP levels over that short period of time unless their 
mitochondrial function was fundamentally disrupted.  
Compounds blocking ATP synthase activity, i.e. via reduction of the proton gradient by the uncoupler FCCP 
or by direct inhibition using oligomycin, ATP levels dropped to 10% of residual levels. Upon treatment with 
inhibitors of the mitochondrial complexes I and III, rotenone and antimycin A, respectively, ATP levels 
decreased to practically zero compared to residual levels after one hour in absence of glucose. Since an inhibitor 
of complex II, 3-nitropropionate, was unable to decrease ATP at all, it seemed that this respiratory complex 
accounted for only minute contributions to total energy production in these cells. 
In presence of antimycin A, FCCP, or oligomycin, idebenone was not able to restore ATP levels. However, 
idebenone was able to rescue ATP levels when complex I was inhibited with rotenone. This is especially 
noteworthy, since (i) complex I is dysfunctional in LHON and MELAS [Mackey et al. 1996, James et al. 1996, 
Kirby et al. 2004, McKenzie et al. 2004, and Malfatti et al. 2007], and (ii) idebenone was reported to ameliorate 
some symptoms in these patients [Mashima et al. 1992, Ikejiri et al. 1996, Napolitano et al. 2000, Carelli et al. 
1998, and Mashima et al. 2000]. Hence, by inhibiting complex I in HepG2 cells relying on mitochondrial energy 
production, a potential disease-relevant model system to test the mode of action of idebenone was established. 
The drop of ATP induced by complex I inhibition could be counteracted by two possible modes: idebenone 
either blocked the inhibitory effect of rotenone or enabled the synthesis of new ATP independent of complex I. 
To rule out the possibility that the observed rescue in ATP levels by idebenone was not an artifact of rotenone 
administration, but was indeed specific to complex I deficiency, six other inhibitors of complex I were employed 
in the same model system [Table 2]. Interestingly, the beneficial effect of idebenone was observed only when 
                                                        
8 NQO1 promotes the reduction of idebenone. 
9 A similar effect was also observed when dicoumarol was substituted with PCP. Drop in ATP levels induced by 
oxidized idebenone was only observed when glycolysis was suppressed, since in presence of galactose (whose 
conversion into pyruvate by glycolysis does not yield in net ATP generation), depletion of ATP content after 
dicoumarol and idebenone treatment was not observed. 
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rotenone, metformin, or—to a lesser extent—pyridaben were used to inhibit complex I. However, this was not 
surprising, since some of these inhibitors are known to bind to different targets which might be involved in the 
mode of action of idebenone-mediated ATP recovery. For example, class C inhibitors, i.e. stigmatellin and 
capsaicin, also block complex III activity as well [Degli Esposti 1998] and both berberine and rhein inhibit several 
oxidoreductases related to NADH:cytochrome P450 oxidoreductase [Tang et al. 2009, Zhou et al. 2011]. Rescue 
in presence of pyridaben was only minor; however, pyridaben was described to be a stronger inhibitor of 
complex I than rotenone [Degli Esposti 1998]. Thus, the fact that the ATP rescue was still observable in 
presence of two complex I inhibitors other than rotenone suggests that this model system is in fact based on 
complex I inhibition. Since the ATP rescue mediated by idebenone was independent of the mode of complex I 
inhibition, it seemed likely that idebenone promotes de novo synthesis of ATP. Indeed, idebenone rescued ATP 
levels when given to cells long after rotenone addition. For example, 5-min treatment with idebenone of cells 
subjected to rotenone for 55 min resulted in ATP levels that were only slightly lower than those induced by 
simultaneous administration of idebenone and rotenone. This also suggests that idebenone is quickly absorbed 
and that restoration of decreased ATP levels can occur extremely fast.  
Hence, an in vitro model system for de novo ATP synthesis in complex I-deficient cells was established which 
showed promising relevance in regards to clinical phenotypes of mitochondrial disorders. 
4.5 ATP Restoration in Presence of Dysfunctional Complex I Is Carried Out by Cytosolic-
Mitochondrial Electron Shuttling 
It was then of interest to find out how this restoration of ATP content in cells with dysfunctional complex I 
was achieved by idebenone. The difficulty of this task lies in the fact that idebenone is a multi-target drug for it 
has been reported to modify various cellular pathways and interact with several enzymes and enzyme complexes. 
Among others for example, idebenone was described to block voltage-gated Ca2+ channels [Houchi et al. 1991, 
Chang et al. 2011, Kaneko et al. 2011, and Newman et al. 2011]. Nevertheless, the main characteristic assigned to 
idebenone is its function as an antioxidant [amongst others Mordente et al. 1998, Jauslin et al. 2002, and Abdel 
Baky et al. 2010]. Interestingly, there is evidence that inhibition of complex I by rotenone increases ROS levels 
[Lenaz et al. 2002, Fato et al. 2008], and that rotenone fatally disrupts Ca2+ homeostasis which could also be a 
trigger for rotenone-induced cell death [Wang and Xu 2005, Freestone et al. 2009]. It was therefore plausible to 
question if the restoration of ATP levels induced by idebenone in presence of rotenone resembled inhibition of 
necrotic or apoptotic pathways activated by rotenone treatment, antioxidant detoxification of rotenone-induced 
damage, or amelioration of Ca2+ homeostasis deranged by rotenone [Figure 48A]. 
Idebenone could also directly block the inhibtory action of rotenone [Figure 48B]. However, since idebenone 
was able to rescue ATP levels in presence of complex I inhibitors other than rotenone, it is unlikely that this 
effect is dependent on the mode of complex I inhibition.  
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Figure 48: Potential Scenarios and Targets for Idebenone-Mediated ATP Rescue in Complex I-Deficient Cells.  
(A) In cells with a deficient complex I (C I), either by reason of rotenone (rot) inhibition or mutation, several pathways are reported to be 
altered: ATP production is reduced [own data], reactive oxygen species (ROS) levels are elevated [Lenaz et al. 2002, Fato et al. 2008], and 
calcium (Ca2+) homeostasis is disturbed [Wang and Xu 2005, Freestone et al. 2009]. Increased levels of ROS and intracellular Ca2+ force the 
mitochondrial permeability transition pore (mPTP) to open which in turn leads to cell death [Gieseler et al. 2009, Kinnally et al. 2011]. This 
multitude of possible pathways for rotenone-induced ATP depletion suggests that idebenone (IDE) might rescue ATP levels by preventing 
the inhibition of complex I by rotenone (B), via an antioxidant effect (C), directly (D), by blocking the opening of mPTP (E), or by 
maintaining Ca2+ homeostasis (F). 
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The antioxidants N-acetyl-L-cystein (NAC) and tempol were added to glucose-deprived cells in presence of 
rotenone to see whether they might restore ATP levels comparable to idebenone. Controversially, whereas 
tempol was not able to counteract the drop in ATP, NAC showed a small, but significant rescue of ATP levels. 
However, this increase was not specific to complex I inhibition by rotenone, since NAC ameliorated cellular 
energy levels also in presence of an uncoupler of mitochondrial respiration or when complex III or ATP synthase 
were dysfunctional. In contrast, idebenone was not able to show a beneficial effect under these conditions. 
Therefore, it seemed that NAC might employ a mode of action not related to that of idebenone, and—in line 
with the inefficacy of tempol—the observed restoration of ATP levels in complex I-deficient cells by idebenone 
was not associated to its antioxidant effect [Figure 48C]. 
A second possibility for the ATP rescue in presence of rotenone was a connection between rotenone toxicity 
and cellular Ca2+ imbalance [Gieseler et al. 2009 and Figure 48F]. The Ca2+ ionophore A23187, which enables 
Ca2+ influx into cells, indeed decreased ATP levels. A23187 seemed to severely disturb Ca2+ homeostasis for even 
a membrane-permeable Ca2+ chelator, BABTA-AM, was not able to prevent the detrimental energy crisis 
triggered by Ca2+ overload. For that reason, Ca2+ was likely to activate secondary pathways which were fatal to 
both cells and mitochondria: increased levels of intracellular Ca2+ increase the probability for mitochondrial 
permeability transition pore (mPTP) to open which then triggers both necrotic and apoptotic pathways [Kinnally 
et al. 2010]. For example, opening of mPTP allows cytochrome c to enter the cytosol where it activates caspase 
9, a protease involved in apoptosis [Lee et al. 2008]. Furthermore, ions and molecules intrude mitochondria 
through the mPTP following a concentration gradient and entrain H2O which causes mitochondria to swell. 
Swelling disrupts the mitochondrial membrane and thereby destroys the proton gradient required to generate 
ATP. In addition, cellular ATP levels are further decreased by hydrolysis in order to maintain the proton gradient 
[Gardew et al. 2010]. Accordingly, rotenone could induce Ca2+-mediated opening of the mPTP [Gieseler et al. 
2009] which could account for the observed ATP drop. 
Intriguingly, idebenone prevented mitochondrial swelling in isolated mitochondria [Suno and Nagaoka 1989b, 
Sokol et al. 2005] and CoQ0 and decylQ were described as inhibitors of mPTP opening comparable to 
cylcosporin A [Fontaine and Bernardi 1999]. These findings suggested that the restoration of ATP content by 
idebenone in presence of rotenone might be due to inhibition of mPTP opening. However, both cyclosporine A 
and CoQ0 were not able to rescue ATP levels under these conditions. In line with this, idebenone did not rescue 
ATP levels in cells treated with A23187. Thus, it seemed unlikely, that the mode of action of ATP rescue was 
dependent on Ca2+ imbalance and mPTP opening [Figure 48E&F]. 
A further potential mechanism responsible for induction of ATP synthesis is via the AMP-activated protein 
kinase (AMPK). Energy shortage activates AMPK by phosphorylation of threonine 172 (Thr172) which in turn 
promotes the employment of alternative sources of energy production by increasing glucose and fatty acid 
uptake, β-oxidation, and induction of mitochondrial biogenesis [Hutchinson et al. 2007, Han et al. 2010, and 
Kelly et al. 2010]. Since the ATP-conserving effect of idebenone was conducted already after a short time, 
phosphorylation of Thr172 was analyzed after 15 min. However, phosphorylation pattern of AMPK was not 
affected by idebenone treatment.  
Hence, it seemed that the drop in ATP levels was solely due to inhibition of complex I-dependent ATP 
synthesis and the antagonizing effect of idebenone was conducted by actuating de novo ATP synthesis [Figure 
48D]. Several groups reported that idebenone is a good substrate for complex III [Sugiyama et al. 1985, Sugiyama 
and Fujita 1985, Degli Esposti et al. 1996a, Rauchovà et al. 2008]. This enzyme complex plays a pivotal role in 
the ETC. Not only does it re-oxidize H2-CoQ10 converted by any of the many mitochondrial quinone 
oxidoreductases, but also adds to the proton gradient across the inner membrane. Given that idebenone was not 
able to rescue ATP levels when complex I was inhibited by class C inhibitors such as stigmatellin, which also 
blocks complex III activity, led to the assumption that the de novo ATP synthesis by idebenone could be 
promoted via complex III. In order to test this hypothesis, the ATP rescue experiment was conducted in 
presence of the complex III inhibitor antimycin A. Indeed, antimycin A successfully blocked the restoration of 
ATP levels by idebenone, indicating that complex III is required for this beneficial effect. 
The involvement of complex III elucidated the mode of action by which idebenone is able to restore ATP 
levels in complex I-deficient cells. In order to interact with complex III, idebenone has to be reduced. Reduced 
idebenone is thought to donate electrons to cytochrome c via complex III and might thereby maintain 
mitochondrial respiration as a substitute for CoQ10. However in this scenario it is imperative to elucidate how 
idebenone is reduced prior to its interaction with complex III.  
In contrast to the lipophilic physiological electron carrier of the ETC, CoQ10, idebenone is an amphiphile—i.e. 
it is both lipophilic and hydrophilic10—and could therefore be reduced by both cytosolic and membrane-bound 
oxidoreductases. Experiments by King et al. [2009] confirmed that idebenone could interact with both the 
CoQ10-binding pocket of complex I (which requires entrance via the lipophilic inner mitochondrial membrane) 
and the NADH binding site of complex I (which is exposed to the aqueous mitochondrial matrix). 
One of the main oxidoreductases to reduce quinones in cellular systems is NAD(P)H:quinone oxidoreductase 
(NQO1) [O’Brien 1991, Monks et al. 1992] and NQO1-dependent reduction of idebenone analogs CoQ0 and 
                                                        
10 Calculated log D values (Advanced Chemistry Development Software Package, Version 12, ACD Labs, 
Toronto, Canada) for idebenone and CoQ10 are 3.91 and 19.12, respectively [Haefeli et al. 2011]. Log D values are 
a measure for lipophilicity incorporating ionization of the compound in which small values indicate affinity for 
the aqueous phase. 
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CoQ1 were previously confirmed in vitro [Chan et al. 2002, Audi et al. 2003]. Indeed, when cells with 
exogenously blocked complex I were subjected to the NQO1 inhibitor dicoumarol, idebenone failed to restore 
ATP levels.  
Although suggestive as a model, a direct interaction of idebenone and NQO1 had to be confirmed. In 
experiments with recombinant NQO1 protein, idebenone was able to oxidize both NADH and NADPH, the 
reductive substrates of NQO1. Turnover rates of idebenone were comparable to those of CoQ1 and in line with 
previous reports of CoQ1 reduction by NQO1 [Beyer et al. 1996]. In addition, idebenone was shown to 
competitively inhibit 2,6-dichlorophenolindophenol (DCPIP) reduction, whose role as electron acceptor for 
NQO1 was described by Cabello et al. [2009 and 2011], indicating that both compounds are converted by the 
same mechanism.  
Thus, idebenone is a substrate for recombinant NQO1. Nevertheless, reduction of idebenone by NQO1 had 
also to be confirmed in vitro. Tan and Berridge [2010] presented an assay measuring NQO1-dependent conversion 
of a hydrophilic quinone which based on a reduction-dependent change in absorption of the tetrazolium dye 
WST-1. The authors demonstrated that WST-1 is converted only in the presence of functional NQO1, since 
inhibition of enzymatic activity by dicoumarol abolished WST-1 reduction. Furthermore, the dye was potently 
reduced in cells expressing NQO1, but failed to change absorption in NQO1-deficient cells such as CHO cells. 
Indeed, results of WST-1 assays revealed that idebenone was reduced by NQO1 in vitro in a dicoumarol-sensitive 
manner.  
Although dicoumarol was described to be a selective NQO1 inhibitor [Ernster et al. 1962], WST-1 is 
supposedly only reduced in presence of NQO1, and dicoumarol potently inhibited recombinant NQO1 activity 
in consistency with previous reports [Wu et al. 1997, Long II and Jaiswal 2000], the possibility of interference 
with potential off-targets in vitro could not be completely excluded. In order to attribute the findings in ATP 
rescue and WST-1 experiments to NQO1, inhibition of NQO1 activity was achieved by short hairpin RNA 
(shRNA)-mediated knock-down. Even though gene silencing using shRNA-expressing lentiviral particles did not 
result in a complete knock-down of NQO1, the rate of in vitro reduction of idebenone and its capacity to restore 
ATP content in presence of rotenone decreased.  
Experiments in cells varying in NQO1 content were in line with this finding, since the capacity to restore ATP 
levels in presence of rotenone was dependent on NQO1 levels quantified by qPCR [Haefeli et al. 2011] and 
western blot [personal communication with D. Robay], providing additional evidence that the beneficial effect of 
idebenone was in fact associated to this oxidoreductase. For example, in NQO1-deficient cells (HEK293 and SH 
SY5Y), neither ATP rescue in presence of rotenone or reduction of idebenone was observed with the latter 
mirroring results described for CHO cells devoid of NQO1 [Tan and Berridge 2010]. However, with increasing 
levels of NQO1, the amount of restoration of ATP levels depleted by rotenone was elevated again, suggesting a 
pivotal role for NQO1 in idebenone-induced ATP de novo synthesis in complex I-deficient cells. In addition, the 
fact that this mechanism was observed as well in other NQO1-expressing cells than HepG2 indicated that this 
beneficial effect of idebenone was not cell type-specific [Haefeli et al. 2011]. Even more, ATP rescue was also 
observed in freshly isolated mouse hepatocytes treated with rotenone and idebenone. 
In conclusion, the previous results concerning how idebenone restores ATP levels in cells with dysfunctional 
complex I could be incorporated into a mechanistic mode of action [Figure 49]. As the experiments pointed out, 
ATP rescue was dependent on complex III and NQO1. A substantial amount of literature confirmed that 
idebenone is readily oxidized by complex III [Sugiyama et al. 1985, Sugiyama and Fujita 1985, Degli Esposti et al. 
1996a, Rauchovà et al. 2008], whereas interaction of idebenone with NQO1 was shown here for the first time 
and the reduction of idebenone by NQO1 was proven by various independent experiments. Since the 
amphiphilic idebenone can be found in both aqueous and lipid environment, it seems likely that it is first 
reduced within the cytosol by NQO1 and subsequently re-oxidized by complex III within the inner 
mitochondrial membrane. Thereby, electrons from cytosolic NAD(P)H are transferred into the ETC and—by 
circumventing complex I—mitochondrial ATP synthesis can be accomplished. Since the reduced idebenone is 
oxidized back into its quinone form by complex III, a new cycle can be triggered resulting in a idebenone-driven 
electron shuttle from cytosolic NAD(P)H to mitochondrial cytochrome c [Figure 49]. 
This mode of action requires an amphiphilic quinone which can easily commute between cytosol and 
mitochondria. In this regard, the lipophilic CoQ10 should not be able to restore ATP levels in the described 
model system. Indeed, when CoQ10 was added to rotenone-treated HepG2 cells, ATP content remained depleted 
after one hour. In additional experiments, CoQ10 was not reduced by NQO1 in both cells and when given to 
recombinant enzyme; not even when complexed with fetal bovine serum (FBS) or incorporated into 
phosphatidylcholine-based liposomes to increase its solubility in water [Mayer et al. 1985, Paolino et al. 2004]. 
The reason for the extremely poor reduction of CoQ10 by NQO enzymes most likely originates from 
compartmentalization of enzyme and substrate. While NQO1 and NQO2 are strictly cytosolic enzymes [O’Brien 
1991, Long II and Jaiswal 2000], CoQ10 is only found integrated into biological membranes under physiological 
conditions [Lenaz 2001]. Therefore, CoQ10 cannot participate in this cytosolic-mitochondrial shuttling of 
electrons. Consistently, even prolonged cellular exposure to CoQ10 for up to one week failed to trigger an ATP 
rescue when complex I was dysfunctional. 
This proposed mechanism can rationalize the observed beneficial effects of idebenone in two disorders with 
impaired complex I, MELAS and LHON [see 4.11]. Given the central role of NQO1 for the benefitial effects of 
idebenone, it is imperative to point out that multiple polymorphisms in the NQO1 gene are described in the 
general population. Of 200 single nucleotide polymorphisms described for NQO1 (NCBI; 
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http://www.ncbi.nlm.nih.gov/projects/SNP), 11 change the coding sequence. Out of those, the 609C>T 
(Ser187) polymorphism is the most intesively studied, since it destabilizes the NQO1 protein. NQO1 activity is 
reduced to 50% in heterozygous carriers and almost completely eliminated in homozygous carriers, respectively 
[Guha et al. 2008]. Heterozygosis of the allele is prevalent in approximately 50% of the Chinese population and 
one sixth of Caucasians, whereas homozygous carriers amount to 5-20% in all ethnics. The high prevalence of 
just this single polymorphism indicates that overall a big portion of the general population might harbour 
polymorphisms within NQO1 that could affect their response to idebenone. Therefore, this possibility should be 
considered in future clinical trials to expose a functional difference within patient populations in responder 
analysis approaches. 
For a mechanistic understanding of this mode of action, findings obtained with idebenone were expanded to 
other short-chain quinones. For CoQ1, both NQO1-dependent reduction and cytosolic-mitochondrial shuttling 
were described [Chan et al. 2010] and confirmed in own experiments. Reduction by NQO1 was also found for 
the idebenone metabolite QS-10 [Okamoto et al. 1998] using recombinant enzyme or WST-1 conversion in a 
cellular system. Despite turnover rates comparable to idebenone and CoQ1 (although slightly reduced), QS-10 
was not able to restore ATP levels in cells with dysfunctional complex I. QS-10 is significantly more hydrophilic 
than idebenone and CoQ1, as manifested in a smaller log D value (3.91 for idebenone, 2.41 for CoQ1, and 1.18 for 
QS-10). It is therefore less likely that reduced QS-10 can pass through the lipophilic mitochondrial membrane to 
donate the electrons to complex III. This could also account for the failure of the highly polar CoQ0 to restore 
ATP content in rotenone-treated cells. In contrast, both CoQ2 and decylQ, which have comparable polarity to 
idebenone and CoQ1, were also able to show ATP rescue and were reduced by NQO1 in vitro. Similarly to 
CoQ10, the lipophilic CoQ4 did not restore ATP levels in rotenone-treated cells. 
Thus, these findings imply several requirements for this form of cytosolic-mitochondrial respiration. Not only 
is it necessary for quinones to enter the cytoplasm and show efficient reduction by NQO1, these compounds 
must also be able to enter the mitochondria. Then, within the mitochondria, they must be able to interact with 
complex III of the respiratory chain and release electrons that contribute to the mitochondrial proton gradient 
which is necessary for ATP synthesis [Figure 49]. 
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Figure 49: Schematic representation of NQO1-dependent cytosolic-mitochondrial electron shuttling.  
(A) During oxidative phosphorylation under normal conditions, CoQ10 transports electrons from complex I (CI) to complex III (CIII) and 
cytochrome c, reduced by complex III, transfers them to complex IV. As a consequence of this electron propagation, all three complexes 
translocate protons (H+) across the mitochondrial membrane, thus generating a proton gradient. ATP synthase utilizes the energy stored in 
this electro-chemical gradient to generate ATP. (B) Upon rotenone-induced (Rot) inhibition of complex I, ATP levels decrease dramatically. 
(C) Some short-chain quinones (Q) such as idebenone or CoQ1 can bypass complex I inhibition via a cytosolic-mitochondrial shuttling of 
electrons. Upon reduction by cytosolic NQO1 (QH2), these quinones can feed electrons into the mitochondrial respiratory chain in a 
complex III-dependent manner, thereby restoring ATP production. 
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4.6 Idebenone Is Reduced by Other Oxidoreductases than NQO1 as Well 
Although the reduction of idebenone by NQO1 was thoroughly demonstrated in various experiments, it 
seemed unlikely that NQO1 was the only cytosolic oxidoreductase reacting with idebenone, regarding the vast 
number of oxidoreductases and even more considering that idebenone was reported to interact with 
mitochondrial oxidoreductases. Besides the aforementioned associations with complexes I, II, and III; glycerol-3-
phosphate dehydrogenase (G3PDH) was also shown to reduce idebenone [Rauchovà et al. 2008 and 2011]. 
G3PDH is used to shuttle electrons from cytosolic NADH onto CoQ10 or quinone analogs such as idebenone 
which are in turn oxidized by complex III. In addition, Frerman and Šimkovič [2004] reported that idebenone 
was a good substrate for electron-transferring-flavoprotein dehydrogenase (ETFDH), the enzyme responsible for 
the donation of electrons from β-oxidation to the ETC via CoQ10.  
Furthermore, due to their reactivity, many quinones exhibit toxic features that are sometimes employed by 
organisms on purpose in order to protect themselves from natural enemies [Monks et al. 1992]. On this account, 
several enzymes used for detoxifying xenobiotics are able to reduce quinones. Among these detoxifying enzymes 
are not only NQO1 or NQO2, but also NADH:cytochrome p450 oxidoreductase and NADH:cytochrome b5 
reductase. In order to test if the ATP rescue mediated by idebenone in cells with dysfunctional complex I was 
not only dependent on NQO1, but also other oxidoreductases, this experiment was conducted in presence of 
inhibitors for ETFDH, NQO2, NADH:cytochrome p450 oxidoreductase, and NADH:cytochrome b5 reductase. 
However, since many of these enzymes share structural analogies, a common problem of these inhibitors is a lack 
of specificity. Indeed, all of the tested inhibitors partially inhibited the activity of recombinant NQO1. In 
addition, diphenylene iodonium (DPI) which blocks NADH:cytochrome p450 was also described to inhibit 
complex I [Degli Esposti 1998]. Interestingly, reduction of idebenone measured by WST-1 assay and ATP 
restoration mediated by idebenone in presence of impaired complex I was not blocked by any of these inhibitors 
– with the exception of pentachlorophenol (PCP). This is noteworthy, since PCP showed the same degree of 
NQO1 inhibition in experiments with recombinant enzyme as the remaining inhibitors and therefore, the 
objection that the prevention of idebenone-mediated cytosolic-mitochondrial electron shuttling was due to 
inhibition of NQO1 could be abandoned. Intriguingly, this effect of PCP was only observed when idebenone was 
used, whereas in presence of CoQ1, PCP failed to impede both ATP rescue and CoQ1 reduction. 
Hence, these experiments revealed a specific connection between PCP and idebenone. PCP was used to inhibit 
ETFDH for which idebenone was described as a good substrate [Frerman and Šimkovič 2004]. Strikingly, also 
CoQ1, CoQ2, and decylQ were converted by ETFDH in a comparable rate as idebenone, but PCP did not prevent 
reduction of these quinones in vitro, suggesting that not ETFDH was responsible for the specific link between 
PCP and idebenone, but another mechanism. 
Nevertheless, involvement of ETFDH could not be excluded a priori. Therefore, ETFDH was knocked down 
using small interference RNA (siRNA). In cells subjected to ETFDH siRNA, idebenone was still reduced. Even 
though, these results should be regarded carefully, since siRNA-induced knock-down of NQO1 prevented 
reduction of idebenone less effectively than dicoumarol. Thus, the objection, that knock-down effects were too 
weak to sufficiently reduce enzyme expression, cannot be eliminated completely. 
For this reason, the activity of ETFDH was blocked upstream. ETFDH links β-oxidation with the ETC 
[Frerman 1987]. During β-oxidation, the electron carrier FADH2 is produced which donates its electrons onto 
electron-transferring flavoprotein (ETF). ETFDH catalyzes the electron transfer from ETF onto CoQ10 which in 
turn supplies the electrons onto complex III. Using its (i) role as a conjunction between lipid metabolism and the 
ETC and (ii) the requirement of electrons derived from β-oxidation for its oxidoreductase activity, inhibition of 
β-oxidation should diminish reduction of idebenone if ETFDH was responsible for the effects observed in 
presence of PCP. However, inhibition of β-oxidation by 3-mercaptopropionic acid (MPA) or valproic acid 
(VPA) did not result in patterns comparable to the use of PCP in either WST-1 or ATP rescue experiments. 
Although each experiment on its own did not provide sufficient evidence to completely rule out the possibility 
of involvement of ETFDH in idebenone reduction or idebenone-mediated ATP rescue in rotenone-treated cells, 
the combination of both experiments made it unlikely, even more so since substrate affinity towards this enzyme 
did not substantially vary between idebenone and related quinones. 
Unfortunately, the nature of the special relationship between idebenone and PCP could not be resolved in this 
thesis due to time constraints. Nevertheless, the finding that the redox properties of idebenone were specifically 
interconnected with PCP in vitro whilst leaving the conversion of analogous short-chain quinones unaltered 
provides sufficient indication for separating the action of idebenone from those of analogs. Despite structural 
similarities, short-chain quinones might vary substantially in their biologic activities [see 4.9]. Hence, further 
research of this topic is not only desirable, but very much required in order to identify an exclusive mode of 
action for idebenone. 
4.7 Idebenone Inhibits Complex I in Vivo and Thereby Changes Metabolism 
In vitro experiments revealed that idebenone is highly involved in mitochondrial energy production: not only 
by inhibiting complex I activity, but also to provide alternative mechanisms of ATP synthesis when complex I is 
dysfunctional. These mechanisms involve NQO1 activity and the glycerolphosphate shuttle [Rauchovà et al. 
2008 and 2011]. Ex vivo experiments in mouse hepatocytes revealed that idebenone-treated animals still 
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exhibited the capacity to restore ATP levels when subjected to rotenone. This is surprising, given the facts that 
(i) idebenone has a short half life in vivo with a peak around 15 min after administration [pharmacokinetic reports 
from Takeda and data by F. Heitz] Furthermore, this problem was replicated in vitro where (ii) idebenone was 
unable to rescue ATP levels in cultured cells when administered one week before the rotenone challenge. 
However, a potential explanation for this discrepancy will be discussed within this subchapter. This hypothesis 
was directly indicated by the results obtained when investigating possible metabolic changes in vivo by 
idebenone and represents a totaly new mode of action for this molecule. 
In the literature, only few studies reported any impact of idebenone on in vivo metabolism, and a great many 
thereof were conducted in ischemia models, suggesting that idebenone attenuated ischemic harm by increasing 
energy metabolism and reducing oxidative damage [Nagaoka et al. 1989, Kakihana et al. 1998, and Abdel Baky et 
al. 2010]. Solely Sugiyama and Fujita [1985] investigated metabolism-related effects of idebenone on healthy 
animals and surprisingly reported an increase in complex I-mediated mitochondrial respiration in isolated 
mitochondria of idebenone-treated rats.  
On the contrary, the vast majority of literature examining the relation of idebenone and complex I, including 
experiments described in this work, favor an inhibitory role on complex I activity of idebenone [Sugiyama et al. 
1985, Degli Esposti et al. 1996a, Brière et al. 2004, Geromel et al. 2008, Fato et al. 2008, Rauchovà et al. 2008, 
and King et al. 2009], suggesting that complex I inhibition could also occur in vivo. In vitro, usage of idebenone or 
rotenone to block complex I activity resulted in a general ATP decrease. Adopting these findings to in vivo 
experiments would suggest that ATP content in tissue would be decreased in idebenone-treated animals; which 
however was not found. In this context it has to be pointed out that, in vivo impairment of mitochondrial 
respiration is usually compensated by the organismn by engaging alternative sources of energy supply. The easiest 
mechanism for providing cells with sufficient energy would be to increase glucose uptake and glycolysis, 
probably by increasing the food intake. 
Indeed, in mice treated with idebenone for three to four weeks with 200-400 mg/kg/day idebenone mixed in 
food, food intake was significantly elevated by idebenone, whilst body weight did not increase compared to 
control group. Although this uncoupling of calorie intake and weight gain was robust and reproducible11, and 
seemed to be a consequence of the reported complex I inhibition by idebenone, this in vivo effect of idebenone 
was described for the first time in this thesis. Additional affirmation was obtained by experiments with another 
complex I inhibitor, metformin, for which lower hepatic glucose release and higher rates of glucose consumption 
in peripheral tissues—and thus, decreased blood glucose levels—were reported [Periello et al. 1994, Baily and 
Turner 1996, Inzucchi et al. 1998, and Brunmair et al. 2004]. Indeed, single-dose p.o. administration of idebenone 
resulted in a transient reduction of blood glucose levels, the timing of which was in line with its short half life in 
vivo. Considering the route of administration in experiments measuring the influence of idebenone on food 
intake and body weight—i.e. idebenone is administered constantly during feeding—complex I inhibition would 
not be a short-lived, once-a-day event, but coincide with food intake and thus, incessantly promote 
supplementary food intake.  
The dependency on a mechanism involving complex I inhibition for the increase the food intake relative to 
body weight by idebenone was further consolidated by the dismissal of other potential explanations. In my 
experiments, idebenone did not increase energy expenditure by promoting higher locomotion or by elevation of 
body temperature which is usually accomplished by mitochondrial uncoupling [Richard and Picard 2011].In 
addition, idebenone did not induce a change in body composition between fat and muscle tissue which could 
account for compensating measurable weight. Finally, the observed increase in relative food intake was not 
explained by any inhibition of insulin release. 
The combination of excess food intake and unchanged body weight observed in idebenone-treated mice led to 
the assumption that idebenone-mediated complex I inhibition mimicked calorie restriction (CR) by a molecular 
mechanism. Indeed, in mice given limited amounts of food which solely allowed for maintenance of body 
weight, administration of idebenone led to weight loss [personal communication by R. Dallmann]. Furthermore, 
CR was reported to increase blood concentrations of β-hydroxybutyrate (β-HB) in C57Bl/6 mice. β-HB is a 
ketone body which can be used as an alternative source of energy [McGarry and Foster 1980]. Strikingly, β-HB 
was reported to rescue mitochondrial respiration in a Parkinson’s disease model based on the complex I inhibitor 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [Tieu et al. 2003]. Intriguingly, subchronic idebenone 
treatment of C57Bl/6 mice led to a trend of increased blood β-HB levels and to a slightly increased expression of 
3-hydroxy-3-methylglutaryl-coenzyme A synthase 2 (HmgCoA), the enzyme responsible for β-HB production, in 
heart tissue. Ketone bodies give rise to acetyl-CoA, the starting product for the citric acid cycle (TCA). In this 
regard, it is noteworthy that idebenone was described to be a good substrate for complex II, a member of TCA 
[Sugiyama et al. 1985, Sugiyama and Fujita 1985, Imada et al. 1989, and Degli Esposti et al. 1996a]. Nevertheless, 
findings concerning ketone body synthesis induced by idebenone are disputable in regards to their poor statistical 
validity. 
Hypothetically, transient idebenone-induced CR could account for the finding that idebenone prolonged life 
span in the nematode caenorhabditis elegans [personal communication M. Ristow]. Several studies showed that a 
                                                        
11 In two out of seven experiments, idebenone did not induce an increase in food intake. However, some 
parameters varying in these experiments from others were accounted for the lack of this effect, as will be 
discussed below. Comparable results in experiments conducted in different mouse strains further confirmed that 
the effects were reliable. 
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decrease in calorie intake increases longevity in different species [Skinner and Lin 2010, Smith et al. 2010a] and 
several compounds such as the complex I inhibitor metforminare thought to mimic this effect [Anisimov et al. 
2008, Smith et al. 2010b]. CR activates different pathways which promote mitochondrial biogenesis and energy 
production, and a shift in energy source from glucose to fatty acid consumption [Guarente 2008]. A pivotal role 
in these pathways is played by sirtuins which enable the expression of required genes by deacetylation of certain 
regions of DNA. As a consequence, sirtuins were implicated in life span extension by the CR-mimetic resveratrol 
in yeast, c. elegans, fruit flies, and mice [Howitz et al. 2003, Wood et al. 2004, and Baur et al. 2006]. Sirtuins 
require NAD+ as a substrate in order to deacetylate DNA and an increase in NAD+/NADH ratio was shown to 
activate sirtuins-dependent gene expression [Lin et al. 2004]. It is important to point out here that reduction of 
idebenone by NQO1 rapidly produces NAD+, as was measured using the fluorescent dye resazurin [Haefeli et al. 
2011]. Hence, idebenone could not only initiate CR-related pathways by direct mimicking of CR, but also via 
NQO1-dependent sirtuins activation.  
Ristow and Zarse [2010] proposed a pro-oxidant-driven mechanism for longevity which is related to CR 
pathways. According to this, sub-pathological doses of pro-oxidants provoke a mitochondrial-dependent 
adaptive response—called mitohormesis—which in turn increases the resistance to stress. Indeed, Nishimoto et 
al. [2010] reported that minor concentrations of H2O2 made cells less susceptible to stress at a later time point. In 
contrast, antioxidants were reported to block mitohormesis [Ristow and Zarse 2010]. This concept is noteworthy 
given the fact that idebenone might also exhibit mild pro-oxidant properties [see 4.8]. It also could explain why 
idebenone failed to show recovery in LHON patients when administered in combination with the antioxidant 
vitamin C [Barnils et al. 2007] which is contrary to reports showing that idebenone alone ameliorated the LHON 
phenotype [Mashima et al. 1992, Carelli et al. 1998, and Mashima et al. 2000, Klopstock et al. 2011]. In line with 
these findings, the relative food intake was not increased in idebenone-treated mice in an in vivo experiment 
using a food chow containing vitamin C (experiment 0423 [Table 10 in Appendix]). The results from Jauslin et 
al. [2007], who reported that a combination of idebenone and the antioxidant vitamin E was more potent in 
protection against oxidative stress-induced cell death, are not contradictory to this hypothesis. Whilst idebenone 
might indeed act as an antioxidant in the presence of oxidative damage, its mild pro-oxidant function could 
promote mitohormesis under physiological conditions. In this regard, it is noteworthy that pre-treatment with 
idebenone in vivo suppressed the formation of ROS induced by ischemic reperfusion injury in pig livers, whereas 
ex vivo treatment with idebenone could not counteract oxidative damage [Schütz et al. 1997, Wieland et al. 
2000]. 
CR-induced longevity was found to be a conserved pathway in many species. In a simplified model, organisms 
mainly require energy for reproduction and maintenance of their own life and they have to divide their limited 
amount of energy between the two. In periods of reduced food supply, it would be disadvantageous to produce 
offspring due to (i) the high associated energy demand and (ii) their reduced survival chances due to a limitation 
of available nutrition. Thus, organisms must wait until environmental conditions become more suitable for 
breeding. By reducing energy consumption, CR does not only increase life span (and thus, the probability to 
reproduce when food supply becomes more promising), but it also represses reproductive functions [Grandison 
et al. 2011]. On the basis of single-cell organisms, this property of CR would translate in a reduction of 
proliferation. Indeed, idebenone suppressed proliferation in a highly dividing cell line, proving further evidence 
for this hypothesis. 
The slight shift in energy source to the use of ketone bodies could also account for the finding that idebenone 
administered in vivo was still able to rescue ATP levels in isolated hepatocytes ex vivo. With regards to the short 
half life of idebenone in vivo [pharmacokinetic reports from Takeda and data by F. Heitz], it can be assumed that 
idebenone tissue levels at the time of the experiment were negligible from tissue and thus, the proposed 
cytosolic-mitochondrial electron shuttle should not have been functional anymore. However, as response to 
complex I inhibition or pro-oxidant activity of idebenone, cells could potentially shift their energy metabolism 
away from complex I-dependent respiration to the use of ketone bodies and fatty acids. Through this adaptation, 
inhibition of complex I by rotenone would not be as detrimental to cells as when they mainly rely on complex I. 
Nevertheless, great efforts are still required to verify this hypothesis. A yet unsolved question, for example, is 
how idebenone could manage to promote transcription- and translation-dependent alterations when it barely 
altered gene expression as observed in micro array experiments. However, it is possible that the lack of 
observable gene expression was due to a timing effect of idebenone administration, since isolation of tissues was 
conducted several hours after last idebenone treatment [Figure 50]. It is likely that idebenone rapidly induces a 
transient transcriptional response in line with its PK profile. However, since some metabolism-related gene 
products display longer half lifes of several hours, the induced proteins would be still present and functional after 
a rapid degradation of the corresponding mRNAs. This hypothesis can explain results which are otherwise 
difficult to reconcile with previously described modes of action of idebenone. Besides offering clues for a 
CR/mitohormesis hypothesis, animal experiment data provided for the first time significant evidence that 
complex I inhibition by idebenone described in vitro takes also place in vivo. 
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Figure 50: Timing Effects of Idebenone Administration and Suggested Development of Gene Expression and 
Protein Half Lifes. 
When given orally, pharamcokinetic experiments revealed that idebenone peaks around 15 min (PK). Consistent with this, blood glucose 
levels transiently drop 20 minutes after administration. Gene expression was not observed in tissue several hours after last idebenone 
administration. However, idebenone could still promote short-term transcription whose protein products would be functional long after 
administration. 
4.8 Idebenone Is a Mild Pro-Oxidant 
As consequence of complex I inhibition, idebenone was suggested to also act as pro-oxidant under certain 
conditions [Degli Esposti et al. 1996, Geromel et al. 2000, and Fato et al. 2008]. Indeed, some results described in 
this thesis support the notion that idebenone exhibits pro-oxidant properties. Nonetheless, these effects were 
only minor compared to exclusively pro-oxidant compounds such as hydrogen peroxide (H2O2) or to other 
short-chain quinones such as CoQ1. 
For example, chronic treatment with idebenone also seemed to have a similar, but milder effect on Akt-1 
compared to short-term H2O2 stress in vitro. In fact, idebenone did not phosphorylate Akt-1 in contrast to H2O2. 
Nonetheless, a modification of Akt-1 resulting in a 9 kDa heavier, yet unpublished protein was reduced by both 
H2O2 and idebenone. In contrast to idebenone, however, H2O2 prevented this modification completely. The 
difference in molecular weight and the distinctiveness of the according band in western blot analysis suggested 
that this modification was due to posttranslational modification of Akt-1 such as the ligation to a small ubiquitin-
like modifier (SUMO). Intriguingly, further experiments in our lab demonstrated that this modified Akt-1 was 
only observed when cells were lysed using SDS which solubilizes all membranes and most higher order protein 
complexes [personal communication with M. Erb and D. Robay]. In this regard, it is noteworthy that 
SUMOylation of proteins is associated with their cytosolic-nuclear transport [Matunis et al. 1996]. Nevertheless, 
characterization of the modification and the resulting implications to the bioactivity of idebenone would have 
exceeded the scope of this work. The important conclusion drawn from this experiment is, however, that 
idebenone indeed showed a mild pro-oxidant effect. 
In contrast to results suggesting a pro-oxidant function of idebenone, there is ample evidence that the picture 
is more complex. Pro-oxidants damage cellular macromolecules such as lipids or DNA. However, idebenone is 
most prominently known for its action as antioxidant. In fact, it was described to reduce lipid peroxidation in 
vitro and in vivo under conditions of oxidative stress [Suno and Nagaoka 1989a&b, Suno et al. 1989, Cardoso et 
al. 1998, Mordente et al. 1998, and Abdel Baky et al. 2010] and own experiments showed that idebenone did not 
increase lipid peroxidation when given to unchallenged cells. Further investigations revealed that idebenone did 
not induce DNA double breaks in different cell types regardless of NQO1 expression levels. NQO1 reduces 
idebenone and thereby, detoxifies a potential pro-oxidant effect. Indeed, NQO1 produces equilibrium between 
quinone and hydroquinone, whereat increasing levels of NQO1 lead to a higher concentration of hydroquinone 
[Merker et al. 2007]. In contrast, an idebenone analog, CoQ1, for which pro-oxidant effects were assumed as well 
[Lenaz et al. 2002] increased both DNA damage and lipid peroxidation.  
Furthermore, a striking concentration-dependency towards the shift in pro- and antioxidant properties of 
idebenone was found. Whereas concentrations up to 1 µM idebenone reduced H2O2-induced ROS, 10 µM 
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idebenone led to a completely contrary result. H2O2 treatment was assumed to increase mitochondrially 
generated ROS, and the pro-oxidant function of idebenone was associated to its inhibition of complex I [Fato et 
al. 2008, Geromel et al. 2008]. Considering the IC50 of 5.9 µM for complex I inhibition by idebenone, one could 
argue that the amplification of H2O2-induced ROS levels is achieved by increasing mitochondrial ROS 
production. 
In conclusion, idebenone might both exhibit pro- and antioxidant activity; however, pro-oxidant properties of 
idebenone seem to be rather minute and are not sufficient to question its good safety record. 
4.9 Idebenone Analogs Exhibit a High Disparity in Biological Function 
Next to the unusual dose effect in scavenging or promoting H2O2-induced ROS, the activities of idebenone are 
not easy to characterize. This is due to the multi-target properties of idebenone covering a broad range of cellular 
functions [Table 11 in the appendix] including (i) action as an antioxidant [Suno and Nagaoka 1989a&b, Suno et 
al. 1989, Amada et al. 1995, Cardoso et al. 1998, Mordente et al. 1998, Rego et al. 1999, Rustin et al. 1999, 
Sortino et al. 1999, Wieland et al. 2000, Yerushalmi et al. 2001, Gumpricht et al. 2002, Jauslin et al. 2002, 2003, 
and 2007, Gil et al. 2003, Sokol et al. 2005, Rauchovà et al. 2006, and Abdel Baky et al. 2010], (ii) altering energy 
status, probably by interaction with the ETC [Shinamoto et al. 1982, Yu et al. 1982, Sugiyama et al. 1985, 
Sugiyama and Fujita 1985, Imada et al. 1989, Nagaoka et al. 1989, Degli Esposti et al. 1996a, Degli Esposti 1998, 
Kakihana et al. 1998, Lenaz et al. 2002 and 2007, Brière et al. 2004, Rauchovà et al. 2008, and King et al. 2009, 
and Watze et al. 2010], (iii) inhibition voltage-gated Ca2+ channels [Houchi et al. 1991, Chang et al. 2011, Kaneko 
et al. 2011, and Newman et al. 2011], (iv) protection from cell death [Miyamoto et al. 1990, Houchi et al. 1991, 
Sortino et al. 1999, Yerushalmi et al. 2001, Gumpricht et al. 2002, Jauslin et al. 2002, 2003, and 2007, Gil et al. 
2003], (v) blockage of arachidonic acid metabolism and prostaglandin synthesis [Suno and Nagaoka 1989c, 
Tsuruo et al. 1994, Civenni et al. 1999], (vi) promoting nerve growth factor (NGF) [Takeuchi et al. 1990, Nitta 
et al. 1993, and Takuma et al. 2000], (vii) augmentation currents of kainate receptors and 2-amino-3-(5-methyl-
3-oxo-1,2- oxazol-4-yl)propanoic acid (AMPA) receptors [Miyamoto et al. 1990 and Kaneko et al. 1991], and 
(viii) mild amelioration of memory [Nagaoaka et al. 1989 and Yamada et al. 1997]. Focusing on interactions with 
enzymes and enzyme complexes, idebenone was described to interact with G3PDH [James et al. 1995, Rauchovà 
et al. 2008 and 2011], ETFDH [Frerman and Šimkovič 2004], cyclooxygenase and lipoxygenase [Civenni et al. 
1999] and with complex I, II, and III [Sugiyama et al. 1985, Sugiyama and Fujita 1985, James et al. 1995, Degli 
Esposti et al. 1996a, Brière et al. 2004, Rauchovà et al. 2008, and King et al. 2009]. Additional to these manifold 
interaction partners of and pathways influenced by idebenone, this thesis showed that idebenone is a substrate 
for NQO1 and NQO2 and might act as an electron carrier between the cytosol and the mitochondria.  
A further difficulty in characterization of idebenone lies in its chemistry: minor structural changes lead to 
(partially) unpredictable alterations in bioactivity as observed in various experiments in this thesis. In contrast to 
this, quinones that are analogous to CoQ10 in the substitution pattern of their quinone moiety have often been 
proposed to share its biological activity. For example, Villalba et al. [2010] suggested idebenone to be a good 
substitute for CoQ10 in different diseases. However, such predictions are questionable, since structural variances 
entail different chemical and physicochemical properties. Indeed, data presented in this thesis showed that 
idebenone and CoQ10 behaved differently in vitro. For example, CoQ10 is not reduced by recombinant NQO1 
and NQO2, nor is it able to reduce WST-1 by an NQO1-dependent mechanism in cellular systems. 
Consequently, the failure of CoQ10 to rescue ATP levels in presence of rotenone was ascribed to its high 
lipophilicity which prevented cytosolic reduction required for cytosolic-mitochondrial electron shuttle. 
Furthermore, being the physiological electron carrier of the ETC, CoQ10 did not inhibit complex I was observed 
and reported for idebenone. In line with these results, idebenone was also not able for substituting a lack of 
CoQ10 since no idebenone-dependent rescue of ATP levels was observed in CoQ10-deficient fibroblasts [López et 
al. 2010]. Clinical data also supported the notion of a substantial difference between idebenone and CoQ10, since 
idebenone ameliorated respiratory function in a patients suffering from Leigh syndrome, where high-dose CoQ10 
had no effect [Haginoya et al. 2009]. In conclusion, despite structural analogies, idebenone and CoQ10 exhibit 
completely different biological activities and cannot substitute for each other. 
Similarly, short-chain analogs of CoQ10 which share a more comparable lipophilicity to idebenone than CoQ10 
showed disparate activities in vitro as could be assumed by the differences described for CoQ0, CoQ1, CoQ2, 
decylQ, and idebenone in their affinity towards respiratory complexes [James et al. 1995, Degli Esposti et al. 
1996].  Even though short-chain quinones such as CoQ1, CoQ2, and decylQ were reduced by NQO1 and restored 
ATP levels after their depletion by idebenone, they showed different results in other assays. For example, CoQ1, 
but not idebenone triggered substantial DNA damage in different cell types. This clearly indicates that, despite 
sharing the protective activity against acute rotenone toxicity, CoQ1 causes DNA damage in contrast to 
idebenone after long-term administration. Furthermore, CoQ0 and CoQ1, but not idebenone, showed depletion 
of ATP levels when given to cells in normal growth medium and markedly increased lipid peroxidation after 
long-term treatment in vitro, demonstrating yet other toxic properties of these compounds. These findings are in 
line with reports on complex I inhibition and ROS production associated to short-chain quinones [Lenaz et al. 
2008, Geromel et al. 2002, and Fato et al. 2008]. On the other hand, QS-10, one of the first metabolites of 
idebenone in vivo [Okamoto et al. 1998], did not reduce ATP levels in glucose-deprived cells, was not able to 
restore ATP levels in presence of rotenone, or did not manifest genotoxic or pro-oxidant effects. 
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Furthermore, the importance of substituents became obvious when characterizing 51 idebenone analogs newly 
synthesized by the Chemistry Department of Santhera Pharmaceuticals in eight biological assays. These 
compounds vary from idebenone in some minor changes, mainly in substitution of the alkyl tail. Due to patent 
protection, chemical structures cannot be disclosed. Nevertheless, comparing the profiles of single compounds it 
became evident that they vastly deviate from each other in regards to their biological effects and that predictions 
with regards to their biological function on the basis of minute structural changes seem nearly impossible. This 
was revealed by a lack of correlation between functional assays and by direct comparison of single molecules. For 
example, a slightly different substitution of a six-membered ring at the terminal carbon atom of the alkyl tail (a 
methyl-piperazine instead of a morpholine) led to a dramatic increase in toxicity by depleting cellular energy 
stores. 
In addition to the broad range of responses induced by the different idebenone analogs, the generated profiles 
provide a valuable tool for the selection of customized solutions in various indications. These findings also 
highlight the influence of modifications to the alkyl tail or to substitutions at the quinoid head group of short-
chain quinones on their biological activity.  
4.10 Idebenone Protects From Oxidative Stress-Induced Cell Death 
Gil et al. [2003] demonstrated that idebenone protected chicken embryonic retinal neurons against 
staurosporin-induced apoptosis. Staurosporin is a bacterially derived antibiotic that inhibits protein kinases, 
increases intracellular ROS and Ca2+ concentrations and activates caspases. Gil et al. showed that one-day pre-
treatment with 1 µM idebenone reduced ROS levels, ameliorated intracellular Ca2+ status and blocked caspase-3 
activity. As a result, idebenone prevented apoptosis which was suggested to be due to its antioxidant effect. 
However, not only did other antioxidants such as glutathione-ethylester or trolox show similar results, but also 
inhibition of oxidative phosphorylation by a rotenone/oligomycin solution or a phospholipase A2 inhibitor, 
arachidonyl trifluoromethyl ketone (AACOCF3), led to comparable findings [Gil et al.  2003]. This is noteworthy 
in the respect that idebenone does inhibit mitochondrial complex I, as showed in this thesis and elsewhere 
[amongst others Degli Esposti et al. 1996, Lenaz et al. 2002], and idebenone was also described as an inhibitor of 
phospholipase A2 [Amada et al. 1995]. Considering the tightly linked interaction of Ca
2+, ROS and apoptotic 
pathways, the finding that idebenone blocks Ca2+ channels [Houchi et al. 1991] further broadens the range of 
potential targets for advocating its beneficial effect. Thus, the rescue from cell death described by Gil et al. could 
not be exclusively accounted to one exact mode of action. Nonetheless, their publication provided the relevant 
information of idebenone effectively preventing apoptosis at a concentration that can be achieved in vivo [Nagai 
et al.  1986].  
Idebenone-dependent protection against toxic insults was also described in a body of work by Jauslin et al. 
[2002, 2003, and 2007]. The authors worked with an in vitro model using L-buthionine (S,R)-sulfoximine (BSO) 
which is an inhibitor of γ-glutamyl cysteine synthase, the rate-limiting enzyme for de novo synthesis of 
glutathione. In its presence, recycling of GSH via reduction of GSSG using NADPH was still possible [Griffith et 
al.  1979]. In fibroblasts of healthy donors, concentrations up to 100 µM BSO did not alter cell viability; whereas 
at already half of this concentration (i.e. 50 µM), cell survival was dramatically reduced to less than 10% in 
fibroblasts of Friedreich’s ataxia (FRDA) patients [Jauslin et al.  2002]. The increase of necrosis—disrupted 
plasma membranes were detected by nuclear inclusion of ethidium homodimer dye—was attributed to the 
increased ROS levels in FRDA cells. Idebenone rescued cell viability of BSO-treated FRDA fibroblasts with an 
EC50, i.e. the half maximal effective concentration, of 0.5 µM. The studies demonstrated that this protection was 
not based on prevention of BSO-induced depletion of GSH levels, since both idebenone- and sham-treated 
FRDA cells exhibited similarly reduced GSH levels eight hours after BSO addition [Jauslin et al. 2002]. Vitamin 
E showed a similar efficacy as idebenone in this assay [Jauslin et al. 2007]. Even though, the results can not solely 
be assigned to the antioxidant effects of these two compounds, since two other antioxidants, trolox (6-hydroxy-
2,5,7,8-tetramethylchroman-2-carboxylic acid) and astaxanthin (3,3’-dihydroxy-4,4’-diketo-β-carotene), were 
unable to rescue viability of FRDA fibroblasts. 
Studies carried out by Takuma et al. [2000] provided further evidence that idebenone is able to protect against 
cytotoxicity. When cultured rat astrocytes were subjected to a 30-min hydrogen peroxide (H2O2) insult, post-
treatment with 1 µM idebenone or higher increased cell survival. In addition, seven-day pre-treatment with 
idebenone rescued cells similarly at even lower doses: as little as 10 nM idebenone was sufficient to significantly 
increase viability [Takuma et al.  2000]. In their work, Takuma et al. considered a contribution of idebenone’s 
antioxidant effect possible for the observed protection. However, they placed emphasis on an active involvement 
of idebenone in the production of neurotrophic factors. Indeed, idebenone has been reported to induce nerve 
growth factor (NGF) both in vitro in cultured mouse astroglial cells [Takeuchi et al. 1991] and in vivo in aged rat 
brains [Nitta et al.  1993]. As a matter of fact, antagonizing NGF by an antibody prevented the beneficial effect 
of idebenone [Takuma et al.  2000]. Furthermore, inhibitors of the mitogen-activated protein 
(MAP)/extracellular signal-regulated kinase (ERK) kinase, 2’-amino-3’-methoxyflavone, or of the 
phosphatidylinositol-3 (PI3) kinase, wortmannin, as well as blocking protein synthesis by cycloheximide blocked 
the beneficial effect on viability induced by idebenone. Whether this was factually linked with the NGF 
pathway as it was suggested by the authors, or if it involved totally independent routes with even new targets of 
interactions for idebenone remained unclear from their study. 
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In addition, Prof. Lavin from Queensland Institute of Medical Research in Brisbane, Australia, reported 
radioprotection by idebenone [personal communication M.F. Lavin and N. Gueven]. Ataxia-telangiectasia (A-T) is 
a neurodegenerative disorder which is characterized by extreme radiosensitivity at the cellular level. After a two-
day pre-incubation with 1 µM idebenone, A-T cells were irradiated and survival after two additional days was 
significantly increased by idebenone. In this thesis, a similar regime was used for assessment of protective action 
of idebenone against oxidative damage induced by H2O2. In this model system, a high concentration of H2O2 was 
added to rat myoblast cells for 30 min, before medium was added back to cells. Two days after this toxic insult, 
only about half of the cells remained alive. However, their morphology attested severe impairment. Idebenone 
markedly increased viability after H2O2 insult when administered to cells one or more hours before H2O2 stress. 
Pre-treatment with 10 µM idebenone did not fully abolish cell death induced by oxidative stress, but markedly 
reduced the extent observed. The morphology of cells which survived due to idebenone testified that they were 
in a stressed condition. Nonetheless, about 80% of cells survived in this model system, which amounted to an 
increase in protection of about 60% compared to sham-treated cells. Interestingly, the duration of pre-treatment 
did not seem to substantially alter the beneficial effect of idebenone, since the number of surviving cells did not 
vary between one, six, or 24 hours pre-incubation time with idebenone prior to H2O2 stress. In contrast, the 
presence of idebenone before H2O2 addition was necessary for its protective effect; when idebenone was 
administered to cells which were already harmed by H2O2 before, rates of cell death were unaltered in the 
presence of idebenone. These findings were in line with studies showing that pre-treatment with idebenone, but 
not administration of idebenone after the induction of oxidative damage, was able to reduce oxidative stress in 
pig livers after ischemic reperfusion injury [Schütz et al. 1997, Wieland et al. 2000]. 
In contrast to the work of Takuma et al. [2000] and Jauslin et al. [2002], which found cyto-protective effects 
of idebenone at concentrations of 10 or 500 nM, respectively, lower concentrations than 10 µM idebenone 
showed no statistical significant prevention of cell death in the model system used in this thesis. Even though 
statistical significance was not reached for concentrations below 10 µM, pre-treatment with a dilution series 
from 370 nM to 10 µM idebenone for 24 hours showed a trend towards dose-dependency.   
An intriguing finding was observed when idebenone and H2O2 were added simultaneously. Co-incubation of 
idebenone with the oxidative stressor almost completely prevented cell death and impairment of the 
morphology of surviving cells. This finding questioned whether idebenone might directly interact with and 
detoxify H2O2 before the latter could execute its fatal properties. Indeed, a series of cell-free experiments using 
two different redox-active dyes revealed a decrease in oxidative force of H2O2 by idebenone which is challenging 
to explain using chemical principles. It is believed from multiple studies that it is the reduced form of idebenone 
(hydroquinone) that acts as antioxidant, therefore further oxidation of oxidized idebenone which was employed 
in these assays is solely possible at the hydroxyl group at the tip of its tail. However, this possibility was ruled 
out, since two derivatives of idebenone, decylQ and QS-10, similarly reduced the oxidative capacity of H2O2. 
These two quinones differ from idebenone in the substitution of the carbon C10 of their alkyl tail. In DecylQ, 
the terminal hydroxyl group of idebenone is replaced by a single hydrogen atom, forming a weakly reactive alkan 
moiety; whereas C10 of QS-10 is fully oxidized and thus, a part of a carboxylic acid group. Additional derivatives 
of idebenone were also tested in this assay to rule out involvement of the two methoxy substituents of the 
quinone ring. Plastoquinones share the quinone head with CoQs with the exception, that the methoxyl groups 
are replaced by methyl groups. SNT210201 and SNT210486 are the plastoquinone analogs of decylQ and 
idebenone, respectively. The fact that these two quinones again provoked a decrease in ability of H2O2 to oxidize 
the fluorescent probes suggested that the functional group for interaction with H2O2 might be the dione 
structure of the quinone. However, even though the experimental data supposed that quinones directly interact 
with H2O2 and lower the latter’s capacity as an oxidizing agent; any chemical explanation therefore would be 
adventurous, if not precarious. However, the search for chemical explanations for this would exceed the scope of 
this biological work. The relevant information of these results was that the near-absence of cell death observed 
when H2O2 was co-incubated with idebenone might not be due to defense mechanisms occurring at a cellular 
level, but to direct interaction of idebenone and H2O2 within the medium. 
The protective effect of idebenone was independent of gene expression, since inhibition of both transcription 
and translation did not decrease the ability of idebenone to rescue cells from death. These findings are in line 
with the results of micro array data which revealed that chronic idebenone treatment in vivo had—if any—only 
minor influence on gene expression patterns. Furthermore, idebenone-mediated survival after H2O2 treatment 
was not sensitive to dicoumarol, indicating that the previously described cytosolic-mitochondrial electron shuttle 
was not involved in the protective action of idebenone. This is not surprising, considering that H2O2 is not 
reported to inhibit complex I.  
Nevertheless, the protective effect of idebenone seemed to be associated to a quicker recovery of energy 
levels. However, the data do not allow for speculation whether the elevated ATP levels six hours after oxidative 
insult were part of the mechanism by which idebenone rescues cell survival or whether they are a secondary 
result of the protective effect by idebenone. Interestingly, during the incubation in H2O2, ATP content was not 
altered; but immediately after restitution of medium to cells, energy levels were depleted. A similar incident is 
observed in ischemic reperfusion injury (IRJ), even though the form of the stress during ischemia is diametrically 
contrary to oxidative insult by H2O2
12: the detrimental effect—i.e. the substantial reduction of ATP levels after 
                                                        
12 In ischemia, interruption of blood supply leads to a reduction of oxygen (hypoxia) in the tissue. 
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IRJ—occurs not until the restoration of normal conditions, be it that the blood supply returns in IRJ or culture 
medium is restituted in survival experiments [Gündüz et al. 2006, Szondy et al. 2006]. Considering these 
parallels, it is noteworthy that idebenone was described to attenuate detrimental effects of IRJ: in isolated pig 
livers treated with idebenone ex vivo or in isolated livers of pigs treated with idebenone in vivo, idebenone 
increased energy metabolism [Schütz et al. 1997]. Nevertheless, the nature of stress in ischemia and these survival 
experiments is completely different. In the latter, ROS formation was markedly increased during H2O2 treatment 
and declined to physiological levels as soon as medium was restituted. These findings are in clear opposition to 
both (i) the time point of ATP drop in IRJ and these experiments and (ii) generation of oxidative damage only 
after restored blood supply in IRJ. Nonetheless, idebenone markedly reduced the degree of ROS formation 
during H2O2 treatment, suggesting that an antioxidant activity of idebenone could in fact account for the 
protection against H2O2-induced cell death.  
This is in line with numerous studies by others, in which idebenone was repeatedly described to exhibit 
potent protection against oxidative stressors [Sortino et al. 1999, Takuma et al. 2000, Yerushalmi et al. 2001, 
Gumpricht et al. 2002, Jauslin et al. 2002, 2003, and 2007, and Gil et al. 2003]. The survival experiments of this 
thesis added to this impressive body of work and confirmed once more that idebenone rescues cell survival after 
oxidative insult. 
4.11 Implications of this Thesis on Mitochondrial Diseases: DMD, MELAS, and LHON 
In conclusion, the data presented in this thesis show that idebenone (i) is able to restore ATP levels when 
complex I is dysfunctional via an NQO1-dependent cytosolic-mitochondrial electron transport, (ii) inhibits 
complex I in accordance with previous publications [Sugiyama et al. 1985, Sugiyama and Fujita 1985, Degli 
Esposti et al. 1996a, Brière et al. 2004, Rauchovà et al. 2008, and King et al. 2009], (iii) protects from H2O2-
induced cell death, (iv) shows both mild pro- and stronger antioxidant capacity, and (v) changes in cellular redox 
status (NAD+/NADH ratio). The question then arrived how beneficial effects of idebenone in several disorders 
could be explained. Thus, it has to be noted that idebenone is not a classical pharmacophore with one mode of 
action—such as kinase inhibitors, for example—but orchestrates several different cellular responses. With 
regards to the differences in pathologies, one particular aspect might be more relevant in one disorder compared 
to another one. 
4.11.1 Duchenne Muscular Dystrophy 
Pre-clinical and clinical data reported an amelioration of pathologic symptoms in the mdx mouse model and in 
DMD patients [Buyse et al. 2009 and 2011]. Unfortunately, both cell and animal models were not suitable for 
studying effects of idebenone on mitochondrial activity in DMD [see 4.1]. Thus, it can only be speculated how 
idebenone could ameliorate the DMD phenotype on a molecular level. 
DMD is characterized by a loss of functional structure protein dystrophin. It was assumed that DMD cells are 
more susceptible to mechanic stress against the plasma membrane which results in transiently disrupted 
membranes and thereby influx of Ca2+ into the cells [Petrof et al. 1993, and Straub et al. 1997]. Increase in 
intracellular Ca2+ concentrations causes a depolarization of cells and thus, opening of voltage-gated Ca2+ channels 
which further increase Ca2+ levels. Several studies reported higher activities of Ca2+ channels showed in DMD 
patients [Hopf et al. 2007, Williams and Allen 2007] and König et al. [2011] linked abnormalities in voltage-gated 
Ca2+ channels to cardiomyopathy in DMD. In dystrophic muscle cells, elevated intracellular Ca2+ concentrations 
are antagonized by mitochondrial uptake of Ca2+ [Chen et al. 2000] and are detrimental to  mitochondrial 
function, promoting depletion ATP levels and elevated ROS production [Brini 2003, Gardew et al. 2010, and 
Kinnally et al. 2011; and Figure 51A]. The fragmentation of mitochondria observed in vitro could also account for 
an imbalance in Ca2+ homeostasis [Diaz and Moraes 2007]. Indeed, decreased mitochondrial respiration and 
oxidative stress were observed in DMD patients and mdx mice [Barbiroli et al. 1992, Kemp et al. 1993, Camiña et 
al. 1995, Gannoun-Zaki et al. 1995, Tidball and Wehlings-Hendrick 2007, Sperl et al. 1997, Kuznetsov et al. 
1998, Brini 2003, Burelle et al. 2010, and Kinnally et al. 2011]. 
Just recently, specific deficiencies of mitochondrial complex I and complex IV were described [poster from 
Sobreira et al. EuroMit 2011, Zaragoza, Spain; and personal communication C. Sobreira and N. Gueven]. Whereas 
impairment of complex I would be a precondition for a NQO1-dependent cytosolic-mitochondrial electron 
transfer driven by idebenone, the lack of complex IV negates such a mechanism: cytochrome c which accepts 
electrons from idebenone in the proposed model via complex III is re-oxidized by complex IV. Therefore, it 
seems unlikely that idebenone could ameliorate respiration by transporting cytosolically generated electrons into 
mitochondria by the suggested NQO1-dependent mechanism.  
Thus, the action of idebenone in DMD is likely to be independent of direct interactions with mitochondria. 
Idebenone was described to inhibit voltage-gated Ca2+ channels [Houchi et al. 1991, Chang et al. 2011, Kaneko et 
al. 2011, and Newman et al. 2011]. Hence, idebenone could prevent the secondary influx of Ca2+ through these 
channels and thereby attenuate the negative effect of high intracellular Ca2+ on mitochondria [Figure 51B]. 
Second, idebenone might reduce oxidative stress either by a direct antioxidant radical scavenging. 
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Figure 51: Schematic Representation of Duchenne Muscular Dystrophy (DMD) Pathology and Suggested 
Mechanisms of Idebenone.  
(A) Absence of functional structure protein dystrophin (Dys) leads to a (1.) disruption of plasma membrane under mechanical stress and 
thus, influx of calcium ions (Ca2+). The resulting depolarization (2.) activates voltage-gated Ca2+ channels (vCaC) which further add to 
intracellular Ca2+ concentration. Elevated Ca2+ levels (3.) are detrimental to mitochondria, thus leading to (4.) decreased respiration (i.e. ATP 
generation) and (5.) increased levels of oxidative stress-generating reactive oxygen species (ROS). (B) Idebenone might (1.) inhibit vCaCs and 
thus reduce Ca2+ influx into cells. Therefore, (2.) Ca2+-driven disruption of mitochondrial function might be attenuated and (3.) energy 
deficiency might be less severe. Furthermore, idebenone might (4.) reduce oxidative stress by direct antioxidant capacity. 
 
4.11.2 Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Syndrome 
In contrast to DMD, results obtained in this thesis were directly applied to the pathomechanism of MELAS 
and can explain the observed beneficial effect of idebenone. Most MELAS patients harbor the 3243G>A 
mutation in the mitochondrial gene for a tRNA which affects impairs translation of mitochondrially encoded 
proteins [Testai and Gorelick 2010]. An impairment of transcription would assume that all mitochondrial 
complexes whose subunits are encoded by mtDNA would be affected similarly. However, complex I holds the 
majority of seven mitochondrially encoded subunits, compared to only one subunit of complex III, three of 
complex IV, and two of ATP synthase. Thus, on a purely statistical basis, complex I is more likely to be 
impaired in its function than the other three enzyme complexes. Indeed, besides decreased complex I activity, 
reduced function of complexes III and IV and ATP synthase was discovered [Sarnat and María-García 2005, 
Sarasman et al. 2008, Davidson et al. 2009]. In contrast, normal or increased activities of complexes III and IV 
and ATP synthase, but not of complex I, were described in MELAS patients harboring the 3243A>G mutation 
[Sano et al. 1995, Malfatti et al. 2007]. In addition, three mutations in subunit ND1 of complex I also caused a 
MELAS phenotype [Kirby et al. 2004]. These controversial data suggest that complex I is indeed dysfunctional in 
MELAS cells, however, the remaining members of the ETC might either be functional or dysfunctional. 
Nevertheless, the impairment of complex I forces MELAS cybrid cells in vitro to rely on anaerobic glycolysis 
in order to generate sufficient ATP, since mitochondrial respiration is decreased [Figure 1]. The price for 
increased glycolysis is the excessive production of lactate which is responsible for lactic acidosis, a hallmark of 
the MELAS phenotype [Kaufmann et al. 2004, Davidson et al. 2009]. It is interesting to note in this context that 
the main function of lactate production from pyruvate is entirely focused on regenerating NAD+ that is needed 
as co-factor for glycolysis [Figure 52]. Alternatively, NAD+ can be generated by NOQ-dependent reduction of 
idebenone. Indeed, experiments in cells with rotenone-mediated complex I deficiency revealed that idebenone is 
able to transfer electrons from NADH into the ETC and thereby, allowing for mitochondrial respiration without 
the need of complex I. An additional benefit of this electron shuttle is the restoration of NAD+ pool which 
eliminates the need for lactate production in order to run glycolysis. 
MELAS cybrids (3243A>G) possess a dysfunctional complex I. As described before, the status of the other 
respiration complexes is controversially discussed. Nonetheless, idebenone-treated MELAS cybrids showed 
reduced lactate levels and an increased mitochondrial membrane potential which is an indicator for 
mitochondrial respiration. These findings clearly suggest that idebenone is able to ameliorate mitochondrial 
energy production, possibly via the proposed NQO1-dependent cytosolic-mitochondrial electron shuttle. The 
observation that at the same time idebenone was unable to increase ATP levels in cybrid cells suggests that 
MELAS cells are switching their metabolism from anaerobic glycolysis to mitochondrial respiration in order to 
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generate the same levels of ATP. Since excess lactate production is considered to be one of the main pathological 
events in MELAS, this switch could be sufficient to alleviate some of the problems associated with the disease.  
Although still some uncertainties about the conditions of complexes III and IV and ATP synthase remain, 
these data provide for the first time a rationale for the treatment with idebenone and the observed amelioration 
of symptoms in MELAS patients [Ikejri et al. 1996, Napolitano et al. 2000, and Lekoubou et al. 2011].  
 
 
Figure 52: Schematic Representation of Energy-Related Pathology of Mitochondrial Encephalomyopathy, Lactic 
Acidosis, and Stroke-like Syndrome (MELAS) and a Suggested Mechanism of Idebenone.  
(A) Dysfunctional complex I (C I) forces MELAS cells to rely mainly on glycolysis in order to produce energy (ATP). Glycolysis is the 
degradation of glucose which results in the production of pyruvate and NADH. In healthy cells, NADH donates its electrons onto complex I, 
thereby initiating the ATP-producing mitochondrial respiration. As a by-product of this NADH oxidation, NAD+ is formed which can then 
be used again in glycolysis. In MELAS, dysfunction of complex I leads to shut-down of mitochondrial respiration. Thus, NADH cannot 
donate its electrons into complex I. In order to restore NAD+ levels for maintenance of glycolysis, pyruvate is reduced to lactate which is 
responsible for the pathologic lactic acidosis observed in MELAS patients. (B). Idebenone (Ide) is able to restore NAD+ by NQO1-dependent 
reduction of NADH. Reduced idebenone can then transfer the electrons onto complex III (C III). Mitochondrial respiration is restored by 
this cytosolic-mitochondrial electron shuttle which circumvents dysfunctional complex I. Consequently, proton gradient (∆Ψm) is increased 
and ATP can be generated by both glycolysis and mitochondrial respiration. As a result, the need to produce the harmful lactate is 
eliminated. 
 
4.11.3 Leber’s Hereditary Optic Neuropathy 
In a clinical trial with patients harboring the LHON mutations 3460G>A, 11778G>A, and 14484T>C—which 
all affect subunits of complex I [Mackey et al. 1996]—idebenone attenuated the pathology associated with these 
mutations [Klopstock et al. 2011]. It can be assumed that mutations in complex I subunits impair the function of 
complex I and that this dysfunction leads to the observed phenotype. Since complex I seems to be the main 
impairment in LHON, idebenone could increase the mitochondrial respiration by bypassing complex I and 
transferring electrons from the cytosol via NQO1 directly to cytochrome c.  
However, own experiments with LHON lymphoblastoid cells showed that they were able to compensate 
glucose-deprivation, supposedly by increasing activities of other respiratory complexes. These findings were in 
line with previous reports showing no reduction in ATP levels in vitro and ex vivo [Beretta et al. 2004, Baracca et 
al. 2005, and Pommer et al. 2008]. Even when complex I was inhibited by rotenone, idebenone was not able to 
restore ATP levels which was attributed to the poor NQO1 expression in these cells. Therefore, the hypothesis 
of an NQO1-dependent electron shuttle from cytosolic NADH to cytochrome c could not be demonstrated. 
Nevertheless, the possibility that idebenone might act via this mode of action is plausible in the light of a report 
of Cortelli et al. [1997]. They showed that idebenone treatment of a patient harboring the 11778G>A mutation 
led to a decrease of serum lactate levels, suggesting that idebenone might in fact ameliorate energy levels in a 
mechanism similar to the one proposed in MELAS. 
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 However, the main reason for the LHON pathology might not be due to an ATP synthesis defect, but rather 
to elevated oxidative damage in retina cells. Indeed, Wong et al. [2002] reported that upon differentiation, 
neuron-like LHON-NT2 cybrid cells exhibited elevated ROS, suggesting that dysfunctional complex I might 
have a more severe effect in neuronal tissue. Surprisingly, the observed ROS levels in these differentiated cybrids 
could be rescued by the complex I inhibitor rotenone. While rotenone generally leads to an overproduction of 
ROS in human skin fibroblasts, higher concentrations of rotenone cause cell death displaying some of the 
characteristics of apoptosis. The data by Wong et al. [2002] suggests that LHON mutations in a neuronal 
environment directly cause elevated ROS production by complex I dysfunction. This finding provides a second 
point of action where idebenone, a class B complex I inhibitor as rotenone [Degli Esposti 1998], could effectuate 
its beneficial impact. 
Nevertheless, Wong et al. [2002] admit that their data do not rule out the possibility that ROS are produced 
by a secondary event downstream of complex I dysfunction. The hypothesis of excess ROS in LHON is 
particularly attractive, since it could explain the three-fold excess of LHON in males versus females [Emery 
1991]. In laboratory animals it has been observed that male animals show higher levels of mitochondrially 
produced ROS compared to females. Indeed, females appear protected from Aβ-induced mitochondrial ROS 
production by an estrogen-dependent mechanism [Viña et al. 2007, Borras et al. 2007] and in LHON cells, 
estrogen also shows a clear protective activity [Giordano et al. 2010 and personal communication between V. 
Carelli and N. Gueven]. Hence, idebenone might also reduce oxidative damage in LHON on behalf of its 
antioxidant effect.  
4.12 Conclusions 
Idebenone is a versatile compound described to interact with different enzymes, enzyme complexes and 
pathways and its mode of action in disorders where it showed promising effects or attenuation of pathology is 
still under investigation [Figure 53]. Although the observed effects of idebenone are mainly attributed to its 
antioxidant function and an interaction with the ETC, new models described herein expand our understanding 
how idebenone can lead to the aleviation of symptoms. 
With my work, emphasis was primarily laid on the role of idebenone in mitochondrial respiration. I confirmed 
that idebenone inhibits complex I and, for the first time, described implications of this inhibition in vivo. 
Idebenone forces mice to increase their food intake in order to maintain their physiological weight and leads to a 
transient drop in blood glucose, supposedly by blocking complex I activity. Further research on these effects is 
required to see if this mechanism for example could be exploited for the treatment of obesity. 
I also showed for the first time that idebenone is reduced by NQO1, both in a cell-free system and in cells 
[Figure 53]. Based on this reduction, I provided evidence that idebenone is able to transfer electrons from the 
cytosol to mitochondria and thereby enables mitochondrial respiration when complex I is dysfunctional. This 
new mechanism allows for a rationale of the use of idebenone in MELAS for the first time. 
My data also separates idebenone from structurally analogous quinones, including CoQ1, CoQ10, and 50 novel 
compounds, in different biochemical assays. These experiments do not only show that the modes of action 
employed by idebenone are distinct from other short-chain analogs, but also strongly distinguish idebenone from 
CoQ10 which was suggested to act similarly to idebenone. Furthermore, the characterization of 50 novel 
idebenone analogs allows for their potential development in new indications. 
In addition, I showed that idebenone prevents cell death induced by hydrogen peroxide. This adds to the great 
body of work ascribing protection against several toxic and pro-oxidant stressors to idebenone. Despite this 
defensive effect which is also in line with the antioxidant capacity of idebenone, moderate pro-oxidant effects of 
idebenone were described. 
Finally, based on my research, I proposed possible mechanisms how idebenone could achieve the observed 
amelioration in diseases with a mitochondrial phenotype such as Duchenne muscular dystrophy, Mitochondrial 
Encephalomyopathy, Lactic Acidosis, Stroke-like episodes (MELAS), and Leber’s Hereditary Optic Neuropathy 
(LHON).  
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Figure 53: Relevant Molecular Interactions of Idebenone. 
Idebenone is not a typical pharmacophore with one specific target, but is able to interact with various pathways, enzymes, and enzyme 
complexes. Inovolvement of idebenone in arachidonic acid metabolism, kainate or 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic 
acid (ARMA) receptors (AMPAR), nerve growth factor (NGF) production, or calcium (Ca2+) channel inhibition were not investigated in 
this thesis (light grey arrows). Instead, pro- and antioxidant effects, protection from cell death and survival, complex I inhibition, interactions 
with other enzyme complexes of the electron transport chain, and alteration of cellular redox status were confirmed (dark grey arrows). In 
addition, a new mechanism of NQO1-dependent cytosolic-mitochondrial electron shuttle was described in this thesis for the first time (black 
bold arrow). 
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5 Methods 
5.1 Enzyme Kinetics 
5.1.1 NQO1 and NQO2 Activity 
Recombinant NQO1 and NQO2 activity in presence of different quinones was measured according to a 
modified protocol by Ernster [Ernster 1967]. Reactions were performed in 1-ml disposable cuvettes at room 
temperature in reaction buffer (25 mM Tris-HCl pH 7.4, 0.7 mg/ml bovine serum albumin (BSA), 1 µg/ml 
enzyme, 10 µM quinone). The reaction was started by addition of NAD(P)H (for NQO1) or 1-(3-
sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine (a NRH-derivate, for NQO2) [Knox et al. 2000]. Enzyme 
activity was measured as decrease of A340 for NAD(P)H and A355 for the NRH-derivate, respectively, during 30 
sec in a spectrophotometer. All assays were performed in triplicate. Electron donor concentrations at start of 
linear phase of the decrease of absorbance were calculated using the absorbance coefficient (εNADH = 6300 M
-1 
cm-1; εNADPH = 6200 M
-1 cm-1; εNRH-derivate = 4430 M
-1 cm-1). Reduction rates per mg enzyme were calculated 
during the linear phase of the reduction. Since NQO1 possesses a single quinone-binding site [Dinkova-Kostova 
and Talalay 2010], steady-state kinetic constants were calculated using the Michealis-Menten equation combined 
with Hanes-Woolf plot because of its independence towards variability at high substrate levels. To determine 
the dicoumarol sensitivity of enzymes, reactions were performed in triplicate in the presence or absence of 20 
µM dicoumarol in reaction buffer (25 mM Tris-HCl pH 7.4, 0.7 mg/ml BSA, and 1 µg/ml enzyme) containing 50 
µM CoQ1 and started with 100 µM NADH or 1-(3-sulfonatopropyl)-3-carbamoyl-1,4-dihydropyrimidine, 
respectively. Electron donor consumption rate was calculated as described above and expressed as percentage of 
the rate in the absence of dicoumarol. For complexing quinones with serum, powdered quinones were dissolved 
in heat-inactivated FBS by vortexing for 1 min. Alternatively, quinones were formulated in liposomes as 
described [Mayer et al. 1985, Paolino et al. 2004]. Briefly, L-α-phosphatidylcholine and quinone were dissolved in 
PBS at a final concentration of 25 mg/ml lipid in a molar drug/lipid fraction of 0.05 (final quinone concentration: 
1.6 mM). The mixture was then subjected to five repetitive freeze-thaw cycles.  
5.2 Cell Culture 
5.2.1 Culturing of Cells 
All cell lines and primary cells were cultivated under normal culture conditions (37 °C, 5% CO2, and 90% 
relative humidity [rH]). All media were supplemented with antibiotics and glutamate was administred to media 
at the same time as serum in order to enhance shelf-life of media. Antibiotics and glutamate were added as 1% of 
volume in a mixed solution to a final concentration of 100 units/ml penicillin, 1 µg/ml streptomycin, and 292 
mg/l L-glutamine. Phosphate-buffered Saline without Ca2+ or Mg2+ (PBS) and Hank’s Buffered Saline Solution 
(HBSS) were supplemented with 1% penicillin-streptomycin. Fetal Bovine Serum “GOLD” from the European 
Union (FBS) was used as serum if not otherwise stated. Cells were handled under sterile conditions in a 
workbench with laminar air flow. Aspirated medium was sterilized by bleaching in Javel water and plastic waste 
was autoclaved for 10 min at 121 °C. 
Adherent cells were cultivated in either 10-cm dishes containing 10 ml medium or 20-cm dishes  containing 15 
ml medium. Cells in suspension were cultivated in flasks of different sizes (25 cm2, 75 cm2, or 150 cm2) with 
maximum one third of the volume filled with medium. 
Primary human fibroblasts from a 32-year old healthy male (called C2;) and from a 19-year old healthy femal 
(called C3), human neuroblastoma cell line SH-SY5Y, spontaneously transformed human keratinocyte cell line 
HaCaT, human embryonic kidney cell line HEK293, rat L6 myoblasts, and human hepatic cell line HepG2 cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 4.5 g/l glucose supplemented with 
10% FBS.  
Wild-type (RN236, WT, homoplastic) and MELAS (RN164, A3243G homoplastic) cybrid cells were cultured 
in DMEM, 7% FBS, and 50 µg/ml uridine. The cybrids were gifts from M. Hirano and M. Davidson (Columbia 
University, New York NY, USA). 
Primary human myoblasts were cultured in minimal essential medium Eagle (MEM EBS; E15-024; Omnilab, 
Mettmenstetten, Switzerland) supplemented with 25% Medium 199 EBS, 10% non heat-unactivated FBS, 10 
µg/ml insulin, 100 ng/ml EGF, 100 ng/ml FGF. Primary human myoblasts were extracted from biospies kindly 
donated by the Association Française contre des Myopathies (AFM, Evry, France) and muscle cells were selected 
using monoclonal anti-NCAM antibody and magnetic beads-based cell sorting (MACS). Biopsies were named as 
following: 2TE myoblasts origined from the paravertebral muslce of a healthy 16-year old female, 4TE myoblasts 
origined from the paravertebral muscle of a healthy 12-year old female, 5TE myoblasts origined from the grand 
dorsal muscle of a healthy 14-year old male, 6TE myoblasts origined from the quadriceps of a healthy 9-year old 
male, 8TE myoblasts origined from the paravertebral muscle of a healthy 15-year old female, 5DMD myoblasts 
origined from the paravertebral muscle of a 12-year old male Duchenne’s Muscular Dystrophy patient (DMD), 
6DMD myoblasts origined from the striated muscle of a 13-year old male DMD patient, 7DMD myoblasts 
origined from muscle of a 9-year old male DMD patient, 9DMD myoblasts origined from muscle of a 14-year old 
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male DMD patient, 12DMD myoblasts origined from the striated muscle of a 16-year old male DMD patient, 
and 18DMD myoblasts origined from the tibialis anterior muslce of a 15-year old male DMD patient. 
Lymphoblastoid cells (GM15851; Coriell, Camden NJ, USA and cells from LHON, Kearns-Sayer syndrome, 
and Leigh syndrome patients listed in 6.4.2) were cultured in Rosewell Park Memorial Institute medium 1640 
(RPMI 1640; E15-039; Omnilab, Mettmenstetten, Switzerland), 10-20% FBS. 
5.2.2 Thawing and Freezing of Cells 
Cells stored in liquid nitrogen were thawed at 37 °C in a water bath and resuspended in growth medium to a 
final volume of 5 ml. After harvesting by centrifugation (700 x g; 5 min; RT) using a swinging bucket centrifuge, 
the cells were resuspended in their growth medium and seeded in the designated repository. 
For cryopreservation of cells, harvested cells [see 5.2.2 for details] were resuspended in DMEM (E15-011; 
Ominlab, Mettmenstetten, Switzerland) supplemented with 8% DMSO and 10% FBS and transferred into 
cryotubes at concentrations of 1,000,000 cells/ml. In a first step, cells were slowly frozen at -80 °C in a 
isopropanol-containing tube box for 24 h and then transferred to liquid nitrogen for long-term storage. 
5.2.3 Passaging of Cells 
Confluent adherent cells were washed once with PBS to remove FBS and cellular debris. Cells were then 
incubated in 1 mg/ml EDTA solution for 1 min at RT before detachment using 1 or 2 ml 0.5 mg/ml trypsin in 1 
mg/ml EDTA/PBS for 10- or 15-cm dishes, respectively. Detached-cells were resuspended in a nine-fold excess 
of HBSS and harvested (700 x g; 5 min; RT) using a swing-out bucket centrifuge. Suspension cells exceeding a 
density of 106 cells/ml were harvested (200 x g; 5 min; RT) using a swing-out bucket centrifuge without 
trypsination. Cells were resuspended in their growth medium [see 5.2.1 for details] and split at a ratio of 1:3 to 
1:10 dependening on on cell type, growth behaviour and passage number.  
5.2.4 Seeding of Cells into Plates 
Resuspended cells after harvesting [see 5.2.2 for details] were counted manually using disposable counting 
chambers and diluted in the required medium to the desired density (1,000-20,000 cells/well according to 
assay). Subsequently, cells were seeded in 6-, 12-, or 24-well plates, or various models of 96-well plates in 
volumes of 2 ml, 1 ml, 0.5 ml or 100 µl, respectively.  
5.2.5 Treatment of Cells 
Compound solutions for treatment of cells were prepared as follows. Most compounds were stored as 1,000x 
stocks at -20 °C in DMSO; except for acids (in H2O), dicoumarol (in 0.1% sodium hydroxide), and metformin 
(as 200x stock in HBSS). Stock solutions were diluted 5-fold in PBS or DMSO, depending on the solubility of the 
compound. For example, rotenone precipitates in PBS at concentrations higher than 100 µM. Compounds and 
controls administred parallel to rotenone were accordingly diluted in DMSO for comparability reasons. The 
resulting 200x dilution was diluted 10-fold in PBS. A twentieth of medium volume was added on top of the 
cells, resulting in a final 1 x concentration of the compound in 0.1 or 0.5% DMSO (v/v), respectively. 
5.2.6 Cell Growth Rates 
Under normal conditions, immortalized cell lines proliferate at a constant rate, whereas primary cells undergo 
senescence and their proliferation rate decreases with increasing passage number. However, exogenous 
compounds bear the risk of negatively altering cell growth rates. To investigate how a selection of quinones 
influences proliferation, human primary myoblasts (4TE) and Epstein-Barr virus (EBV)-immortalized 
lymphoblastoid cells (BC1 LCL) were cultivated over a long period in absence or presence of the quinones at 
different concentrations. Therefore, cells were seeded in 12-well plates in normal growth medium at 
concentrations of 1,000-20,000 cells/well according to assay. Cells were passaged every three to four days. After 
washing with PBS, adherent cells were incubated in 100 µl 0.5 mg/ml trypsin in 1 mg/ml EDTA/PBS and 
resuspended in a 900 µl HBSS before harvesting (200 x g; 5 min; RT). Suspension cells were harvested (200 x g; 5 
min; RT) without trypsination. Subsequently, cells were resuspended in normal growth medium and counted 
manually using disposable counting chambers. The cells were then diluted to the density at start of the 
cultivation, freshly supplemented with compounds and seeded into 12-well plates for another three to four days. 
Proliferation rates were expressed as cumulative cell doubling (CDD) which is defined as the binary logarithm of 
the quotient of the cell density from counted after three or four days relative to the cell density at seeding.  
5.3 Assays 
5.3.1 Determination of ATP Levels 
Cellular ATP levels were quantified by an ATP-driven enzymatic reaction of luciferase (enzyme) with 
luciferin (substrate) which results in a quantifiable change of the luminescent signal. Two different buffer 
systems with the same underlying reaction have been used. Although a high luminescence outpout kit system 
was commercially available, due to poor availability and unreliable delivery, a second buffer system was 
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developped in-house. When using the same samples, the two buffer systems differed only quantitatively in their 
signal magnitude, whereas qualitatively, the two systems showed no difference.  
Initially, a commercially available method (CellTiter-Glo® Luminescent Cell Viability Assay) using the mono-
oxygenation of luciferin by luciferase, ATP and molecular oxygen was used as recommended by the 
manufacturer. Briefly, cells cultured in a 96-well plate and treated as described in the Results section were 
washed once with 200 µl PBS. After addition of 50 µl PBS to each well, the cells were lysed by an addition of 25 
µl lysis buffer (CellTiter-Glo® buffer). The lysate was thoroughly mixed (15 min; 300 rpm; RT), and then 10 µl 
thereof was transferred into the corresponding well of a 96-well plate designed for luminescence measurements. 
As a standard, ATP diluted in 1x PBS (concentrations: 0, 1, 2, 4, 6, and 8 µM) were added into the 96-well plate. 
After addition of 80 µl PBS each well, the reaction was started by 25 µl of substrate buffer (5 ml CellTiter-Glo® 
buffer added to the CellTiter-Glo® substrate). The reaction is thoroughly mixed on a shaker for 1 min at 300 
rpm at RT and the luminescence signal was immediatelty quantified in a multimode plate reader (integration 
time: 100 ms, settle time: 10 ms; attenuation: OD1). ATP levels were calculated according to the linear range of 
the standard and values were standardized to protein levels determined by BCA assay [see 5.3.9 for details]. 
The second buffer system was developped in-house and used as follows. Briefly, cells cultured and treated as 
described in the Results section were lysed in a volume of 50 µl (4 mM EDTA, 0.2% Triton X-100) for 5 min at 
RT. In 96-well plates designed for luminescence measurements, 100 µl of ATP measurement buffer (25 mM 
HEPES pH 7.25, 300 µM D-luciferin, 5 µg/ml firefly luciferase, 75 µM DTT, 6.25 mM MgCl2, 625 µM EDTA and 
1 mg/ml BSA) was combined with 10 µl lysate to start the reaction. ATP measurement buffer was stored as 
separate substrate (25 mM HEPES pH 7.25, 600 µM D-luciferin, 75 µM DTT, 6.25 mM MgCl2, 625 µM EDTA 
and 1 mg/ml BSA) and enzyme solutions (25 mM HEPES pH 7.25, 10 µg/ml firefly luciferase, 75 µM DTT, 6.25 
mM MgCl2, 625 µM EDTA and 1 mg/ml BSA) at -80 °C. Shortly before the assay, aliquots of both solutions 
were thawed at 37 °C in a water bath and mixed at a 1:1 ratio only just before the assay. Luminescence was 
quantified immediately as described for the CellTiter-Glo Assay.  
Adjustments of these standard protocols for experiments in different cells types are described in the following 
paragraphs.  
Since idebenone inhibits complex I [Degli Esposti 1996, King et al. 2010, and James et al. 2005], idebenone and 
some analogs synthezised in-house were screened for their ability to decrease cellular ATP levels under 
conditions where cells rely less on glycolysis and are forced to generate ATP by oxidative phosphorylation. 
Therefore, human lymphoblastoid cells were incubated with the compound over three days in medium with low 
glucose content. Briefly, cells were seeded in a 24-well plate at a density of 5*105 cells per ml in differend media 
containing 25 mM glucose as a control (high glucose medium; DMEM 4.5 g/l glucose) and 500 µM glucose as 
mitochondrial activity medium (low glucose medium; DMEM without glucose). Both media were supplemented 
with 10% fetal bovine serum—which accounts for approximately 0.1 g/l (0.5 mM) glucose—and 1% 
Penicilin/Strepomycin and L-glutamine. Cells were treated with 0.1% (v/v) of compounds (10 mM in DMSO; 
final concentration: 10 µM) and incubated for 72 h under normal culture conditions (37 °C, 5% CO2, and 90% 
rH). After dissociation by pipetting up and down, cells were counted before clearing (5 min; 200 x g) using a 
tabletop centrifuge. Cells were lysed in a volume of 500 µl (4 mM EDTA, 0.2% Triton X-100) for 15 min on ice. 
After thorough vortexing, a triplicate of 10 µl of the mixture was added into a 96-well plate designed for 
luminescence measurements. The reaction was started by adding 100 µl reaction mix (300 µM D-Luciferin, 5 
µg/ml firefly luciferase, 75 µM DTT, 25 mM HEPES, 6.25 mM MgCl2, 625 µM EDTA and 1 mg/ml BSA). The 
luminesence signal was immediatly quantified in a multimode plate reader (integration time: 100 ms, settle time: 
10 ms; attenuation: OD1). The concentration of cellular ATP was calculated for each well and then, triplicates 
were averaged and normalized to cell number. Average and standard error of mean were calculated from 
percentages of DMSO control for cell density and ATP/cell density and of individual experiments. A new batch 
of BC1 LCL was thawed after every 1.5-2 months to get reproducable results. Results showing aberrations which 
could be attributed to either a loss of normal LCL behaviour or loss of compound activity due to continued 
thaw-freeze cycles, and from experiments in which control compounds failed to show efficacy were omitted 
from final calculation. Rotenone (10 nM) and idebenone were always included as positive controls. 
Freshly isolated hepatocytes [see 5.7.1 for details] were lysed in 200 µl lysis solution (4 mM EDTA, 0.2% Triton 
X-100) and results were standardized to cell number. 
5.3.2 Determination of Reactive Oxygen Species  
Membrane permeable derivates of reduced fluorescein can be used to detect reactive oxygen species within 
live cells. The commercially available 5-(and-6)-chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate, acetyl 
ester (CM-H2DCFDA) possesses chloromethyl groups which react with thiols of proteins and thus enhance its 
localization within the cell. Upon cleavage by intracellular esterases, a redox-active moiety is released. Only by 
oxidation of this moiety by cytosolic reactive oxigen spieces (ROS) the compound reveals its fluorescence. The 
dye was used according to the manufacturer’s instructions. Briefly, adherent cells were seeded in black 96-well 
plates and treated as described in the Results section. On the day of the assay, cells were washed with 100 µl PBS. 
One vial (50 µg) of CM-H2DCFCA was supplemented with 100 µl DMSO (concentration: 865.4 µM) and diluted 
in PBS (final concentration: 865.4 nM). The reaction is started by adding 100 µl of the diluted dye to each well. 
After a 5-min incubation at normal culture conditions (37 °C, 5% CO2, and 90% rH), the cells were washed once 
with 200 µl PBS. Each well was supplemented with 50 µl PBS and the fluorescence signal was quantified in a 
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multimode plate reader (excitation: 496 nm (bandwidth: 5nm); emission: 535 nm (bandwidth: 5nm); 50x 400 Hz 
flashes (settle time: 10 ms) gain: 255). Mean background fluorescence values from cell-free wells incubated dye 
were substracted from signals in individual wells before signal of each well was normalized to its protein content 
[see 5.3.9 for details]. 
5.3.3 Measurement of Mitochondrial Mass 
The fluorescent dye MitoTracker® Green FM was used to quantify the number of mitochondria in live cells. 
The dye accumulates in active mitochondria where it reacts with thiol moieties of proteins and forms a 
fluorescent conjugate. The dye is not only useful in live cells, but is also retained after fixation. The method was 
performed as instructed by the manufacturer. Briefly, adherent cells were seeded in black 96-well plates and 
treated as described in Results section. On the day of the assay, cells were washed with 100 µl HBSS. An aliquot 
of 1 mM MitoTracker® Green FM in DMSO stored at -80 °C was thawed at RT and diluted in HBSS to a final 
volume of 50 nM. Cells were incubated in a volume of 100 µl per well thereof for 30 min at normal culture 
conditions (37 °C, 5% CO2, 90% rH). Subsequent, cells are washed twice with 50 µl PBS and fluorescence signals 
were measured immediately in 50 µl PBS (excitation: 490 nm (bandwidth: 10 nm); emission: 520 nm (bandwidth: 
10 nm); 50x 400 Hz flashes (settle time: 10 ms) gain: 150). Mean background value from cell-free wells 
incubated dye was substracted from signals in individual wells before signal of each well was normalized to its 
protein content [see 5.3.9 for details]. 
5.3.4 Measurement of Mitochondrial ROS Production 
The non-fluorescent MitoTracker® Red CM-H2XRos passively diffuses into cells and accumulates in 
mitochondria where it is covalently anchored after reaction with thiols. Upon oxidation by superoxide and other 
reactive oxigene species produced by mitochondria it changes to a fluorescent confirmation. The method was 
performed as instructed by the manufacturer. Briefly, adherent cells were seeded in black 96-well plates and 
treated as described in Results section. On the day of the assay, cells were washed with 100 µl HBSS. An aliquot 
of 1 mM MitoTracker® Red CM-H2XRos in DMSO stored at -80 °C was thawed at RT and diluted in HBSS to 
a final volume of 100 nM. Cells were incubated in a volume of 100 µl per well thereof for 30 min at normal 
culture conditions (37 °C, 5% CO2, 90% rH). Subsequent, cells are washed twice with 50 µl PBS and 
fluorescence signals were measured immediately in 50 µl PBS (excitation: 570 nm (bandwidth: 10 nm); emission: 
600 nm (bandwidth: 10 nm); 50x 400 Hz flashes (settle time: 10 ms) gain: 150). Mean background value from 
cell-free wells incubated dye was subtracted from signals in individual wells before signal of each well was 
normalized to its protein content [see 5.3.9 for details]. 
Lipid peroxidation was measured using the fluorescent dye Bodipy 581/591 (4,4-difluoro-5-(4-phenyl-1,3-
butadienyl)-4-bora-3a,4a-diaza-s-indacene-3-undecanoic acid). This lipophilic dye accumulates in cellular 
compartments of high fatty acid content and oxidation results in a shift of fluorescent emission from 590 to 510 
nm. The method was performed as instructed by the manufacturer. Briefly, adherent cells were seeded in black 
96-well plates and treated as described in Results section. On the day of the assay, cells were washed with 100 µl 
PBS. Cells were incubated with 100 µM Bodipy dye in a volume of 100 µl per well for 30 min at normal culture 
conditions (37 °C, 5% CO2, 90% rH). Subsequently, cells are washed twice with 50 µl PBS and fluorescence 
signals were measured immediately in 50 µl PBS (excitation: 490 nm (bandwidth: 10 nm); emission: 530 and 600 
nm for oxidized or reduced form of the dye, respectively (bandwidth: 10 nm); 50x 400 Hz flashes (settle time: 
10 ms) gain: 150). Mean background value from cell-free wells incubated dye was subtracted from signals in 
individual wells before ratio of ratio of red/green signal of each well was calculated. An increase in red/green 
ratio represented an increase in lipid peroxidation. 
5.3.5 Measurement of Mitochondrial Membrane Potential 
Two different dyes were employed to measure mitochondrial membrane potential. JC-1 accumulates within 
mitochondria and changes its fluorescence on behalf of the potential. In contrast to JC-1, results obtained with 
TMRM, which accumulates in a membrane potential-dependent manner, may not only represent membrane 
potential but also total mitochondrial content.  
Method using JC-1: Determination of the mitochondrial membrane potential was assayed, using 5,5’,6,6’-
tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide as instructed by the manufacturer. JC-1 is a 
fluorescent dye accumulating in mitocondria in a membrane potential-dependent fashion. At high 
concentrations, JC-1 forms spontaneously aggregates with a strong red fluorescence. Hence, a high membrane 
potential shifts the emission wavelength of JC-1 from 530 nm (green) in its monomeric form to 590 nm (red) 
when aggregated. Therefore, a decreased ratio of the red to green signal indicates a depolarization of the 
mitochondrial membrane. Briefly, adherent cells were seeded in 96-well plates and treated as described in Results 
section. On the day of the assay, cells were washed with 100 µl/well HBSS. An aliquot of stock solution of the 
dye (1 mg/ml in DMSO) stored at -80 °C was thawed at RT and diluted 10,000-fold in HBSS. A volume of 100 
µl per well of dye solution was added and cells were incubated for 15 min under normal cell culture conditions 
(37 °C, 5% CO2, and 90% rH). Cells were washed once with 50 µl PBS and fluorescence signals were measured 
immediately (JC-1 (green): excitation: 485 nm (bandwidth: 10 nm); emission: 535 nm (bandwidth: 10 nm); 50x 
400 Hz flashes (settle time: 0 ms) gain: 150; JC-1 (red): excitation: 550 nm (bandwidth: 10 nm); emission: 600 
nm (bandwidth: 10 nm); 50x 400 Hz flashes (settle time: 0 ms) gain: 150). Mean background value from cell-free 
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wells incubated with dye was substracted from signals in individual wells before ratio of red to green signals was 
calculated for each well. Average and standard deviation was calculated from these values and expressed as 
percantage of DMSO-control. A low value signifies a depolarized membrane potential. 
Method using TMRM: The cell-permeable fluorescent tetramethylrhodamine methyl ester (TMRM) 
accumulates selectively in mitochondria due to a cationic moiety. TMRM diffuses rapidly across the 
mitochondrial membrane and does not bind to mitochondria. Hence, it can be used for live monitoring of 
membrane potential. If membrane potential increases—meaning that mitochondrial matrix exhibits a more 
negative net charge relative to the cytosol—the affinity of TMRM to mitochondria further increases. Briefly, 
adherent cells were seeded black in 96-well plates and treated as described in the Results section. On the day of 
the assay, cells were washed with 100 µl HBSS per well. An aliquot of stock solution of the dye (20 mM in 
DMSO) stored at -20 °C was thawed at RT and diluted 1,000-fold in HBSS (final volume: 20 µM). A volume of 
100 µl per well of dye solution was added and cells are incubated for 15 min under normal cell culture conditions 
(37 °C, 5% CO2, and 90% rH). Cells were washed once with 50 µl PBS and resuspended in 50 µl PBS. 
Fluorescence signals were measured immediately (excitation: 540 nm (bandwidth: 10 nm); emission: 595 nm 
(bandwidth: 10 nm); 50x 400 Hz flashes (settle time: 0 ms) gain: 100). Mean background value from cell-free 
wells incubated with dye was substracted from signals in individual wells before normalization to protein 
content [see 5.3.9 for details]. Average and standard deviation was calculated from these values and expressed as 
percantage of DMSO-control. A low value signifies a depolarized membrane potential. 
5.3.6 Measurement of Quinone Reduction (WST-1 Assay) 
Water-soluble tetrazolium salts (WST) are converted into the corresponding formazan dye upon reduction by 
hydroquinones. The use of change in WST-1 (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-
tetrazolium) absorbance for determination of intracellular reduction of quinones was performed as described by 
Tan et al. [2010]. Briefly, cells were seeded in 96-well plates and cultivated in glucose-free DMEM with 2% FBS 
and 0.3 g/l glucose on the day before the WST-1 experiment. Inhibitors of quinone-reducing enzymes are 
preincubated for 1 h in the overnight medium. Shortly before start of the assay, an aliquot of 4.5 mM WST-1 in 
HBSS stored at -20 °C was thawed in a 37 °C-water bath. After the preincubation time, the medium is replaced 
by HBSS containing 450 µM WST-1. Inhibitors are re-administred into the according wells. The reaction is 
started by the addition of the quinone and conducted under normal culture conditions (37 °C, 5% CO2, and 90% 
rH). WST-1 reduction as was followed over a period of 120 min using a multimode plate reader. Mean 
background value from cell-free wells incubated dye was substracted from signals in individual wells. 
5.3.7 Determination of Extracellular Lactate Levels 
Elevated lactate levels in supernatant were described as a hallmark of MELAS cybrids [Davidson et al. 2009]. 
Briefly, MELAS and WT cybrid cells were seeded at a density of 150,000 cells per 3.5-cm diameter cell culture 
dish in normal growth medium. After 24 hours, the medium was changed to 1 ml challenge medium (DMEM, 2 
mg/ml glucose, 10% FBS, 50 µg/ml uridine, 2.5 mg/ml galactose, 0.11 mg/ml pyruvate, +% Penicillin-
Streptomycin) containing either DMSO or compounds. After 48 hours, the medium was removed for lactate 
measurement and the cells were lysed in 500 µl lysis solution (4 mM EDTA, 0.2% NP-40, 0.2%Tween-20) for 10 
minutes. In a 96-well plate, 90 µl of reaction buffer (10 mM KH2PO4 pH 7.8, 2 mM EDTA, 1 mg/ml BSA, 0.6 
mM DCPIP, 0.5 mM PMS, 0.8 mM NAD+, 1.5 mM glutamate, 5 U/ml glutamate-pyruvate-transaminase, 12.5 
U/ml lactate dehydrogenase) was mixed with 10 µl medium. After incubation at 30 °C for 30 minutes, 
absorption at 600 nm was quantified using a multimode plate reader. A lactate standard curve was run in 
parallel. Finally, the calculated lactate concentration in the medium using the standard was also normalized to 
protein content of the lysate using BCA assay [see 5.3.9 for details].  
5.3.8 Quantification of Live and Dead Cells  
To investigate potential protective actions of quinones against several toxic agents, two fluorescent dyes were 
used. Calcein AM is transported into live cells where esterases remove an acetomethyl group thereby capturing 
the strongly green fluorescent dye within the cell. The required activity of esterases leads to selective staining of 
live cells. In contrast, ethidium homodimer is a cell-impermeable red fluorescent that binds selectively to DNA 
in dead cells whose membrane integrity is compromised, but not in live cells. Briefly, adherent cells were seeded 
in 96-well plates and cultivated in DMEM 4.5 g/l glucose with 10% FBS. Two days after seeding, medium was 
carefully transferred into new plates and DMEM without FBS was added to cells. Subsequently, toxic insults 
such as etoposide (10 µM for six h) or H2O2 (10 µM for 10 min) were administred. After the incubation period 
with the toxins, the medium was aspirated and replaced by the previous medium to avoid potential artefacts 
evoked by growth factors in fresh medium. Idebenone (10 µM) was administred 24 and one h before, six or 24 h 
after or co-incubated with stressor treatment, respectively. Subsequently, 48-h post stressor treatment, aliquots 
stored at -80 °C of calcein AM (4 mM in DMSO) and ethidium homodimer (2 mM in DMSO) were thawed at 
RT and diluted 150 or 100-fold in PBS, respectively before 5 µl of this dye solution was added on top of the 
medium (final concentration: 1.3 µM calcein AM, 1 µM ethidium homodimer). After a 5-min incubation at 
normal culture conditions (37 °C, 5% CO2, and 90% rH), microscopic images of the cells were aquired using the 
red and green fluorescence channels (FITC: 50 ms, TRITC: 400 ms; 4 x magnification) and analysed using Image J 
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software. For the red channel, the following macro script was used to count individual dead cells: run("Find 
Edges");↵ run("Make Binary");↵ run("Analyze Particles...", "size=12-100 pixel 
circularity=0.00-1.00 show=Outlines include summarize");↵ close();. The result of the macro 
represented the number of dead cells when applied to pictures aquired using the red channel. A similar script 
was used for counting live L6 myoblast cells which were larger than dead cells: run("Enhance Contrast", 
"saturated=0.8");↵ run("Make Binary"); ↵ run("Analyze Particles...", "size=40-500 pixel 
circularity=0.00-1.00 show=Outlines include summarize"); close. To calculate survival, the number of 
living cells was divided by total cell number, i.e. the sum of live and dead cells.  
5.3.9 Protein Determination  
Protein levels were quantified using two different assays.  
The first assay’s mechanism is based on a combination of the peptide bonds-dependent reduction of copper(II) 
to copper(I) and the colorimetric detection of copper(I) by bicinchoninic acid. The method was performed as 
instructed by the manufacturer (BCATM Protein Assay Kit). Protein levels were determined for normalization 
of results obtained in other assays performed on the same cells. Briefly, cells cultured in a 96-well plate were 
washed once with 200 µl PBS. Cells were lysed with 50 µl lysis buffer (4 mM EDTA, 0.2% Triton X-100) for 5 
min on a shaker at 300 rpm. In a 96-well plate, 70 µl of BCA working reagent (50 parts of component ¨A¨ mixed 
with 1 part of component ¨B¨) were added. The reaction was started by addition of 10 µl cell lysate. After 2-h 
incubation at 37 °C, absorbtion at 562 nm was quantified in a multimode plate reader. Protein concentration was 
calculated using the linear range of a BSA standard (15 – 1000 µg/ml). 
For certain methods such as western blotting it was imperative to process protein extracts as quickly as 
possible. For this purpose, protein concentrations were also analysed using the DC assay instead of the BCA assay 
due to significantly reduced turn-around times for the DC assay. In a first step, aromatic amino acids are oxidized 
by copper(II), which then reacts as copper(I) with the second reagent, Folin. The method was performed as 
instructed by the manufacturer. Briefly, 2.5 µl of cell lysate or protein standard was added to a transparent 96-
well and 25 µl of working reagent A’ was added on top. A’ was a prepared as a mixture of 1 part reagent S and 49 
parts of reagent A. Subsequently, a volume of 200 µl reagent B was added into the wells. After 15-min incubation 
at room temperature, absorption at 750 nm was quantified in a multimode plate reader. Protein concentration 
was calculated using the linear range of a BSA standard (15-1000 µg/ml). 
5.3.10 GAPDH Assay 
Glycerolaldehyde phosphate dehydrogenase (GAPDH) assay was used to quantify the silencing of GAPDH 
expression by siRNA. The assay employs a fluorescent dye which is converted proportionally to the reduction of 
NAD+ to NADH by GAPDH. Providing a surplus of all substrates, the enzyme is the limiting factor of this 
reaction; thus, change in fluorescence signal indicates the amount of GAPDH protein in a given sample. The 
method was performed as instructed by the kit’s manufacturer. Briefly, HepG2 cells were seeded in 96-well 
plates and transfected with small interfering RNA (siRNA) by reverse transfection [see 5.4.1]. Two days after, 
cells were lysed using the provided in the kit. After 20-min incubation at 4 °C, 10 µl of lysate was transferred 
into a transparent 96-well plate and 90 µl of the reaction buffer (88.8 µl solution A, 0.68 µl solution B, and 0.47 
µl solution C; all provided in the kit) was added. Fluorescence signals were measured immediately (excitation: 
560 nm (bandwidth: 10 nm); emission: 590 nm (bandwidth: 10 nm); 50x 400 Hz flashes (settle time: 0 ms) gain: 
100). Concentrations of GAPDH were calculated using a standard of recombinant GAPDH and normalized to 
protein levels [for details see 5.3.9]. 
5.3.11 Creatine Kinase Assay 
Creatine kinase (CK) is a cytosolic enzyme which is used as a marker for decreased membrane integrity. If 
membranes become leaky, CK blood concentrations increase. A twenty-fold dilution of blood samples in PBS 
warmed to 37 °C was added to transparent 96-well plates containing 20 µl R1 buffer. Freshly prepared R1/R2 
mix (ratio 3:1; 80 µl per well; incubated shortly at 37 °C) was added to samples and the absorbtion signal at 340 
nm was quantified in 15 kinetic cycles with 60 s interval time at 37 °C. The relative difference between creatine 
kinase concentration in mdx and wt mice was calculated from the average difference in emission signal per 
minute in 15 kinetic cylces. A standard (serial 1:2 dilution in PBS, ranging from 500- to 32,000-fold dilution of 
hCPK-MM) was used to compare different assays. 
5.3.12 Determination of Blood Levels of Ketone Bodies 
β-Hydroxybutyrate (β-HB) is a ketone body which can be used as an energy source instead of glucose.  The 
method was performed as instructed by the manufacturer. Briefly, blood was collected from mice from the vena 
cava and transferred into ice cold heparin-coated tubes for clearing (10 min, 700 x g, and 4 °C). Supernatant was 
stored at -80 °C until day of assay. After thawing, 5 µl serum samples and 45 µl of β-HB assay buffer were added 
in dublicates into the designated wells of a transparent 96-well plate. A reaction mix was prepared by assembling 
4.6 ml β-HB assay buffer, 200 µl β-HB enzyme mix, and 200 µl β-HB substrate mix. Reaction was started by 
adding 50 µl reaction mix to each well. After 30-min incubation at RT and protected from light, absorption at 
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450 nm was quantified in a multimode plate reader. β-HB serum concentration was calculated using the linear 
range of a standard (0, 4, 8, 12, 16, 20, 50 mM). 
5.4 Gene Knock-Down 
5.4.1 Small interfering Ribonucleic Acid-Meidated Gene Knock-Down 
Short double-stranded ribonculeic acid (RNA) polymers, so-called small interfering RNA (siRNA), can be 
designed to selectively bind to a certain messenger RNA (mRNA) and can therefore be employed to selectively 
silence the expression of a given gene. The method was performed as instructed by the manufacturer. Briefly, a 
volume of 0.5 µl siPORT NeoFX was diluted in 9.5 µl Opti-MEM I medium in a sterile conical tube and 
incubated for 10 min at RT. In the meantime, 1.5 µl of 2 μM siRNA was diluted in 8.5 µl Opti-MEM I medium. 
Beside siRNA against NQO1 or ETFDH, non-sense negative siRNA was used as a control. The diluted siRNA 
was mixed with the dilution containing siPORT NeoFX. After 10-min incubation at RT, 20 µl siRNA/siPORT 
NeoFX complexes were dispensed into empty wells of a culture plate. HepG2 cells were washed, trypsinized, 
cleared, and harvested in normal growth medium at a concentration of 105 cells/ml [for methods in culturing 
cells, see 5.2]. After transferring 80 µl of cells onto siRNA/siPORT NeoFX complexes, plates were gently mixed 
by shaking. After 24-h incubation under normal culture conditions (37 °C, 5% Co2, and 90% rH), medium was 
replaced by normal growth medium and cells were allowed to grow for additional 24 h. subsequently, cells were 
analyzed using WST-1 assay [see 5.3.6 for details], ATP assay [see 5.3.1 for details], and qPCR [see subchapters 
5.5.1 – 5.5.3 for details].  
5.4.2 Lentiviral Gene Knock-Down of NQO1 
In contrast to siRNA, small hairpin RNA (shRNA) is single-stranded and therefore bears the advantage to be 
easily built up in vitro when transduced into cells using a lentiviral plasmid.  In order to knock down NQO1 
expression levels, NQO1 shRNA lentiviral particles were transduced into two different cell lines. Briefly, HEK 
and HepG2 cells were seeded in 12-well plates at a concentration of 30,000 cells per well in normal growth 
medium for 24 h. Medium was replaced by 180 µl growth medium and 20 µl stock solution containing 4,000-
1,000,000 infectious units (IFU) of lentivirus encoding shRNA against and incubated for 24 h. Cells were then 
immediately used to quantify NQO1 mRNA expression using qPCR [see subchapters 5.5.1 – 5.5.3 for details] and 
for ATP rescue experiments [for details see 5.3.1]. Stable clones were cultivated in presence of 2 µg/ml of the 
selector puromycin. Cells infected with lentiviral particles—regardless of the applied concentration—showed 
instant protection against puromycin in mixed cultures, whereas untransduced control cells died immeadiatly.  
5.5 Nucleotide Manipulations 
5.5.1 Isolation of Ribonucleic Acid  
Expression levels of specific genes can be analyzed using quantitative real-time polymerase chain reaction 
(qPCR). Since gene expression results in transcipt products called messenger RNA (mRNA), RNA has to be 
isolated from the tissue or from cells first. Using reverse transcription, complementary DNA (cDNA) is 
produced from RNA [see 5.5.2 for details] which in turn serves as template for RNA synthesis [see 5.5.3 for 
details]. By measuring the amount of produced RNA, expression levels can be calculated, since the two are 
exponentially proportional. Briefly, RNA was extracted from cultured cells using the High Pure RNA Isolation 
kit (Roche, Switzerland) according to the manufacturer’s recommendations. Briefly, cells were resuspended in 
200 µl PBS before addition of 400 µl lysis buffer. After thorough 15-sec vortexing, RNA was bound to High Pure 
filter (8,000 x g, 15 sec). Flow through was discarded and DNA was degraded by incubation with 90 µl DNase I 
incubation buffer added into filter tube for 15 min at RT. Degraded DNA was washed from filter using 500 µl 
wash buffer I (8,000 x g, 15 sec). Flow through was discarded and filter was washed using 500 µl wash buffer II 
(8,000 x g, 15 sec). After repetition of this step using 200 µl wash buffer II, filter tube was placed into a sterile 
1.5-ml tube and RNA was eluted using 50 µl H2O. Isolated RNA was stored at -80 °C until day of cDNA 
synthesis [see 5.5.2 for details]. 
5.5.2 Synthesis of Complementary Desoxyribonucleic Acid 
Synthesis of first-strand cDNA was conducted using High Fidelity Transcriptor cDNA Synthesis kit (Roche, 
Switzerland) and random hexamer primers in a total volume of 20 ml containing 5 mg RNA. Briefly, an amount 
of 2 ng total RNA was denaturated at 65 °C for 10 min and cooled on ice, before 60 µM random hexamer 
primers were added in a total volume of 11.4 µl per sample. Reaction mix (Transcriptor High Fidelity Reverse 
Transcriptase Reaction Buffer (8 mM MgCl2), 20 U/µl Protector RNase inhibitor, 1 mM deoxynucleotide each, 5 
mM DTT, and 10 U Transcriptor High Fidelity Transcriptase) was added and incubated for 10 min at 55 °C. The 
resulting cDNA was ready to use for qPCR without further procession or purification steps [see 5.5.3 for details]. 
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5.5.3 Quantitative Real-Time Polymerase Chain Reaction 
Real-time PCR was performed with LightCycler® 480 SYBR green 1 Master Mix (Roche, Switzerland) in a 
LightCycler® 480 mastercycler and results were analyzed with the corresponding software (version 1.5.0.39). 
Protocol parameters used: 5 minutes at 95 °C followed by 40 cycles of 10 seconds at 95 °C for denaturing, 10 
seconds at 56 °C for annealing, and 10 seconds at 72 °C for extension. GAPDH was used as internal control. 
Target gene sequences were amplified with the primer pairs listed in 6.5.2. 
5.6 Proteins Analysis 
5.6.1 Western Blotting 
Abundance, quantity or phosphorylation status of a specific protein was determined using western blots. 
Briefly, cells treated according to the respective regime were harvested in ice-cold PBS (200 x g; 5 min) and lysed 
in an SDS-containing lysis buffer (50 mM Tris pH 7.4, 0.1% SDS, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 
mM β-glyerolphosphate, 0.2% Triton X-100, 0.3% NP-40, and freshly added 25 mM NaF, 0.1 mM NaVa, 1 µM 
DTT, 0.1% saturated PMSF) for 15 min on ice. SDS was added in order to permeabilize nuclei. After 
determination of protein levels using DC assay [see 5.3.9 for details], aliquots containing 20 µg protein were 
diluted in SDS sample buffer (1 M Tris pH 6.8, 30% acrylamide, 20% SDS, 10% glycerol, 5% β-mercaptoethanol, 
0.01% bromphenol) in a 2:1 ratio and stored at -20 °C until day of use. Gel chambers were assembled and filled 
with separation buffer (1.5 M Tris pH 8.8, 30% acrylamide, 10% SDS, and freshly added 0.1% APS and 1% 
TEMED). Isopropanol was added on top of gel to smoothen the border. After the hardening of the gel, 
isopropanol was removed and cleft was rinsed with water and dryed with a filter paper. Stacking buffer (1 M 
Tris pH 6.8, 30% acrylamide, 10% SDS, and freshly added 0.1% APS and 1% TEMED) was poured on top and 
comb was positioned. After the hardening of stacking gel, the comb was gently removed and gaps were 
thoroughly rinsed with water. Gels were placed into electrophoresis rack and tank was filled with running buffer 
(25 mM Tris, 192 mM glycine, 10 % SDS). Protein samples were denaturated for three min at 95 °C and then 
loaded into slots. Electrophoresis was performed at a constant current (25 mA/gel) until gel has run full distance 
(approximately two hours). Gel was carefully removed from glass and stacking gel was removed. A Whatman 
paper membrane was placed onto gel and enclosed in each two filter papers on both sides in transfer buffer (25 
mM Tris, 192 mM glycine, 20 % SDS, 20% methanol). Gel and membrane were clamped into the running 
apparatus with the gel facing the anode. Western blot was run at a constant voltage (100 V) for one hour and 
tank was cooled with ice. Subsequently, membrane was washed in water and stained shortly with penceau to 
control if protein was on membrane. Membrane is washed in TBST (50 mM TrisHCl pH 7.4, 150 mM NaCl, 
0.1% Tween 20). After incubation for one hour in blocking buffer (5% milk powder in TBST), membranes were 
subjected to primary antibodies in cold blocking buffer overnight at 4 °C. Membranes were washed several times 
with TBST before secondary antibodies were added in blocking buffer for one hour. After washing with TBST, 
intensity of IR signal from secondary antibodies were measured in an Odyssey reader. 
5.6.2 Histological Staining of Oxidative Stress Markers 
Histological stainings were mostly performed in 8-well µ-slides but also conducted in transparent 96-well 
plates. Cells were seeded at desired density and in the required medium, and treated for the designated duration. 
For staining of mitochondria, 50 nM MitoTracker® Green FM was added one h prior to fixation. Cells were 
either fixated in ice-cold methanol for 10 min at RT or in 4% paraformaldehyde (PFA) in PBST (0.25% Triton 
X-100 in PBS) for 10 min at RT. After several thorough washing steps using PBS, background noise was 
diminished by incubation of cells in blocking buffer (5% FBS in PBST) for one h at RT. First antibodies were 
diluted in blocking buffer according to manufacturer’s instructions (Nrf-2: 1:1000, γH2AX: 1:2,500; Akt-1: 1:1000; 
phospho-Akt: 1:200). Cells were incubated with first antibody at 4 °C overnight. After several washing steps 
using PBST; secondary antibodies (1:2000 in blocking buffer) were incubated for one h at RT. Four subsequent 
washing steps using PBS were performed with the second step including 1 µM DAPI. Cells were analyzed using 
fluorescent microscopy and pictures were taken.  
5.7 Ex vivo Experiments 
5.7.1 Isolation of Hepatocytes 
Primary hepatocytes were isolated from 6-week old female NMRI mice as described [Boutin et al.  2005]. 
Briefly, animals were sacrificed by CO2 inhalation and immediately perfused with 50 ml perfusion buffer (10 
mM HEPES pH 7.4, 140 mM NaCl, 5 mM KCl, 2.5 mM Na2HPO4, 6 mM glucose and 0.2 mM EGTA; 37 °C). 
The liver was removed and minced in pre-warmed collagenase buffer (10 mM HEPES pH 7.4, 140 mM NaCl, 5 
mM KCl, 2.5 mM Na2HPO4, 6 mM glucose, 0.2 mM CaCl2, 1.3 mM MgSO4 and 0.05% collagenase D). After 
incubation for 30 min at 37 °C, hepatocytes were dissociated using a 5-ml syringe. The homogenous solution was 
filtered through gauze and the viability of cells was assessed using trypan blue staining. Typical viability of 
isolated hepatocytes was about 90%. 
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5.7.2 Isolation of Murine Blood and Tissues 
Muscle tissues and cerebella from mice were isolated for the determination of ATP levels in vivo. Blood 
samples were taken from either the tail vein of living mice (β-hydroxybutyrate determination of 21-day treated 
mice) or from the vena cava from euthanized animals (creatine kinase determination in mdx and WT mice, β-
hydroxybutyrate determination of 21-day treated mice). Briefly, animals were sacrificed by CO2 inhalation and 
immediately dissected. Cerebella, m. soleus, gastrocnemicus lateralis, diaphragm, and heart tissue were snap-
frozen in liquid nitrogen and stored at -20 °C until analyzed.  
5.8 In vivo Experiments 
5.8.1 Animal Husbandry 
All animal experiments were approved by the governmental authorities (Kantonales Verterinäramt Basel-
Land, Switzerland; permit number BL404) and were in accordance with international guidelines. Animals were 
kept under standard laboratory conditions (12 h light per day, 22 °C, 40–60% humidity) with food and water 
available ad libitum, if not otherwise stated. Mice were obtained from RCC/Harlan (RCC, Füllinsdorf, 
Switzerland) or Janvier SAS (Le Genest Saint Isle, France). The strain C57Bl/6 JRj The black mice show a high 
spontaneous locomotor activity and are used as genetic background for many mutations. Since it is the inbred 
strain mostly used in labs, it has been chosen for microarray and food intake experiments in order to obtain 
comparability to other or later studies. In the strain C57Bl/10, Bulfield et al. [1984] described a spontaneous 
mutation in the dystrophin (mdx) gene. Mice homozygous for this mutation were called C57Bl/10 mdx and 
showed signs resembling DMD in humans [Bulfied et al. 1984]. Albino RjHan:NMRI mice are used in many 
fields of pharmaceutical and toxicological research. Upon arrival, mice were allowed to acclimatize for one week 
before experiments started.  
Administration of compounds was performed as adviced by the Institute of Laboratory Animal Science of the 
University of Zurich. Oral drug administration was executed using gavages for per os (p.o.) application or drug 
was mixed into the food using carboxymethyl cellulose (CMC) as vehicle if not otherwise stated. Therefore, the 
appropriate amount of idebenone was dissolved in 0.5% CMC and mixed with rodent chow (the different 
brands and types used are stated in the according subchapters of Methods; CMC without idebenone for mock 
treatment) and saccharin or succrose for taste preference. Weighed portions of food mash were administered to 
single-caged animals at the start of the dark cycle while supplementary food ad libitum was allowed or restricted 
according to the particular experiment. Other routes of drug or compound administration, such as interperitoneal 
(i.p.) or subcutaneous (s.c.) administration, were not used for the experiments of this thesis. 
5.8.2 Glucose Tolerance Test 
The glucose tolerance test (GTT) determines the velocity of glucose clearance in blood. In the series of GTT 
performed, mice differed in strain, age, and sex. Mice were fasted overnight for 16 h and randomized after basal 
blood glucose levels as determined using a glucometer. For this purpose, the tail was slightly slit using a razor 
blade. A drop of blood was sufficient for the glucometer to quantify the blood glucose level. After 
randomization, mice were administered with 2000 mg/kg glucose, 200 or 400 mg/kg idebenone, 300 mg/kg 
metformin [Foretz et al. 2010] or a mixture of 2000 mg/kg glucose and 200 mg/kg idebenone per os using a 
gavage. Olive Oil or 0.5% carboxymethyl cellulose (CMC) were used as vehicle. Blood glucose levels were 
measured after predetermined time intervals. The average of the percental change from basal values for 
individual animals was calculated.  
5.8.3 Genotyping 
To confirm the genetical background of wild-type (WT) and mutant mice bearing a dysfunctional dystrophin 
gene (C57Bl/10 and C57Bl710 mdx, respectively), the animals were genotyped in regard to the dystrophin gene. 
Briefly, biopsies were obtained from 2-3 mm-long tips of the tail. DNA from biopsies was extracted by 
incubation in 250 µl PCR buffer with nonionic detergents (PBND)-buffer (10 mM Tris-HCl pH 8.3, 50 mM KCl, 
2.5 mM MgCl2, 0.1 mg/ml gelatin, 0.45% v/v Nonidet P40 (NP40), and 0.45% v/v Tween 20) supplemented 
with 133 µg/ml proteinase K at 55 °C overnight. Samples are then heated to 95 °C for 10 min to inactivate ProK. 
Cleared samples (10 min; 18,000 x g; RT) are directly used for PCR or store at -20 °C. Melting curves of 
amplified gene sequences are analyzed using a LightCycler® 480. A sample volume of 1 µl is added to 19 µl of 
PCR buffer (1.3 µl 3 µM DyAnchor; 1.3 µM 3 µM DySensor, 1 µl of each 10 µM of primers Dy-S and Dy-A, and 
10 µl LightCycler® 480 Probes Master in H2O) onto an according 96-well plate, which is sealed with an adhesive 
foil. Gene sequence is amplified by PCR (pre-incubation at 95 °C for 5 min followed by 40 cycles of 
amplification (10 s, 95 °C, ramp rate: 4.4 °C/s; 30 s, 52 °C, ramp rate: 2.2 °C/s; 10 s, 72 °C, ramp rate: 4.4 °C/s) 
and subsequent melting curve analysis (5 s, 95 °C, ramp rate: 4.4 °C/s; 1 min, 40 °C, ramp rate: 2.2 °C). The 
melting curves and peaks of the samples are compared to three known genotype standards (WT, homo- and 
heterozygous mdx). 
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5.8.4 Food Intake Experiments 
Male mice of different strains (C57Bl/6 JRk, C57Bl/10 mdx, and RjHan:NMRI) were used for investigating the 
effects of idebenone on whole-body metabolism. Animals were acclimatized for one week before start of 
treatment and kept under standard laboratory conditions (12 h light per day, 22±2 °C, 40–60% humidity). The 
age at start of the experiments differed from seven to 14 weeks and duration of experiments ranged from three 
to four weeks. Animals had unrestricted access to water and food was available ad libitum if not otherwise 
stated. Idebenone (200 or 400 mg/kg) was administered daily using p.o. administration via food. Briefly, the 
appropriate amount of idebenone was dissolved in 0.5% CMC and mixed with rodent chow (either Teklad 2018s 
(autoclaved or not) or KLIBAG NAFAG 3436; CMC without idebenone for mock treatment) and 5% (w/w) 
saccharin for taste preference (in some experiments explicitly mentioned in the Results section, sugar was used 
for taste preference). Portions of food mash amounting to approximately 60-75% of normal daily food intake 
were administered to single-caged animals at the start of the dark cycle. Animals had access to homemade 
running wheels for voluntary locomotor activity if not otherwise stated. Body weight was measured in intervals 
of two to five days and cummulative change in body weight was calculated.  Simultaneously, food intake 
supplementary to food mash portions was calaculated from the difference of food dispenser weight and displayed 
as averaged cummulative food intake. In addition, relative food intake was calculated as the cummulative change 
in food intake relative to change in body weight. 
5.9 Determination of Changes in Gene Expression Using Microarray 
5.9.1 Treatment of Mice 
Male C57Bl/6 mice (8 weeks when delivered, acclimatized for 1 week before start of treatment) were kept 
under standard laboratory conditions (12 h light per day, 22±2 °C, 40–60% humidity) with food and water 
available ad libitum. At the age of nine weeks, idebenone (200 mg/kg) was administered p.o. for a period of 
three weeks. Briefly, the appropriate amount of idebenone was dissolved in 0.5% CMC and mixed with standard 
rodent chow (Teklad 2018s, autoclaved; CMC without idebenone for mock treatment) and 5% (w/w) saccharin 
for taste preference. Portions of 8 g food mash were administered to single-caged animals at the start of the dark 
cycle while allowing access to supplementary food ad libitum. After the treatment period, animals were 
sacrificed and the left heart ventricle was immediately excised and lysed in 1 ml trizol reagent to stabilize total 
RNA. Homogenates were snap-frozen in liquid nitrogen and stored at -80 °C until further processing. 
5.9.2 RNA Isolation and MicroArray 
Total RNA was purified from deep-frozen tissue homogenates (trizol) following the standard protocol as 
described by the manufacturer (PureLink™ RNA Mini kit). Briefly, 50 µl 4-bromoanisol were added to 
homogenates. After centrifugation (2,000 x g, 5 min, 4 °C), an equal amount of 70% ethanol was added to 
supernatant and RNA was bound in columns (12,000 x g, 15 sec, RT). RNA was washed using twice 350 µl wash 
buffer I (each 12,000 x g, 20 sec, RT), separated by a 15-min incubation for DNase treatment. Subsequently, 
RNA was washed twice using 500 µl wash buffer II, respectively, and eluted in 50 µl H2O (12,000 x g, 1 min, 
RT). An average of 4,145 ± 1,271 ng RNA was yielded. After removal of ribosomal RNA using the RiboMinusTM 
kit and subsequent quality control by the Agilent 2100 Bioanalyzer (mean integrity RNA number value was 8.4 
± 0.4), first-strand cDNA was synthesized from 1.8 µg RNA via reverse transcription using SuperScript II 
polymerase. Briefly, 4 µl RNA and 1 µl 500 ng/µl T7-(N)6 primers were annealed at 70 °C for 5 min. 
Subsequently, a volume of 5 µl SuperScript II polymerase solution (5 U/µl enzyme, 20 U/µl RNase inhibitor, 1 
mM dNTP mix, 200 mM DTT, 1x 1st strand buffer) was added and reaction was performed (25 °C for 10 min, 42 
°C for 60 min, 70 °C for 10 min).  
Subsequently, double-stranded cDNA was synthesized using DNA polymerase 1. Following overnight in vitro 
transcription (37 °C, 16 h), single-stranded cDNA was synthesized from cRNA by reverse transcription using 
SuperScript II, random primers and dUTP and thereafter cleaned from RNA templates. cDNA was fragmented 
using UDG and APE1 and labeled with a biotinylated ribonucleotide analog. Samples were hybridized to the 
Affymetrix GeneChip® Mouse Exon 1.0 ST Arrays (Affymetrix, Santa Clara, CA, USA) covering over one 
milllion exon clusters. Hybridization, washing and staining were performed according to instructions of 
Affymetrix. All steps following tissue homogenization were executed in cooperation with the Life Sciences 
Training (LST) facilities of the University of Basel. 
5.9.3 Statistical Analyses 
In microarray experiments, the expression of thousands of genes is measured across different conditions.  
Therefore, it becomes impossible to make a visual inspection of the relationship between genes or conditions in 
a multi-dimensional matrix.  One way to make sense of the data load is to reduce its dimensionality. Principal 
component analysis (PCA) is a method that reduces data dimensionality by performing covariance analysis 
between possibly correlated factors and thus, it summarizes the data. The iterative integration of correlated 
variables finally condenses into three uncorrelated components of a three-dimensional space which permits 
visual interpretation of treatment effects. The closer the single representatives of a particular treatment lie 
together and hence, the smaller the elipsoid comprising them, the more distinct its effect on gene expression by 
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this treatment; whereas a wide gap between two elipsoids of different treatments represents a clear difference in 
their gene expression pattern. For PCA, as well as for the determination of changes in individual gene expression, 
two programs were used: Partek gene analysis software (Partek Incorporated, Buchs, Switzerland) and Aligent 
Genespring GX 10 (Agilent Technologies, Santa Clara, CA, USA). Differences in expression levels of individual 
genes were expressed as fold change in signal and p-values were computed by unpaired, two-tailed and 
uncorrected t-test. Different methods were used for discovery of biological pathways which are regulated by 
idebenone on a gene expression level. Functional analysis includes only gene scores which reach significant 
difference in expression levels and was performed using DAVID (Database for Annotation, Visualization and 
Integrated Discovery) [Huang et al. 2008, Dennis et al. 2003]. DAVID is able to extract biological meaning 
associated with large gene list. It adopts a strategy to systematically map a large number of genes in a list to the 
associated biological annotation, i.e. gene ontology (GO) terms, and then statistically highlight the most enriched 
biological annotations. When the relevant biological differences are modest compared to the noise, as 
experienced in this experiment, effects of the treatment might not be searched in individual gene expression but 
in orchestrated modifications of a coherent set of genes. Gene score resampling (GSR) provides a p-value for 
each gene set and does not require a threshold for gene selection. This means that genes which do not meet a 
statistical significance for selection can contribute to the score. This analysis was performed using the software 
ermineJ [Lee et al. 2005]. Another method adressing the same problems but utilising a different algorithm was 
performed using Ariadne Pathway Studio 6 (Ariadne Genomics, Rockville, MD, USA). The so-called gene set 
enrichment analysis (GSEA) compares the expression pattern of a given gene set and tests if it is significantly 
different from a random expression pattern of this list. 
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6 Materials 
6.1 Animals 
6.1.1 Strains 
C57Bl/6 JRj  Janvier SAS Le Genest Saint Isle, 
France 
C57Bl/10  Harlan Füllinsdorf, Switzerland 
C57Bl/10 mdx  Harlan Füllinsdorf, Switzerland 
RjHan:NMRI  Janvier SAS Le Genest Saint Isle, 
France 
6.1.2 Animal Chow 
Teklad Global 18% Protein Rodent Diet, 
autoclaved 
2018S Harlan Indianapolis IN, USA 
Extreudat 3436 KLIBA NAFAG Kaiseraugst, Switzerland 
6.1.3 Animal Facility Material 
Mouse cage (189mm x 297mm x 128mm) PC7115 
HT 
Allentown Inc. Allentown NJ, USA 
Mouse wire bar lid rear pocket WBL7115 
RP 
Allentown Inc. Allentown NJ, USA 
6.2 Software 
DAVID 6.7  NIH USA 
ErmineJ  Columbia University New York NY, USA 
Genespring GX 10  Aligent Technologies Santa Clara CA, USA 
GIMP 2  GIMP Developper 
Team 
 
Ingenuity Pathway Analysis®  Ingenuity® Systems Redwood City CA, USA 
i-controlTM  Tecan Austria GmbH Grödig, Austria 
imageJ 1.43u NIH USA 
Partek® Genomic Suite™  Partek Inc. St. Louis MO, USA 
Odyssey® Infrared Scanning Sytem 3.0  LI-COR Bad-Homburg, Germany 
6.3 Machines 
Autoclave SX-700E Tomy Tech USA, Inc. Fremont CA, USA 
Bioanalyzer 2100 G2940CA Agilent Technologies Santa Clara CA, USA 
Cell Culture Incubator BBD6220 Heraeus Hanau, Germany 
Dispomix® Drive  Medic Tools Zug, Switzerland 
Electrophoresis power supply PS305 Gibco BRL Carlsbad CA, USA 
Eppendorf centrifuge 5417R 5417R Eppendorf Hamburg, Germany 
Eppendorf centrifuge 5804 (swing-out 
bucket) 
5804 Eppendorf Hamburg, Germany 
GeneChip® Fluidics Station 450 00-0079 Affymetrix Santa Clara CA, USA 
GeneChip® Scanner 3000 7G 00-0213 Affymetrix Santa Clara CA, USA 
GeneChip® AutoLoader with External 
Barcode Reader 
00-0129 Affymetrix Santa Clara CA, USA 
Glucometer Contour  Bayer Vital Leverkusen, Germany 
Infinite® M1000 microplate reader  Tecan Austria GmbH Austria, Grödig, Austria 
Inverted Microscope IX81 Olympus Volketswil, Switzerland 
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LightCycler® 480  Roche Diagnostics 
GmbH 
Mannheim, Germany 
Microscope XI80  Olympus  
MTS 2/4 digital shaker 3208000 IKA® Staufen, Germany 
Odyssey® Imager  LI-COR Bad-Homburg, Germany 
Refrigerated, table-top swinging bucket 
centrifuge with 11150 rotor and 13550 
buckets 
6K15 Sigma Buchs, Switzerland 
Ultrospec® 3000 spectophotometer  Amersham 
Pharmaceutical Biotech 
Little Chalfont, UK 
Vortex-Genie 2  Verrière de Carouge 
Sàrl 
Carouge, Switzerland 
Workbench with laminar air flow SFE.150 SKAN Basel, Switzerland 
Thermocycler T1 Biometra Goettingen, Germany 
Thermomixer  Eppendorf Hamburg, Germany 
Sartorius balance MS204 Mettler Toledo Greifensee, Switzerland 
Xenophot HLX 6425 halogen lamp FCR 12 
V 100W 
 OSRAM Munich, Germany 
6.3.1 Pipets 
Pipetman P20 F123600 Gilson Middleton WI, USA 
Pipetman P200 F123601 Gilson Middleton WI 
Pipetman P1000 F123602 Gilson Middleton WI 
Eppendorf Reference 0.5-10 µl  Eppendorf Hamburg, Germany 
SwiftPet® Pipetboy 0301 High Tec Lab Warsaw, Poland 
6.3.2 Miscellaneous 
Quick-Chill Box DS5114-
0012 
Nalgene Rochester NY, USA 
 
6.4 Cells and Cell Lines 
6.4.1 Human Primary Cells 
3DMD primary myoblast cells from human 
tibialis anterior muscle of a 8-year old male 
donor suffering from DMD 
3DMD AFM-BTR Evry, France 
5DMD primary myoblast cells from human 
paravertebral muscle of a 12-year old male 
donor suffering from DMD 
5DMD AFM-BTR Evry, France 
6DMD primary myoblast cells from human 
striated muscle of a 13-year old male donor 
suffering from DMD 
6DMD AFM-BTR Evry, France 
7DMD primary myoblast cells from human 
muscle of a 9-year old male donor 
suffering from DMD 
7DMD AFM-BTR Evry, France 
9DMD primary myoblast cells from human 
paravertebral muscle of a 14-year old male 
donor suffering from DMD 
9DMD AFM-BTR Evry, France 
12DMD primary myoblast cells from human 
striated muscle of a 16-year old male 
donor suffering from DMD 
12DMD AFM-BTR Evry, France 
18DMD primary myoblast cells from human 
tibialis anterior muscle of a 15-year old 
male donor suffering from DMD 
18DMD AFM-BTR Evry, France 
2TE primary myoblast cells from human 
paravertebral muscle of a 16-year old 
healthy female dono 
2TE AFM-BTR Evry, France 
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4TE primary myoblast cells from human 
paravertebral muscle of a 12-year old 
healthy female donor 
4TE AFM-BTR Evry, France 
5TE primary myoblast cells from human 
grand dorsal muscle of a 14-year old 
healthy male donor 
5TE AFM-BTR Evry, France 
6TE primary myoblast cells from human 
striated muscle of a 9-year old healthy 
male donor 
6TE AFM-BTR Evry, France 
8TE primary myoblast cells from human 
paravertebral muscle of a 15-year old 
healthy female donor 
8TE AFM-BTR Evry, France 
Primary human fibroblasts from a 32-year old 
healthy male (C2) 
GM08402 Corriell Cell 
Repositories 
Camden NJ, USA 
Primary human fibroblasts from a 19-year 
old healthy femal (C3) 
GM08402 Corriell Cell 
Repositories 
Camden NJ, USA 
 
6.4.2 Human Cell Lines 
BC1 LCL EBV-Immortalized Human 
Lymphoblastoid Cell Line; from 14 year 
old male human 
GM15851 Corriell Cell 
Repositories 
Camden NJ, USA 
Control EBV-Immortalized Human 
Lymphoblastoid Cell Line; from 33 year 
old male human 
GM17214 Corriell Cell 
Repositories 
Camden NJ, USA 
Control EBV-Immortalized Human 
Lymphoblastoid Cell Line; from 33 year 
old female human 
GM17229 Corriell Cell 
Repositories 
Camden NJ, USA 
Control EBV-Immortalized Human 
Lymphoblastoid Cell Line; from 25 year 
old female human 
GM17040 Corriell Cell 
Repositories 
Camden NJ, USA 
HaCaT spontaneously transformed human 
keratinocyte cell line  
330493 CLS Eppelheim, Germany 
HEK293 human embryonic kidney cell line  CRL-1573 ATCC Molsheim, France 
HepG2 human hepatic cell line  330198 CLS Eppelheim, Germany 
Kearns-Sayer Syndrom EBV-Immortalized 
Human Lymphoblastoid Cell Line; from 
10 year old male human 
GM06224 Corriell Cell 
Repositories 
Camden NJ, USA 
Kearns-Sayer Syndrom mtND4 EBV-
Immortalized Human Lymphoblastoid 
Cell Line; from 10 year old male human 
GM04368 Corriell Cell 
Repositories 
Camden NJ, USA 
Leber-Like Optic Atrophy mtND1 EBV-
Immortalized Human Lymphoblastoid 
Cell Line; from 40 year old female human  
GM11605 Corriell Cell 
Repositories 
Camden NJ, USA 
Leber’s Optic Atrophy EBV-Immortalized 
Human Lymphoblastoid Cell Line; from 
33 year old male human  
GM03857 Corriell Cell 
Repositories 
Camden NJ, USA 
Leber’s Optic Atrophy EBV-Immortalized 
Human Lymphoblastoid Cell Line; from 
50 year old male human 
GM10624 Corriell Cell 
Repositories 
Camden NJ, USA 
Leigh Syndrom mtATP6 EBV-Immortalized 
Human Lymphoblastoid Cell Line; from 2 
year old male human 
GM13741 Corriell Cell 
Repositories 
Camden NJ, USA 
Leigh Syndrom mtATP6 EBV-Immortalized 
Human Lymphoblastoid Cell Line; from 12 
year old male human 
GM13740 Corriell Cell 
Repositories 
Camden NJ, USA 
LHON mtND4 EBV-Immortalized Human 
Lymphoblastoid Cell Line; from 30 year 
old male human  
GM10742 Corriell Cell 
Repositories 
Camden NJ, USA 
LHON mtND4 EBV-Immortalized Human 
Lymphoblastoid Cell Line; from 53 year 
old male human  
GM10744 Corriell Cell 
Repositories 
Camden NJ, USA 
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MELAS A3243G homoplastic cybrid cells RN164 Gift from M. Hirano 
and M. Davidson 
Columbia University, 
New York NY, USA 
SH-SY5Y Human Neuroblastoma Cell Line; 
from bone marrow tumor from a 4 year 
old female human, passage 36 
330154 CLS Eppelheim, Germany 
Wild-type homoplastic cybrid cells RN236 Gift from M. Hirano 
and M. Davidson 
Columbia University, 
New York NY, USA 
 
6.4.3 Rodent Cell Lines 
C2C12 mouse myoblastoids 400476 CLS Eppenheim, Germany 
L6 rat myoblastoids CRL-
1458 
ATCC Molsheim, France 
RGC-5 retinal ganglion cell line  Gift from XXX Zurich, Switzerland 
 
6.5 Macromolecules 
6.5.1 Recombinant Enzymes 
Collagenase D 11 088 
858 00 
Roche Diagnostics AG Rotkreuz, Switzerland 
DNAse 1 10 104 
159 001 
Roche Diagnostics AG Rotkreuz, Switzerland 
DNA polymerase 1    
GAPDH 2039G1 Ambion Austin TX, USA 
hCKP-MM; 965 U/ml 238407 Calbiochem San Diego CA, USA 
Luciferase BIF1350 Apollo Scientific Ltd. Chesire, UK 
NAD(P)H:quinone oxidoreductase (NQO1) D1315 Sigma  Buchs, Switzerland 
Proteinase K, recombinatant, PCR Grade 03 115 
887 001 
Roche Diagnostics 
GmbH 
Mannheim, Germany 
PureLinkTM DNase 12185-
010 
Invitrogen Carlsbad CA, USA 
Quinone oxdioreductase 2 (NQO2) Q0380 Sigma Buchs, Switzerland 
SuperScript II polymerase  Invitrogen Carlsbad CA, USA 
 
6.5.2 Oligonucleotices 
T7-(N)6 primer    
Ccdc12 forward primer; GAA GTG AAA 
AGG AGG TGG GG 
 Microsynth AG Balgach, Switzerland 
Ccdc12 reverse primer; CCT CTT CCT CTA 
GGC GGC 
 Microsynth AG Balgach, Switzerland 
Cd24a forward primer; TCT CAC TCA 
CCA CAA GCA CC 
 Microsynth AG Balgach, Switzerland 
Cd24a reverse primer; GAA ATT AGC 
CAA GGC CAA CA 
 Microsynth AG Balgach, Switzerland 
Dnajc17 forward primer; GAA ATT AGC 
CAA GGC CAA CA 
 Microsynth AG Balgach, Switzerland 
Dnajc17 reverse primer; GAT GAT TCA 
GAA AGG GTG 
 Microsynth AG Balgach, Switzerland 
Dy-A primer; CCT CAA TCT CTT CAA 
ATT CTG AC 
 Microsynth AG Balgach, Switzerland 
Dy-S primer; AAC TCA TCA AAT ATG 
CGT GTT A 
 Microsynth AG Balgach, Switzerland 
DyAnchor; CTA TCT GAG TGA CAC 
TGT GAA GGA GAT GGC-PH 
 Microsynth AG Balgach, Switzerland 
DySensor; GAA AGA GCA ACA AAA 
TGG CTT C-FL 
 Microsynth AG Balgach, Switzerland 
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Eml5 forward primer; GCA TGC ATT GGA 
GAA AGG AT 
 Microsynth AG Balgach, Switzerland 
Eml5 reverse primer; AAA GGA ATC ATC 
CCA AAG GG 
 Microsynth AG Balgach, Switzerland 
Fgf18 forward primer; GGA GTG CGT 
GTT CAT TGA GA 
 Microsynth AG Balgach, Switzerland 
Fgf18 reverse primer; AGC CCA CAT ACC 
AAC CAG AG 
 Microsynth AG Balgach, Switzerland 
GAPDH forward primer; GAA GGT GAA 
GGT CGG AGT C 
 Microsynth AG Balgach, Switzerland 
GAPDH reverse primer; GAA GAT GGT 
GAT GGG ATT TC 
 Microsynth AG Balgach, Switzerland 
His1h1b forward primer; AAG CCT AAG 
AAG ACT GCG GG 
 Microsynth AG Balgach, Switzerland 
His1h1b reverse primer; AAC TTT CTT 
CAC TCC AGC CG 
 Microsynth AG Balgach, Switzerland 
Hist1h4h forward primer; TGT GCC TTC 
CAC TCT GTT GA 
 Microsynth AG Balgach, Switzerland 
Hist1h4h reverse primer; CTT TGC CAA 
GAC CTT TAC CG 
 Microsynth AG Balgach, Switzerland 
Mapksp1 forward primer; TTT CTT TGC 
ATT GTG AGG AAG A 
 Microsynth AG Balgach, Switzerland 
Mapksp1 reverse primer; CCG AGA ACA 
CAG AGA GAG GG 
 Microsynth AG Balgach, Switzerland 
Med29 forward primer; GGT GGT TCC 
TGT TGC TGA TT 
 Microsynth AG Balgach, Switzerland 
Med29 reverse primer; GAG GTC TGT 
GCT GTC TGC AA 
 Microsynth AG Balgach, Switzerland 
Nfyc forward primer; CGG AGT AGA 
GGC CTT TGT GA 
 Microsynth AG Balgach, Switzerland 
Nfyc reverse primer; CAG AAG GAC TGG 
AGG CTT TG 
 Microsynth AG Balgach, Switzerland 
NQO1 forward primer; 
CACACTCCAGCAGACGCCCG 
 Microsynth AG Balgach, Switzerland 
NQO1 reverse primer; 
TGCCCAAGTGATGGCCCACAG 
 Microsynth AG Balgach, Switzerland 
Olf550 forward primer; CTC TTC TGG 
CTG GGT ACT CG 
 Microsynth AG Balgach, Switzerland 
Olf550 reverse primer; ATT CCA CAT 
AGG TGA AGG CG 
 Microsynth AG Balgach, Switzerland 
Pcdhb15 forward primer; GAG AAG GCA 
CCC CTC TCT TC 
 Microsynth AG Balgach, Switzerland 
Pcdhb15 reverse primer; CCT GCA GCT 
GGA ATC CTT AG 
 Microsynth AG Balgach, Switzerland 
Ppbp forward primer; GGC GTC AAG 
AGA ATC GTC AT 
 Microsynth AG Balgach, Switzerland 
Ppbp reverse primer; AGG AAA ATG GTT 
TGG CAC AG 
 Microsynth AG Balgach, Switzerland 
Tdg forward primer; GTG ATG TAG CAG 
CGT GGG AG 
 Microsynth AG Balgach, Switzerland 
Tdg reverse primer; GAC TCA CCA CAG 
GAT CGG G 
 Microsynth AG Balgach, Switzerland 
Xpo7 forward primer; TGC TGG GAC 
AGA TAA GGG AC 
 Microsynth AG Balgach, Switzerland 
Xpo7 reverse primer; ): CTG TCC CCA 
TGT CTC GTT TT 
 Microsynth AG Balgach, Switzerland 
Zfp68 forward primer; CAT AGG GAG 
GAC GCT CCA 
 Microsynth AG Balgach, Switzerland 
Zfp68 reverse primer; CCA GGT GAA TTC 
CAC AGC TA 
 Microsynth AG Balgach, Switzerland 
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6.5.3 siRNAs 
ETFDH Silencer® Pre-designed siRNA (ID 
No 113116); Target Transcript: 
NM_004453, OMID ID: 231675; 
GGACAUCCGUGUGUGUCUAtt-3;  
AM16708 Ambion Autstin TX, USA 
ETFDH Silencer® Pre-designed siRNA (ID 
No 14819); Target Transcript: NM_004453, 
OMID ID: 231675; 
GGAGUUAUGGGUUAUUGAUtt;  
AM16708 Ambion Autstin TX, USA 
NQO1 Silencer® Validated siRNA (ID No 
9134); Target Transcript: NM_004453, 
OMID ID: 231675; 
GGAAUAAAUGAGAGGGAAUtt;  
AM51331 Ambion Autstin TX, USA 
 
6.5.4 Lentiviral Particles 
NQO1 shRNA (h) lentiviral particles sc-37139-
V 
Santa Cruz Santa Cruz CA, USA 
6.5.5 Antibodies 
anti-8-oxo-dG (2E2), mouse, monoclonal 
 
4354-mc-
050 
Trevigen Helgerman CT, USA 
anti-Akt-1 (2H10), mouse, monoclonal 2967 Cell Signaling Danvers MA, USA 
Anti-AMPK alpha (F6) 2793 Cell Signaling Danvers MA, USA 
anti-NCAM (H28.123), mouse, monoclonal MAB310 Millipore Volketswil, Swizterland 
anti-Nrf 2, rabbit, polyclonal ab31163-
500 
Abcam Cambridge, UK 
anti-P-histone γH2AX (S139), rabbit 2577S Cell Signaling Danvers MA, USA 
anti-P-AMPK-alpha (Thr172), rabbit, 
monoclonal 
7955 Cell Signaling Danvers MA, USA 
anti-phopho-Akt (Ser473) (D9E), rabbit, 
monoclonal 
4060 Cell Signaling Danvers MA, USA 
Cy3-goat-anti-rabbit 2nd AB  undeclared  
Cy3-donkey-anti-goat 2nd AB  undeclared  
Cy3-goat-anti-mouse 2nd AB  undeclared  
FITC-goat-anti-rabbit 2nd AB  undeclared  
IRDye 680LT Conjugated Goat (polyclonal) 
Anti-Rabbit IgG (H+L), Highly Cross 
Absorbed 
926-
68021 
LI-COR Bad-Homburg, Germany 
IRDye 800CW Conjugated Goat (polyclonal) 
Anti-Mouse IgG (H+L), Highly Cross 
Absorbed 
926-32210 LI-COR Bad-Homburg, Germany 
6.6 Media, Cell Cultures Supplements and Buffers 
6.6.1 Cell Culture Media 
RPMI 1640, 500 ml E15-039 Omnilab Mettmenstetten, 
Switzerland 
DMEM high glucose (4.5 g/l), without L-
glutamine, 500 ml 
E15-011 Omnilab Mettmenstetten, 
Switzerland 
DMEM without L-glutamine, without 
glucose, 500 ml 
P11-013 Omnilab Mettmenstetten, 
Switzerland 
Medium 199 EBS E15-033 Omnilab Mettmenstetten, 
Switzerland 
Opti-MEM I 31985-
047 
Gibco, Invitrogen Carlsbad CA, USA 
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6.6.2 Sera 
Fetal Bovine Serum ¨Gold¨ A15-151 Omnilab Mettmenstetten, 
Switzerland 
Fetal Bovine Serum ¨Hyclone¨, from 
European Union 
 
SH30070. 
03 
Hyclone Logan UT, USA 
6.6.3 Cell Culture Chemicals 
EGF 100-15 Prepro Tec London, UK 
FGF 100-18B Prepro Tec London, UK 
Insulin I5500 Sigma Buchs, Switzerland 
Penicillin/Streptomycin, L-glutamine (200 
mM) 
P11-013 Omnilab Mettmenstetten, 
Switzerland 
Penicillin, Streptomycin P11-010 Omnilab Mettmenstetten, 
Switzerland 
Trypsin 10 x, 5 mg/ml in 10 mg/ml 
EDTA/PBS 
L11-003 Omnilab Mettmenstetten, 
Switzerland 
Uridine U3003 Sigma Buchs, Switzerland 
6.6.4 Buffers 
Phosphate-buffered Saline without Ca2+ or 
Mg2+ (PBS) 
H15-002 Omnilab Mettmenstetten, 
Switzerland 
Hank’s Buffered Saline Solution (HBSS) H15-007 Omnilab Mettmenstetten, 
Switzerland 
6.7 Chemicals 
6.7.1 Chemicals for Formulation 
Carboxymethylcellulose (CMC), sodium salt  21903 Fluka Buchs, Switzerland 
Hydroxypropyl-beta-cyclodextrin (CyDex) 297561000 Acros Organics Geel, Belgium 
Myglyol 812 050 223 Sasol Germany GmbH Witten, Germany 
Olive Oil, extra vergine  Bertolli Lucca, Italy 
D-α-Tocopherol polyethylene glycol 1000 
succinate 
S7668 Fluka Buchs, Switzerland 
6.7.2 Chemicals 
A23187 C7522 Sigma Buchs, Switzerland 
Acetic acid 42425 
5000 
 
Acros Organics Geel, Belgium 
Acetic acid glacial 12404 
0010 
Acros Organics Geel, Belgium 
N-acetyl-L-cysteine (NAC) A7250 Sigma Buchs, Switzerland 
30% Acrylamide/Bis Solution, 29:1 (3,3% C) 161-0156 Bio-Rad San Diego CA, USA 
Actinomycin D A9415 Sigma Buchs, Switzerland 
Adenosine-5’-triphosphate sodium salt (ATP) A2754 Sigma Buchs, Switzerland 
Albumin from bovine serum (BSA), 
minimum 98% electrophoresis 
A7906 Sigma Buchs, Switzerland 
Antimycin A A8674 Sigma Buchs, Switzerland 
L-(+)-Arabinose, minimum 99% S3256 Sigma Buchs, Switzerland 
2,2’-Azobis(2-methylpropionamidine) 
dihydrochloride 
44,091-4 Sigma Buchs, Switzerland 
BAPTA/AM 196419 Calbiochem® San Diego CA, USA 
Berberine B3251 Sigma Buchs, Switzerland 
Bromphenol Blue, sodium salt B5525 Sigma Buchs, Switzerland 
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Capsaicin M2028 Sigma Buchs, Switzerland 
Coenzyme Q0 D9150 Sigma Buchs, Switzerland 
Coenzyme Q1 C7965 Sigma Buchs, Switzerland 
Coenzyme Q2 C8081 Sigma Buchs, Switzerland 
Coenzyme Q4 C2470 Sigma Buchs, Switzerland 
Coenzyme Q10 C9538 Sigma Buchs, Switzerland 
Cytochrome C, 90%, from bovine heart muscle 11208 
0050 
Arcos Organics Geel, Belgium 
DecylQ D7911 Sigma Buchs, Switzerland 
3,3’-Diaminobenzidine, 99% 11208 
0050 
Arcos Organics Geel, Belgium 
Dicoumarol (3,3′-Methylene-bis(4-
hydroxycoumarin)) 
M1390 Sigma Buchs, Switzerland 
Dimethyl sulfoxide (DMSO) 27,685-5 Sigma Buchs, Switzerland 
Diphenyleneiodonium chloride (DPI) D2926 Sigma Buchs, Switzerland 
Dithiothreitol (DTT) D9779 Sigma Buchs, Switzerland 
Dodecyl sulfate, sodium salt (SDS), 
electrophoresis grade, 98% 
41953 
0010 
Acros Organics Geel, Belgium 
ECL AdvanceTM blocking agent RPN 418V GE Healthcare Little Chalfont 
Buckinghamshire, UK 
Ethylenediaminetetraacetic acid (EDTA) 11843 
0010 
Acros Organics Geel, Belgium 
Ethylene glycol-bis(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid (EGTA) 
E4378 Sigma Buchs, Switzerland 
Ethanol 02854 Fluka Buchs, Switzerland 
FCCP C2920 Sigma Buchs, Switzerland 
Ficoll® PM 400 F4375 Sigma Buchs, Switzerland 
Fluor SaveTM Reagent 345789 Calbiochem® San Diego CA, USA 
D-(+)-Galactose G5388 Sigma Buchs, Switzerland 
Gelatin G1890 Sigma Buchs, Switzerland 
D-(+)-Glucose G7021 Sigma Buchs, Switzerland 
Glycerol Phosphate, disodium salt hydrate G6501 Sigma Buchs, Switzerland 
HEPES 441476L VWR International 
AG 
Dietikon, Switzerland 
4-(Hydroxymercuri)benzoic acid sodium salt 
(HMB) 
55540 Sigma Buchs, Switzerland 
Hydrogen chloride AC0739 Scharlau Sentmenat, Spain 
Hydrogen peroxide, 50% wt solution in water 51,681-3 Sigma Buchs, Switzerland 
Imatinib mesylate ALX-270-
492 
Enzo Life Sciences Lausen, Switzerland 
Iron(II) sulfate, heptahydrate, minimum 99% F8632 Sigma Buchs, Switzerland 
Isopropanol 1.09634. 
1000 
Merck Darmstadt, Germany 
β-lapachone L2037 Sigma Buchs, Switzerland 
D-Luciferin 360202 Regis Technologies, 
Inc. 
Morton Grove IL, USA 
LumigenTM TMA-6 solution A RPN 
2135V1 
GE Healthcare Little Chalfont 
Buckinghamshire, UK 
LumigenTM TMA-6 solution B RPN 
2135V2 
GE Healthcare Little Chalfont 
Buckinghamshire, UK 
Magneium chloride M2670 Sigma Buchs, Switzerland 
3-Mercaptopropionic acid M5801 Sigma Buchs, Switzerland 
Malonic acid M1750 Sigma Buchs, Switzerland 
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D-Mannitol 6350 Fluka Buchs, Switzerland 
Metformin (1,1-Dimethylbiguanide 
hydrochloride) 
D15095-9 Aldrich Buchs, Switzerland 
Methanol 200-659-6 Biosolve Valkenswaard, 
Netherlands 
β-Nicotinamide adenine dinucleotide 
(NADH), reduced dipotassium salt 
N4505 Sigma Buchs, Switzerland 
β-Nicotinamide adenine dinucleotide 2′-
phosphate (NADPH), reduced 
tetrasodium salt 
N9660 Sigma Buchs, Switzerland 
3-Nitropropionate N5636 Sigma Buchs, Switzerland 
Nitro blue tetrazolium N6876 Sigma Buchs, Switzerland 
Nonidet® P 40 substitue 74385 Sigma Buchs, Switzerland 
Oligomycin O4876 Sigma Buchs, Switzerland 
Paraformaldehyde (PFA) 441244 Fluka Buchs, Switzerland 
Pentachlorophenol (PCP) P2604 Sigma Buchs, Switzerland 
L-α-phosphatidylcholine P3556 Sigma Buchs, Switzerland 
Phosphatungstic acid S3674 Sigma Buchs, Switzerland 
PJ34 P4365 Sigma Buchs, Switzerland 
Potassium hydroxide 1.05033. 
1000  
Merck Darmstadt, Germany 
PageRulerTM Plus Prestained Protein Ladder 5M1811 Fermentas Basel, Switzerland 
PD 98,059 P215 Sigma Buchs, Switzerland 
Phenazine methosulfate P9625 Sigma Buchs, Switzerland 
Puromycin    
Pyridaben 46047 Sigma Buchs, Switzerland 
Retionic acid (vitamin A acid) 95152 Fluka Buchs, Switzerland 
Rhein R7269 Sigma Buchs, Switzerland 
Rotenone R8875 Sigma Buchs, Switzerland 
Salicylic acid    
Sodium orthovanadate S6508 Sigma Buchs, Switzerland 
Sodium chloride (NaCl) No 
1.06404. 
1000 
Merck Darmstadt, Germany 
Sodium hydroxide (NaOH) 1.06498. 
1000 
Merck Darmstadt, Germany 
Sodium phosphate dibasic (Na2HPO4) 7558-79-4 Juro Supply GmbH Lucerne, Switzerland 
Sodium phosphate monobasic (NaH2PO4) 10049-21-5 Acros Organics Geel, Belgium 
Sodium salicylate 71945 Fluka Buchs, Switzerland 
Sodium succinate dibasic 14160 Sigma Buchs, Switzerland 
Succinic acid S3674 Sigma Buchs, Switzerland 
Sucrose 59378 Sigma Buchs, Switzerland 
1-(3-sulfonatopropyl)-3-carbamoyl-1,4-
dihydropyrimidine (NRH-derivate) 
S0190 Sigma Buchs, Switzerland 
Stigmatellin 85865 Fluka Buchs, Switzerland 
Tempol ALX-430-
081-M500 
Enzo Life Sciences Lausen, Switzerland 
Thapsigargin T9033 Sigma Buchs, Switzerland 
α-Tocopherol  (Vitamin E) T3251 Sigma Buchs, Switzerland 
Tragacanth No G1128 Sigma Buchs, Switzerland 
Tris-hydroxymethyl (Tris)    
Tris-(hydroxymethyl)-aminomethane, reagent 
ACS 
42457 
5000 
Acros Organics Geel, Belgium 
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Tris-(hydroxmethyl)-aminomethane 
hydrochloride (TRIS-HCl) 
1028 Gerbu Gaiberg, Germany 
Triton X-100 T8787 Sigma Buchs, Switzerland 
Trizol 15596-026 Invitrogen Carlsbad CA, USA 
Tween 20 93773 Fluka Buchs, Switzerland 
Valproic acid P4543 Sigma Buchs, Switzerland 
Wortmannin W1628 Sigma Buchs, Switzerland 
6.7.3 Fluorescent Dyes 
Bodipy 581/591 (4,4-difluoro-5-(4-phenyl-1,3-
butadienyl)-4-bora-3a,4a-diaza-s-indacene-
3-undecanoic acid) 
D3861 Invitrogen Carlsbad CA, USA 
Calcein AM 
 
C-1430 Molecular Probes Eugen OR, USA 
CM-H2DCFCA (5-(and-6)-chloromethyl-
2’,7’-dichlorodihydrofluorescein diacetate, 
acetyl ester) 
C6827 Invitrogen Carlsbad CA, USA 
DAPI (4′,6-diamidino-2-phenylindole 
dihydrochloride) 
D9542 Sigma Buchs, Switzerland 
Ethidium homodimer 
 
E1169 Sigma Buchs, Switzerland 
JC-1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzimidazolylcarbocyanine 
iodide) 
T3168 Invitrogen Carlsbad CA, USA 
MitoTracker® Green FM M7514 Invitrogen Carlsbad CA, USA 
MitoTracker® Red CM-H2XRos M7513 Invitrogen Carlsbad CA, USA 
MitoSOX™ Red  M36008 Invitrogen Carlsbad CA, USA 
TMRM (tetramethylrhodamine methyl ester) 
 
87919 Sigma Buchs, Switzerland 
WST-1 (2-(4-iodophenyl)-3-(4-nitrophenyl)-
5-(2,4-disulfophenyl)-2H-tetrazolium, 
monosodium salt) 
W201 Dojindo Laboratiories Kumamoto, Japan 
6.8 Kits 
BCATM Protein Assay kit 23227 Pierce Rockford IL, USA 
CellTiter-Glo® Luminescent Cell Viability 
Assay kit 
G7571 Promega Madison WI, USA 
CK-NAC FS kit 13-11631021 DiaSys Diagnostic 
Systems GmbH 
Holzheim, Germany 
DC Protein Assay kit 
 
500-0116 BioRad San Diego CA, USA 
GeneChip® WT cDNA Synthesis Kit  Invitrogen Carlsbad CA, USA 
High Fidelity Transcriptor cDNA Synthesis 
Kit 
050912 
84001 
Roche Diagnostics 
GmbH 
Mannheim, Germany 
High Pure RNA Isolation kit 11 828 665 
001 
Roche Diagnostics 
GmbH 
Mannheim, Germany 
β-Hydroxybutyrate (β-HB) Assay Kit  L632-100 BioVision, Inc. Mountain View CA, 
USA 
KDalert™ GAPDH Assay AM1639 Ambion Austin TX, USA 
LightCycler® 480 Probes Master 047074 
94001 
Roche Diagnostics 
GmbH 
Mannheim, Germany 
LightCycler® 480 SYBR Green I Master 047075 
16001 
Roche Diagnostics 
GmbH 
Mannheim, Germany 
MACS Magnetic-Beads Based Cell Sorting 
kit 
130-142-201 Miltenyi Biotech Bergisch Gladbach, 
Germany 
PureLink™ RNA Mini kit 12183-018A Invitrogen Carlsbad, CA, USA 
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RealTime Ready Lysis Kit 06366821001 Roche Diagnostics 
GmbH 
Mannheim, Germany 
RibominusTM Transcriptome Isolation kit 
(human/mouse) 
K155002 Invitrogen Carlsbad, CA, USA 
Silencer® siRNA Starter kit AM1640 Ambion Austin TX, USA 
Transcriptor High Fidelity cDNA Synthesis 
Kit 
01 091 284 
001 
Roche Diagnostics 
GmbH 
Mannheim, Germany 
6.9 Consumables 
6.9.1 Cell Culture Flasks 
25-cm2 Cell culture flasks; screw cap with 
filter 
9061 TPP Trasadingen, Switzerland 
75-cm2 Cell culture flasks; screw cap with 
filter 
90076 TPP Trasadingen, Switzerland 
150-cm2 Cell culture flasks; screw cap with 
filter 
90151 TPP Trasadingen, Switzerland 
6.9.2 Cell Culture Dishes 
3.5-cm Cell culture dish 353001 BD Falcon Franklin Lakes NJ, USA 
10-cm Cell culture dish 353003 BD Falcon Franklin Lakes NJ, USA 
20-cm Cell culture dish 353025 BD Falcon Franklin Lakes NJ, USA 
6.9.3 Microplates 
µClear black sterile Greiner Bio-one 96-well 
plate 
655090 Greiner Bio-one Frickenhausen, Germany 
µClear white sterile Greiner Bio-one 96-well 
plate 
655098 Greiner Bio-one Frickenhausen, Germany 
Falcon® MicrotestTM tissue culture plate, 96 
well, flat bottom with low evaporation lid 
353075 Becton Dickinson 
Labware 
Franklin Lakes NJ, USA 
96 Flat Bottom Transparent Polystyrol 655101 Greiner Bio-one Frickenhausen, Germany 
LightCycler® 480 Multiwell Plate 96 04 729 
692 001 
Roche Diagnostics 
GmbH 
Mannheim, Germany 
6-well plate, sterile with lid for cell culture FA-
353046 
BD Falcon Franklin Lakes NJ, USA 
8-well µ-slide for immunohistochemistry 80826 Ibidi GmbH Martinsried, Germany 
12-well plate, sterile with lid for cell culture FA-
353043 
BD Falcon Franklin Lakes NJ, USA 
24-well plate, sterile with lid for cell culture FA-
353047 
BD Falcon Franklin Lakes NJ, USA 
 
6.9.4 Pipet Tips 
ART® 10 pipet tips 2139 Molecular BioProducts, 
Inc. 
San Diego CA, USA 
ART® 20P pipet tips 2149P Molecular BioProducts, 
Inc. 
San Diego CA, USA 
ART® 200 pipet tips 2069 Molecular BioProducts, 
Inc. 
San Diego CA, USA 
ART® 1000 pipet tips 2279 Molecular BioProducts, 
Inc. 
San Diego CA, USA 
2-ml Falcon® pipettes 357507 Becton Dickinson 
Labware 
Franklin Lakes NJ, USA 
5-ml Falcon® pipettes 357529 Becton Dickinson 
Labware 
Franklin Lakes NJ, USA 
10-ml Falcon® pipettes 357530 Becton Dickinson 
Labware 
Franklin Lakes NJ, USA 
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25-ml Falcon® pipettes 357525 Becton Dickinson 
Labware 
Franklin Lakes NJ, USA 
T-300-C-R 0.5-10 µl Maxymum Recovery 
clear, racked pipette tips 
301-03-
251 
Axygen Scientific Union City CA, USA 
T-200-C-R 1-200 µl clear, racked pipette tips 301-02-
151 
Axygen Scientific Union City CA, USA 
T-1000-C-L-R 1-1000 µl Maxymum 
Recovery clear, racked pipette tips 
301-01-
501 
Axygen Scientific Union City CA, USA 
6.9.5 Tubes 
Cryotubes, 2 ml 5000-
0020 
Nalgene Rochester NY, USA 
0.5-ml safe-lock tube 0030 
121.023 
Eppendorf Hamburg, Germany 
1.5-ml safe-lock tube 0030 
120.086 
Eppendorf Hamburg, Germany 
2-ml safe-lock tube 0030 
120.094 
Eppendorf Hamburg, Germany 
15-ml Falcon tube 91015 TPP Trasadingen, Switzerland 
50-ml Faclon tube 91050 TPP Trasadingen, Switzerland 
gentleMACS™ M tubes 130-093-
458 
Miltenyi Biotec GmbH Bergisch Gladbach, 
Germany 
Microvette 100 Plasma/Lithium-heparin 20.1282 Sarstedt AG Sevelen, Switzerland 
6.9.6 Miscellaneous 
1-ml disposable cuvettes 759015 Brand Wertheim, Germany 
Fast-Read 102® disposable counting chambers  326349 Biosigma Cona, Italy 
GeneChip® Mouse Exon 1.0 ST Arrays 900817 Affimetrix Santa Clara CA, USA 
LightCycler® 480 Sealing Foil 04 729 
757 001 
Roche Diagnostics 
GmbH 
Mannheim, Germany 
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8 Abbreviations 
3-NPA 3-nitropropionate  
8-oxo-dG 8-hydroxy-2’-deoxyguanosine  
A adenine 
A-T ataxia-telangiectasia 
AACOCF3 arachidonyl trifluoromethyl ketone 
AD Alzheimer's disease 
AD actinomycin D 
ad lib ad libitum 
ADP adenonsine diphosphate 
AMP adenosine monophosphate 
AMPA 2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl)propanoic acid 
AMPAR AMPA receptor 
AMPK AMP-activated protein kinase 
ANOVA analysis of variance 
Ant antimycin A 
ARE antioxidant response element 
Astaxanthin 3,3’-dihydroxy-4,4’-diketo-β-carotene 
ATP adenosine triphosphate  
BAD Bcl2/Bclx antagonist 
BAPTA BAPTA-AM (1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid 
tetrakis(acetoxymethyl ester)) 
Bcl apoptosis-inducing factor B-cell lymphoma 
BDM Becker muscular dystrophy 
Berb berberine 
BSA bovine serum albumin 
BSO L-buthionine (S,R)-sulfoximine 
C cytosine 
C I complex I 
C II complex II 
C III complex III 
C IV complex IV 
Ca2+  calcium ion 
Cap capsaicine 
CCD cumulative cell doubling 
cDNA complementary DNA 
cFI cumulative supplementary food intake 
CHX cyclohexin 
CK creatin kinase 
CMC carboxymethyl cellulose 
CM-H2DCFDA 5-(and-6)-chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate, acetyl ester  
CO2 carbon dioxide 
CoA coenzyme A 
CoQ coenzyme Q 
CPT carnitine palmitoyl transferase  
Cr chrome 
CR calorie restriction 
cRNA complementary RNA 
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CsA cyclosporin A 
ctrl control 
cyt c cytochrome c 
DAPI 4',6-diamidino-2-phenylindole dihydrochloride 
dBW differences in body weight 
DCPIP 2,6-dichlorophenolindophenol  
DCPIP 2,6-dichlorophenolindophenol 
DHAP dihydroxyacetone 
Dic dicoumarol 
DMD Duchenne muscular dystrophy 
DMEM Dulbecco's modified Eagle's medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DPI diphenylene iodonium 
DQ decylQ 
DTT dithiothreitol 
Dys dystrophin 
∆Ψm mitochondrial membrane potential 
EBV Ebstein-Barr virus 
EC50 half maximal effective concentration 
EDTA ethylenediaminetetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
EPR electron paramagnetic resonance 
ERK extracellular signal-regulated kinase  
et al. et altris 
ETC electron transport chain 
ETF electron-transferring flavoprotein 
ETFDH electron-transferring flavoprotein dehydrogenase 
FADH2 flavin adenine dinucleotide 
FBS fetal bovine serum 
FCCP Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone 
FCCP Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone 
Fe3+ ferric iron 
Fe-S iron-sulfur 
FMN flavin mononucleotide 
FoxO forkhead 
FRDA Friedreich's ataxia 
G guanine 
G3P glycerol-3-phosphate 
G3PDH glycerol-3-phosphate dehydrogenase 
GABA γ-aminobutyric acid  
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n nano 
NAC N-acetyl-L-cystein  
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Nrf2 nuclear factor (erythroid-derived 2)-like 2  
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O2 molecular oxygen 
O2
•— superoxide 
Oli oligomycin 
OXPHOS oxidative phosphorylation 
p.o. per os 
pAkt Akt-1 phosphorylated at Thr172 
pAMPK AMPK phosphorlyated at Ser473 
PARP1 poly(ADP-ribose) polymerase 1 
PBMC peripheral blood mononuclear cell 
PBS phosphate-buffered saline 
PCA principal component analysis 
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PD Parkinson's disease 
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Pi inorganic phosphate  
PKB protein kinase B 
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Q quinone 
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rH relative humidity 
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ROS reactive oxygen species 
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SAR structure activity relationship 
SDS sodium dodecyl sulfate 
SEM standart error of mean 
Ser serine 
shRNA small hairpin RNA 
siRNA small-interfering RNA 
SOD superoxide dismutase 
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stdev standard deviation 
Stig stigmatellin 
SUMO small ubiquitin-like modifier 
T thymidine 
TCA citric acid cycle 
Tdg thymine DNA glycosylase  
Temp tempol (4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl) 
Thap thapsigargin 
Thr threonine 
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v/v volume per volume 
vCaC voltage-gated calcium channel 
vmax maximal reduction velocity 
VPA valproic acid 
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WT wild-type 
Zn zinc 
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12 Appendices 
12.1 Appendix I: Tables of Gene Ontology from Micro Array Data 
Table 8: Gene Ontology: Biological Functions According to Expression Pattern of Whole Genome.  
Expression Data of whole genome was analyzed for gene ontology of biological function using ermineJ software.  
 
Biological Function GO Number p-value 
Calcium ion homeostasis GO:0055074 5.27E-04 
negative regulation of immune system process GO:0002683 3.47E-04 
myeloid cell differentiation GO:0030099 2.37E-04 
metal ion homeostasis GO:0055065 1.82E-04 
membrane lipid biosynthetic process GO:0046467 1.80E-04 
microtubule-based movement GO:0007018 1.68E-04 
chromosome segregation GO:0007059 5.21E-04 
cytoskeleton-dependent intracellular transport GO:0030705 5.08E-04 
DNA packaging GO:0006323 1.68E-03 
transforming growth factor beta receptor signaling pathway GO:0007179 2.28E-03 
regulation of DNA binding GO:0051101 5.21E-03 
sphingolipid metabolic process GO:0006665 6.02E-03 
regulation of leukocyte mediated immunity GO:0002703 6.79E-03 
lymphocyte differentiation GO:0030098 7.20E-03 
transmembrane receptor protein serine/threonine kinase signaling GO:0007178 7.39E-03 
DNA damage response, signal transduction GO:0042770 8.25E-03 
regulation of cytokine production GO:0001817 9.67E-03 
glycoprotein metabolic process GO:0009100 9.47E-03 
DNA-dependent DNA replication GO:0006261 1.04E-02 
regulation of protein kinase cascade GO:0010627 1.44E-02 
extracellular matrix organization GO:0030198 1.42E-02 
protein amino acid glycosylation GO:0006486 1.71E-02 
phospholipid biosynthetic process GO:0008654 1.92E-02 
DNA recombination GO:0006310 2.57E-02 
ribonucleoside triphosphate metabolic process GO:0009199 2.96E-02 
regulation of MATPKKK cascade GO:0043408 3.57E-02 
response to hormone stimulus GO:0009725 3.50E-02 
sterol metabolic process GO:0016125 3.69E-02 
integrin-mediated signaling pathway GO:0007229 3.80E-02 
anti-apoptosis GO:0006916 4.34E-02 
cell cycle checkpoint GO:0000075 4.25E-02 
acyl-CoA metabolic process GO:0006637 4.21E-02 
regulation of cell adhesion GO:0030155 4.37E-02 
electron transport chain GO:0022900 4.36E-02 
antigen processing and presentation GO:0019882 4.43E-02 
transmembrane transport GO:0055085 4.71E-02 
negative regulation of T cell proliferation GO:0042130 4.91E-02 
regulation of cytoskeleton organization GO:0051493 4.91E-02 
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Table 9: Gene Ontology: Biological Functions According to Expression Pattern of Significantly Differently 
Expressed Genes.  
Expression Data of genes expressed differently with a significance of at least 0.05 as calculated using GeneSpring GX 10 software was 
analyzed for gene ontology of biological function using DAVID software.  
 
Biological Function GO Number p-value 
sphingolipid metabolic process GO:0006665 0.001139 
membrane lipid metabolic process GO:0006643 0.001376 
M phase of mitotic cell cycle GO:0000087 0.005133 
positive regulation of leukocyte migration GO:0002687 0.006496 
cell division GO:0051301 0.00731 
mitosis GO:0007067 0.011559 
nuclear division GO:0000280 0.011559 
mitotic cell cycle GO:0000278 0.012205 
organelle fission GO:0048285 0.0149 
regulation of leukocyte migration GO:0002685 0.017264 
M phase GO:0000279 0.017488 
vesicle-mediated transport GO:0016192 0.021238 
establishment of protein localization GO:0045184 0.023734 
cellular protein localization GO:0034613 0.025921 
DNA replication initiation GO:0006270 0.026804 
cellular macromolecule localization GO:0070727 0.027546 
intracellular protein transport GO:0006886 0.030189 
cellular calcium ion homeostasis GO:0006874 0.032183 
regulation of apoptosis GO:0042981 0.034256 
protein transport GO:0015031 0.036048 
regulation of programmed cell death GO:0043067 0.038445 
calcium ion homeostasis GO:0055074 0.038529 
protein localization GO:0008104 0.039355 
regulation of cell death GO:0010941 0.04067 
cellular metal ion homeostasis GO:0006875 0.047511 
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12.2 Appendix II: Figures of Additional in Vivo Experiments 
 
Figure 54: Idebenone Promotes Increased Food Intake but Does Not Affect Body Weight in Vivo (Experiment 
0305).  
Male C57Bl/10 mdx mice (age seven weeks at start of experiment; n = 8) were treated with 400 mg/kg idebenone (IDE; filled) or vehicle 
(VEH; empty) p.o. in food for four weeks. Animals had either no supplementary food on top of food mash for idebenone administration 
(squares) or access to food ad libitum (ad lib; diamonds) which was weighted to calculate (A) their cumulative supplementary food intake 
(cFI). Body weight was also measured to calculate (B) differences in body weight (dBW) and (C) the relative cumulative food intake (rFI) 
which was defined as difference in food intake divided by body weight. Tall animals had access to a wheel all the time for voluntary 
locomotion. 
Appendices   
 
 
164  Molecular Effects of Idebenone 
 
Figure 55: Idebenone Does Not Affect Food Intake but Prevents Increase in Body Weight in Vivo (Experiment 
0319).  
Male C57Bl/6 mice (age nine weeks at start of experiment; n = 5) were treated with 200 mg/kg idebenone (IDE; filled) or vehicle (VEH; 
empty) p.o. in food for four weeks. Animals had access to food ad libitum (ad lib) which was weighted to calculate (A) their cumulative 
supplementary food intake (cFI). Body weight was also measured to calculate (B) differences in body weight (dBW) and (C) the relative 
cumulative food intake (rFI) which was defined as difference in food intake divided by body weight. 
  Appendices 
 
 
Molecular Effects of Idebenone  165 
 
Figure 56: Idebenone Does Not Affect Food Intake or Body Weight in Vivo (Experiment 0423).  
Male C57Bl/6 mice (age eight weeks at start of experiment; n = 10) were treated with 200 mg/kg idebenone (IDE; filled) or vehicle (VEH; 
empty) p.o. in food for three weeks. Animals had either no supplementary food on top of food mash for idebenone administration (circles) or 
access to food ad libitum (ad lib; triangles) which was weighted to calculate (A) their cumulative supplementary food intake (cFI). Body 
weight was also measured to calculate (B) differences in body weight (dBW) and (C) the relative cumulative food intake (rFI) which was 
defined as difference in food intake divided by body weight. 
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Figure 57: Idebenone Does Not Affect Food Intake or Body Weight in Vivo (Experiment 0436).  
Male C57Bl/10 mdx mice (age eight weeks at start of experiment; n = 10) were treated with 400 mg/kg idebenone (IDE; filled) or vehicle 
(VEH; empty) p.o. in food for four weeks. Animals had access to food ad libitum (ad lib) which was weighted to calculate (A) their 
cumulative supplementary food intake (cFI). Body weight was also measured to calculate (B) differences in body weight (dBW) and (C) the 
relative cumulative food intake (rFI) which was defined as difference in food intake divided by body weight. All animals had access to a 
wheel all the time for voluntary locomotion. 
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Figure 58: Idebenone Promotes Increased Food Intake but Does Not Affect Body Weight in Vivo (Experiment 
0444).  
Male C57Bl/6 mice (age six weeks at start of experiment; n = 10) were treated with 400 mg/kg idebenone (IDE; filled) or vehicle (VEH; 
empty) p.o. in food for four weeks. Animals had access to food ad libitum (ad lib) which was weighted to calculate (A) their cumulative 
supplementary food intake (cFI). Body weight was also measured to calculate (B) differences in body weight (dBW) and (C) the relative 
cumulative food intake (rFI) which was defined as difference in food intake divided by body weight. All animals had access to a wheel all the 
time for voluntary locomotion. 
 
Appendices   
 
 
168  Molecular Effects of Idebenone 
 
Figure 59: Idebenone Promotes Increased Food Intake but Does Not Affect Body Weight in Vivo (Experiment 
0459a).  
Male C57Bl/6 mice (age six weeks at start of experiment; n = 6) were treated with 400 mg/kg idebenone (IDE; filled) or vehicle (VEH; 
empty) p.o. in food for four weeks. Animals had access to food ad libitum (ad lib) which was weighted to calculate (A) their cumulative 
supplementary food intake (cFI). Body weight was also measured to calculate differences in (B) body weight (dBW) and (C) the relative 
cumulative food intake (rFI) which was defined as difference in food intake divided by body weight. All animals had access to a wheel all the 
time for voluntary locomotion. 
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Figure 60: Idebenone Promotes Increased Food Intake but Does Not Affect Body Weight in Vivo (Experiment 
0459b).  
Male RjHan:NMRI mice (age six weeks at start of experiment; n = 6) were treated with 400 mg/kg idebenone (IDE; filled) or vehicle 
(VEH; empty) p.o. in food for four weeks. Animals had access to food ad libitum (ad lib) which was weighted to calculate (A) their 
cumulative supplementary food intake (cFI). Body weight was also measured to calculate (B) differences in body weight (dBW) and (C) the 
relative cumulative food intake (rFI) which was defined as difference in food intake divided by body weight. All animals had access to a 
wheel all the time for voluntary locomotion. 
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12.3 Appendix III: Vitamin Composition of Different Chows Used in Vivo 
Table 10: Vitamin Composition of Different Chows Used in Vivo.  
Teklad 2018S was used in all in vivo experiments described in this work with the exception of experiment 0423 in which KLIBAG NAFAG 
3436 was used.  
 
 KLIBAG NAFAG 3436 Teklad 2018S 
Vitamin A  14,000 IU/kg 30,700 IU/kg 
Vitamin  D3 1,000 IU/kg 2,050 IU/kg 
Vitamin E  110 mg/kg 126 mg/kg 
Vitamin K3  2 mg/kg 102 mg/kg 
Vitamin B1  30 mg/kg 117.6 mg/kg 
Vitamin B2  20 mg/kg 27.2 mg/kg 
Vitamin B6  14 mg/kg 26.8 mg/kg 
Vitamin B12  0.05 mg/kg 0.15 mg/kg 
Nicotinic acid  70 mg/kg 87.3 mg/kg 
Pantothenic acid  33 mg/kg 141.6 mg/kg 
Folic acid  2 mg/kg 8.41 mg/kg 
Biotin  0.22 mg/kg 0.82 mg/kg 
Choline  2,000 mg/kg 1,120 mg/kg 
Vitamin C  40 mg/kg 0 mg/kg 
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12.4 Appendix IV: Relevant Publications Describing Molecular Effects by Idebenone 
Table 11: A Selection of Publications on Molecular Effects of Idebenone Relevant to this Thesis. 
 
Effect Authors Finding Test system Ceffective, EC50, 
or IC50 
Antioxidant Abdel Baky et al. 
(2010) 
Idebenone rescues 
partially from hemic 
hypoxia in rats 
(decreases lipid 
peroxidation, and 
increases GSH and 
SOD levels) 
Hemic hypoxia 100 mg/kg 
 Amano et al. (1995) Idebenone stabilizes 
membranes and 
inhibits phospholipase 
A2 activity 
Porcine pancreas cells 32 µM 
 Cardoso et al. 
(1998) 
Idebenone prevents 
ROS formation in the 
cytosol and 
mitochondria and 
inhibits lipid 
peroxidation 
Ascorbate/iron-induced 
ROS 
50 µM 
 Geromel et al. 
(2002) 
Idebenone is a pro-
oxidant. 
Review - 
 Gil et al. (2003) Idebenone reduces 
ROS levels and 
intracellular Ca2+ 
concentration and thus, 
caspase-3 activity, and 
rescues cells from 
staurosporine-induced 
cell death.  
Staurosporin-induced 
apoptosis in retinal cells 
1 µM 
 Gumpricht et al. 
(2002) 
Idebenone reduces 
apoptosis. 
Bile acid-treated, freshly 
isolated rat hepatocytes 
100 µM 
 Jauslin et al. (2002) Idebenone protects 
against BSO toxicity. 
FRDA lymphoblastoid 
cells 
0.5 µM 
 Jauslin et al. (2003) Idebenone protects 
against BSO toxicity. 
FRDA lymphoblastoid 
cells 
0.43 µM 
 Jauslin et al. (2007) Combination of 
idebenone and vitamin 
E protects against BSO 
toxicity. 
FRDA lymphoblastoid 
cells 
0.41 µM 
 Mordente et al. 
(1998) 
Idebenone is a radical 
scavenger and linhibits 
lipid peroxidation. 
Cell free assays and 
isolated rat liver 
microsomes 
> 2 µM 
 Rustin et al. (1999) Idebenone has an 
antioxidative effect in 
human heart 
homogenates. 
Human FRDA heart 
homogenates 
60 µM 
 Sortino et al. (1999) Idebenone ameliorates 
viability. 
GSH-depleted cells 1 µM 
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 Suno and Nagaoka 
(1989a) 
Idebenone protects 
againstlipid 
peroxidation and this 
effect is enhanced in 
presence of succinate. 
 Iron/ADP-induced 
ROS 
84 µM 
 Suno and Nagaoka 
(1989b) 
Idebenone inhibits 
mitochondrial swelling 
and lipid peroxidation. 
Isolated brain 
mitochondria 
37-50 µM 
 Suno et al. (1989) Idebenone inhibits lipid 
peroxidation stabilizes 
membranes. 
Erythrocytes 30 mg/kg 
 Suno and Nagaoka 
(1989) 
Idebenone inhibits 
platelet aggregation, 
prostaglandin synthesis, 
and thromboxane B2 
production. 
Platelets >125 µM 
 Rauchovà et al. 
(2006) 
Idebenone inhibits 
H2O2 generated by 
either 
glycerophosphate 
dehydrogenase and 
FeCN. 
Isolated brown adipose 
mitochondria 
50 nM 
 Rauchovà et al. 
(2011) 
Idebenone increases 
glycerolphosphate 
dehydrogenase activity. 
Isolated liver 
mitochondria 
14 µM 
 Rego et al. (1999) Idebenone protects 
against oxidative stress. 
Ischema and 
hypoglycoma renal 
model 
10 µM 
 Wieland et al. 
(2000) 
Idebenone attenuates 
lipid peroxidation and 
decreases c-jun and c-
fos expression. 
Perfused pig livers 280 mg/kg 
 Zhani et al. (2008) Idebenone is an 
antioxidant. 
Superoxide quenching 30 mM 
 Sokol et al. (2005) Idebenone reduces 
ROS production and 
mitochondrial swelling. 
Bile acid-treated 
mitochondria 
100 µM 
 Yerushalmi et al. 
(2001) 
Idebenone rescues 
apoptosis. 
Bile-acid treated, 
isolated rat hepatocytes 
100 µM 
Pro-oxidant Geromel et al. 
(2002) 
Review  - 
 Genova et al. (2003) Idebenone is a pro-
oxidant via complex I 
interaction. 
Bovine mitochondria 2 µmol/mg 
protein 
 Lenaz et al. (2002) Idebenone is a pro-
oxidant via complex I 
interaction. 
Bovine mitochondria 2 μmol/mg 
protein 
Survival Gumpricht et al. 
(2002) 
Idebenone reduces 
apoptosis. 
Bile acid-treated, freshly 
isolated rat hepatocytes 
100 µM 
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 Jauslin et al. (2002) Idebenone protects 
against BSO toxicity. 
FRDA lymphoblastoid 
cells 
0.5 µM 
 Jauslin et al. (2003) Idebenone protects 
against BSO toxicity. 
FRDA lymphoblastoid 
cells 
0.43 µM 
 Jauslin et al. (2007) Combination of 
idebenone and vitamin 
E protects against BSO 
toxicity. 
FRDA lymphoblastoid 
cells 
0.41 µM 
 Sortino et al. (1999) Idebenone ameliorates 
viability. 
GSH-depleted cells 1 µM 
 Yerushalmi et al. 
(2001) 
Idebenone rescues 
apoptosis. 
Bile-acid treated, 
isolated rat hepatocytes 
100 µM 
Mitochondrial 
Interactions 
Chapela et al. 
(2008) 
Idebenone increases 
mitochondrial 
membrane potential 
and ameliorates growth 
rates. 
Yeast under low oxygen 
conditions 
44-88 µM 
 Degli Esposti 
(1996a) 
Idebenone inhibits 
complex I and 
complex I-dependent 
reduction of idebenone 
is 63% rotenone-
sensitive. 
Isolated beef 
mitochondria 
40 µM 
 Degli Esposti (1998) Idebenone inhibits 
complex I. 
Review - 
 García-Giménez et 
al. (2011) 
Idebenone inhibits 
mitogenesis. 
FRDA cells 5 µM 
 Imada et al. (1989) Idebenone restores 
succinate oxidase and 
NADH oxidase. In 
normal canine 
mitochondria, 
idebenone 
inhibitsNADH oxidase. 
CoQ10-depleted and 
normal canine 
mitochondria 
1-10 µM 
 Kakihana et al. 
(1998) 
Idebenone increases 
lactate levels and 
decreases ATP and 
acetylcholine levels. 
Rat brains with cerebral 
ischemia 
10 mg/kg 
 King et al. (2009) Idebenone binds at 
NADH-binding site of 
complex I and 
competes for Q binding 
site due to slow 
reaction. 
Recomibnant enzyme 
complex 
100 µM 
 Lenaz et al. (2002) Idebenone is a pro-
oxidant via complex I 
interaction. 
Bovine mitochondria 2 μmol/mg 
protein 
 Lenaz et al. (2007) Idebenone inhibits 
complex I. 
Review - 
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 Nagaoka et al. 
(1989) 
Idebenone inhibits 
increase in lactate and 
decrease in ATP and 
ameliorates 
neurological deficits 
related to cerebral 
ischemia. 
Ischemia in rats 10-100 mg/kg 
 Rauchovà et al. 
(2008) 
Idebenone stimulates 
glycerolphosphate 
dehydrogenase and 
inhibits complex I.  
Isolated brown adipose 
mitochondria 
13 µM 
 Watzke (2010) Idebenone inhibits 
complex I. 
Isolated mitochondria 4 µM 
 Sugiyama and Fujita 
(1985) 
IIdebenone reduces 
state 3 respiration with 
NADH-linked 
substrates. 
Ex vivo treatment of 
isolated mitochondria 
250 nM-100 
µM 
 Sugiyama et al. 
(1985) 
Idebenone increases 
state 3 respiration, 
decreases state 4 
respiration and 
increases respiration 
control rate (RCI; state 
3/state4 resp.) with 
glutamate as substrate. 
With succinate, only 
RCI is increased 
significantly. 
In vivo treamtment of 
isolated mitochondria 
100-300 
mg/kg 
 Yu and Yu (1982) Idebenone shows only 
80% of succinate:Q 
reductase activity and 
only 20% of 
succinate:cytochrome c 
activity compared to 
CoQ2. 
Isolated enzymes 20 µM 
Ca2+ 
Homeostasis 
Chang et al. (2011) Idebenone blocks 
Cav2.2 and Cav2.1 
calcium channels and 
suppresses protein 
kinase A signaling 
cascade. 
Rat cerebral nerve 
endings 
50 µM 
 Gil et al. (2003) Idebenone reduces 
ROS levels and 
intracellular Ca2+ 
concentration and thus, 
caspase-3 activity, and 
rescues cells from 
staurosporine-induced 
cell death.  
Staurosporin-induced 
apoptosis in retinal cells 
1 µM 
 Houchi et al. (1991) Idebenone blocks 
calcium channels. 
Adrenal chromafin cells 1-100 µM 
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 Kaneko et al. (1990) Idebenone inhibits 
voltage-gated calcium 
channels. 
Xenopus oocytes 10-100 µM 
 Newman et al. 
(2011) 
Idebenone inhibits 
voltage-gated 
potassium channels 
(Kv1.5 and Kv2.1) 
Hight hrough put assay 50 µM 
Neurological 
Biochemistry 
Gillis et al. (1994) Pharmakokinetics: 300-
400 µg/l peak plasma 
after 1-2 h and 30-50 
mg in adults. Mild to 
moderate improvement 
of mild form of 
dementia. 
Humans 30-50 
mg/patient 
 Kakihana et al. 
(1998) 
Idebenone increases 
lactate levels and 
decreases ATP and 
acetylcholine levels. 
Rat brains with cerebral 
ischemia 
10 mg/kg 
 Kaneko et al. (1991) Idebenone augments 
currents of KARs or 
AMPARs in presence 
of their agonists. No 
influence on 
NMDARs. 
Xenopus oocytes > 10 µM 
 Nagaoka et al. 
(1989) 
Idebenone inhibits 
increase in lactate and 
decrease in ATP and 
ameliorates 
neurological deficits 
related to cerebral 
ischemia 
Ischemia in rats 10-100 mg/kg 
 Nitta et al. (1993) Idebenone increases 
NGF levels in 
hippocampus, frontal 
and pariental cortices 
of aged rats. 
Aged rats 10-20 mg/kg 
 Miyamoto et al. 
(1990) 
Idebenone rescued 
survival of cholinergic 
and GABAergic cells in 
presence of AMPAR or 
KAR agonists, but not 
NMDAR agonist. 
Excitotoxicity in 
striatum 
3-10 mg/kg 
 Takeuchi et al. 
(1990) 
Idebeone increases 
NGF production. 
Astrocytes 10-18 µM 
 Takuma et al. 
(2000) 
Idebenone protects 
astrocytes not by 
reducing ROS levels, 
but by increased NGF 
production.  
Reperfusion injury in 
astrocytes 
10 nM - 10 
µM 
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 Yamada et al. (1997) Idebenone ameloriates 
behavioural tests 
(water maze, passive 
avoidance, habituation 
test), increases 
acetylcholine activity. 
Review - 
Enzyme 
Interaction 
Civenni et al. (1999) Idebenone inhibits 
cylcooxygenase and 
lipoxygenase. 
Astroglia and plateletes 1-20 µM 
 Tsuruo et al. (1994) Idebenone is a 
substrate for a nitric 
oxygen synthesizing 
NADPH diaphorase in 
the brain. 
Brain homogenates 3-10 µM 
 Schütz et al. (1997) Idebenone metabolism 
during reperfusion after 
cold preservation. 
Reperfusion in pig liver 280 mg/kg 
 Suno and Nagaoka 
(1989) 
Idebenone inhibits 
platelet aggregation, 
prostaglandin synthesis, 
and thromboxane B2 
production. 
Platelets >125 µM 
Toxicity Lustyik et al. (1990) Idebenone is cytotoxic 
at concentrations 
higher than 75 uM. 
Human lymphoblastoid 
cells 
> 75 µM 
 Tai et al. (2011) Idebenone induces 
apoptosis. 
Human neuroblastoid 
cells 
> 25 µM 
 Wempe et al. 
(2009) 
Idebenone might lead 
to toxicity. 
Pig ears 1-10 µM 
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